[
    {
        "ArticleTitle": "Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data.",
        "AuthorList": [
            "Laurie H Sehn",
            "Mark Hertzberg",
            "Stephen Opat",
            "Alex F Herrera",
            "Sarit Assouline",
            "Christopher R Flowers",
            "Tae Min Kim",
            "Andrew McMillan"
        ],
        "AffiliationList": [
            "BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, BC, Canada.",
            "Prince of Wales Hospital and University of New South Wales, Sydney, NSW, Australia.",
            "Clinical Haematology, Monash Health and Monash University, Clayton, VIC, Australia.",
            "City of Hope Medical Centre, Duarte, CA.",
            "Jewish General Hospital, Montreal, QC, Canada.",
            "Winship Cancer Institute of Emory University, Atlanta, GA.",
            "Seoul National University Hospital, Seoul, South Korea.",
            "Center for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.",
        "AuthorList": [
            "Rakesh Awasthi",
            "Lida Pacaud",
            "Edward Waldron",
            "Constantine S Tam",
            "Ulrich Jäger",
            "Peter Borchmann",
            "Samantha Jaglowski",
            "Stephen Ronan Foley"
        ],
        "AffiliationList": [
            "Novartis Institutes for BioMedical Research, East Hanover, NJ.",
            "Novartis Pharmaceuticals Corporation, East Hanover, NJ.",
            "Novartis Pharmaceuticals Corporation, East Hanover, NJ.",
            "Hematology Department, Peter MacCallum Cancer Center, University of Melbourne, Melbourne, Australia.",
            "Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.",
            "Department of Hematology and Oncology, University Hospital of Cologne, Cologne, Germany.",
            "The James Cancer Hospital and Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH.",
            "Juravinski Hospital and Cancer Center, McMaster University, Hamilton, ON, Canada."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.",
        "AuthorList": [
            "H Hagberg",
            "C Gisselbrecht"
        ],
        "AffiliationList": [
            "Department of Oncology, Akademiska Sjukhuset, Uppsala, Sweden. hans.hagberg@akademiska.se",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.",
        "AuthorList": [
            "Bertrand Coiffier",
            "Catherine Thieblemont",
            "Eric Van Den Neste",
            "Gérard Lepeu",
            "Isabelle Plantier",
            "Sylvie Castaigne",
            "Sophie Lefort",
            "Gérald Marit"
        ],
        "AffiliationList": [
            "Hospices Civils de Lyon and Université Lyon-1, Lyon, France. bertrand.coiffier@chu-lyon.fr",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2010",
                "Month": "06",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis.",
        "AuthorList": [
            "Carlo Visco",
            "Francesca Pregnolato",
            "Isacco Ferrarini",
            "Beatrice De Marco",
            "Valentina Bonuomo",
            "Eugenio Sbisà",
            "Costanza Fraenza",
            "Andrea Bernardelli"
        ],
        "AffiliationList": [
            "Department of Medicine, Section of Hematology, University of Verona, Verona, Italy. Electronic address: carlo.visco@univr.it.",
            "Experimental Laboratory of Immuno-rheumatology, Istituto Auxologico Italiano, IRCCS, Cusano Milanino, Milan, Italy.",
            "Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.",
            "Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.",
            "Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.",
            "Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.",
            "Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.",
            "Department of Medicine, Section of Hematology, University of Verona, Verona, Italy."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "06",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results.",
        "AuthorList": [
            "Ulrich Jaeger",
            "Nina Worel",
            "Joseph P McGuirk",
            "Peter A Riedell",
            "Isabelle Fleury",
            "Yan Du",
            "Xia Han",
            "David Pearson"
        ],
        "AffiliationList": [
            "Division of Hematology and Hemostaseology and Comprehensive Cancer Center, Department of Medicine I, Medical University of Vienna, Vienna, Austria.",
            "Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria.",
            "Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Health System, Kansas City, KS.",
            "David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL.",
            "Maisonneuve-Rosement Hospital, Montreal, QC, Canada.",
            "Novartis Institutes for Biomedical Research, Shanghai, China.",
            "Novartis Pharmaceuticals Corporation, East Hanover, NJ.",
            "Novartis Institutes for BioMedical Research, Basel, Switzerland."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis.",
        "AuthorList": [
            "Zhijuan Lin",
            "Xing Chen",
            "Long Liu",
            "Hanyan Zeng",
            "Zhifeng Li",
            "Bing Xu"
        ],
        "AffiliationList": [
            "Department of Hematology, the First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China; Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, China.",
            "Department of Nephrology, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.",
            "Department of Hematology, the First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China; Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, China.",
            "Department of Hematology, the First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China; Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, China.",
            "Department of Hematology, the First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China; Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, China. Electronic address: lzf_xm@163.com.",
            "Department of Hematology, the First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China; Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, China. Electronic address: xubingzhangjian@126.com."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "07",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "Superiority of polatuzumab vedotin over other novel agents in previously untreated ABC-type diffuse large B-cell lymphoma: a network meta-analysis of 20 RCTs.",
        "AuthorList": [
            "Zhixin Sheng",
            "Dianfang Li",
            "Bing Chen",
            "Chunwu Zhao",
            "Wenxing Zhang",
            "Baolong Ding",
            "Lida Wang"
        ],
        "AffiliationList": [
            "Department of Hematology, Weifang People's Hospital, Weifang, China.",
            "Department of Hematology, Weifang People's Hospital, Weifang, China.",
            "Department of Neurosurgery, Weifang People's Hospital, Weifang, China.",
            "Department of General surgery, Weifang People's Hospital, Weifang, Shandong, China.",
            "Department of General surgery, Weifang People's Hospital, Weifang, Shandong, China.",
            "Department of Thoracic Surgery, Weifang People's Hospital, Weifang, Shandong, China.",
            "Department of E.N.T, Weifang People's Hospital, Weifang, Shandong, China. 30520293@qq.com."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "03",
                "Day": "22"
            }
        ]
    },
    {
        "ArticleTitle": "Central nervous system (CNS) prophylaxis in antiCD20-CHOP treated DLBCL at intermediate to high risk for CNS relapse: A systematic review and meta-analysis.",
        "AuthorList": [
            "Guiyi Ho",
            "Cherie Tan",
            "Sanjay de Mel",
            "Limei Poon",
            "Esther H L Chan",
            "Joanne Lee",
            "Xin Liu",
            "Wee Joo Chng"
        ],
        "AffiliationList": [
            "Department of Haematology-Oncology, National University Hospital, Singapore.",
            "Department of Haematology-Oncology, National University Hospital, Singapore.",
            "Department of Haematology-Oncology, National University Hospital, Singapore.",
            "Department of Haematology-Oncology, National University Hospital, Singapore.",
            "Department of Haematology-Oncology, National University Hospital, Singapore.",
            "Department of Haematology-Oncology, National University Hospital, Singapore.",
            "Department of Haematology-Oncology, National University Hospital, Singapore.",
            "Department of Haematology-Oncology, National University Hospital, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "10",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "SHP1 loss augments DLBCL cellular response to ibrutinib: a candidate predictive biomarker.",
        "AuthorList": [
            "Wenjun Wu",
            "Pin Lu",
            "Priyal Patel",
            "Ji Ma",
            "Kathy Qi Cai",
            "Vinay S Mallikarjuna",
            "Sahar Poureghbali",
            "Shazia R Nakhoda"
        ],
        "AffiliationList": [
            "Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA.",
            "Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA.",
            "Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA.",
            "Department of Medical Oncology, Shandong Cancer Hospital and Institute, Jinan, China.",
            "Histopathology Facility, Fox Chase Cancer Center, Philadelphia, USA.",
            "Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA.",
            "Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA.",
            "Malignant Hematology, Fox Chase Cancer Center, Philadelphia, PA, USA."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "12",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.",
        "AuthorList": [
            "Wyndham H Wilson",
            "Ryan M Young",
            "Roland Schmitz",
            "Yandan Yang",
            "Stefania Pittaluga",
            "George Wright",
            "Chih-Jian Lih",
            "P Mickey Williams"
        ],
        "AffiliationList": [
            "Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA.",
            "Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA.",
            "Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA.",
            "Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA.",
            "Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, Maryland, USA.",
            "Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland, USA.",
            "Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.",
            "Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "07",
                "Day": "20"
            }
        ]
    },
    {
        "ArticleTitle": "Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.",
        "AuthorList": [
            "Prokop Vodicka",
            "Katerina Benesova",
            "Andrea Janikova",
            "Vit Prochazka",
            "David Belada",
            "Heidi Mocikova",
            "Katerina Steinerova",
            "Juraj Duras"
        ],
        "AffiliationList": [
            "First Department of Medicine, Charles University and General University Hospital, Prague, Czech Republic.",
            "First Department of Medicine, Charles University and General University Hospital, Prague, Czech Republic.",
            "Department of Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital, Brno, Czech Republic.",
            "Department of Haemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.",
            "4th Department of Internal Medicine - Hematology, Faculty of Medicine, Charles University and University Hospital, Hradec Kralove, Czech Republic.",
            "Department of Internal Medicine - Hematology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic.",
            "Department of Haemato-Oncology, Faculty of Medicine, Charles University and University Hospital Pilsen, Pilsen, Czech Republic.",
            "Department of Hematology, Medical Faculty of the Ostrava University and University Hospital, Ostrava, Czech Republic."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "05",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "Predictive value of interim PET/CT in DLBCL treated with R-CHOP: meta-analysis.",
        "AuthorList": [
            "Na Sun",
            "Jinhua Zhao",
            "Wenli Qiao",
            "Taisong Wang"
        ],
        "AffiliationList": [
            "Department of Nuclear Medicine, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai 200080, China.",
            "Department of Nuclear Medicine, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai 200080, China.",
            "Department of Nuclear Medicine, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai 200080, China.",
            "Department of Nuclear Medicine, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai 200080, China."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "02",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.",
        "AuthorList": [
            "Pallawi Torka",
            "Adrienne Groman",
            "Jerry Wong",
            "Jenna Nichols",
            "Angela Kader",
            "Cory Mavis",
            "Andrea Anampa-Guzmán",
            "Sheila Jani Sait"
        ],
        "AffiliationList": [
            "Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.",
            "Department of Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY.",
            "Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.",
            "Department of Clinical Research Services, Roswell Park Comprehensive Cancer Center, Buffalo, NY.",
            "Department of Clinical Research Services, Roswell Park Comprehensive Cancer Center, Buffalo, NY.",
            "Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.",
            "Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.",
            "Department of Cytogenetics, Roswell Park Comprehensive Cancer Center, Buffalo, NY."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.",
        "AuthorList": [
            "Ranjana Advani",
            "Ian Flinn",
            "Leslie Popplewell",
            "Andres Forero",
            "Nancy L Bartlett",
            "Nilanjan Ghosh",
            "Justin Kline",
            "Mark Roschewski"
        ],
        "AffiliationList": [
            "From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.).",
            "From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.).",
            "From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.).",
            "From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.).",
            "From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.).",
            "From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.).",
            "From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.).",
            "From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.",
        "AuthorList": [
            "Grzegorz S Nowakowski",
            "Annalisa Chiappella",
            "Randy D Gascoyne",
            "David W Scott",
            "Qingyuan Zhang",
            "Wojciech Jurczak",
            "Muhit Özcan",
            "Xiaonan Hong"
        ],
        "AffiliationList": [
            "Division of Hematology, Mayo Clinic, Rochester, MN.",
            "Division of Hematology, A.O.U. Città della Salute e della Scienza Hospital and University, Torino, Italy.",
            "Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.",
            "Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.",
            "Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.",
            "Maria Sklodowska-Curie Institute-Oncology Centre, Cracow, Poland.",
            "Department of Hematology, Ankara University, Ankara, Turkey.",
            "Cancer Hospital, Fudan University, Shanghai, China."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "02",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "PD-L1 and tumor-associated macrophages in de novo DLBCL.",
        "AuthorList": [
            "Ronald McCord",
            "Christopher R Bolen",
            "Hartmut Koeppen",
            "Edward E Kadel",
            "Mikkel Z Oestergaard",
            "Tina Nielsen",
            "Laurie H Sehn",
            "Jeffrey M Venstrom"
        ],
        "AffiliationList": [
            "Oncology Biomarker Development.",
            "Bioinformatics, and.",
            "Research Pathology, Genentech, South San Francisco, CA.",
            "Oncology Biomarker Development.",
            "Oncology Biomarker Development and.",
            "Clinical Development Oncology, Roche, Basel, Switzerland; and.",
            "Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada.",
            "Oncology Biomarker Development."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.",
        "AuthorList": [
            "Hua-Jay J Cherng",
            "Stefan K Alig",
            "Yasuhiro Oki",
            "Loretta J Nastoupil",
            "Luis Fayad",
            "Sattva S Neelapu",
            "Francesco Turturro",
            "Fredrick Hagemeister"
        ],
        "AffiliationList": [
            "Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA.",
            "Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA.",
        "AuthorList": [
            "Laurie H Sehn",
            "Maurizio Martelli",
            "Marek Trněný",
            "Wenxin Liu",
            "Christopher R Bolen",
            "Andrea Knapp",
            "Deniz Sahin",
            "Gila Sellam"
        ],
        "AffiliationList": [
            "BC Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, BC, Canada. Lsehn@bccancer.bc.ca.",
            "Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.",
            "Charles University General Hospital, Prague, Czech Republic.",
            "Roche Pharma Development, Shanghai, China.",
            "Genentech, Inc., South San Francisco, CA, USA.",
            "F. Hoffmann-La Roche Ltd, Basel, Switzerland.",
            "F. Hoffmann-La Roche Ltd, Basel, Switzerland.",
            "F. Hoffmann-La Roche Ltd, Basel, Switzerland."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "06",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.",
        "AuthorList": [
            "Matthew J Maurer",
            "Hervé Ghesquières",
            "Jean-Philippe Jais",
            "Thomas E Witzig",
            "Corinne Haioun",
            "Carrie A Thompson",
            "Richard Delarue",
            "Ivana N Micallef"
        ],
        "AffiliationList": [
            "Matthew J. Maurer, Hervé Ghesquières, Thomas E. Witzig, Carrie A. Thompson, Ivana N. Micallef, William R. Macon, Paul J. Kurtin, Cristine Allmer, Susan L. Slager, Thomas M. Habermann, and James R. Cerhan, Mayo Clinic, Rochester, MN; Hervé Ghesquières and Emmanuelle Nicolas-Virelizier, Centre Léon Bérard; Hervé Ghesquières and Gilles Salles, Université Claude Bernard, Unite Mixte de Recherche (UMR), Centre National de la Recherche Scientifique 5239, Lyon; Jean-Philippe Jais, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR S 872, Necker Hospital, Assistance Publique-Hopitaux de Paris; Richard Delarue, Necker Hospital; Thierry Jo Molina, Paris Descartes University, Paris Centre University Hospital, Paris; Corinne Haioun, Henri Mondor Hospital, Université Paris-Est, Créteil; Frédéric Peyrade, Centre Antoine Lacassagne, Nice; Olivier Fitoussi, Polyclinique Bordeaux-Nord, Bordeaux; Gilles Salles, Hospices Civils de Lyon, Pierre Benite; Hervé Tilly, INSERM U918, Institute for Research and Innovation in Biomedicine, Centre Henri Becquerel, Rouen, France; Nicolas Ketterer, Lausanne Hospital, Lausanne, Switzerland; and Sergei I. Syrbu and Brian K. Link, University of Iowa College of Medicine, Iowa City, IA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "02",
                "Day": "18"
            }
        ]
    },
    {
        "ArticleTitle": "Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.",
        "AuthorList": [
            "Keenan T Hartert",
            "Kerstin Wenzl",
            "Jordan E Krull",
            "Michelle Manske",
            "Vivekananda Sarangi",
            "Yan Asmann",
            "Melissa C Larson",
            "Matthew J Maurer"
        ],
        "AffiliationList": [
            "Division of Hematology, Mayo Clinic, Rochester, MN, USA.",
            "Division of Hematology, Mayo Clinic, Rochester, MN, USA.",
            "Division of Hematology, Mayo Clinic, Rochester, MN, USA.",
            "Division of Hematology, Mayo Clinic, Rochester, MN, USA.",
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.",
            "Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA.",
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.",
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "03",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study.",
        "AuthorList": [
            "Asma Beldi-Ferchiou",
            "Jean-Philippe Jais",
            "Hervé Ghesquieres",
            "Rene Olivier Casasnovas",
            "Hervé Tilly",
            "Christophe Fruchart",
            "Franck Morschhauser",
            "Corinne Haioun"
        ],
        "AffiliationList": [
            "Biological Hematology and Immunology department, APHP, INSERM U 955, Hopital Henri Mondor, Creteil, France.",
            "Biostatistics Unit, APHP, Univ Paris Descartes, Paris, France.",
            "Hematology, Centre Hospitalier Lyon Sud, PIERRE-BENITE, Lyon, France.",
            "Hematology, CHU Dijon Bourgogne and INSERM U 1231, Dijon, France.",
            "INSERM U918, Centre Henri Becquerel, Rouen, France.",
            "Institut d'Hématologie de Basse Normandie, CHU Caen, Caen, France.",
            "Clinical Hematology, Univ. Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.",
            "Lymphoid Malignancies Unit, APHP, Hopital Henri Mondor, Creteil, France."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "02",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study.",
        "AuthorList": [
            "Kana Miyazaki",
            "Naoko Asano",
            "Tomomi Yamada",
            "Kohta Miyawaki",
            "Rika Sakai",
            "Tadahiko Igarashi",
            "Momoko Nishikori",
            "Kinya Ohata"
        ],
        "AffiliationList": [
            "Department of Hematology and Oncology, Mie University Graduate School of Medicine, Mie. kmiyazaki@clin.medic.mie-u.ac.jp.",
            "Department of Molecular Diagnostics, Nagano Prefectural Shinshu Medical Center, Suzaka.",
            "Department of Medical Innovation, Osaka University Hospital, Suita.",
            "Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka.",
            "Department of Medical Oncology, Kanagawa Cancer Center, Yokohama.",
            "Hematology/Oncology Division, Gunma Cancer Center, Ohta.",
            "Department of Hematology and Oncology, Kyoto University Graduate School of Medicine, Kyoto.",
            "Department of Hematology, Kanazawa University, Kanazawa."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "09",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.",
        "AuthorList": [
            "C Soussain",
            "S Choquet",
            "M Blonski",
            "D Leclercq",
            "C Houillier",
            "K Rezai",
            "F Bijou",
            "R Houot"
        ],
        "AffiliationList": [
            "Hematology, Institut Curie, Site Saint-Cloud, France. Electronic address: carole.soussain@curie.fr.",
            "Hematology, APHP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.",
            "Neurology, Centre Hospitalier Universitaire de Nancy, France.",
            "Neuro-Radiology, APHP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.",
            "APHP, Sorbonne Université, IHU, ICM, Neurology,Groupe Hospitalier Pitié-Salpêtrière, Paris, France.",
            "Radio-Pharmacology, Institut Curie, Site Saint-Cloud, France.",
            "Hematology, Institut Bergonié, Bordeaux, France.",
            "Univ. Rennes, CHU Rennes, Department of Hematology, Inserm, MICMAC (MIcroenvironment, Cell differentiation, iMmunology and Cancer), UMR_S 1236, F-35000, Rennes, France."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "07",
                "Day": "03"
            }
        ]
    },
    {
        "ArticleTitle": "PD-L1 expression predicts efficacy in the phase II SPiReL trial with MVP-S, pembrolizumab, and low-dose CPA in R/R DLBCL.",
        "AuthorList": [
            "Irina Amitai",
            "Kim Roos",
            "Iran Rashedi",
            "Yidi Jiang",
            "Kathryn Mangoff",
            "Gail Klein",
            "Nicholas Forward",
            "Douglas Stewart"
        ],
        "AffiliationList": [
            "Sunnybrook Health Sciences Centre, Toronto, Canada.",
            "Sunnybrook Research Institute, Toronto, Canada.",
            "Sunnybrook Research Institute, Toronto, Canada.",
            "Sunnybrook Research Institute, Toronto, Canada.",
            "Sunnybrook Research Institute, Toronto, Canada.",
            "Sunnybrook Research Institute, Toronto, Canada.",
            "Queen Elizabeth II Health Sciences Centre, Halifax, Canada.",
            "Tom Baker Cancer Centre, Calgary, Canada."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "05",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.",
        "AuthorList": [
            "H Ghesquieres",
            "M Chevrier",
            "M Laadhari",
            "O Chinot",
            "S Choquet",
            "C Moluçon-Chabrot",
            "P Beauchesne",
            "R Gressin"
        ],
        "AffiliationList": [
            "Department of Hematology, Centre Hospitalier Lyon Sud, Université Claude Bernard Lyon 1, Pierre-Bénite; Department of Hematology, Centre Léon Bérard, Université Claude Bernard Lyon 1, Lyon.",
            "Departments of Biostatistics, Aix Marseille University, AP-HM, Marseille.",
            "Radiology, Institut Curie, Saint-Cloud, Aix Marseille University, AP-HM, Marseille.",
            "Department of Neuro-Oncology, Hôpital de la Timone, Aix Marseille University, AP-HM, Marseille.",
            "Department of Hematology, Groupe Hospitalier Pitié-Salpêtrière, Université Pierre et Marie Curie, Paris.",
            "Department of Hematology, CHU Clermont Ferrand, Clermond Ferrand.",
            "Department of Neuro-Oncology, CHU Nancy, Nancy.",
            "Department of Hematology, CHU La Tronche, Grenoble."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Tarun Kewalramani",
            "Andrew D Zelenetz",
            "Stephen D Nimer",
            "Carol Portlock",
            "David Straus",
            "Ariela Noy",
            "Owen O'Connor",
            "Daniel A Filippa"
        ],
        "AffiliationList": [
            "Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. kewalrat@mskcc.org",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2004",
                "Month": "01",
                "Day": "22"
            }
        ]
    },
    {
        "ArticleTitle": "Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis.",
        "AuthorList": [
            "Sirpa Leppä",
            "Judit Jørgensen",
            "Anne Tierens",
            "Leo Meriranta",
            "Ingunn Østlie",
            "Peter de Nully Brown",
            "Unn-Merete Fagerli",
            "Thomas Stauffer Larsen"
        ],
        "AffiliationList": [
            "Department of Oncology, Helsinki University Hospital Comprehensive Cancer Centre and Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.",
            "Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.",
            "Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.",
            "Department of Oncology, Helsinki University Hospital Comprehensive Cancer Centre and Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.",
            "Department of Pathology, Oslo University Hospital, Oslo, Norway.",
            "Department of Hematology, Rigshospitalet, Copenhagen, Denmark.",
            "Department of Oncology, St. Olavs Hospital, Trondheim, Norway.",
            "Department of Hematology, Odense University Hospital, Odense, Denmark."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL.",
        "AuthorList": [
            "Deborah A Katz",
            "Joan D Morris",
            "Michael P Chu",
            "Kevin A David",
            "Catherine Thieblemont",
            "Nicholas J Morley",
            "Sharif S Khan",
            "Andreas Viardot"
        ],
        "AffiliationList": [
            "Division of Hematology/Oncology/Cell Therapy, Rush University Medical Center, Chicago, IL, USA.",
            "Amgen Inc, Thousand Oaks, CA, USA.",
            "Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada.",
            "Rutgers Cancer Institute of New Jersey, Rutgers Wood Johnson Medical School, New Brunswick, NJ, USA.",
            "APHP, Hôpital Saint-Louis, Hemato-Oncology Unit Paris, France.",
            "Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.",
            "Hematology & Oncology, Bon Secours St. Francis, Greenville, SC, USA.",
            "Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "05",
                "Day": "03"
            }
        ]
    },
    {
        "ArticleTitle": "Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study.",
        "AuthorList": [
            "Eliza A Hawkes",
            "Tycel Phillips",
            "Lihua Elizabeth Budde",
            "Armando Santoro",
            "Nakhle S Saba",
            "Fernando Roncolato",
            "Gareth P Gregory",
            "Gregor Verhoef"
        ],
        "AffiliationList": [
            "Olivia Newton-John Cancer Research Institute, Austin Health, 145 Studley Road, Heidelberg, VIC, Australia. eliza.hawkes@onjcri.org.au.",
            "University of Michigan Health System, Ann Arbor, MI, USA.",
            "City of Hope, Duarte, CA, USA.",
            "Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.",
            "Section of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University, New Orleans, LA, USA.",
            "St. George Hospital, Kogarah, NSW, Australia.",
            "School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC, Australia.",
            "UZ Leuven, Leuven, Belgium."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "10",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial.",
        "AuthorList": [
            "Qing Shi",
            "Yang He",
            "Hong-Mei Yi",
            "Rong-Ji Mu",
            "Xu-Feng Jiang",
            "Di Fu",
            "Lei Dong",
            "Wei Qin"
        ],
        "AffiliationList": [
            "State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.",
            "State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.",
            "Department of Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.",
            "Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.",
            "Department of Nuclear Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.",
            "State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.",
            "Department of Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.",
            "State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "07",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Safety and efficacy of durvalumab with R-CHOP or R<sup>2</sup>-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.",
        "AuthorList": [
            "Grzegorz S Nowakowski",
            "Wolfgang Willenbacher",
            "Richard Greil",
            "Thomas S Larsen",
            "Krish Patel",
            "Ulrich Jäger",
            "Robert F Manges",
            "Lorenz Trümper"
        ],
        "AffiliationList": [
            "Division of Hematology, Mayo Clinic Rochester, 200 1st St SW, Rochester, MN, 55902, USA. nowakowski.grzegorz@mayo.edu.",
            "Internal Medicine, Hematology and Oncology Department, Innsbruck Medical University, Innsbruck, Austria.",
            "Salzburg Cancer Research Institute and Cancer Cluster, Paracelsus Medical University Salzburg, Salzburg, Austria.",
            "Department of Hematology, Odense University Hospital, Odense, Denmark.",
            "Swedish Cancer Institute Hematology and Oncology Department, Center for Blood Disorders and Stem Cell Transplantation, Seattle, WA, USA.",
            "Division of Hematology and Hemostseology, Medical University of Vienna, Vienna, Austria.",
            "Parkview Health, Parkview Cancer Institute, Hematology Tumor Site, Fort Wayne, IN, USA.",
            "Department of Hematology-Oncology, Universitätsmedizin Göttingen, Göttingen, Germany."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "11",
                "Day": "19"
            }
        ]
    },
    {
        "ArticleTitle": "Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.",
        "AuthorList": [
            "Michael Schuster",
            "Josée Zijlstra",
            "Rene-Olivier Casasnovas",
            "Joost S P Vermaat",
            "Nagesh Kalakonda",
            "Andre Goy",
            "Sylvain Choquet",
            "Eric Van Den Neste"
        ],
        "AffiliationList": [
            "Stony Brook University Hospital Cancer Center, Stony Brook, NY. Electronic address: Michael.Schuster@stonybrookmedicine.edu.",
            "Amsterdam UMC, Vrije Universiteit, Cancer Center, Amsterdam, Netherlands.",
            "Hématologie Clinique and INSERM 1231, Dijon, France.",
            "LUMC, Leiden, Netherlands.",
            "University of Liverpool, Liverpool, United Kingdom.",
            "Hackensack University Medical Center, Hackensack, NJ, United States.",
            "Hôpital Pitié Salpêtrière, Paris, France.",
            "Cliniques Universitaires Saint-Luc, Brussels, Belgium."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "12",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment.",
        "AuthorList": [
            "Mark Roschewski",
            "Manish R Patel",
            "Patrick M Reagan",
            "Nakhle S Saba",
            "Graham P Collins",
            "Hendrik-Tobias Arkenau",
            "Sven de Vos",
            "Barrett Nuttall"
        ],
        "AffiliationList": [
            "Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.",
            "Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, Florida.",
            "Division of Hematology/Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York.",
            "Section of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University, New Orleans, Louisiana.",
            "NIHR Oxford Biomedical Research Centre, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom.",
            "Sarah Cannon Research Institute and University College London, London, United Kingdom.",
            "David Geffen School of Medicine at UCLA, Los Angeles, California.",
            "AstraZeneca, Waltham, Massachusetts."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.",
        "AuthorList": [
            "Peter Martin",
            "Nancy L Bartlett",
            "Julio C Chavez",
            "John L Reagan",
            "Sonali M Smith",
            "Ann S LaCasce",
            "Jeffrey Jones",
            "James Drew"
        ],
        "AffiliationList": [
            "Weill Cornell Medical College, New York, NY.",
            "Washington University School of Medicine, St Louis, MO.",
            "Moffitt Cancer Center, Tampa, FL.",
            "The Warren Alpert Medical School of Brown University, Providence, RI.",
            "University of Chicago Comprehensive Cancer Center, Chicago, IL.",
            "Dana-Farber Cancer Institute, Boston, MA; and.",
            "Bristol Myers Squibb, Princeton, NJ.",
            "Bristol Myers Squibb, Princeton, NJ."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial.",
        "AuthorList": [
            "Yuqin Song",
            "Hui Zhou",
            "Huilai Zhang",
            "Wei Liu",
            "Yuerong Shuang",
            "Keshu Zhou",
            "Fangfang Lv",
            "Hao Xu"
        ],
        "AffiliationList": [
            "Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China.",
            "Department of Lymphoma and Hematology, Hunan Province Cancer Hospital, Changsha, China.",
            "Department of Lymphoma, Tianjin Cancer Hospital, Tianjin, China.",
            "State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.",
            "Cancer Chemotherapy Center, Jiangxi Province Cancer Hospital, Nanchang, China.",
            "Hematology Department, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.",
            "Oncology Department, Fudan University Cancer Hospital, Shanghai, China.",
            "Hematology Department, Yancheng City No. 1 People's Hospital, Yancheng, China."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "03",
                "Day": "09"
            }
        ]
    },
    {
        "ArticleTitle": "FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.",
        "AuthorList": [
            "N George Mikhaeel",
            "David Cunningham",
            "Nicholas Counsell",
            "Andrew McMillan",
            "John A Radford",
            "Kirit M Ardeshna",
            "Anthony Lawrie",
            "Paul Smith"
        ],
        "AffiliationList": [
            "Guy's Cancer Centre, Guy's and St Thomas' Hospital NHS Trust and School of Cancer and Pharmaceutical sciences, King's College London University, London, UK.",
            "The Royal Marsden NHS Trust, London, UK.",
            "Cancer Research UK and University College London (UCL) Cancer Trials Centre, London, UK.",
            "Nottingham University Hospital NHS Trust, Nottingham, UK.",
            "Manchester Academic Health Science Centre, University of Manchester and the Christie NHS Foundation Trust, Manchester, UK.",
            "University College London Hospital NHS Trust, London, UK.",
            "Cancer Research UK and University College London (UCL) Cancer Trials Centre, London, UK.",
            "Cancer Research UK and University College London (UCL) Cancer Trials Centre, London, UK."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "07",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Therapeutic effects of chimeric antigen receptor T cells (CAR-T) on relapse/refractory diffuse large B-cell lymphoma (R/R DLBCL): a meta-analysis.",
        "AuthorList": [
            "H-H Cao",
            "L-L Wang",
            "C-K Geng",
            "W-W Mao",
            "L-L Yang",
            "Y Ma",
            "M He",
            "R Zhang"
        ],
        "AffiliationList": [
            "Department of Hematology, The Third Affiliated Hospital of Kunming Medical University, Kunming,  China. szl1020@163.com.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients.",
        "AuthorList": [
            "Jordan E Krull",
            "Kerstin Wenzl",
            "Keenan T Hartert",
            "Michelle K Manske",
            "Vivekananda Sarangi",
            "Matthew J Maurer",
            "Melissa C Larson",
            "Grzegorz S Nowakowski"
        ],
        "AffiliationList": [
            "Mayo Clinic Graduate Program in Biomedical Science, Mayo Clinic, Rochester, MN, USA.",
            "Division of Hematology, Mayo Clinic, Rochester, MN, USA.",
            "Division of Hematology, Mayo Clinic, Rochester, MN, USA.",
            "Division of Hematology, Mayo Clinic, Rochester, MN, USA.",
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.",
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.",
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.",
            "Division of Hematology, Mayo Clinic, Rochester, MN, USA."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "11",
                "Day": "09"
            }
        ]
    },
    {
        "ArticleTitle": "Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Karen Thudium Mueller",
            "Stephan A Grupp",
            "Shannon L Maude",
            "John E Levine",
            "Michael A Pulsipher",
            "Michael W Boyer",
            "Keith J August",
            "G Doug Myers"
        ],
        "AffiliationList": [
            "Novartis Institutes for BioMedical Research, East Hanover, NJ.",
            "Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.",
            "Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.",
            "Department of Pediatrics, University of Michigan, Ann Arbor, MI.",
            "Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA.",
            "Department of Pediatrics and Internal Medicine, University of Utah, Salt Lake City, UT.",
            "Children's Mercy Hospital, Kansas City, MO.",
            "Children's Mercy Hospital, Kansas City, MO."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation.",
        "AuthorList": [
            "Naoko Tsuyama",
            "Seiji Sakata",
            "Satoko Baba",
            "Yuko Mishima",
            "Noriko Nishimura",
            "Kyoko Ueda",
            "Masahiro Yokoyama",
            "Yasuhito Terui"
        ],
        "AffiliationList": [
            "Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.",
            "Pathology Project for Molecular Targets.",
            "Pathology Project for Molecular Targets.",
            "Department of Hematology Oncology, and.",
            "Department of Hematology Oncology, and.",
            "Department of Hematology Oncology, and.",
            "Department of Hematology Oncology, and.",
            "Department of Hematology Oncology, and."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "05",
                "Day": "18"
            }
        ]
    },
    {
        "ArticleTitle": "In situ BCL2 expression is an independent prognostic factor in HIV-associated DLBCL, a LYMPHOVIR cohort study.",
        "AuthorList": [
            "Laure Philippe",
            "Remi Lancar",
            "Camille Laurent",
            "Michele Algarte-Genin",
            "Catherine Chassagne-Clément",
            "Bettina Fabiani",
            "Marie Pierre Chenard",
            "Thierry Lazure"
        ],
        "AffiliationList": [
            "Unit of Haematology-Oncology, Centre Hospitalier Versailles, Le Chesnay, France.",
            "INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Sorbonne Université, Paris, France.",
            "Department of Pathology, Institut Universitaire du Cancer-Oncopole, CHU Toulouse, Toulouse, France.",
            "INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Sorbonne Université, Paris, France.",
            "Department of Pathology, Centre Léon Bérard, Lyon, France.",
            "Department of Pathology, Hôpital Saint Antoine, AP-HP, Paris, France.",
            "Department of Pathology, Hôpital de Hautepierre, University Hospital of Strasbourg, Strasbourg, France.",
            "Faculté de médecine Paris Sud, Université Paris Sud, Le Kremlin-Bicêtre, France."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "08",
                "Day": "29"
            }
        ]
    },
    {
        "ArticleTitle": "Genetically informed therapy for lymphoma: the discomfiting benefit of lumping splits.",
        "AuthorList": [
            "Cynthia K Hahn",
            "Adam C Palmer",
            "David M Weinstock"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.",
            "Department of Pharmacology, Computational Medicine Program, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.",
            "Merck & Co., Rahway, NJ, USA. Electronic address: david.weinstock@merck.com."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "09",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.",
        "AuthorList": [
            "Andre Goy",
            "Radhakrishnan Ramchandren",
            "Nilanjan Ghosh",
            "Javier Munoz",
            "David S Morgan",
            "Nam H Dang",
            "Mark Knapp",
            "Maria Delioukina"
        ],
        "AffiliationList": [
            "John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ.",
            "Karmanos Cancer Institute, Wayne State University, Detroit, MI.",
            "Levine Cancer Institute, Charlotte, NC.",
            "Banner MD Anderson Cancer Center, Gilbert, AZ.",
            "Vanderbilt-Ingram Cancer Center, Nashville, TN.",
            "Division of Hematology/Oncology, University of Florida, Gainesville, FL.",
            "Mid Ohio Oncology/Hematology, Inc, Columbus, OH.",
            "Johnson & Johnson, Horsham, PA."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "07",
                "Day": "22"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic impact of the TP53 rs1625895 polymorphism in DLBCL patients.",
        "AuthorList": [
            "Elena N Voropaeva",
            "Mikhail I Voevoda",
            "Tatiana I Pospelova",
            "Vladimir N Maksimov"
        ],
        "AffiliationList": [
            "Institute of Internal and Preventive Medicine, Siberian Branch, Russian Academy of Medical Sciences, Novosibirsk, Russia.",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "11",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.",
        "AuthorList": [
            "Frank Vari",
            "David Arpon",
            "Colm Keane",
            "Mark S Hertzberg",
            "Dipti Talaulikar",
            "Sanjiv Jain",
            "Qingyan Cui",
            "Erica Han"
        ],
        "AffiliationList": [
            "University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia.",
            "University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia.",
            "University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia.",
            "Haematology, Prince of Wales Hospital, Sydney, NSW, Australia.",
            "Canberra Hospital, Canberra, ACT, Australia.",
            "Canberra Hospital, Canberra, ACT, Australia.",
            "University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia.",
            "University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "02",
                "Day": "15"
            }
        ]
    },
    {
        "ArticleTitle": "Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis.",
        "AuthorList": [
            "Guillermo Villacampa",
            "Rodrigo Dienstmann",
            "Francesc Bosch",
            "Pau Abrisqueta"
        ],
        "AffiliationList": [
            "Oncology Data Science (OdysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.",
            "Oncology Data Science (OdysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.",
            "Department of Hematology, Vall d'Hebron University Hospital, Pssg Vall d'Hebron 119-129, 08035, Barcelona, Spain.",
            "Department of Hematology, Vall d'Hebron University Hospital, Pssg Vall d'Hebron 119-129, 08035, Barcelona, Spain. pabrisqueta@vhio.net."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "08",
                "Day": "10"
            }
        ]
    },
    {
        "ArticleTitle": "<i>PiggyBac</i>-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report.",
        "AuthorList": [
            "Chenggong Li",
            "Yan Sun",
            "Jing Wang",
            "Lu Tang",
            "Huiwen Jiang",
            "Tao Guo",
            "Lin Liu",
            "Yaohui Wu"
        ],
        "AffiliationList": [
            "Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.",
            "Shanghai Cell Therapy Group Co. Ltd., Shanghai, China.",
            "Radiology Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.",
            "Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.",
            "Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.",
            "Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.",
            "Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.",
            "Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "05",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Alessandra Rossi",
            "Stefania Orecchioni",
            "Paolo Falvo",
            "Valentina Tabanelli",
            "Elena Baiardi",
            "Claudio Agostinelli",
            "Federica Melle",
            "Giovanna Motta"
        ],
        "AffiliationList": [
            "Onco-Hematology Division, IEO European Institute of Oncology IRCCS, Milan, Italy.",
            "Laboratory of Hematology-Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.",
            "Laboratory of Hematology-Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.",
            "Division of diagnostic Haematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy.",
            "Onco-Hematology Division, IEO European Institute of Oncology IRCCS, Milan, Italy.",
            "Hematopathology Unit, Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna, Italy.",
            "Division of diagnostic Haematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy.",
            "Division of diagnostic Haematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "07",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis.",
        "AuthorList": [
            "Zhijuan Lin",
            "Xing Chen",
            "Zhifeng Li",
            "Yong Zhou",
            "Zhihong Fang",
            "Yiming Luo",
            "Jintao Zhao",
            "Bing Xu"
        ],
        "AffiliationList": [
            "Department of Hematology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Xiamen, 361003, Fujian, People's Republic of China.",
            "Department of Nephrology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Xiamen, 361003, Fujian, People's Republic of China.",
            "Department of Hematology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Xiamen, 361003, Fujian, People's Republic of China.",
            "Department of Hematology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Xiamen, 361003, Fujian, People's Republic of China.",
            "Department of Hematology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Xiamen, 361003, Fujian, People's Republic of China.",
            "Department of Hematology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Xiamen, 361003, Fujian, People's Republic of China. 1830655132@qq.com.",
            "Department of Hematology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Xiamen, 361003, Fujian, People's Republic of China. zhaojintao737@163.com.",
            "Department of Hematology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Xiamen, 361003, Fujian, People's Republic of China. xubingzhangjian@126.com."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "07",
                "Day": "19"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic value of circulating tumor DNA in lymphoma: a meta-analysis.",
        "AuthorList": [
            "Laiyu Yao",
            "Hong Xu",
            "Jinshan Wo",
            "Meiqing Zhao",
            "Zhihe Liu",
            "Tieying Dong",
            "Shuxin Xiao"
        ],
        "AffiliationList": [
            "Department of Medicine, Medical College of Qingdao University, 266003, Qingdao, China.",
            "Department of Hematology, The Affiliated Hospital of Qingdao University, 266003, Qingdao, China.",
            "Department of Cardiovascular Medicine, The Affiliated Hospital of Qingdao University, 266003, Qingdao, China.",
            "Department of Hematology, Eighth People's Hospital of Qingdo, 266003, Qingdao, China.",
            "Department of Hematology, The Affiliated Hospital of Qingdao University, 266003, Qingdao, China.",
            "Department of Hematology, The Affiliated Hospital of Qingdao University, 266003, Qingdao, China.",
            "Department of Hematology, The Affiliated Hospital of Qingdao University, 266003, Qingdao, China. xsxa@sina.com."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "05",
                "Day": "15"
            }
        ]
    },
    {
        "ArticleTitle": "The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review.",
        "AuthorList": [
            "Peng-Peng Xu",
            "Rong Shen",
            "Zi-Yang Shi",
            "Shu Cheng",
            "Li Wang",
            "Yang Liu",
            "Lu Zhang",
            "Ruiqi Huang"
        ],
        "AffiliationList": [
            "Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.",
            "Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.",
            "Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.",
            "Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.",
            "Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Laboratory of Molecular Pathology, Shanghai, China.",
            "BeiGene (Shanghai) Co. Ltd., Shanghai, China.",
            "BeiGene (Shanghai) Co. Ltd., Shanghai, China.",
            "BeiGene (Shanghai) Co. Ltd., Shanghai, China."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "08",
                "Day": "20"
            }
        ]
    },
    {
        "ArticleTitle": "CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.",
        "AuthorList": [
            "Ayed O Ayed",
            "Annalisa Chiappella",
            "Levi Pederson",
            "Betsy R Laplant",
            "Angela Giovanna Congiu",
            "Gianluca Gaidano",
            "Michele Spina",
            "Alessandro Re"
        ],
        "AffiliationList": [
            "Division of Hematology, Mayo Clinic, Rochester, MN, USA.",
            "Division of Hematology, Città della Salute e della Scienza Hospital and University, Torino, Italy.",
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.",
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.",
            "Department of Hematology, IRCCS San Martino Hospital and University, Genova, Italy.",
            "Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.",
            "Division of Medical Oncology A, National Cancer Institute, Aviano, Italy.",
            "Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "06",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "Outcomes of allogeneic stem cell transplantation for DLBCL: a multi-center study from the Kyoto Stem Cell Transplantation Group.",
        "AuthorList": [
            "Kiyotaka Izumi",
            "Junya Kanda",
            "Momoko Nishikori",
            "Yasuyuki Arai",
            "Takayuki Ishikawa",
            "Satoshi Yoshioka",
            "Yasunori Ueda",
            "Takeshi Maeda"
        ],
        "AffiliationList": [
            "Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.",
            "Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. jkanda16@kuhp.kyoto-u.ac.jp.",
            "Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.",
            "Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.",
            "Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.",
            "Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.",
            "Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan.",
            "Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "11",
                "Day": "12"
            }
        ]
    },
    {
        "ArticleTitle": "<sup>18</sup>F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients.",
        "AuthorList": [
            "Sylvain Chantepie",
            "Narinée Hovhannisyan",
            "Stéphane Guillouet",
            "Jean-Pierre Pelage",
            "Méziane Ibazizene",
            "Caroline Bodet-Milin",
            "Thomas Carlier",
            "Anne-Claire Gac"
        ],
        "AffiliationList": [
            "Hematology Institute, CHU de Caen, Caen, France.",
            "CEA, CNRS, ISTCT/LDM-TEP Group, GIP Cyceron, Université de Caen Normandie, Caen, France.",
            "CEA, CNRS, ISTCT/LDM-TEP Group, GIP Cyceron, Université de Caen Normandie, Caen, France.",
            "Department of Radiology CHU de Caen, Caen, France.",
            "CEA, CNRS, ISTCT/LDM-TEP Group, GIP Cyceron, Université de Caen Normandie, Caen, France.",
            "Department of Nuclear Medicine, CHU de Nantes, Nantes, France.",
            "Department of Nuclear Medicine, CHU de Nantes, Nantes, France.",
            "Hematology Institute, CHU de Caen, Caen, France."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "02",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study.",
        "AuthorList": [
            "Chava Perry",
            "Sharon Ben Barouch",
            "Neta Goldschmidt",
            "Nadav Sarid",
            "Yair Herishanu",
            "Lev Shvidel",
            "Osnat Bairey",
            "Noa Lavi"
        ],
        "AffiliationList": [
            "Sourasky Medical Center, Institute of Hematology, Tel-Aviv, Israel.",
            "Sourasky Medical Center, Institute of Hematology, Tel-Aviv, Israel.",
            "Department of Hematology, Hadassah Medical Center, Jerusalem, Israel.",
            "Sourasky Medical Center, Institute of Hematology, Tel-Aviv, Israel.",
            "Sourasky Medical Center, Institute of Hematology, Tel-Aviv, Israel.",
            "Department of Hematology, Kaplan Medical Centre, Rehovot, Israel.",
            "Davidoff Cancer Center, Rabin Medical Center, Institute of Hematology, Petah-Tikva, Israel.",
            "Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "06",
                "Day": "18"
            }
        ]
    },
    {
        "ArticleTitle": "Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.",
        "AuthorList": [
            "James Godfrey",
            "Matthew Mei",
            "Lu Chen",
            "Joo Y Song",
            "Victoria Bedell",
            "Elizabeth Budde",
            "Saro Armenian",
            "Sandrine Puverel"
        ],
        "AffiliationList": [
            "Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.",
            "Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.",
            "Department of Information Sciences, City of Hope, Duarte, CA.",
            "Department of Pathology, City of Hope, Duarte, CA.",
            "Department of Pathology, City of Hope, Duarte, CA.",
            "Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.",
            "Department of Pediatrics, City of Hope, Duarte, CA.",
            "Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA."
        ],
        "Years": [
            {
                "Year": "2024",
                "Month": "02",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.",
        "AuthorList": [
            "Craig S Sauter",
            "Matthew J Matasar",
            "Heiko Schoder",
            "Sean M Devlin",
            "Pamela Drullinsky",
            "John Gerecitano",
            "Anita Kumar",
            "Ariela Noy"
        ],
        "AffiliationList": [
            "Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY.",
            "Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY.",
            "Molecular Imaging and Therapy Service, Department of Radiology, and.",
            "Department of Epidemiology and Biostatistics, MSKCC, New York, NY.",
            "Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY.",
            "Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY.",
            "Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY.",
            "Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "01",
                "Day": "31"
            }
        ]
    },
    {
        "ArticleTitle": "MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.",
        "AuthorList": [
            "Christiane Copie-Bergman",
            "Peggy Cuillière-Dartigues",
            "Maryse Baia",
            "Josette Briere",
            "Richard Delarue",
            "Danielle Canioni",
            "Gilles Salles",
            "Marie Parrens"
        ],
        "AffiliationList": [
            "Assistance Publique-Hôpitaux de Paris, Groupe Henri Mondor-Albert Chenevier, Département de Pathologie, Creteil, France; Universite Paris-Est, Faculté de Médecine, Unité Mixte de Recherche Scientifique 955, Créteil, France; INSERM, Unité 955, Creteil, France;",
            "Institut Gustave Roussy, Villejuif, France;",
            "INSERM, Unité 955, Creteil, France;",
            "Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Department of Pathology, Institut Universitaire d'Hématologie, Paris, France;",
            "Assistance Publique-Hôpitaux de Paris, Hôpital Necker, Department of Hematology, Paris, France;",
            "Assistance Publique-Hôpitaux de Paris, Hôpital Necker, Department of Pathology, Université Paris Descartes, Paris, France;",
            "Hospices Civils de Lyon, Université Claude Bernard Lyon-1, Service d'Hématologie, Unité Mixte de Recherche 5239, Centre National de la Recherche Scientifique, Lyon, France;",
            "Centre Hospitalier Universitaire Bordeaux, Université de Bordeaux, EA2406, Bordeaux, France;"
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "09",
                "Day": "15"
            }
        ]
    },
    {
        "ArticleTitle": "Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials.",
        "AuthorList": [
            "Inna Y Gong",
            "Mahmood Aminilari",
            "Ivan Landego",
            "Katrina Hueniken",
            "Qianghua Zhou",
            "John Kuruvilla",
            "David C Hodgson"
        ],
        "AffiliationList": [
            "Department of Radiation Medicine, University of Toronto, Toronto, Ontario, Canada.",
            "Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",
            "Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",
            "Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",
            "Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.",
            "Department of Radiation Medicine, University of Toronto, Toronto, Ontario, Canada.",
            "Department of Radiation Medicine, University of Toronto, Toronto, Ontario, Canada."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "08",
                "Day": "07"
            }
        ]
    },
    {
        "ArticleTitle": "Nebivolol versus placebo in patients undergoing anthracyclines (CONTROL Trial): rationale and study design.",
        "AuthorList": [
            "Francesco Cannata",
            "Giulio Stefanini",
            "Carmelo Carlo-Stella",
            "Mauro Chiarito",
            "Stefano Figliozzi",
            "Laura Novelli",
            "Costanza Lisi",
            "Sara Bombace"
        ],
        "AffiliationList": [
            "Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan.",
            "Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan.",
            "Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan.",
            "Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan.",
            "Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan.",
            "Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan.",
            "Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan.",
            "Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.",
        "AuthorList": [
            "Toby A Eyre",
            "Catherine Hildyard",
            "Angela Hamblin",
            "Ayesha S Ali",
            "Aimee Houlton",
            "Louise Hopkins",
            "Daniel Royston",
            "Kim M Linton"
        ],
        "AffiliationList": [
            "Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK.",
            "Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK.",
            "Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK.",
            "Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.",
            "Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.",
            "Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.",
            "Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.",
            "Department of Medical Oncology, The Christie Hospital NHS Trust, Manchester, UK."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "09",
                "Day": "09"
            }
        ]
    },
    {
        "ArticleTitle": "Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis.",
        "AuthorList": [
            "Kelu Hou",
            "Zhiying Yu",
            "Yueping Jia",
            "Huihui Fang",
            "Shuai Shao",
            "Lin Huang",
            "Yufei Feng"
        ],
        "AffiliationList": [
            "Department of Pharmacy, Peking University People's Hospital, Beijing, 100044, China.",
            "Department of Pharmacy, Peking University People's Hospital, Beijing, 100044, China.",
            "Department of Pediatric, Peking University People's Hospital, Beijing, 100044, China.",
            "Department of Pharmacy, Huainan First People's Hospital, The First Affiliated Hospital of Anhui University of Science and Technology, Huainan, 232001, China.",
            "Department of Pharmacy, Affiliated Hospital of Beihua University, Jilin, 132011, China.",
            "Department of Pharmacy, Peking University People's Hospital, Beijing, 100044, China. Electronic address: huanglin@pkuph.edu.cn.",
            "Department of Pharmacy, Peking University People's Hospital, Beijing, 100044, China. Electronic address: fenyufei@126.com."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "05",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India.",
        "AuthorList": [
            "Ankit Patel",
            "Niraj Bhatt",
            "S S Prakash",
            "Ghanashyam Biswas",
            "Rajnish Nagarkar",
            "Bodhisatta Roy",
            "Priyanka Samal",
            "Narendra Agrawal"
        ],
        "AffiliationList": [
            "Unique Hospital Multispecialty & Research Institute, Surat, India.",
            "Kailash Cancer Hospital and Research Center, Vadodara, India.",
            "MMC and RI, K R Hospital, Mysore, India.",
            "Sparsh Hospital & Critical Care (P) Ltd, Bhubaneswar, India.",
            "HCG Manavata Cancer Centre, Nashik, Maharashtra, India.",
            "Netaji Subhash Chandra Bose Cancer Hospital, Kolkata, West Bengal, India.",
            "Institute of Medical Sciences (IMS) and SUM Hospital, Bhubaneswar, Odisha, India.",
            "Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "04",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "Rituximab-PECC induction followed by <sup>90</sup> Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study.",
        "AuthorList": [
            "Pieternella J Lugtenburg",
            "Josee M Zijlstra",
            "Jeanette K Doorduijn",
            "Lara H Böhmer",
            "Mels Hoogendoorn",
            "Henriette W Berenschot",
            "Aart Beeker",
            "Nicole C van der Burg-de Graauw"
        ],
        "AffiliationList": [
            "Department of Haematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.",
            "Department of Haematology, Amsterdam University Medical Centre VUmc, Amsterdam, The Netherlands.",
            "Department of Haematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.",
            "Department of Haematology, Haga Teaching Hospital, The Hague, The Netherlands.",
            "Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.",
            "Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.",
            "Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, The Netherlands.",
            "Department of Internal Medicine, Bravis Hospital, Roosendaal, The Netherlands."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "07",
                "Day": "10"
            }
        ]
    },
    {
        "ArticleTitle": "Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Anas Younes",
            "John M Burke",
            "Bruce D Cheson",
            "Catherine S Diefenbach",
            "Silvia Ferrari",
            "Uwe H Hahn",
            "Eliza A Hawkes",
            "Cyrus Khan"
        ],
        "AffiliationList": [
            "Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.",
            "Rocky Mountain Cancer Centers & US Oncology, Aurora, CO.",
            "Georgetown University Hospital, Washington, DC.",
            "Clinical Lymphoma Program, Perlmutter Cancer Center at NYU Langone Health, New York, NY.",
            "Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.",
            "Department of Hematology, Royal Adelaide and Queen Elizabeth Hospital, Adelaide, SA, Australia.",
            "Department of Hematology, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, VIC, Australia.",
            "Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Meta-Analysis of MS-Based Proteomics Studies Indicates Interferon Regulatory Factor 4 and Nucleobindin1 as Potential Prognostic and Drug Resistance Biomarkers in Diffuse Large B Cell Lymphoma.",
        "AuthorList": [
            "Mostafa Ejtehadifar",
            "Sara Zahedi",
            "Paula Gameiro",
            "José Cabeçadas",
            "Maria Gomes da Silva",
            "Hans C Beck",
            "Ana Sofia Carvalho",
            "Rune Matthiesen"
        ],
        "AffiliationList": [
            "Computational and Experimental Biology Group, iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NMS|FCM, Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal.",
            "Computational and Experimental Biology Group, iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NMS|FCM, Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal.",
            "Departament of Hematology, Instituto Português de Oncologia, 1099-023 Lisbon, Portugal.",
            "Departament of Hematology, Instituto Português de Oncologia, 1099-023 Lisbon, Portugal.",
            "Departament of Hematology, Instituto Português de Oncologia, 1099-023 Lisbon, Portugal.",
            "Centre for Clinical Proteomics, Department of Clinical Biochemistry, Odense University Hospital, DK-5000 Odense, Denmark.",
            "Computational and Experimental Biology Group, iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NMS|FCM, Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal.",
            "Computational and Experimental Biology Group, iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NMS|FCM, Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "01",
                "Day": "03"
            }
        ]
    },
    {
        "ArticleTitle": "University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.",
        "AuthorList": [
            "Natalie Galanina",
            "Sonali M Smith",
            "Chuanhong Liao",
            "Adam Petrich",
            "Bernadette Libao",
            "Ronald Gartenhaus",
            "Jason R Westin",
            "Kenneth S Cohen"
        ],
        "AffiliationList": [
            "Department of Hematology/Oncology, University of California San Diego, Moores Cancer Center, San Diego, CA, USA.",
            "Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.",
            "Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.",
            "Division of Hematology/Oncology Northwestern University, Chicago, IL, USA.",
            "Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.",
            "Department of Hematology/Oncology, University of Maryland, Baltimore, MD, USA.",
            "MD Anderson Cancer Center, Houston, TX, USA.",
            "Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "04",
                "Day": "17"
            }
        ]
    },
    {
        "ArticleTitle": "Suboptimal dosing of rituximab in male and female patients with DLBCL.",
        "AuthorList": [
            "Michael Pfreundschuh",
            "Carsten Müller",
            "Samira Zeynalova",
            "Evelyn Kuhnt",
            "Martin H J Wiesen",
            "Gerhard Held",
            "Tanja Rixecker",
            "Viola Poeschel"
        ],
        "AffiliationList": [
            "Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg, Germany;",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "12",
                "Day": "02"
            }
        ]
    },
    {
        "ArticleTitle": "Managing early failures with R-CHOP in patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Vincent Camus",
            "Hervé Tilly"
        ],
        "AffiliationList": [
            "a Department of Hematology, Centre Henri Becquerel , Université de Rouen, IRIB , Rouen , France.",
            "a Department of Hematology, Centre Henri Becquerel , Université de Rouen, IRIB , Rouen , France."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "11",
                "Day": "16"
            }
        ]
    },
    {
        "ArticleTitle": "Influence of Statins on the Survival Outcomes of Patients with Diffuse Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.",
        "AuthorList": [
            "Yanbing Li",
            "Huijie Zhou",
            "Liqun Zou"
        ],
        "AffiliationList": [
            "Department of Medical Oncology of Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.",
            "Department of Medical Oncology of Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.",
            "Department of Medical Oncology of Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "07",
                "Day": "30"
            }
        ]
    },
    {
        "ArticleTitle": "Efficacy of Helicobater pylori eradication in patients with diffuse large B-cell lymphoma of the stomach: A systematic review.",
        "AuthorList": [
            "Vincenzo De Francesco",
            "Raffaele Manta",
            "Riccardo Marmo",
            "Clelia Marmo",
            "Angela Rago",
            "Giulio Antonelli",
            "Cesare Hassan",
            "Angelo Zullo"
        ],
        "AffiliationList": [
            "Gastroenterology Unit, 'Riuniti' Hospital, Foggia, Italy.",
            "Gastroenterology and Digestive Endoscopy, 'Generale' Hospital, Perugia, Italy.",
            "Division of Gastroenterology, 'Curto' Hospital, Polla, Italy.",
            "Division of Gastroenterology, 'Curto' Hospital, Polla, Italy.",
            "Haematolgy Unit, 'Santo Spirito' Hospital, Rome, Italy.",
            "Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, 'Sapienza' University of Rome, Rome, Italy.",
            "Division of Gastroenterology and Digestive Endoscopy, Humanitas Research Hospital - IRCCS, Milan, Italy.",
            "Gastroenterology and Digestive Endoscopy, 'Nuovo Regina Margherita' Hospital, Rome, Italy."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "10",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "Outcomes after (90) Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis.",
        "AuthorList": [
            "Sophie Auger-Quittet",
            "Yohan Duny",
            "Jean-Pierre Daures",
            "Philipe Quittet"
        ],
        "AffiliationList": [
            "Department of Internal Medicine, Mutualist Clinic Beausoleil, Montpellier, France.",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "04",
                "Day": "16"
            }
        ]
    },
    {
        "ArticleTitle": "Comparison of first-line treatments for elderly patients with diffuse large B-cell lymphoma: A systematic review and network meta-analysis.",
        "AuthorList": [
            "Yangyang Wang",
            "Xiyang Ren",
            "Keke Huang",
            "Xue Liang",
            "Lianfang Pu",
            "Linhui Hu",
            "Zhimin Zhai"
        ],
        "AffiliationList": [
            "Department of Hematology/Hematological Lab, The Second Hospital of Anhui Medical University, Hefei, Anhui, China.",
            "Department of Hematology/Hematological Lab, The Second Hospital of Anhui Medical University, Hefei, Anhui, China.",
            "Department of Hematology/Hematological Lab, The Second Hospital of Anhui Medical University, Hefei, Anhui, China.",
            "Department of Hematology/Hematological Lab, The Second Hospital of Anhui Medical University, Hefei, Anhui, China.",
            "Department of Hematology/Hematological Lab, The Second Hospital of Anhui Medical University, Hefei, Anhui, China.",
            "Department of Hematology/Hematological Lab, The Second Hospital of Anhui Medical University, Hefei, Anhui, China.",
            "Department of Hematology/Hematological Lab, The Second Hospital of Anhui Medical University, Hefei, Anhui, China."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "01",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies.",
        "AuthorList": [
            "Kuangguo Zhou",
            "Danmei Xu",
            "Yang Cao",
            "Jue Wang",
            "Yunfan Yang",
            "Mei Huang"
        ],
        "AffiliationList": [
            "Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.",
            "Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.",
            "Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.",
            "Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.",
            "Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.",
            "Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "04",
                "Day": "16"
            }
        ]
    },
    {
        "ArticleTitle": "Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.",
        "AuthorList": [
            "Eric D Jacobsen",
            "Jeff P Sharman",
            "Yasuhiro Oki",
            "Ranjana H Advani",
            "Jane N Winter",
            "Celeste M Bello",
            "Gary Spitzer",
            "Maria Corinna Palanca-Wessels"
        ],
        "AffiliationList": [
            "Dana-Farber Cancer Institute, Boston, MA;",
            "Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR;",
            "University of Texas MD Anderson Cancer Center, Houston, TX;",
            "Stanford University Medical Center, Stanford, CA;",
            "Northwestern University, Chicago, IL;",
            "H. Lee Moffitt Cancer Center, Tampa, FL;",
            "St. Francis Hospital, Upstate Oncology Associates, Greenville, SC;",
            "Seattle Genetics, Inc., Bothell, WA; and."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "01",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Jeffrey P Ward",
            "Melissa M Berrien-Elliott",
            "Felicia Gomez",
            "Jingqin Luo",
            "Michelle Becker-Hapak",
            "Amanda F Cashen",
            "Nina D Wagner-Johnston",
            "Kami Maddocks"
        ],
        "AffiliationList": [
            "Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.",
            "Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.",
            "Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.",
            "Division of Public Health Sciences, Washington University School of Medicine, St. Louis, MO.",
            "Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.",
            "Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.",
            "Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.",
            "Division of Hematology, The Ohio State University, Columbus, OH; and."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study.",
        "AuthorList": [
            "Peng-Peng Xu",
            "Zi-Yang Shi",
            "Ying Qian",
            "Shu Cheng",
            "Yue Zhu",
            "Lu Jiang",
            "Jian-Feng Li",
            "Hai Fang"
        ],
        "AffiliationList": [
            "Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai.",
            "Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai.",
            "Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai.",
            "Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai.",
            "Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai.",
            "Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai.",
            "Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai.",
            "Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.",
        "AuthorList": [
            "Lan-Hsi Lin",
            "Mohammad Ghasemi",
            "Sarah M Burke",
            "Cory K Mavis",
            "Jenna R Nichols",
            "Pallawi Torka",
            "Donald E Mager",
            "Francisco J Hernandez-Ilizaliturri"
        ],
        "AffiliationList": [
            "Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.",
            "Bioanalytics, Metabolomics, and Pharmacokinetics Shared Resource, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.",
            "Bioanalytics, Metabolomics, and Pharmacokinetics Shared Resource, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.",
            "Department of Medicine-Lymphoma, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.",
            "Clinical Research Services, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.",
            "Department of Medicine-Lymphoma, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.",
            "Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.",
            "Department of Medicine-Lymphoma, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "08",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study.",
        "AuthorList": [
            "Kate Manos",
            "Geoffrey Chong",
            "Colm Keane",
            "Sze-Ting Lee",
            "Charmaine Smith",
            "Leonid Churilov",
            "Joseph McKendrick",
            "William Renwick"
        ],
        "AffiliationList": [
            "Olivia Newton John Cancer Research Institute at Austin Health, Heidelberg, VIC, Australia.",
            "Ballarat Regional Integrated Cancer Centre, Ballarat Central, VIC, Australia.",
            "Princess Alexandra Hospital, Woolloongabba, QLD, Australia.",
            "Olivia Newton John Cancer Research Institute at Austin Health, Heidelberg, VIC, Australia.",
            "Olivia Newton John Cancer Research Institute at Austin Health, Heidelberg, VIC, Australia.",
            "Melbourne Medical School, University of Melbourne, Parkville, VIC, Australia.",
            "Eastern Health, Box Hill, VIC, Australia.",
            "Western Health, Footscray, VIC, Australia."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "03",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806.",
        "AuthorList": [
            "Daniel O Persky",
            "Hongli Li",
            "Lisa M Rimsza",
            "Paul M Barr",
            "Leslie L Popplewell",
            "Charles L Bane",
            "Ann Von Gehr",
            "Michael LeBlanc"
        ],
        "AffiliationList": [
            "University of Arizona, Tucson, Arizona.",
            "SWOG Statistical Center, Seattle, Washington.",
            "Mayo Clinic, Scottsdale, Arizona.",
            "University of Rochester, Rochester, New York.",
            "City of Hope, Duarte, California.",
            "Dayton NCORP/Dayton Physicians LLC, Dayton, Ohio.",
            "Kaiser Permanente NCORP/Kaiser Permanente San Jose, San Jose, California.",
            "SWOG Statistical Center, Seattle, Washington."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "01",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.",
        "AuthorList": [
            "Jonathan W Friedberg",
            "Joseph M Unger",
            "W Richard Burack",
            "Ajay K Gopal",
            "Robert N Raju",
            "Auayporn P Nademanee",
            "Mark S Kaminski",
            "Hongli Li"
        ],
        "AffiliationList": [
            "James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "04",
                "Day": "18"
            }
        ]
    },
    {
        "ArticleTitle": "Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.",
        "AuthorList": [
            "A Martín García-Sancho",
            "M Baile",
            "G Rodríguez",
            "I Dlouhy",
            "J M Sancho",
            "I Jarque",
            "E González-Barca",
            "A Salar"
        ],
        "AffiliationList": [
            "Hematology Department, Hospital Universitario de Salamanca-IBSAL, CIBERONC, Universidad de Salamanca, Salamanca, Spain.",
            "Hematology Department, Hospital Universitario de Salamanca-IBSAL, CIBERONC, Universidad de Salamanca, Salamanca, Spain.",
            "Hematology Department, Hospital Universitario Virgen del Rocío/Virgen Macarena, Sevilla, Spain.",
            "Hematology Department, Hospital Clinic, Barcelona, Spain.",
            "Hematology Department, Hospital Germans Trias i Pujol/ICO-IJC, Badalona, Spain.",
            "Hematology Department, Hospital Universitari i Plotècnic La Fe, CIBERONC, Valencia, Spain.",
            "Institut Català d'Oncologia-Hospitalet, IDIBELL, Universitat de-Barcelona, Barcelona, Spain.",
            "Hematology Department, Hospital del Mar, Barcelona, Spain."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "07",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.",
        "AuthorList": [
            "Patrick R Hagner",
            "Hon-Wah Man",
            "Celia Fontanillo",
            "Maria Wang",
            "Suzana Couto",
            "Mike Breider",
            "Chad Bjorklund",
            "Courtney G Havens"
        ],
        "AffiliationList": [
            "Celgene Corporation, Summit, NJ;",
            "Celgene Corporation, Summit, NJ;",
            "Celgene Corporation, Sevilla, Spain;",
            "Celgene Corporation, San Diego, CA; and.",
            "Celgene Corporation, San Diego, CA; and.",
            "Celgene Corporation, San Diego, CA; and.",
            "Celgene Corporation, Summit, NJ;",
            "Celgene Corporation, San Diego, CA; and."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "05",
                "Day": "22"
            }
        ]
    },
    {
        "ArticleTitle": "A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.",
        "AuthorList": [
            "Sven de Vos",
            "Andres Forero-Torres",
            "Stephen M Ansell",
            "Brad Kahl",
            "Bruce D Cheson",
            "Nancy L Bartlett",
            "Richard R Furman",
            "Jane N Winter"
        ],
        "AffiliationList": [
            "David Geffen School of Medicine at UCLA, University of California Los Angeles, 650 Charles E, Young Drive 11-934 Factor Bldg, Los Angeles, CA 90095-1678, USA. deVos@mednet.ucla.edu.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "06",
                "Day": "12"
            }
        ]
    },
    {
        "ArticleTitle": "The Role of Consolidative Radiotherapy after a Complete Response to Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma in the Rituximab Era: Results from a Systematic Review with a Meta-Analysis.",
        "AuthorList": [
            "Chunhong Hu",
            "Chao Deng",
            "Wen Zou",
            "Guangsen Zhang",
            "Jingjing Wang"
        ],
        "AffiliationList": [
            "Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, PR China.",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "04",
                "Day": "22"
            }
        ]
    },
    {
        "ArticleTitle": "Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies.",
        "AuthorList": [
            "Rui Zhu",
            "Dan Lu",
            "Yu-Waye Chu",
            "Akiko Chai",
            "Michelle Green",
            "Nancy Zhang",
            "Jin Yan Jin"
        ],
        "AffiliationList": [
            "Department of Clinical Pharmacology, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA. zhu.rui@gene.com.",
            "Department of Clinical Pharmacology, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.",
            "Department of Clinical Science Oncology, Genentech, South San Francisco, California, USA.",
            "Department of Biostatistics, Genentech, South San Francisco, California, USA.",
            "Quantitative Solutions, Menlo Park, California, USA.",
            "Quantitative Solutions, Menlo Park, California, USA.",
            "Department of Clinical Pharmacology, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "02",
                "Day": "21"
            }
        ]
    },
    {
        "ArticleTitle": "A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma.",
        "AuthorList": [
            "Carmelo Carlo-Stella",
            "Pier Luigi Zinzani",
            "Anna Sureda",
            "Luis Araújo",
            "Olivier Casasnovas",
            "Cecilia Carpio",
            "Su-Peng Yeh",
            "Krimo Bouabdallah"
        ],
        "AffiliationList": [
            "Department of Biomedical Sciences, Humanitas University and Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Milano, Italy.",
            "IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia \"Seràgnoli\" and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy.",
            "Institut Català D'Oncologia - Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, Barcelona, Spain.",
            "Universitário de Coimbra, Coimbra, Portugal.",
            "Hématologie Clinique, CHU Dijon Bourgogne, Dijon, France.",
            "Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain.",
            "China Medical University Hospital, Taichung, Taiwan.",
            "Hematology and Cellular Therapy Department, University Hospital of Bordeaux, Bordeaux, France."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "10",
                "Day": "31"
            }
        ]
    },
    {
        "ArticleTitle": "Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.",
        "AuthorList": [
            "Fritz Offner",
            "Olga Samoilova",
            "Evgenii Osmanov",
            "Hyeon-Seok Eom",
            "Max S Topp",
            "João Raposo",
            "Viacheslav Pavlov",
            "Deborah Ricci"
        ],
        "AffiliationList": [
            "Department of Hematology, University Hospital Ghent, Ghent, Belgium;",
            "Nizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, Russian Federation;",
            "N.N. Blokhin Cancer Research Center, Russian Academy of National Sciences, Moscow, Russian Federation;",
            "National Cancer Center, Goyang Gyeonggi, Republic of Korea;",
            "Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany;",
            "Servicio de Hematologia, Santa Maria Hospital, Lisbon, Portugal;",
            "Medical Scientific Radiology Center, Obninsk, Russian Federation;",
            "Janssen Research & Development, LLC, Raritan, NJ;"
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "07",
                "Day": "31"
            }
        ]
    },
    {
        "ArticleTitle": "Clinicopathological features of HCV-positive splenic diffuse large B cell lymphoma.",
        "AuthorList": [
            "Joji Shimono",
            "Hiroaki Miyoshi",
            "Fumiko Arakawa",
            "Kyohei Yamada",
            "Takeshi Sugio",
            "Kohta Miyawaki",
            "Tetsuya Eto",
            "Takuto Miyagishima"
        ],
        "AffiliationList": [
            "Department of Pathology, Kurume University, School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan.",
            "Department of Pathology, Kurume University, School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan. miyoshi_hiroaki@med.kurume-u.ac.jp.",
            "Department of Pathology, Kurume University, School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan.",
            "Department of Pathology, Kurume University, School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan.",
            "Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.",
            "Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.",
            "Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.",
            "Department of Hematology, Kushiro Rosai Hospital, Kushiro, Japan."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "02",
                "Day": "07"
            }
        ]
    },
    {
        "ArticleTitle": "A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).",
        "AuthorList": [
            "Ian W Flinn",
            "Nancy L Bartlett",
            "Kristie A Blum",
            "Kirit M Ardeshna",
            "Ann S LaCasce",
            "Christopher R Flowers",
            "Andrei R Shustov",
            "Kenneth S Thress"
        ],
        "AffiliationList": [
            "Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA. Electronic address: iflinn@tnonc.com.",
            "Siteman Cancer Center/Washington University School of Medicine, St. Louis, MO, USA.",
            "The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.",
            "Sarah Cannon Research Institute United Kingdom/University College London, London, UK.",
            "Dana-Farber Cancer Institute, Boston, MA, USA.",
            "Winship Cancer Institute, Atlanta, GA, USA.",
            "Seattle Cancer Care Alliance/University of Washington, Seattle, WA, USA.",
            "AstraZeneca, Waltham, MA, USA."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "12",
                "Day": "18"
            }
        ]
    },
    {
        "ArticleTitle": "Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study.",
        "AuthorList": [
            "Yu Ri Kim",
            "Jin Seok Kim",
            "Won Seog Kim",
            "Hyeon Seok Eom",
            "Deok-Hwan Yang",
            "Sung Hwa Bae",
            "Hyo Jung Kim",
            "Jae Hoon Lee"
        ],
        "AffiliationList": [
            "Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.",
            "Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.",
            "Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.",
            "Hematology-Oncology Clinic, National Cancer Center, Goyang, Korea.",
            "Department of Hematology/Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.",
            "Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu, Korea.",
            "Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea.",
            "Departments of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "03",
                "Day": "30"
            }
        ]
    },
    {
        "ArticleTitle": "Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using <sup>90</sup>Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma.",
        "AuthorList": [
            "Matthew Mei",
            "Joycelynne Palmer",
            "Nicole Ni-Chun Tsai",
            "Jennifer Simpson",
            "James O'Hearn",
            "Anthony Stein",
            "Stephen Forman",
            "Ricardo Spielberger"
        ],
        "AffiliationList": [
            "Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA. Electronic address: mamei@coh.org.",
            "Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA.",
            "Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA.",
            "Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.",
            "Department of Clinical and Translational Project Development, City of Hope National Medical Center, Duarte, CA.",
            "Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.",
            "Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.",
            "Department of Bone Marrow Transplantation, Southern California Permanente Medical Group, Los Angeles, CA."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "05",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report.",
        "AuthorList": [
            "Mira Tout",
            "Olivier Casasnovas",
            "Michel Meignan",
            "Thierry Lamy",
            "Franck Morschhauser",
            "Gilles Salles",
            "Emmanuel Gyan",
            "Corinne Haioun"
        ],
        "AffiliationList": [
            "Université François-Rabelais de Tours, National Center for Scientific Research (CNRS), Genetics, Immunotherapy, Chemistry, and Cancer (GICC), UMR 7292, Tours, France.",
            "Department of Clinical Hematology, Centre Hospitalier Universitaire (CHU) Dijon, INSERM Lipids, Nutrition, Cancer (LNC) UMR 866, Dijon, France.",
            "Lymphoma Study Association (LYSA) Imaging, Henri Mondor University Hospital, Créteil, France.",
            "Department of Clinical Hematology, CHU Rennes, U917, Rennes 1 University, Rennes, France.",
            "Department of Clinical Hematology, CHU Lille, Groupe de Recherches sur les formes Injectables et les Technologies Associées (GRITA), Université de Lille 2, Lille, France.",
            "Department of Hematology, Hospices Civils de Lyon, Université Claude Bernard Lyon-1, France.",
            "Department of Hematology and Cell Therapy, Clinical Investigations Center INSERM U1415, CHU Tours, Tours, France.",
            "Lymphoid Malignancies Unit, Henri Mondor University Hospital, Assistance Publique - Hôpitaux de Paris and Universités Paris-Est Créteil (UPEC), Créteil, France."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "03",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Clinical significance of aberrant microRNAs expression in predicting disease relapse/refractoriness to treatment in diffuse large B-cell lymphoma: A meta-analysis.",
        "AuthorList": [
            "Choo-Yuen Ting",
            "Su-May Liew",
            "Amy Price",
            "Gin-Gin Gan",
            "Diana Bee-Lan Ong",
            "Soo-Yong Tan",
            "Ping-Chong Bee"
        ],
        "AffiliationList": [
            "Department of Medicine, Faculty of Medicine, University of Malaya, Malaysia.",
            "Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Malaysia.",
            "University of Oxford, Centre for Evidence Based Medicine, England, United Kingdom.",
            "Department of Medicine, Faculty of Medicine, University of Malaya, Malaysia.",
            "Department of Pathology, Faculty of Medicine, University of Malaya, Malaysia.",
            "Department of Pathology, National University of Singapore, Singapore.",
            "Department of Medicine, Faculty of Medicine, University of Malaya, Malaysia. Electronic address: pcbee@um.edu.my."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "11",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Rituximab treatment strategy for patients with diffuse large B-cell lymphoma after first-line therapy: a systematic review and meta-analysis.",
        "AuthorList": [
            "Yuan-Rong Ren",
            "Yong-Dong Jin",
            "Zhi-Hui Zhang",
            "Li Li",
            "Ping Wu"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Chengdu, Sichuan 610000, China.",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) With Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results From the Pyramid Trial (NCT00931918).",
        "AuthorList": [
            "Yuan-Rong Ren",
            "Yong-Dong Jin",
            "Zhi-Hui Zhang",
            "Li Li",
            "Ping Wu"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Chengdu, Sichuan 610000, China.",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.",
        "AuthorList": [
            "Carsten Müller",
            "Niels Murawski",
            "Martin H J Wiesen",
            "Gerhard Held",
            "Viola Poeschel",
            "Samira Zeynalova",
            "Michael Wenger",
            "Christina Nickenig"
        ],
        "AffiliationList": [
            "Institut für Pharmakologie der Uniklinik, Köln, Germany;",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "02",
                "Day": "15"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis.",
        "AuthorList": [
            "Hugo J A Adams",
            "Thomas C Kwee"
        ],
        "AffiliationList": [
            "Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: h.j.a.adams@gmail.com.",
            "Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "07",
                "Day": "16"
            }
        ]
    },
    {
        "ArticleTitle": "A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.",
        "AuthorList": [
            "Andrew M Evens",
            "Steven T Rosen",
            "Irene Helenowski",
            "Justin Kline",
            "Annette Larsen",
            "Jennifer Colvin",
            "Jane N Winter",
            "Koen M van Besien"
        ],
        "AffiliationList": [
            "Division of Hematology/Oncology, Tufts University School of Medicine, Boston, MA, USA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "08",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.",
        "AuthorList": [
            "C Knight",
            "D Hind",
            "N Brewer",
            "V Abbott"
        ],
        "AffiliationList": [
            "School of Health and Related Research, University of Sheffield, UK.",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial.",
        "AuthorList": [
            "S Luminari",
            "A Montanini",
            "D Caballero",
            "S Bologna",
            "M Notter",
            "M J S Dyer",
            "A Chiappella",
            "J Briones"
        ],
        "AffiliationList": [
            "Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy.",
            "Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy.",
            "Department of Haematology, University Hospital of Salamanca, Salamanca, Spain.",
            "Department of Hematology, Hospital of Brabois, Vandoeuvre les Nancy, Cedex, France.",
            "Department of Medicine III (Hematology and Oncology), Campus Benjamin Franklin, Charité, University of Berlin, Berlin, Germany.",
            "Medical Research Council Toxicology Unit, University of Leicester, Leicester, UK.",
            "Division of Hematology 2, Department of Oncology, San Giovanni Battista Hospital and University, Torino, Italy.",
            "Department of Haematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain."
        ],
        "Years": [
            {
                "Year": "2009",
                "Month": "12",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).",
        "AuthorList": [
            "Nicolas Mounier",
            "Josette Briere",
            "Christian Gisselbrecht",
            "Jean-Francois Emile",
            "Pierre Lederlin",
            "Catherine Sebban",
            "Francoise Berger",
            "Andre Bosly"
        ],
        "AffiliationList": [
            "Service d'Onco-Hématologie, INSERM ERM0220-Hôpital Saint Louis, AP-HP, Paris, France. nicolas.mounier@sls.ap-hop-paris.fr",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2003",
                "Month": "02",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma.",
        "AuthorList": [
            "Cheng Fang",
            "Wei Xu",
            "Jian-Yong Li"
        ],
        "AffiliationList": [
            "Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2010",
                "Month": "05",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "Diffuse large B-cell lymphoma genotyping on the liquid biopsy.",
        "AuthorList": [
            "Davide Rossi",
            "Fary Diop",
            "Elisa Spaccarotella",
            "Sara Monti",
            "Manuela Zanni",
            "Silvia Rasi",
            "Clara Deambrogi",
            "Valeria Spina"
        ],
        "AffiliationList": [
            "Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.",
            "Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.",
            "Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.",
            "Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.",
            "Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.",
            "Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.",
            "Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.",
            "Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "01",
                "Day": "17"
            }
        ]
    },
    {
        "ArticleTitle": "FcγRIIa-H131R variant is associated with inferior response in diffuse large B cell lymphoma: A meta-analysis of genetic risk.",
        "AuthorList": [
            "Panayiotis D Ziakas",
            "Loukia S Poulou",
            "Elias Zintzaras"
        ],
        "AffiliationList": [
            "Warren Alpert Medical School of Brown University, Providence RI, USA.",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma: a meta-analysis.",
        "AuthorList": [
            "Jianhua Feng",
            "Zhujun Wang",
            "Xiaoping Guo",
            "Yuanyuan Chen",
            "Yuping Cheng",
            "Yongmin Tang"
        ],
        "AffiliationList": [
            "Division of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People's Republic of China.",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "12",
                "Day": "29"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis.",
        "AuthorList": [
            "Hugo J A Adams",
            "Rutger A J Nievelstein",
            "Thomas C Kwee"
        ],
        "AffiliationList": [
            "Department of Radiology and Nuclear Medicine, University Medical Centre Utrecht, Utrecht, the Netherlands.",
            "Department of Radiology and Nuclear Medicine, University Medical Centre Utrecht, Utrecht, the Netherlands.",
            "Department of Radiology and Nuclear Medicine, University Medical Centre Utrecht, Utrecht, the Netherlands."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "04",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.",
        "AuthorList": [
            "Yi-An Zhang",
            "Xue Yang",
            "Jiamei Yao",
            "Yuhong Ren",
            "Peng Liu"
        ],
        "AffiliationList": [
            "Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.",
            "Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.",
            "Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.",
            "Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.",
            "Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "06",
                "Day": "21"
            }
        ]
    },
    {
        "ArticleTitle": "Association of Interleukin-10 -3575T>A and -1082A>G polymorphisms with non-Hodgkin lymphoma susceptibility: a comprehensive review and meta-analysis.",
        "AuthorList": [
            "Yan Zhang",
            "Zu-Guang Xia",
            "Jin-Hong Zhu",
            "Min-Bin Chen",
            "Tong-Min Wang",
            "Wen-Xiang Shen",
            "Jing He"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, 215300, Jiangsu, China.",
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.",
            "Molecular Epidemiology Laboratory and Laboratory Medicine, Harbin Medical University Cancer Hospital, Harbin, 150040, Heilongjiang, China.",
            "Department of Medical Oncology, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, 215300, Jiangsu, China.",
            "State Key Laboratory of Oncology in South China, Department of Experimental Research, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, China.",
            "Department of Medical Oncology, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, 215300, Jiangsu, China. xnhongsci@126.com.",
            "Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, Guangdong, China. hejing198374@gmail.com."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "05",
                "Day": "15"
            }
        ]
    },
    {
        "ArticleTitle": "[Diffuse large B-cell lymphoma with monoclonal immunoglobulin secretion].",
        "AuthorList": [
            "O A Gavrilina",
            "E N Parovichnikova",
            "E E Zvonkov",
            "V V Troitskaya",
            "S K Kravchenko",
            "V G Savchenko"
        ],
        "AffiliationList": [
            "National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia.",
            "National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia.",
            "National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia.",
            "National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia.",
            "National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia.",
            "National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL.",
        "AuthorList": [
            "Craig H Moskowitz",
            "Andrew D Zelenetz",
            "Tarun Kewalramani",
            "Paul Hamlin",
            "Simone Lessac-Chenen",
            "Jane Houldsworth",
            "Adam Olshen",
            "Raju Chaganti"
        ],
        "AffiliationList": [
            "Lymphoma and Hematology Services of the Division of Hematological Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. moskowic@mskcc.org",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2005",
                "Month": "08",
                "Day": "09"
            }
        ]
    },
    {
        "ArticleTitle": "Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma.",
        "AuthorList": [
            "Xiaoshuang Kong",
            "Xudong Zhang",
            "Mengjie Ding",
            "Xiaoyan Feng",
            "Meng Dong",
            "Lei Zhang",
            "Xiaorui Fu",
            "Ling Li"
        ],
        "AffiliationList": [
            "Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.",
            "Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.",
            "Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.",
            "Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.",
            "Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.",
            "Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.",
            "Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.",
            "Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "01",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "The predictive value of interim and final [18F] fluorodeoxyglucose positron emission tomography after rituximab-chemotherapy in the treatment of non-Hodgkin's lymphoma: a meta-analysis.",
        "AuthorList": [
            "Yuyuan Zhu",
            "Jianda Lu",
            "Xin Wei",
            "Shaoli Song",
            "Gang Huang"
        ],
        "AffiliationList": [
            "Department of Nuclear Medicine, Renji Hospital, Jiaotong University, Shanghai 200127, China ; Department of Nuclear Medicine, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China.",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "08",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "Genetic polymorphisms in the DNA repair gene, XRCC1 associate with non-Hodgkin lymphoma susceptibility: A systematic review and meta-analysis.",
        "AuthorList": [
            "Yuying Li",
            "Ou Bai",
            "Jiuwei Cui",
            "Wei Li"
        ],
        "AffiliationList": [
            "Cancer Center, First Hospital of Jilin University, Changchun, China.",
            "Cancer Center, First Hospital of Jilin University, Changchun, China.",
            "Cancer Center, First Hospital of Jilin University, Changchun, China.",
            "Cancer Center, First Hospital of Jilin University, Changchun, China. Electronic address: 294251999@qq.com."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "12",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "Low-dose radiotherapy in diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Carlo Furlan",
            "Vincenzo Canzonieri",
            "Michele Spina",
            "Mariagrazia Michieli",
            "Anna Ermacora",
            "Roberta Maestro",
            "Sara Piccinin",
            "Riccardo Bomben"
        ],
        "AffiliationList": [
            "Department of Radiation Oncology, Centro di Riferimento Oncologico (CRO), National Cancer Institute, Aviano, Italy.",
            "Division of Pathology, Centro di Riferimento Oncologico (CRO), National Cancer Institute, Aviano, Italy.",
            "Division of Medical Oncology A, Centro di Riferimento Oncologico (CRO), National Cancer Institute, Aviano, Italy.",
            "Unit of Cell Therapy and High Dose Chemotherapy, Centro di Riferimento Oncologico (CRO), National Cancer Institute, Aviano, Italy.",
            "Second Division of Medicine, Azienda Ospedaliera Santa Maria degli Angeli, Pordenone, Italy.",
            "Experimental Oncology 1, Centro di Riferimento Oncologico (CRO), National Cancer Institute, Aviano, Italy.",
            "Experimental Oncology 1, Centro di Riferimento Oncologico (CRO), National Cancer Institute, Aviano, Italy.",
            "Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico (CRO), National Cancer Institute, Aviano, Italy."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "10",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis.",
        "AuthorList": [
            "Hugo J A Adams",
            "Thomas C Kwee",
            "Bart de Keizer",
            "Rob Fijnheer",
            "John M H de Klerk",
            "Rutger A J Nievelstein"
        ],
        "AffiliationList": [
            "Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "11",
                "Day": "27"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic value of red blood cell distribution width and D-Dimer in diffuse large B-cell lymphoma: Systematic review and meta-analysis.",
        "AuthorList": [
            "Maryam Rahchamani",
            "Mohammad Sedghi",
            "Ali Hakimi",
            "Mahdi Nejatianfar",
            "Tohid Javaheri",
            "Reza Tavakoli",
            "Ramtin Ahmadi",
            "Mansoureh Makarem"
        ],
        "AffiliationList": [
            "Department of Internal Medicine, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.",
            "Molecular and Cellular Biology, Department of Biology, Yadegar-e-Imam Khomeini (RAH) Shahr-e-Ray Branch, Islamic Azad University, Tehran, Iran.",
            "Department of Clinical Biochemistry, Mashhad University of Medical Sciences, Mashhad, Iran.",
            "Department of Research and Development, Organic Chemistry Hila Pharmaceutical Co, Mashhad, Iran.",
            "Department of Genetics, Young Research and Elites Club, Islamic Azad University, Mashhad Branch, Mashhad, Iran.",
            "Department of Radiology, Arak University of Medical Sciences, Arak, Iran.",
            "Cellular and Molecular, Islamic Azad University of Mashhad, Mashhad, Iran.",
            "Health Vice-Chancellor, Torbat-e Jam Faculty of Medical Sciences, Torbat-e Jam, Iran."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "11",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool.",
        "AuthorList": [
            "Elizabeth A Brem",
            "Hongli Li",
            "Anne W Beaven",
            "Paolo F Caimi",
            "Leandro Cerchietti",
            "Ash A Alizadeh",
            "Rebecca Olin",
            "N Lynn Henry"
        ],
        "AffiliationList": [
            "Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA, USA. Electronic address: ebrem@hs.uci.edu.",
            "SWOG Statistics and Data Management Center, Seattle, WA, USA; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.",
            "Lineberger Comprehensive Cancer Center University of North Carolina, Chapel Hill, NC, USA.",
            "Cleveland Clinic, Cleveland, OH, USA.",
            "Weill Cornell Medicine, New York, NY, USA.",
            "Stanford University Medical Center, Stanford, CA, USA.",
            "Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.",
            "University of Michigan, Ann Arbor, MI, USA."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "10",
                "Day": "20"
            }
        ]
    },
    {
        "ArticleTitle": "Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).",
        "AuthorList": [
            "Leo I Gordon",
            "Reem Karmali",
            "Jason B Kaplan",
            "Rakesh Popat",
            "Howard A Burris",
            "Silvia Ferrari",
            "Sumit Madan",
            "Manish R Patel"
        ],
        "AffiliationList": [
            "Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA.",
            "Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA.",
            "Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA.",
            "Department of Haematology, NIHR/UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK.",
            "Drug Development, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN 37203, USA.",
            "Dipartimento di Oncologia ed Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy.",
            "Division of Hematology and Oncology, Cancer Therapy and Research Center at University of Texas Health Science Center, San Antonio, TX 78229, USA.",
            "Drug Development Unit, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL 34232, USA."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "01",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "Circulating immune markers and risks of non-Hodgkin lymphoma subtypes: A pooled analysis.",
        "AuthorList": [
            "Jongeun Rhee",
            "Brenda M Birmann",
            "Anneclaire J De Roos",
            "Mara M Epstein",
            "Otoniel Martinez-Maza",
            "Elizabeth C Breen",
            "Larry I Magpantay",
            "Lynn I Levin"
        ],
        "AffiliationList": [
            "Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.",
            "Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.",
            "Department of Environmental and Occupational Health, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania, USA.",
            "Department of Medicine and the Meyers Health Care Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.",
            "Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, California, USA.",
            "Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.",
            "UCLA AIDS Institute, Los Angeles, California, USA.",
            "Statistics and Epidemiology Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "10",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.",
        "AuthorList": [
            "Changju Qu",
            "Rui Zou",
            "Peng Wang",
            "Qian Zhu",
            "Liqing Kang",
            "Nana Ping",
            "Fan Xia",
            "Hailing Liu"
        ],
        "AffiliationList": [
            "National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.",
            "National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.",
            "National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.",
            "National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.",
            "School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.",
            "National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.",
            "Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, China.",
            "Department of Radiology, People's Hospital of Binhai County, Binhai Cinlical College of Yangzhou University, Yancheng, China."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "08",
                "Day": "17"
            }
        ]
    },
    {
        "ArticleTitle": "Genetic polymorphism and transcriptional regulation of <i>CREBBP</i> gene in patient with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Haifeng Zhao",
            "Yutian Kan",
            "Xinyuan Wang",
            "Leiyuan Chen",
            "Peng Ge",
            "Zhengzi Qian"
        ],
        "AffiliationList": [
            "Department of Hematology and Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin, P.R. China zhaohaifeng457@163.com qianzhengzi123@163.com.",
            "Department of Hematology and Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin, P.R. China.",
            "Department of Hematology and Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin, P.R. China.",
            "Department of Hematology and Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin, P.R. China.",
            "Department of Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin, P.R. China.",
            "Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin, P.R. China zhaohaifeng457@163.com qianzhengzi123@163.com."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "08",
                "Day": "13"
            }
        ]
    },
    {
        "ArticleTitle": "Association between polymorphic sites in thymidylate synthase gene and risk of non-Hodgkin lymphoma: a systematic review and pooled analysis.",
        "AuthorList": [
            "Jue-Yu Zhou",
            "Rong Shi",
            "Hai-Lang Yu",
            "Ye Zeng",
            "Wen-Ling Zheng",
            "Wen-Li Ma"
        ],
        "AffiliationList": [
            "Institute of Genetic Engineering, Southern Medical University, Guangzhou, China.",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "04",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Richard T Maziarz",
            "Jie Zhang",
            "Hongbo Yang",
            "Xinglei Chai",
            "Chengbo Yuan",
            "Elisabeth Schwarz",
            "Mihael Jakovac",
            "Marcela Martinez-Prieto"
        ],
        "AffiliationList": [
            "Knight Cancer Institute, Oregon Health and Science University, Portland, OR.",
            "Novartis Pharmaceuticals, East Hanover, NJ.",
            "Analysis Group, Inc., Boston, MA.",
            "Analysis Group, Inc., Boston, MA.",
            "Analysis Group, Inc., Boston, MA.",
            "Novartis Pharmaceuticals, East Hanover, NJ.",
            "Novartis Pharmaceuticals, East Hanover, NJ.",
            "Novartis Pharmaceuticals, East Hanover, NJ."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.",
        "AuthorList": [
            "Benet Pera",
            "Tiffany Tang",
            "Rossella Marullo",
            "Shao-Ning Yang",
            "Haelee Ahn",
            "Jayeshkumar Patel",
            "Rebecca Elstrom",
            "Jia Ruan"
        ],
        "AffiliationList": [
            "Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10065 USA.",
            "Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10065 USA.",
            "Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10065 USA.",
            "Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10065 USA.",
            "Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10065 USA.",
            "Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10065 USA.",
            "Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10065 USA.",
            "Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10065 USA."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "07",
                "Day": "22"
            }
        ]
    },
    {
        "ArticleTitle": "Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients.",
        "AuthorList": [
            "Jeff Hosry",
            "Roberto N Miranda",
            "Felipe Samaniego",
            "Minas P Economides",
            "Harrys A Torres"
        ],
        "AffiliationList": [
            "Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "11",
                "Day": "03"
            }
        ]
    },
    {
        "ArticleTitle": "Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma.",
        "AuthorList": [
            "L Magnano",
            "O Balagué",
            "I Dlouhy",
            "J Rovira",
            "K Karube",
            "M Pinyol",
            "A Rivas-Delgado",
            "D Costa"
        ],
        "AffiliationList": [
            "Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;; Hematopathology Unit, Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona;; CIBERONC, Barcelona.",
            "CIBERONC, Barcelona;; Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.",
            "Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;; CIBERONC, Barcelona.",
            "Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;; CIBERONC, Barcelona.",
            "Department of Pathology and Cell Biology, Graduate School of Medicine, University of the Ryukyus;; Faculty of Medicine, University of the Ryukyus, Japan.",
            "CIBERONC, Barcelona;; Genomics Unit, IDIBAPS, Barcelona, Spain.",
            "Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;; CIBERONC, Barcelona.",
            "Hematopathology Unit, Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona;; CIBERONC, Barcelona."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Association between statin use & risk of diffuse large B-cell lymphoma: A systematic review & meta-analysis.",
        "AuthorList": [
            "Ben Ponvilawan",
            "Nipith Charoenngam",
            "Patompong Ungprasert"
        ],
        "AffiliationList": [
            "Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.",
            "Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.",
            "Department of Research & Development, Clinical Epidemiology Unit, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "The significance of upfront autologous stem cell transplantation for high-intermediate/high-risk stage IV diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Aleksei K Koviazin",
            "Larisa V Filatova",
            "Ilia S Zyuzgin",
            "Anna S Artemyeva",
            "Ilia L Poliatskin",
            "Darya S Burda",
            "Stanislav A Volchenkov",
            "Svetlana S Elkhova"
        ],
        "AffiliationList": [
            "Department of Hematology and Chemotherapy with Intensive Care Unit, NMRC of Oncology n.a. N.N.Petrov of MoH of Russia, Federal State Budgetary Institution \"Petrov National Medical Cancer Research Centre\" of the Ministry of Health of the Russian Federation, Saint-Petersburg, Russian Federation.",
            "Department of Hematology and Chemotherapy with Intensive Care Unit, NMRC of Oncology n.a. N.N.Petrov of MoH of Russia, Federal State Budgetary Institution \"Petrov National Medical Cancer Research Centre\" of the Ministry of Health of the Russian Federation, Saint-Petersburg, Russian Federation.",
            "Department of Hematology and Chemotherapy with Intensive Care Unit, NMRC of Oncology n.a. N.N.Petrov of MoH of Russia, Federal State Budgetary Institution \"Petrov National Medical Cancer Research Centre\" of the Ministry of Health of the Russian Federation, Saint-Petersburg, Russian Federation.",
            "Laboratory of Tumor Morphology, Federal State Budgetary Institution \"Petrov National Medical Cancer Research Centre\" of the Ministry of Health of the Russian Federation, Saint-Petersburg, Russian Federation.",
            "Laboratory of Tumor Morphology, Federal State Budgetary Institution \"Petrov National Medical Cancer Research Centre\" of the Ministry of Health of the Russian Federation, Saint-Petersburg, Russian Federation.",
            "Laboratory of Tumor Morphology, Federal State Budgetary Institution \"Petrov National Medical Cancer Research Centre\" of the Ministry of Health of the Russian Federation, Saint-Petersburg, Russian Federation.",
            "Department of Hematology and Chemotherapy with Intensive Care Unit, NMRC of Oncology n.a. N.N.Petrov of MoH of Russia, Federal State Budgetary Institution \"Petrov National Medical Cancer Research Centre\" of the Ministry of Health of the Russian Federation, Saint-Petersburg, Russian Federation.",
            "Department of Hematology and Chemotherapy with Intensive Care Unit, NMRC of Oncology n.a. N.N.Petrov of MoH of Russia, Federal State Budgetary Institution \"Petrov National Medical Cancer Research Centre\" of the Ministry of Health of the Russian Federation, Saint-Petersburg, Russian Federation."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "02",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals.",
        "AuthorList": [
            "Annarita Conconi",
            "Emanuele Zucca",
            "Gloria Margiotta-Casaluci",
            "Katharine Darling",
            "Barbara Hasse",
            "Manuel Battegay",
            "Cornelia Staehelin",
            "Urban Novak"
        ],
        "AffiliationList": [
            "Division of Hematology, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy.",
            "IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.",
            "Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont and AOU Maggiore della Carità, Novara, Italy.",
            "Infectious Disease Service, Lausanne University Hospital, Lausanne, Switzerland.",
            "Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, University of Zurich, Zurich, Switzerland.",
            "Division of Infectious Diseases, University Hospital, Basel, Switzerland.",
            "Department of Infectious Diseases, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.",
            "Department of Medical Oncology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "08",
                "Day": "16"
            }
        ]
    },
    {
        "ArticleTitle": "Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA.",
        "AuthorList": [
            "Alex F Herrera",
            "Samuel Tracy",
            "Brandon Croft",
            "Stephen Opat",
            "Jill Ray",
            "Alex F Lovejoy",
            "Lisa Musick",
            "Joseph N Paulson"
        ],
        "AffiliationList": [
            "City of Hope, Duarte, CA.",
            "Genentech, Inc., South San Francisco, CA.",
            "Genentech, Inc., South San Francisco, CA.",
            "Clinical Haematology, Monash Health and Monash University, Clayton, Australia.",
            "Genentech, Inc., South San Francisco, CA.",
            "Roche Sequencing Solutions, Pleasanton, CA; and.",
            "Genentech, Inc., South San Francisco, CA.",
            "Genentech, Inc., South San Francisco, CA."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Diabetes and the Prognosis in Patients With Non-Hodgkin Lymphoma: A Meta-analysis of Cohort Studies.",
        "AuthorList": [
            "Zhen Han",
            "Hong Xu",
            "Meiqing Zhao",
            "Fanjing Jing",
            "Hongwei Xue",
            "Shuxin Xiao"
        ],
        "AffiliationList": [
            "Department of Lymphoma, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, 26600, China.",
            "Department of Hematology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, 26600, China.",
            "Department of Hematology, the Eighth People's Hospital of Qingdao, Qingdao, Shandong, 26600, China.",
            "Department of Lymphoma, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, 26600, China.",
            "Department of Lymphoma, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, 26600, China.",
            "Department of Lymphoma, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, 26600, China. Electronic address: shuxinxiao_8332@21cn.com."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "08",
                "Day": "31"
            }
        ]
    },
    {
        "ArticleTitle": "Response to therapy in Richter syndrome: a systematic review with meta-analysis of early clinical trials.",
        "AuthorList": [
            "Mário Sousa-Pimenta",
            "Ângelo Martins",
            "José Mário Mariz",
            "Pedro Berraondo"
        ],
        "AffiliationList": [
            "Department of Hematology and Bone Marrow Transplantation, Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal.",
            "Department of Hematology and Bone Marrow Transplantation, Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal.",
            "Department of Hematology and Bone Marrow Transplantation, Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal.",
            "Department of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "11",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Grzegorz S Nowakowski",
            "Annalisa Chiappella",
            "Thomas E Witzig",
            "Michele Spina",
            "Randy D Gascoyne",
            "Lei Zhang",
            "Jocelyne Flament",
            "Jacqueline Repici"
        ],
        "AffiliationList": [
            "Division of Hematology, Mayo Clinic, Rochester, MN 55902, USA.",
            "Division of Hematology, Città della Salute e della Scienza Hospital & University, Torino, Italy.",
            "Division of Hematology, Mayo Clinic, Rochester, MN 55902, USA.",
            "Division of Medical Oncology, National Cancer Institute, Aviano, Italy.",
            "Department of Pathology & Lymphoid Cancer Research, BC Cancer Agency & BC Cancer Research Centre, Vancouver, BC, Canada.",
            "Celgene Corporation, Summit, NJ 07901, USA.",
            "Celgene Corporation, Summit, NJ 07901, USA.",
            "Celgene Corporation, Summit, NJ 07901, USA."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "04",
                "Day": "18"
            }
        ]
    },
    {
        "ArticleTitle": "Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Wyndham H Wilson",
            "Tycel Phillips",
            "Leslie Popplewell",
            "Sven de Vos",
            "Saurabh Chhabra",
            "Amy S Kimball",
            "Darrin Beaupre",
            "Da Wei Huang"
        ],
        "AffiliationList": [
            "Lymphoma Therapeutics Section, National Cancer Institute, Bethesda, MD, USA.",
            "Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.",
            "Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.",
            "Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.",
            "Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.",
            "University of Maryland School of Medicine, Baltimore, MD, USA.",
            "Early Development and Immunotherapy, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.",
            "Lymphoma Therapeutics Section, National Cancer Institute, Bethesda, MD, USA."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "04",
                "Day": "15"
            }
        ]
    },
    {
        "ArticleTitle": "Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.",
        "AuthorList": [
            "Grzegorz S Nowakowski",
            "Fangxin Hong",
            "David W Scott",
            "William R Macon",
            "Rebecca L King",
            "Thomas M Habermann",
            "Nina Wagner-Johnston",
            "Carla Casulo"
        ],
        "AffiliationList": [
            "Division of Hematology, Mayo Clinic, Rochester, MN.",
            "Department of Data Sciences, Dana Farber Cancer Institute, Boston, MA.",
            "British Columbia Cancer Center for Lymphoid Cancer, Vancouver, Canada.",
            "Division of Hematopathology, Mayo Clinic Rochester MN.",
            "Division of Hematopathology, Mayo Clinic Rochester MN.",
            "Division of Hematology, Mayo Clinic, Rochester, MN.",
            "Johns Hopkins University, Baltimore, MD.",
            "University of Rochester, NY."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "02",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Alex F Herrera",
            "Andre Goy",
            "Amitkumar Mehta",
            "Radhakrishnan Ramchandren",
            "John M Pagel",
            "Jakub Svoboda",
            "Shanhong Guan",
            "John S Hill"
        ],
        "AffiliationList": [
            "Department of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.",
            "John Theurer Cancer Center Division of Lymphoma, Hackensack University Medical Center, Hackensack, New Jersey.",
            "Division of Hematology and Oncology, University of Alabama, Birmingham, Alabama.",
            "Department of Hematology/Oncology, Karmanos Cancer Institute, Detroit, Michigan.",
            "Center for Blood Disorders and Stem Cell Transplantation, Division of Oncology, Swedish Cancer Institute, Seattle, Washington.",
            "Department of Medicine, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.",
            "Department of Biostatistics, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California.",
            "Department of Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "11",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.",
        "AuthorList": [
            "Vaishali Aggarwal",
            "Ashim Das",
            "Amanjit Bal",
            "Radhika Srinivasan",
            "Reena Das",
            "Gaurav Prakash",
            "Pankaj Malhotra",
            "Subhash Varma"
        ],
        "AffiliationList": [
            "Departments of Histopathology.",
            "Departments of Histopathology.",
            "Departments of Histopathology.",
            "Cytology and Gynaecological Pathology.",
            "Haematology.",
            "Internal Medicine and Hemato-oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.",
            "Internal Medicine and Hemato-oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.",
            "Internal Medicine and Hemato-oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Georg Lenz",
            "Eliza Hawkes",
            "Gregor Verhoef",
            "Corinne Haioun",
            "Soon Thye Lim",
            "Dae Seog Heo",
            "Kirit Ardeshna",
            "Geoffrey Chong"
        ],
        "AffiliationList": [
            "Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany. georg.lenz@ukmuenster.de.",
            "Eastern Health Clinical School, Monash University, Olivia Newton John Cancer Research and Wellness Centre, Melbourne, VIC, Australia.",
            "University Hospitals Leuven, Leuven, Belgium.",
            "Lymphoid Malignancies Unit, Groupe Hospitalier Henri Mondor-Albert Chenevier, Creteil, France.",
            "National Cancer Centre Singapore and Duke-NUS Medical School, Singapore, Singapore.",
            "Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.",
            "University College London Hospitals NHS Foundation Trust, London, UK.",
            "Ballarat Regional Integrated Cancer Centre, Ballarat, VIC, Australia."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "02",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells.",
        "AuthorList": [
            "Imane Azzaoui",
            "Fabrice Uhel",
            "Delphine Rossille",
            "Celine Pangault",
            "Joelle Dulong",
            "Jerome Le Priol",
            "Thierry Lamy",
            "Roch Houot"
        ],
        "AffiliationList": [
            "Pôle Biologie and.",
            "Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Rennes, France; INSERM, Unité Mixte de Recherche U917, Equipe Labellisée Ligue Contre le Cancer, Rennes, France; Université Rennes 1, Unité Mixte de Recherche U917, Rennes, France; Etablissement Français du Sang Bretagne, Rennes, France;",
            "Pôle Biologie and INSERM, Unité Mixte de Recherche U917, Equipe Labellisée Ligue Contre le Cancer, Rennes, France; Université Rennes 1, Unité Mixte de Recherche U917, Rennes, France; Etablissement Français du Sang Bretagne, Rennes, France;",
            "Pôle Biologie and INSERM, Unité Mixte de Recherche U917, Equipe Labellisée Ligue Contre le Cancer, Rennes, France; Université Rennes 1, Unité Mixte de Recherche U917, Rennes, France; Etablissement Français du Sang Bretagne, Rennes, France;",
            "Pôle Biologie and INSERM, Unité Mixte de Recherche U917, Equipe Labellisée Ligue Contre le Cancer, Rennes, France; Université Rennes 1, Unité Mixte de Recherche U917, Rennes, France; Etablissement Français du Sang Bretagne, Rennes, France;",
            "Pôle Biologie and.",
            "INSERM, Unité Mixte de Recherche U917, Equipe Labellisée Ligue Contre le Cancer, Rennes, France; Université Rennes 1, Unité Mixte de Recherche U917, Rennes, France; Etablissement Français du Sang Bretagne, Rennes, France; Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France;",
            "INSERM, Unité Mixte de Recherche U917, Equipe Labellisée Ligue Contre le Cancer, Rennes, France; Université Rennes 1, Unité Mixte de Recherche U917, Rennes, France; Etablissement Français du Sang Bretagne, Rennes, France; Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France;"
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "06",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study.",
        "AuthorList": [
            "Sanjal H Desai",
            "Betsy LaPlant",
            "William R Macon",
            "Rebecca L King",
            "Yucai Wang",
            "David J Inwards",
            "Ivana Micallef",
            "Patrick B Johnston"
        ],
        "AffiliationList": [
            "Division of Hematology, Mayo Clinic, Rochester, MN, USA.",
            "Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.",
            "Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.",
            "Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.",
            "Division of Hematology, Mayo Clinic, Rochester, MN, USA.",
            "Division of Hematology, Mayo Clinic, Rochester, MN, USA.",
            "Division of Hematology, Mayo Clinic, Rochester, MN, USA.",
            "Division of Hematology, Mayo Clinic, Rochester, MN, USA."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "09",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation.",
        "AuthorList": [
            "Matthew J Frigault",
            "Philippe Armand",
            "Robert A Redd",
            "Erin Jeter",
            "Reid W Merryman",
            "Kimberly C Coleman",
            "Alex F Herrera",
            "Parastoo Dahi"
        ],
        "AffiliationList": [
            "Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA.",
            "Department of Medical Oncology and.",
            "Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.",
            "Department of Medical Oncology and.",
            "Department of Medical Oncology and.",
            "Department of Medical Oncology and.",
            "Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.",
            "Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study.",
        "AuthorList": [
            "M Lia Palomba",
            "Brian G Till",
            "Steven I Park",
            "Franck Morschhauser",
            "Guillaume Cartron",
            "Reinhard Marks",
            "Mahesh Shivhare",
            "Wan-Jen Hong"
        ],
        "AffiliationList": [
            "Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.",
            "Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA.",
            "Levine Cancer Institute, Charlotte, NC.",
            "Department of Clinical Hematology, Lille University Hospital Center, Lille, France.",
            "Department of Clinical Hematology, University Hospital Center of Montpellier, Montpellier, France.",
            "Department of Hematology, Oncology and Stem Cell Transplantation, Universitätsklinikum Freiburg, Freiburg, Germany.",
            "Roche Products, Welwyn Garden City, UK.",
            "Product Development Oncology, Genentech, Inc., South San Francisco, CA."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "12",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "High total metabolic tumor volume at baseline predicts survival independent of response to therapy.",
        "AuthorList": [
            "Laetitia Vercellino",
            "Anne-Segolene Cottereau",
            "Olivier Casasnovas",
            "Hervé Tilly",
            "Pierre Feugier",
            "Loic Chartier",
            "Christophe Fruchart",
            "Louise Roulin"
        ],
        "AffiliationList": [
            "Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Nuclear Medecine, Paris, France.",
            "Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Nuclear Medecine, René Descartes University, Paris, France.",
            "Service d'Hématologie Clinique, Centre Hospitalier Universitaire Dijon, INSERM UMR1231, Dijon, France.",
            "Department of Hematology, Centre Henri Becquerel, University Rouen, INSERM U1245, Rouen, France.",
            "Department of Hematology, Centre Hospitalier Universitaire Nancy, INSERM 1256, Nancy, France.",
            "The Lymphoma Academic Research Organisation, Statistic, Centre Hospitalier Lyon Sud, Pierre-Benite, France.",
            "Hématologie, Institut d'Hématologie de Basse Normandie, Centre Hospitalier Universitaire, Caen, France.",
            "University Hospital Henri-Mondor Assistance Publique-Hôpitaux de Paris, Creteil, France."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Nomogram based on the systemic immune-inflammation index for predicting the prognosis of diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Jing Wu",
            "Haizhen Zhu",
            "Qi Zhang",
            "Yi Sun",
            "XinYun He",
            "Jiaqun Liao",
            "Yuncong Liu",
            "Limin Huang"
        ],
        "AffiliationList": [
            "Department of Oncology, Guizhou Provincial People's Hospital, Guizhou Cancer Center, Guiyang, China.",
            "Department of Oncology, Guizhou Provincial People's Hospital, Guizhou Cancer Center, Guiyang, China.",
            "Department of Oncology, Guizhou Provincial People's Hospital, Guizhou Cancer Center, Guiyang, China.",
            "Department of Oncology, Guizhou Provincial People's Hospital, Guizhou Cancer Center, Guiyang, China.",
            "Department of Oncology, Guizhou Provincial People's Hospital, Guizhou Cancer Center, Guiyang, China.",
            "Department of Oncology, Guizhou Provincial People's Hospital, Guizhou Cancer Center, Guiyang, China.",
            "Department of Oncology, Guizhou Provincial People's Hospital, Guizhou Cancer Center, Guiyang, China.",
            "Department of Oncology, Guizhou Provincial People's Hospital, Guizhou Cancer Center, Guiyang, China."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "06",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis.",
        "AuthorList": [
            "Yangyang Ding",
            "Cheng Sun",
            "Linhui Hu",
            "Shudao Xiong",
            "Zhimin Zhai"
        ],
        "AffiliationList": [
            "Department of Hematology/Hematological Lab, The Second Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.",
            "Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.",
            "Department of Hematology/Hematological Lab, The Second Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.",
            "Department of Hematology/Hematological Lab, The Second Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China. xshdao@ahmu.edu.cn.",
            "Department of Hematology/Hematological Lab, The Second Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "06",
                "Day": "29"
            }
        ]
    },
    {
        "ArticleTitle": "Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation.",
        "AuthorList": [
            "Narendranath Epperla",
            "Talha Badar",
            "Aniko Szabo",
            "John Vaughn",
            "Steve Borson",
            "Neeraj Y Saini",
            "Romil D Patel",
            "Nirav N Shah"
        ],
        "AffiliationList": [
            "Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH.",
            "Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI.",
            "Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI.",
            "Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH.",
            "Division of Hematology, Washington University School of Medicine, St. Louis, MO; and.",
            "Department of Stem Cell Transplant and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Department of Stem Cell Transplant and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "The effects of erythropoiesis-stimulating agents on the management of chemotherapy-induced anemia and tumor growth in diffuse large B-cell lymphoma patients.",
        "AuthorList": [
            "Lee Chun Park",
            "Yeon-Joo Song",
            "Da Jung Kim",
            "Min-Jung Kim",
            "Jae-Cheol Jo",
            "Won Sik Lee",
            "Ho-Jin Shin",
            "Sung Yong Oh"
        ],
        "AffiliationList": [
            "Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea.",
            "Central Medical Research Institute, Kosin University Gospel Hospital, Busan, South Korea.",
            "Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea.",
            "Cancer Research Institute, Kosin University College of Medicine, Busan, South Korea.",
            "Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.",
            "Department of Internal Medicine, Busan Paik Hospital, Busan, South Korea.",
            "Department of Internal Medicine, Busan National University Hospital, Busan, South Korea.",
            "Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "05",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.",
        "AuthorList": [
            "Marie Maerevoet",
            "Josee M Zijlstra",
            "George Follows",
            "Rene-Olivier Casasnovas",
            "J S P Vermaat",
            "Nagesh Kalakonda",
            "Andre Goy",
            "Sylvain Choquet"
        ],
        "AffiliationList": [
            "Service Hématologie, Institut Jules Bordet, 1000, Brussels, Belgium. marie.maerevoet@bordet.be.",
            "Amsterdam UMC, Vrije Universiteit, Cancer Center, Amsterdam, Netherlands.",
            "Addenbrooke's Hospital, Cambridge, UK.",
            "Hématologie Clinique and INSERM 1231, CHU Dijon, Dijon, France.",
            "LUMC, Leiden, Netherlands.",
            "University of Liverpool, Liverpool, UK.",
            "Hackensack University Medical Center, Hackensack, USA.",
            "Hôpital Pitié Salpêtrière, Paris, France."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "07",
                "Day": "16"
            }
        ]
    },
    {
        "ArticleTitle": "Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Thomas Clozel",
            "ShaoNing Yang",
            "Rebecca L Elstrom",
            "Wayne Tam",
            "Peter Martin",
            "Matthias Kormaksson",
            "Samprit Banerjee",
            "Aparna Vasanthakumar"
        ],
        "AffiliationList": [
            "1Division of Hematology and Oncology, Department of Medicine, 2Division of Biostatistics and Epidemiology, Department of Public Health, 3Weill Cornell Cancer Center, and Departments of 4Pathology and 5Pharmacology, Weill Cornell Medical College, Cornell University, New York, New York; 6Section of Hematology/Oncology, Department of Medicine, The University of Chicago; Department of Pathology, Northwestern University, Chicago, Illinois; 8Institute for Research in Immunology and Cancer and Department of Pathology and Cell Biology, University of Montreal, Montreal, Quebec; 9Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, British Columbia, Canada; 10IBM Research, Rio de Janeiro, Brazil; and 11Department of Oncological Sciences, University of Turin, Turin, Italy.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "08",
                "Day": "16"
            }
        ]
    },
    {
        "ArticleTitle": "Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma.",
        "AuthorList": [
            "Joseph A Sparano",
            "Jeannette Y Lee",
            "Lawrence D Kaplan",
            "Juan Carlos Ramos",
            "Richard F Ambinder",
            "William Wachsman",
            "David Aboulafia",
            "Ariela Noy"
        ],
        "AffiliationList": [
            "Montefiore-Einstein Cancer Center, Montefiore Medical Center, Bronx, NY, USA.",
            "University of Arkansas for Medical Sciences, Little Rock, AR, USA.",
            "University of California, San Francisco, San Francisco, CA, USA.",
            "University of Miami, Sylvester Comprehensive Cancer Center, Miami, USA.",
            "Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA.",
            "Moores University of California, San Diego Cancer Center, La Jolla, CA, USA.",
            "Virginia Mason Cancer Institute, Seattle, WA, USA.",
            "Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "03",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Hua-Jay J Cherng",
            "Hubert H Chuang",
            "Raphael Steiner",
            "Luis Fayad",
            "Paolo Strati",
            "Ranjit Nair",
            "Fredrick Hagemeister",
            "Loretta J Nastoupil"
        ],
        "AffiliationList": [
            "Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.",
            "Department of Nuclear Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.",
            "Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.",
            "Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.",
            "Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.",
            "Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.",
            "Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.",
            "Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "08",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.",
        "AuthorList": [
            "Jia Jin",
            "Dongmei Ji",
            "Zuguang Xia",
            "Kai Xue",
            "Qunling Zhang",
            "Yizhen Liu",
            "Junning Cao",
            "Xiaonan Hong"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China.",
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China.",
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China.",
            "Department of Hematology, Shanghai Jiao Tong University School of Medicine, Affiliated Ruijin Hospital, Shanghai, 200025, China.",
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China.",
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China.",
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China.",
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "04",
                "Day": "13"
            }
        ]
    },
    {
        "ArticleTitle": "Exposure to glyphosate and risk of non-Hodgkin lymphoma: an updated meta-analysis.",
        "AuthorList": [
            "Paolo Boffetta",
            "Catalina Ciocan",
            "Carlotta Zunarelli",
            "Enrico Pira"
        ],
        "AffiliationList": [
            "Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY, USA; Department of Medical and Surgical Sciences, University of Bologna, Italy. paolo.boffetta@unibo.it.",
            "Department of Pediatrics and Public Health, University of Turin, Italy. catalina.ciocan@unito.it.",
            "University of Bologna. carlotta.zunarelli@studio.unibo.it.",
            "Department of Pediatrics and Public Health, University of Turin, Italy. enrico.pira@unito.it."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "06",
                "Day": "15"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.",
        "AuthorList": [
            "Beenu Thakral",
            "L Jeffrey Medeiros",
            "Parth Desai",
            "Pei Lin",
            "C Cameron Yin",
            "Guilin Tang",
            "Joseph D Khoury",
            "Shimin Hu"
        ],
        "AffiliationList": [
            "Department of Hematopathology, UT MD Anderson Cancer Center, Houston, TX, USA.",
            "Department of Hematopathology, UT MD Anderson Cancer Center, Houston, TX, USA.",
            "Department of Hematopathology, UT MD Anderson Cancer Center, Houston, TX, USA.",
            "Department of Hematopathology, UT MD Anderson Cancer Center, Houston, TX, USA.",
            "Department of Hematopathology, UT MD Anderson Cancer Center, Houston, TX, USA.",
            "Department of Hematopathology, UT MD Anderson Cancer Center, Houston, TX, USA.",
            "Department of Hematopathology, UT MD Anderson Cancer Center, Houston, TX, USA.",
            "Department of Hematopathology, UT MD Anderson Cancer Center, Houston, TX, USA."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "01",
                "Day": "30"
            }
        ]
    },
    {
        "ArticleTitle": "Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib.",
        "AuthorList": [
            "Sriram Balasubramanian",
            "Songbai Wang",
            "Christopher Major",
            "Brendan Hodkinson",
            "Michael Schaffer",
            "Laurie H Sehn",
            "Peter Johnson",
            "Pier Luigi Zinzani"
        ],
        "AffiliationList": [
            "Clinical Oncology, Janssen Research and Development, San Diego, CA, USA.",
            "Clinical Oncology, Janssen Research and Development, Raritan, NJ, USA.",
            "Oncology Translational Research, Janssen Research and Development, Spring House, PA, USA.",
            "Oncology Translational Research, Janssen Research and Development, Spring House, PA, USA.",
            "Oncology Translational Research, Janssen Research and Development, Spring House, PA, USA.",
            "BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada.",
            "Cancer Research UK Clinical Centre, University of Southampton, Southampton, UK.",
            "IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italia."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "05",
                "Day": "03"
            }
        ]
    },
    {
        "ArticleTitle": "Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.",
        "AuthorList": [
            "Gilles Salles",
            "Ajay K Gopal",
            "Monique C Minnema",
            "Karen Wakamiya",
            "Huaibao Feng",
            "Jordan M Schecter",
            "Michael Wang"
        ],
        "AffiliationList": [
            "Hématologie, Hospices Civils de Lyon and Université de Lyon, Lyon, France.",
            "Department of Medicine, University of Washington, Seattle, WA.",
            "Department of Hematology, UMC Utrecht Cancer Center, Utrecht, The Netherlands.",
            "Agilent Technologies Inc, Carpinteria, CA.",
            "Janssen Research & Development, Raritan, NJ.",
            "Janssen Research & Development, Raritan, NJ.",
            "Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: miwang@mdanderson.org."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "01",
                "Day": "02"
            }
        ]
    },
    {
        "ArticleTitle": "Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.",
        "AuthorList": [
            "Nancy L Bartlett",
            "Mitchell R Smith",
            "Tanya Siddiqi",
            "Ranjana H Advani",
            "Owen A O'Connor",
            "Jeff P Sharman",
            "Tatyana Feldman",
            "Kerry J Savage"
        ],
        "AffiliationList": [
            "a Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine , St. Louis , MO , USA.",
            "b Hematology and Oncology, The Cleveland Clinic , Cleveland , OH , USA.",
            "c Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center , Duarte , CA , USA.",
            "d Medicine ? Oncology, Stanford University Medical Center , Stanford , CA , USA.",
            "e Medicine and Experimental Therapeutics, Columbia University Medical Center/New York Presbyterian Hospital , New York , NY , USA.",
            "f Medical Oncology ? Hematology Research, Willamette Valley Cancer Institute and Research Center/US Oncology Research , Eugene , OR , USA.",
            "g Oncology ? Lymphoma Division, Hackensack University Medical Center , Hackensack , NJ , USA.",
            "h Centre for Lymphoid Cancer, British Columbia Cancer Agency , Vancouver , BC , Canada."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "11",
                "Day": "20"
            }
        ]
    },
    {
        "ArticleTitle": "Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy.",
        "AuthorList": [
            "Stephen D Smith",
            "Brian G Till",
            "Mazyar S Shadman",
            "Ryan C Lynch",
            "Andrew J Cowan",
            "Qian V Wu",
            "Jenna Voutsinas",
            "Heather A Rasmussen"
        ],
        "AffiliationList": [
            "Division of Medical Oncology, Department of Internal Medicine, University of Washington, Seattle, WA, USA.",
            "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.",
            "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.",
            "Division of Medical Oncology, Department of Internal Medicine, University of Washington, Seattle, WA, USA.",
            "Division of Medical Oncology, Department of Internal Medicine, University of Washington, Seattle, WA, USA.",
            "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.",
            "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.",
            "Division of Medical Oncology, Department of Internal Medicine, University of Washington, Seattle, WA, USA."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "02",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity?",
        "AuthorList": [
            "J Y Hong",
            "D H Yoon",
            "C Suh",
            "J Huh",
            "I-G Do",
            "I Sohn",
            "J Jo",
            "S-H Jung"
        ],
        "AffiliationList": [
            "Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul.",
            "Department of Oncology.",
            "Department of Oncology.",
            "Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul.",
            "Department of Samsung Cancer Research Institute, Samsung Medical Center, Seoul, Korea.",
            "Department of Samsung Cancer Research Institute, Samsung Medical Center, Seoul, Korea.",
            "Department of Samsung Cancer Research Institute, Samsung Medical Center, Seoul, Korea.",
            "Department of Samsung Cancer Research Institute, Samsung Medical Center, Seoul, Korea Department of Biostatistics and Bioinformatics, Duke University, Durham, USA."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "12",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Sarcopenia predicts overall survival in patients with malignant hematological diseases: A meta-analysis.",
        "AuthorList": [
            "Alexey Surov",
            "Andreas Wienke"
        ],
        "AffiliationList": [
            "Department of Radiology and Nuclear Medicine, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39112, Magdeburg, Germany. Electronic address: Alexey.Surov@medizin.uni-leipzig.de.",
            "Institute of Medical Epidemiology, Biostatistics, and Informatics, Martin-Luther-University Halle-Wittenberg, Magdeburger Str. 8, 06097, Halle, Germany. Electronic address: andreas.wienke@uk-halle.de."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "07",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "The role of body mass index in survival outcome for lymphoma patients: US intergroup experience.",
        "AuthorList": [
            "F Hong",
            "T M Habermann",
            "L I Gordon",
            "H Hochster",
            "R D Gascoyne",
            "V A Morrison",
            "R I Fisher",
            "N L Bartlett"
        ],
        "AffiliationList": [
            "Dana Farber Cancer Institute, Boston, MA. Electronic address: fxhong@jimmy.harvard.edu.",
            "Mayo Clinic, Rochester, MN.",
            "Northwestern University, Chicago, IL.",
            "Yale University, New Haven, CT, USA.",
            "British Columbia Cancer Agency, Vancouver, Canada.",
            "University of Minnesota, VA Medical Center, Minneapolis, MN.",
            "Fox Chase Cancer Center, Philadelphia, PA.",
            "Washington University, St Louis, MO."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.",
        "AuthorList": [
            "John Timmerman",
            "Charles Herbaux",
            "Vincent Ribrag",
            "Andrew D Zelenetz",
            "Roch Houot",
            "Sattva S Neelapu",
            "Theodore Logan",
            "Izidore S Lossos"
        ],
        "AffiliationList": [
            "UCLA Medical Center, Los Angeles, California.",
            "Centre Hospitalier Régional Universitaire de Lille, Lille, France.",
            "Institut Gustave Roussy, Villejuif, France.",
            "Memorial Sloan Kettering Cancer Center, New York, New York.",
            "CHU Rennes, Service Hématologie Clinique, Rennes, France.",
            "The University of Texas MD Anderson Cancer Center, Houston, Texas.",
            "Simon Cancer Center, Indiana University, Indianapolis, Indiana.",
            "University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "02",
                "Day": "29"
            }
        ]
    },
    {
        "ArticleTitle": "A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.",
        "AuthorList": [
            "Graham P Collins",
            "Tracy N Clevenger",
            "Kathleen A Burke",
            "Buyue Yang",
            "Alex MacDonald",
            "David Cunningham",
            "Christopher P Fox",
            "Andre Goy"
        ],
        "AffiliationList": [
            "NIHR Oxford Biomedical Research Center, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, UK.",
            "Acerta Pharma, South San Francisco, CA, USA.",
            "Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA.",
            "Acerta Pharma, South San Francisco, CA, USA.",
            "Clinical Pharmacology & Safety Sciences, Oncology R&D, AstraZeneca, Cambridge, UK.",
            "Gastrointestinal and Lymphoma Unit, Royal Marsden and Institute of Cancer Research Biomedical Research Centre, London, UK.",
            "Department of Clinical Haematology, Nottingham University Hospitals NHS Trust and Division of Cancer and Stem Cells, University of Nottingham, Nottingham, UK.",
            "Department of Medicine, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "07",
                "Day": "16"
            }
        ]
    },
    {
        "ArticleTitle": "Network meta-analysis of targeted therapies for diffuse large B cell lymphoma.",
        "AuthorList": [
            "Jie Wang",
            "Jun Huang",
            "Qing Zeng"
        ],
        "AffiliationList": [
            "Department of Hematology, West China Hospital of Sichuan University, No. 37 Guoxuexiang Street, Chengdu, 610041, Sichuan, China. wangjie_hema@163.com.",
            "West China Medical School, Sichuan University, Chengdu, Sichuan, China.",
            "West China Medical School, Sichuan University, Chengdu, Sichuan, China."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "12",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system.",
        "AuthorList": [
            "Kamraan Z Gill",
            "Fabio Iwamoto",
            "Ashleigh Allen",
            "Daniela Hoehn",
            "Vundavalli V Murty",
            "Bachir Alobeid",
            "Govind Bhagat"
        ],
        "AffiliationList": [
            "Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, 10032, United States of America.",
            "Department of Neurology, Columbia University Medical Center, New York, NY, 10032, United States of America.",
            "Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, 10032, United States of America.",
            "Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, 10032, United States of America.",
            "Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, 10032, United States of America.",
            "Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, 10032, United States of America.",
            "Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, 10032, United States of America."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "12",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic value of FOXP3<sup>+</sup> regulatory T cells in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.",
        "AuthorList": [
            "Yuping Bai",
            "Tingting He",
            "Liyan Zhang",
            "Qianqian Liu",
            "Jing Yang",
            "Ziru Zhao",
            "Kehu Yang",
            "Min Zhang"
        ],
        "AffiliationList": [
            "School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, China.",
            "School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, China.",
            "Department of Pathology, Hebei Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Cangzhou, China.",
            "School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, China.",
            "School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, China.",
            "School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, China.",
            "Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.",
            "Department of Pathology, Gansu Provincial Hospital, Lanzhou, China sallyzhangmin@126.com."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "09",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.",
        "AuthorList": [
            "Georg Hess",
            "Andreas Hüttmann",
            "Mathias Witzens-Harig",
            "Martin H Dreyling",
            "Ulrich Keller",
            "Reinhard Marks",
            "Thomas Ernst",
            "Christiane Pott"
        ],
        "AffiliationList": [
            "Department of Internal Medicine III, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.",
            "Department of Hematology, University Hospital Essen, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.",
            "Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.",
            "Department of Internal Medicine III, Ludwig-Maximilians University of Munich, Munich, Germany.",
            "Internal Medicine III, Technical University of Munich, Munich, Germany.",
            "Department of Hematology/Oncology and Stem Cell Transplantation, University Medical Center, Freiburg, Germany.",
            "Department of Internal Medicine II, Jena University Hospital, Jena, Germany.",
            "Department of Internal Medicine II, University of Schleswig-Holstein, Kiel, Germany."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "04",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial.",
        "AuthorList": [
            "Richard T Maziarz",
            "Stephen J Schuster",
            "Vadim V Romanov",
            "Elisha S Rusch",
            "Junlong Li",
            "James E Signorovitch",
            "David G Maloney",
            "Frederick L Locke"
        ],
        "AffiliationList": [
            "Center for Hematologic Malignancies, Oregon Health & Science Knight Cancer Institute, Portland, OR.",
            "Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.",
            "Novartis Pharmaceuticals Corporation, East Hanover, NJ.",
            "Novartis Pharmaceuticals Corporation, East Hanover, NJ.",
            "Health Economics and Outcomes Research, Analysis Group, Inc., Boston, MA.",
            "Health Economics and Outcomes Research, Analysis Group, Inc., Boston, MA.",
            "Fred Hutchinson Cancer Research Center, Seattle, WA; and.",
            "Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.",
        "AuthorList": [
            "Julia Garcia-Reyero",
            "Nerea Martinez Magunacelaya",
            "Ainara Gonzalez Pereña",
            "Sara Marcos Gonzalez",
            "Nuria Teran-Villagra",
            "Ainara Azueta",
            "Ana Batlle",
            "Sonia Gonzalez de Villambrosia"
        ],
        "AffiliationList": [
            "Pathology Department.",
            "Translational Hematopathology Lab, IDIVAL, CIBERONC.",
            "Translational Hematopathology Lab, IDIVAL, CIBERONC.",
            "Pathology Department.",
            "Pathology Department.",
            "Pathology Department.",
            "Hematology Department, Cytogenetics Unit, Marques de Valdecilla University Hospital.",
            "Hematology Department, Cytogenetics Unit, Marques de Valdecilla University Hospital."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS)-associated lymphomas.",
        "AuthorList": [
            "Manju Sengar",
            "Hasmukh Jain",
            "Tanuja Shet",
            "Epari Sridhar",
            "Vikram Gota",
            "Venkatesh Rangarajan",
            "Siddhartha S Laskar",
            "Aruna Alahari"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.",
            "Department of Medical Oncology, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.",
            "Department of Pathology, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.",
            "Department of Pathology, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.",
            "Department of Clinical Pharmacology, ACTREC, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.",
            "Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.",
            "Department of Radiation Oncology, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.",
            "Department of General Medicine, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "11",
                "Day": "02"
            }
        ]
    },
    {
        "ArticleTitle": "Higher infiltration of intratumoral CD25+ FOXP3+ lymphocytes correlates with a favorable prognosis in patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Chen Chang",
            "Ya-Ping Chen",
            "L Jeffrey Medeiros",
            "Tsai-Yun Chen",
            "Kung-Chao Chang"
        ],
        "AffiliationList": [
            "Department of Pathology, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan.",
            "Department of Internal Medicine, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan.",
            "Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.",
            "Department of Internal Medicine, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan.",
            "Department of Pathology, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "09",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.",
        "AuthorList": [
            "Connie L Batlevi",
            "Michael Crump",
            "Charalambos Andreadis",
            "David Rizzieri",
            "Sarit E Assouline",
            "Susan Fox",
            "Richard H C van der Jagt",
            "Amanda Copeland"
        ],
        "AffiliationList": [
            "Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.",
            "Princess Margaret Cancer Center, Toronto, ON, Canada.",
            "UCSF, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.",
            "Duke University School of Medicine, Durham, NC, USA.",
            "McGill University, Montreal, QC, Canada.",
            "Charles LeMoyne Hospital, Greenfield Park, QC, Canada.",
            "University of Ottawa, Ottawa, ON, Canada.",
            "Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "04",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "Association between interleukin-10-3575T>A (rs1800890) polymorphism and cancer risk.",
        "AuthorList": [
            "Zhi-Ming Dai",
            "Jie Liu",
            "Xing-Mei Cao",
            "Yang Zhang",
            "Meng Wang",
            "Xing-Han Liu",
            "Chang-Ji Li",
            "Zhi-Jun Dai"
        ],
        "AffiliationList": [
            "1 Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University , Xi'an, China .",
            "1 Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University , Xi'an, China .",
            "1 Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University , Xi'an, China .",
            "1 Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University , Xi'an, China .",
            "2 Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University , Xi'an, China .",
            "2 Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University , Xi'an, China .",
            "3 Department of Pediatrics, Jiuquan City People's Hospital , Jiuquan, China .",
            "2 Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University , Xi'an, China ."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "05",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "Plasma fibrinogen level as possible prognostic biomarker in diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Amira Mohamed Foad Shehata",
            "Amira I Aldesoky",
            "Suzy F Gohar"
        ],
        "AffiliationList": [
            "a Clinical and Chemical Pathology Department, Faculty of Medicine , Menoufia University , Egypt.",
            "b Clinical Oncology Department, Faculty of Medicine , Menoufia University , Egypt.",
            "b Clinical Oncology Department, Faculty of Medicine , Menoufia University , Egypt."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "09",
                "Day": "10"
            }
        ]
    },
    {
        "ArticleTitle": "Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.",
        "AuthorList": [
            "Jason Westin",
            "Michael B Maris",
            "Caron A Jacobson",
            "Prapti Patel",
            "Nehal Lakhani",
            "Wael Harb",
            "Dipti Patel-Donnelly",
            "Kelly McCaul"
        ],
        "AffiliationList": [
            "University of Texas M.D. Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, TX.",
            "Colorado Blood Cancer Institute, Denver, CO.",
            "Dana Farber Cancer Institute, Department of Medicine, Boston, MA.",
            "University of Texas Southwestern Medical Center, Department of Hematology/Oncology Dallas, TX.",
            "Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI.",
            "Horizon Oncology Research, Inc., Lafayette, IN.",
            "Virginia Cancer Specialists, Fairfax, VA.",
            "Avera Cancer Institute, Hematology and Bone Marrow Transplant, Sioux Falls, SD."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "07",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.",
        "AuthorList": [
            "Michael Schaffer",
            "Shalini Chaturvedi",
            "Cuc Davis",
            "Jan de Jong",
            "Regina Aquino",
            "Yasuhiro Oki",
            "Nele Fourneau",
            "Anas Younes"
        ],
        "AffiliationList": [
            "Janssen Research & Development, 1400 McKean Road, Spring House, PA 19477, United States.",
            "Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ 07936, United States.",
            "Janssen Research & Development, 1400 McKean Road, Spring House, PA 19477, United States.",
            "Janssen Research & Development LLC, 3210 Merryfield Row, San Diego, CA 92121, United States.",
            "Genmab US, Inc., 902 Carnegie Center Blvd, Princeton, NJ 08540, United States.",
            "Jazz Pharmaceuticals, 3170 Porter Dr, Palo Alto, CA 94304, United States.",
            "Janssen Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium.",
            "Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, United States."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "11",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "The impact of SOCS1 mutations in diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Kevin Mellert",
            "Melanie Martin",
            "Jochen K Lennerz",
            "Manuel Lüdeke",
            "Annette M Staiger",
            "Markus Kreuz",
            "Markus Löffler",
            "Norbert Schmitz"
        ],
        "AffiliationList": [
            "Institute of Pathology, University Hospital, Ulm, Germany.",
            "Institute of Pathology, University Hospital, Ulm, Germany.",
            "Institute of Pathology, University Hospital, Ulm, Germany.",
            "Institute of Human Genetics, University Hospital, Ulm, Germany.",
            "Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.",
            "Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany.",
            "Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany.",
            "Asklepios Klinik St Georg, Hamburg, Germany."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "08",
                "Day": "12"
            }
        ]
    },
    {
        "ArticleTitle": "Genetic susceptibility to diffuse large B-cell lymphoma in a pooled study of three Eastern Asian populations.",
        "AuthorList": [
            "Bryan A Bassig",
            "James R Cerhan",
            "Wing-Yan Au",
            "Hee Nam Kim",
            "Suleeporn Sangrajrang",
            "Wei Hu",
            "Jovic Tse",
            "Sonja Berndt"
        ],
        "AffiliationList": [
            "Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA.",
            "Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.",
            "Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, China.",
            "Genome Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, South Korea.",
            "Research Division, National Cancer Institute, Bangkok, Thailand.",
            "Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA.",
            "Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, China.",
            "Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "03",
                "Day": "13"
            }
        ]
    },
    {
        "ArticleTitle": "Clinicopathological analysis of sinonasal malignant lymphoma in an HTLV-1 endemic area in Japan -special focus on primary sinonasal diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Daisuke Murakami",
            "Kaname Miyashita",
            "Tetsuya Koyama",
            "Hirofumi Omori",
            "Yusuke Miyamoto",
            "Motohiro Sawatsubashi",
            "Takashi Nakagawa"
        ],
        "AffiliationList": [
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "08",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "Impact of therapeutic management and geriatric evaluation on patient of eighty years and older with diffuse large B-cell lymphoma on survival: A systematic review.",
        "AuthorList": [
            "Marguerite Briand",
            "Stephane Gerard",
            "Martin Gauthier",
            "Marie Garric",
            "Zara Steinmeyer",
            "Laurent Balardy"
        ],
        "AffiliationList": [
            "Geriatric Department, Internal Medicine and Oncogeriatry Unit, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.",
            "Geriatric Department, Internal Medicine and Oncogeriatry Unit, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.",
            "Department of Hematology, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.",
            "Geriatric Department, Internal Medicine and Oncogeriatry Unit, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.",
            "Geriatric Department, Internal Medicine and Oncogeriatry Unit, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.",
            "Geriatric Department, Internal Medicine and Oncogeriatry Unit, Centre Hospitalier Universitaire de Toulouse, Toulouse, France."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "09",
                "Day": "21"
            }
        ]
    },
    {
        "ArticleTitle": "Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas.",
        "AuthorList": [
            "Adam J Olszewski",
            "Thomas Ollila",
            "John L Reagan"
        ],
        "AffiliationList": [
            "Department of Medicine, Alpert Medical School of Brown University, Providence, RI, USA.",
            "Department of Medicine, Alpert Medical School of Brown University, Providence, RI, USA.",
            "Department of Medicine, Alpert Medical School of Brown University, Providence, RI, USA."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "04",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Mu-Chen Zhang",
            "Ying Fang",
            "Li Wang",
            "Shu Cheng",
            "Di Fu",
            "Yang He",
            "Yan Zhao",
            "Chao-Fu Wang"
        ],
        "AffiliationList": [
            "Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine At Shanghai, Ruijin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, China.",
            "Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine At Shanghai, Ruijin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, China.",
            "Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine At Shanghai, Ruijin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, China.",
            "Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine At Shanghai, Ruijin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, China.",
            "Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine At Shanghai, Ruijin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, China.",
            "Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine At Shanghai, Ruijin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, China.",
            "Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine At Shanghai, Ruijin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, China.",
            "Department of Pathology, Ruijin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, China."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "10",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "Survival after diffuse large B-cell lymphoma among children, adolescents, and young adults in California, 2001-2014: A population-based study.",
        "AuthorList": [
            "Renata Abrahão",
            "Raul C Ribeiro",
            "Daphne Y Lichtensztajn",
            "Aaron S Rosenberg",
            "Theresa H M Keegan"
        ],
        "AffiliationList": [
            "Greater Bay Area Cancer Registry, Cancer Prevention Institute of California, Fremont, California.",
            "Department of Oncology and Global Pediatric Medicine, Division of Leukemia and Lymphoma, St. Jude Children's Research Hospital, Memphis, Tennessee.",
            "Greater Bay Area Cancer Registry, Cancer Prevention Institute of California, Fremont, California.",
            "Division of Hematology and Oncology, Center of Oncology Hematology Outcomes Research and Training, University of California Davis School of Medicine, Sacramento, California.",
            "Division of Hematology and Oncology, Center of Oncology Hematology Outcomes Research and Training, University of California Davis School of Medicine, Sacramento, California."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "12",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism.",
        "AuthorList": [
            "Wade T Iams",
            "Megan L Hames",
            "Judy P Tsai",
            "Kimberly B Dahlman",
            "Mahsa S Talbott",
            "Kristy L Richards",
            "Nishitha M Reddy"
        ],
        "AffiliationList": [
            "Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.",
            "Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.",
            "Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.",
            "Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN, USA.",
            "Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.",
            "Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.",
            "Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: nishitha.reddy@vanderbilt.edu."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "10",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.",
        "AuthorList": [
            "Ju-Han Lee",
            "Hoiseon Jeong",
            "Jung-Woo Choi",
            "HwaEun Oh",
            "Young-Sik Kim"
        ],
        "AffiliationList": [
            "Department of Pathology, Korea University Ansan Hospital, Ansan, Republic of Korea.",
            "Department of Pathology, Korea University Ansan Hospital, Ansan, Republic of Korea.",
            "Department of Pathology, Korea University Ansan Hospital, Ansan, Republic of Korea.",
            "Department of Pathology, Korea University Ansan Hospital, Ansan, Republic of Korea.",
            "Department of Pathology, Korea University Ansan Hospital, Ansan, Republic of Korea. apysk@korea.ac.kr."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "05",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.",
        "AuthorList": [
            "Alexander Spira",
            "Xiaolei Zhou",
            "Lei Chen",
            "Ari Gnanasakthy",
            "Luqiang Wang",
            "David Ungar",
            "Rafael Curiel",
            "Laura Liao"
        ],
        "AffiliationList": [
            "Virginia Cancer Specialists, US Oncology Research, Johns Hopkins Medicine, Fairfax, VA.",
            "RTI Health Solutions, Research Triangle Park, NC.",
            "ADC Therapeutics America Inc., Murray Hill, NJ. Electronic address: Lei.Chen@adctherapeutics.com.",
            "RTI Health Solutions, Research Triangle Park, NC.",
            "ADC Therapeutics America Inc., Murray Hill, NJ.",
            "ADC Therapeutics America Inc., Murray Hill, NJ.",
            "ADC Therapeutics America Inc., Murray Hill, NJ.",
            "ADC Therapeutics America Inc., Murray Hill, NJ."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "09",
                "Day": "22"
            }
        ]
    },
    {
        "ArticleTitle": "Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.",
        "AuthorList": [
            "Changju Qu",
            "Nana Ping",
            "Liqing Kang",
            "Hailing Liu",
            "Songbin Qin",
            "Qian Wu",
            "Xiaochen Chen",
            "Meng Zhou"
        ],
        "AffiliationList": [
            "Departments of Hematology, Jiangsu Institute of Hematology.",
            "Departments of Hematology, Jiangsu Institute of Hematology.",
            "School of Chemistry and Molecular Engineering, East China Normal University.",
            "Department of Radiology, People's Hospital of Binhai County, Jiangsu, China.",
            "Radiotherapy.",
            "Departments of Hematology, Jiangsu Institute of Hematology.",
            "Departments of Hematology, Jiangsu Institute of Hematology.",
            "Departments of Hematology, Jiangsu Institute of Hematology."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan.",
        "AuthorList": [
            "Shiho Wakase",
            "Takanori Teshima",
            "Jie Zhang",
            "Qiufei Ma",
            "Taizo Fujita",
            "Hongbo Yang",
            "Xinglei Chai",
            "Cynthia Z Qi"
        ],
        "AffiliationList": [
            "Novartis Pharma, Tokyo, Japan. Electronic address: shiho.wakase@novartis.com.",
            "Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan.",
            "Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.",
            "Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.",
            "Novartis Pharma, Tokyo, Japan.",
            "Analysis Group, Inc., Boston, Massachusetts.",
            "Analysis Group, Inc., Boston, Massachusetts.",
            "Analysis Group, Inc., Boston, Massachusetts."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "03",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "Body size and risk of non-Hodgkin lymphoma by subtype: A pooled analysis from six prospective cohorts in the United States.",
        "AuthorList": [
            "Lauren R Teras",
            "Kimberly A Bertrand",
            "Emily L Deubler",
            "Chun R Chao",
            "James V Lacey",
            "Alpa V Patel",
            "Bernard A Rosner",
            "Yu-Hsiang Shu"
        ],
        "AffiliationList": [
            "Department of Population Science, American Cancer Society, Atlanta, Georgia, USA.",
            "Slone Epidemiology Center, Boston University, Boston, Massachusetts, USA.",
            "Department of Population Science, American Cancer Society, Atlanta, Georgia, USA.",
            "Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.",
            "Beckman Research Institute, City of Hope, Duarte, California, USA.",
            "Department of Population Science, American Cancer Society, Atlanta, Georgia, USA.",
            "Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.",
            "Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "03",
                "Day": "29"
            }
        ]
    },
    {
        "ArticleTitle": "Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma.",
        "AuthorList": [
            "Jessica El-Asmar",
            "Lisa Rybicki",
            "Brian J Bolwell",
            "Mohamed A Kharfan-Dabaja",
            "Robert Dean",
            "Betty K Hamilton",
            "Rabi Hanna",
            "Deepa Jagadeesh"
        ],
        "AffiliationList": [
            "Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio.",
            "Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.",
            "Blood and Marrow Transplant Program, Cleveland Clinic, Cleveland, Ohio.",
            "Blood and Marrow Transplant Program, Mayo Clinic, Jacksonville, Florida.",
            "Blood and Marrow Transplant Program, Cleveland Clinic, Cleveland, Ohio.",
            "Blood and Marrow Transplant Program, Cleveland Clinic, Cleveland, Ohio.",
            "Department of Pediatric Hematology, Oncology and Transplantation, Cleveland Clinic, Cleveland, Ohio.",
            "Blood and Marrow Transplant Program, Cleveland Clinic, Cleveland, Ohio."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "09",
                "Day": "13"
            }
        ]
    },
    {
        "ArticleTitle": "Mature outcomes and prognostic indices in diffuse large B-cell lymphoma in Malawi: a prospective cohort.",
        "AuthorList": [
            "Matthew S Painschab",
            "Edwards Kasonkanji",
            "Takondwa Zuze",
            "Bongani Kaimila",
            "Tamiwe Tomoka",
            "Richard Nyasosela",
            "Ruth Nyirenda",
            "Bal M Dhungel"
        ],
        "AffiliationList": [
            "UNC Project-Malawi, Lilongwe, Malawi.",
            "UNC Project-Malawi, Lilongwe, Malawi.",
            "UNC Project-Malawi, Lilongwe, Malawi.",
            "UNC Project-Malawi, Lilongwe, Malawi.",
            "UNC Project-Malawi, Lilongwe, Malawi.",
            "Kamuzu Central Hospital, Lilongwe, Malawi.",
            "Kamuzu Central Hospital, Lilongwe, Malawi.",
            "UNC Project-Malawi, Lilongwe, Malawi."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "11",
                "Day": "18"
            }
        ]
    },
    {
        "ArticleTitle": "Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell Transplantation.",
        "AuthorList": [
            "Alan P Skarbnik",
            "Michele L Donato",
            "Rena Feinman",
            "Scott D Rowley",
            "David H Vesole",
            "Andre H Goy",
            "Pashna N Munshi",
            "Tatyana Feldman"
        ],
        "AffiliationList": [
            "John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey; Novant Health Cancer Institute, Charlotte, North Carolina. Electronic address: azskarbnik@novanthealth.org.",
            "John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey; Georgetown Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC.",
            "Georgetown Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC; Center for Discovery and Innovation, Hackensack Meridian Health, Hackensack, New Jersey.",
            "John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey; Georgetown Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC.",
            "John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey; Georgetown Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC.",
            "John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey; Georgetown Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC.",
            "Georgetown Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC; Georgetown University Medical Center, Washington, DC.",
            "John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey; Georgetown Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "12",
                "Day": "30"
            }
        ]
    },
    {
        "ArticleTitle": "Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.",
        "AuthorList": [
            "Birte Friedrichs",
            "Maike Nickelsen",
            "Marita Ziepert",
            "Bettina Altmann",
            "Mathias Haenel",
            "Andreas Viardot",
            "Christian Schmidt",
            "Christian Ruebe"
        ],
        "AffiliationList": [
            "Department of Haematology, Oncology, Haemostaseology, and Pneumology, University Hospital, Münster, Germany.",
            "Onkologie Lerchenfeld, Hamburg, Germany.",
            "Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.",
            "Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.",
            "Department Internal Medicine III, Klinikum, Chemnitz, Germany.",
            "Department Internal Medicine III, University Hospital of Ulm, Ulm, Germany.",
            "Department Internal Medicine III, Ludwig-Maximilians University of Munich, Munich, Germany.",
            "Department Radiotherapy, University Hospital Saarland, Homburg, Germany."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "12",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "B cell lymphoma with lung involvement: what is it about?",
        "AuthorList": [
            "Michael Mian",
            "Ines Wasle",
            "Stefan Gritsch",
            "Wolfgang Willenbacher",
            "Michael Fiegl"
        ],
        "AffiliationList": [
            "Department of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "11",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic Significance of Pretreatment Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients with Diffuse Large B-Cell Lymphoma.",
        "AuthorList": [
            "Siqian Wang",
            "Yongyong Ma",
            "Lan Sun",
            "Yifen Shi",
            "Songfu Jiang",
            "Kang Yu",
            "Shujuan Zhou"
        ],
        "AffiliationList": [
            "Department of Prosthodontics, School & Hospital of Stomatology Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.",
            "Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.",
            "Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.",
            "Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.",
            "Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.",
            "Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.",
            "Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "12",
                "Day": "12"
            }
        ]
    },
    {
        "ArticleTitle": "Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study.",
        "AuthorList": [
            "Ricardo García-Muñoz",
            "Cristina Quero",
            "Ernesto Pérez-Persona",
            "Abel Domingo-García",
            "Cristina Pérez-López",
            "Teresa Villaescusa-de-la-Rosa",
            "Ana M Martínez-Castro",
            "José M Arguiñano-Pérez"
        ],
        "AffiliationList": [
            "Department of Haematology, Complejo Hospitalario San Millán-San Pedro, Logroño, Spain.",
            "Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain.",
            "Department of Haematology, Hospital de Txagorritxu, Vitoria-Gasteiz, Spain.",
            "Department of Haematology, Hospital General de Granollers, Granollers, Spain.",
            "Department of Haematology, Hospital Universitario Clínico San Carlos, Madrid, Spain.",
            "Department of Haematology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.",
            "Department of Haematology, Complejo Hospitalario Universitario de Vigo, Vigo, Spain.",
            "Department of Haematology, Hospital de Navarra, Pamplona, Spain."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "10",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.",
        "AuthorList": [
            "Yu-Wen Wang",
            "Xavier Cheng-Hong Tsai",
            "Hsin-An Hou",
            "Feng-Ming Tien",
            "Jia-Hau Liu",
            "Wen-Chien Chou",
            "Bor-Sheng Ko",
            "Yu-Wen Chen"
        ],
        "AffiliationList": [
            "Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan.",
            "Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. xavierchtsai@ntu.edu.tw.",
            "Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.",
            "Department of Hematological Oncology, National Taiwan University Cancer Center, National Taiwan University Hospital, Taipei, Taiwan.",
            "Department of Hematological Oncology, National Taiwan University Cancer Center, National Taiwan University Hospital, Taipei, Taiwan.",
            "Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.",
            "Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.",
            "Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "11",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "Genetic association of interleukin-10 promoter polymorphisms and susceptibility to diffuse large B-cell lymphoma: a meta-analysis.",
        "AuthorList": [
            "Hai-Yan Cao",
            "Ping Zou",
            "Hao Zhou"
        ],
        "AffiliationList": [
            "Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, PR China.",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "02",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.",
        "AuthorList": [
            "W Jurczak",
            "P L Zinzani",
            "G Gaidano",
            "A Goy",
            "M Provencio",
            "Z Nagy",
            "T Robak",
            "K Maddocks"
        ],
        "AffiliationList": [
            "Department of Hematology, Jagiellonian University, Kraków, Poland. Electronic address: wojciech.jurczak@uj.edu.pl.",
            "Institute of Hematology \"L. e A. Seràgnoli\", University of Bologna, Bologna.",
            "Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.",
            "John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, USA.",
            "Department of Medical Oncology, University Hospital Puerta De Hierro, Madrid, Spain.",
            "First Department of Internal Medicine, Semmelweis University, Budapest, Hungary.",
            "Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland.",
            "Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, USA."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Alcohol consumption and risk of hematological malignancies: A meta-analysis of prospective studies.",
        "AuthorList": [
            "Theodora Psaltopoulou",
            "Theodoros N Sergentanis",
            "Ioannis Ntanasis-Stathopoulos",
            "Ioannis-Georgios Tzanninis",
            "Diamantis I Tsilimigras",
            "Meletios A Dimopoulos"
        ],
        "AffiliationList": [
            "Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.",
            "Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.",
            "Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.",
            "Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.",
            "Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.",
            "Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "03",
                "Day": "30"
            }
        ]
    },
    {
        "ArticleTitle": "Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Junichi Kiyasu",
            "Hiroaki Miyoshi",
            "Akie Hirata",
            "Fumiko Arakawa",
            "Ayako Ichikawa",
            "Daisuke Niino",
            "Yasuo Sugita",
            "Yuji Yufu"
        ],
        "AffiliationList": [
            "Department of Pathology, Kurume University, School of Medicine, Kurume, Japan; Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Hematology, Iizuka Hospital, Iizuka, Japan;",
            "Department of Pathology, Kurume University, School of Medicine, Kurume, Japan;",
            "Department of Geriatric Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;",
            "Department of Pathology, Kurume University, School of Medicine, Kurume, Japan;",
            "Department of Pathology, Kurume University, School of Medicine, Kurume, Japan;",
            "Department of Pathology, Kurume University, School of Medicine, Kurume, Japan;",
            "Department of Pathology, Kurume University, School of Medicine, Kurume, Japan;",
            "Department of Hematology, Iizuka Hospital, Iizuka, Japan;"
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "08",
                "Day": "03"
            }
        ]
    },
    {
        "ArticleTitle": "Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas.",
        "AuthorList": [
            "John Zhai",
            "Yan Qin",
            "Jun Zhu",
            "Yuqin Song",
            "Zhixiang Shen",
            "Xin Du",
            "Candice Jamois",
            "Michael Brewster"
        ],
        "AffiliationList": [
            "Roche Innovation Center Shanghai, Shanghai, China.",
            "Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing, China.",
            "Department of Lymphoma, Beijing Cancer Hospital, Peking University, Beijing, China.",
            "Department of Lymphoma, Beijing Cancer Hospital, Peking University, Beijing, China.",
            "Department of Hematology, Ruijin Homainlyspital, Shanghai Jiaotong University, Shanghai, China.",
            "Department of Hematology, Guangdong General Hospital/Guandong Academy of Medical Sciences, Guangzhou, Guangdong, China.",
            "Roche Innovation Center Basel, Basel, Switzerland.",
            "Roche Innovation Center Welwyn, Welwyn Garden City, UK."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "02",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.",
        "AuthorList": [
            "Wei Sang",
            "Ming Shi",
            "Jingjing Yang",
            "Jiang Cao",
            "Linyan Xu",
            "Dongmei Yan",
            "Meixue Yao",
            "Hui Liu"
        ],
        "AffiliationList": [
            "Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.",
            "Cancer Institute, Xuzhou Medical University, Xuzhou, China.",
            "Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.",
            "Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China.",
            "Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China.",
            "Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.",
            "Department of Epidemiology and Biostatistics, School of Public Health, Xuzhou Medical University, Xuzhou, China.",
            "Department of Pathology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "07",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.",
        "AuthorList": [
            "A K McMillan",
            "E H Phillips",
            "A A Kirkwood",
            "S Barrans",
            "C Burton",
            "S Rule",
            "R Patmore",
            "R Pettengell"
        ],
        "AffiliationList": [
            "Haematology Department, Nottingham University Hospitals NHS Trust, Nottingham, UK. Electronic address: andrew.mcmillan@nuh.nhs.uk.",
            "Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, UK; Division of Cancer Sciences, University of Manchester and The Christie Hospital NHS Trust, Manchester, UK.",
            "Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, UK.",
            "HMDS, St James' University Hospital, Leeds, UK.",
            "HMDS, St James' University Hospital, Leeds, UK.",
            "Plymouth University Medical School, Plymouth, UK.",
            "Haematology Department, Castle Hill Hospital, Hull, UK.",
            "Clinical Sciences, St George's University of London, London, UK."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "05",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.",
        "AuthorList": [
            "Prioty Islam",
            "David Rizzieri",
            "Chenyu Lin",
            "Carlos de Castro",
            "Louis Diehl",
            "Zhiguo Li",
            "Joseph Moore",
            "Tod Morris"
        ],
        "AffiliationList": [
            "Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA.",
            "Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA.",
            "Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA.",
            "Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA.",
            "Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA.",
            "Duke Cancer Institute, Biostatistics Shared Resources, Duke University, Durham, North Carolina, USA.",
            "Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA.",
            "Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "10",
                "Day": "13"
            }
        ]
    },
    {
        "ArticleTitle": "Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma.",
        "AuthorList": [
            "Divya Samineni",
            "Weize Huang",
            "Leonid Gibiansky",
            "Hao Ding",
            "Rong Zhang",
            "Chunze Li",
            "Arijit Sinha",
            "Richa Rajwanshi"
        ],
        "AffiliationList": [
            "Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA. samineni.divya@gene.com.",
            "Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA.",
            "QuantPharm LLC, North Potomac, MD, USA.",
            "Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA.",
            "Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA.",
            "Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA.",
            "Roche Products Ltd, Welwyn Garden City, UK.",
            "Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "11",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma.",
        "AuthorList": [
            "Paul A Hamlin",
            "Vasile Musteata",
            "Steven I Park",
            "Christine Burnett",
            "Kristina Dabovic",
            "Thomas Strack",
            "Eric T Williams",
            "Banmeet S Anand"
        ],
        "AffiliationList": [
            "Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York.",
            "Institute of Oncology, ARENSIA EM, Chisinau, Republic of Moldova.",
            "Levine Cancer Institute, Charlotte, North Carolina.",
            "Molecular Templates, Inc., Jersey City, New Jersey.",
            "Molecular Templates, Inc., Jersey City, New Jersey.",
            "Molecular Templates, Inc., Jersey City, New Jersey.",
            "Molecular Templates, Austin, Texas.",
            "Molecular Templates, Austin, Texas."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "05",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients.",
        "AuthorList": [
            "Lei Fan",
            "Li Wang",
            "Lei Cao",
            "Huayuan Zhu",
            "Wei Xu",
            "Jianyong Li"
        ],
        "AffiliationList": [
            "Department of Hematology, Pukou CLL Center, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.",
            "Department of Hematology, Pukou CLL Center, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.",
            "Department of Hematology, Pukou CLL Center, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.",
            "Department of Hematology, Pukou CLL Center, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.",
            "Department of Hematology, Pukou CLL Center, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. xuwei0484@jsph.org.cn.",
            "Department of Hematology, Pukou CLL Center, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. lijianyonglm@126.com."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "11",
                "Day": "02"
            }
        ]
    },
    {
        "ArticleTitle": "Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial.",
        "AuthorList": [
            "Stephen Kimani",
            "Matthew S Painschab",
            "Bongani Kaimila",
            "Edwards Kasonkanji",
            "Takondwa Zuze",
            "Tamiwe Tomoka",
            "Maurice Mulenga",
            "Richard Nyasosela"
        ],
        "AffiliationList": [
            "Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; University of North Carolina Project-Malawi, Lilongwe, Malawi.",
            "Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; University of North Carolina Project-Malawi, Lilongwe, Malawi.",
            "University of North Carolina Project-Malawi, Lilongwe, Malawi; University of Malawi, College of Medicine, Lilongwe Campus, Lilongwe, Malawi.",
            "University of North Carolina Project-Malawi, Lilongwe, Malawi.",
            "University of North Carolina Project-Malawi, Lilongwe, Malawi.",
            "Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; University of North Carolina Project-Malawi, Lilongwe, Malawi; University of Malawi, College of Medicine, Lilongwe Campus, Lilongwe, Malawi.",
            "Kamuzu Central Hospital, Malawi Ministry of Health, Lilongwe, Malawi.",
            "Kamuzu Central Hospital, Malawi Ministry of Health, Lilongwe, Malawi."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "05",
                "Day": "19"
            }
        ]
    },
    {
        "ArticleTitle": "Impact on survival through consolidation radiotherapy for diffuse large B-cell lymphoma: a comprehensive meta-analysis.",
        "AuthorList": [
            "Martin D Berger",
            "Sven Trelle",
            "Annina E Büchi",
            "Sabrina Jegerlehner",
            "Codruta Ionescu",
            "Thierry Lamy de la Chapelle",
            "Urban Novak"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Switzerland.",
            "CTU Bern, University of Bern, Switzerland.",
            "General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland.",
            "General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland.",
            "Dept of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Switzerland.",
            "Hematology Department, Rennes University Hospital, INSERM Research Unit 1236, Rennes, France.",
            "Dept of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Switzerland."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "07",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Selenium Supplementation Alter the Frequency of Th17 but not Th1/Th2 Lymphocytes in Diffuse Large B Cell Lymphoma Patients.",
        "AuthorList": [
            "Mehdi Dehghani",
            "Mani Ramzi",
            "Vida Moayed",
            "Narges Rezaei",
            "Mehdi Kalani",
            "Hossein Golmoghaddam",
            "Nargess Arandi"
        ],
        "AffiliationList": [
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study.",
        "AuthorList": [
            "Alexandra-Cristina Paunescu",
            "Christiane Bergman Copie",
            "Sandra Malak",
            "Steven Le Gouill",
            "Vincent Ribrag",
            "Krimo Bouabdallah",
            "David Sibon",
            "Gerhard Rumpold"
        ],
        "AffiliationList": [
            "Inserm CESP U1018, Gustave Roussy, 114 Rue Édouard Vaillant, 94805, Villejuif, France.",
            "Department of Pathology, CHU Henri Mondor, AP-HP, Paris, France.",
            "Hematology, Curie, Saint-Cloud, France.",
            "Service d'hématologie clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France.",
            "DITEP and Hematology department, Gustave Roussy, Villejuif, France.",
            "Department Hematology, University Hospital of Bordeaux, Pessac, France.",
            "INSERM UMR 1163 & CNRS URL 8254, Hematology Department, Necker University Hospital, APHP, Paris, France.",
            "Department of Medical Psychology, Medical University Innsbruck, Innsbruck, Austria."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "10",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "The Prognostic Impact of Body Mass Index in Patients with Diffuse Large B-Cell Lymphoma: A Meta-Analysis.",
        "AuthorList": [
            "Zanzan Wang",
            "Shuna Luo",
            "Xiaoying Zhao"
        ],
        "AffiliationList": [
            "Department of Hematology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, China.",
            "Department of Hematology, Zhejiang University School of Medicine Fourth Affiliated Hospital, Yiwu, China.",
            "Department of Hematology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, China."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "09",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "Clinical impact of prognostic nutritional index in diffuse large B cell lymphoma.",
        "AuthorList": [
            "Se-Il Go",
            "Sungwoo Park",
            "Myoung Hee Kang",
            "Hoon-Gu Kim",
            "Hye Ree Kim",
            "Gyeong-Won Lee"
        ],
        "AffiliationList": [
            "Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Samjeongja-ro 11, Changwon, 51472, Republic of Korea.",
            "Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Republic of Korea.",
            "Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Samjeongja-ro 11, Changwon, 51472, Republic of Korea.",
            "Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Samjeongja-ro 11, Changwon, 51472, Republic of Korea.",
            "Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Republic of Korea.",
            "Institute of Health Science, Gyeongsang National University College of Medicine, Jinju, Republic of Korea. brightree@naver.com."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "11",
                "Day": "09"
            }
        ]
    },
    {
        "ArticleTitle": "CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.",
        "AuthorList": [
            "Lourdes Hontecillas-Prieto",
            "Daniel J García-Domínguez",
            "Natalia Palazón-Carrión",
            "Alejandro Martín García-Sancho",
            "Esteban Nogales-Fernández",
            "Carlos Jiménez-Cortegana",
            "María L Sánchez-León",
            "Silvia Silva-Romeiro"
        ],
        "AffiliationList": [
            "Clinical Biochemistry Service, Virgen Macarena University Hospital, University of Seville, Seville, Spain.",
            "Department of Medical Biochemistry and Molecular Biology and Immunology, Medical School, Virgen Macarena University Hospital, University of Seville, Seville, Spain.",
            "Clinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain.",
            "Department of Hematology, Hospital Universitario de Salamanca, IBSAL, CIBERONC, University of Salamanca, Salamanca, Spain.",
            "Clinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain.",
            "Department of Medical Biochemistry and Molecular Biology and Immunology, Medical School, Virgen Macarena University Hospital, University of Seville, Seville, Spain.",
            "Clinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain.",
            "Clinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain."
        ],
        "Years": [
            {
                "Year": "2024",
                "Month": "02",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "K C Lakshmaiah",
            "Vikas Asati",
            "Govind Babu K",
            "Lokanath D",
            "Linu Abraham Jacob",
            "Suresh Babu M C",
            "Lokesh K N",
            "Rajeev L K"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India.",
            "Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India.",
            "Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India.",
            "Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India.",
            "Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India.",
            "Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India.",
            "Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India.",
            "Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "04",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "The Prognostic Impact of Dose-attenuated R-CHOP Therapy for Elderly Patients with Diffuse Large B-cell Lymphoma.",
        "AuthorList": [
            "Akira Tanimura",
            "Risen Hirai",
            "Miki Nakamura",
            "Masataka Takeshita",
            "Shotaro Hagiwara",
            "Akiyoshi Miwa"
        ],
        "AffiliationList": [
            "Department of Hematology, Tokyo-Kita Medical Center, Japan.",
            "Department of Hematology, Tokyo-Kita Medical Center, Japan.",
            "Division of Hematology, National Center for Global Health and Medicine, Japan.",
            "Department of Hematology, Tokyo-Kita Medical Center, Japan.",
            "Division of Hematology, National Center for Global Health and Medicine, Japan.",
            "Department of Hematology, Tokyo-Kita Medical Center, Japan."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "08",
                "Day": "10"
            }
        ]
    },
    {
        "ArticleTitle": "Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study.",
        "AuthorList": [
            "Marco Picardi",
            "Claudia Giordano",
            "Novella Pugliese",
            "Maria Esposito",
            "Melania Fatigati",
            "Francesco Muriano",
            "Maria G Rascato",
            "Roberta Della Pepa"
        ],
        "AffiliationList": [
            "Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.",
            "Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.",
            "Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.",
            "Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.",
            "Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.",
            "Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.",
            "Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.",
            "Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "07",
                "Day": "12"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic value of geriatric nutritional risk index in patients with diffuse large B-cell lymphoma: a meta-analysis.",
        "AuthorList": [
            "Chengkun Yan",
            "Yanyou Xie",
            "Yaqi Hua",
            "Sihui Li",
            "Huanxu Fu",
            "Zhiqiang Cheng",
            "Jiehua Wu"
        ],
        "AffiliationList": [
            "The Second Affiliated Hospital of Nanchang University, 1 Min De Road, Nanchang, 330006, Jiangxi, China.",
            "The Second Affiliated Hospital of Nanchang University, 1 Min De Road, Nanchang, 330006, Jiangxi, China.",
            "The Second Affiliated Hospital of Nanchang University, 1 Min De Road, Nanchang, 330006, Jiangxi, China.",
            "Red Flag Hospital Affiliated to Mudanjiang Medical College, 5 Tong Xiang Road, Mudanjiang, 157011, Heilongjiang, China.",
            "School of Nursing, Nanchang University, 461 Ba Yi Road, Nanchang, 330006, Jiangxi, China.",
            "School of Nursing, Nanchang University, 461 Ba Yi Road, Nanchang, 330006, Jiangxi, China.",
            "The Second Affiliated Hospital of Nanchang University, 1 Min De Road, Nanchang, 330006, Jiangxi, China. Wjh_2023@126.com."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "07",
                "Day": "12"
            }
        ]
    },
    {
        "ArticleTitle": "Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.",
        "AuthorList": [
            "Jonathan Pan",
            "Sushil Ghimire",
            "S Onder Alpdogan",
            "Andrew Chapman",
            "Matthew Carabasi",
            "Martina DiMeglio",
            "Jerald Gong",
            "Ubaldo Martinez-Outschoorn"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.",
            "Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.",
            "Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.",
            "Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.",
            "Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.",
            "Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.",
            "Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.",
            "Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "11",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Utility of routine surveillance imaging for diffuse large B-cell lymphoma post autologous transplant: A single center experience.",
        "AuthorList": [
            "Ghulam Rehman Mohyuddin",
            "Ashley Elizabeth Clark",
            "John Roller",
            "Leyla Shune",
            "Tara Lin",
            "Neil Dunavin",
            "Ajoy Dias",
            "Siddhartha Ganguly"
        ],
        "AffiliationList": [
            "University of Kansas Medical Center, USA. Electronic address: gmohy-ud-din@kumc.edu.",
            "University of Kansas Medical Center, USA.",
            "University of Kansas Medical Center, USA.",
            "Division of Hematologic Malignancies and Cellular Therapeutic (HMCT), University of Kansas Medical Center, USA.",
            "Division of Hematologic Malignancies and Cellular Therapeutic (HMCT), University of Kansas Medical Center, USA.",
            "Division of Hematologic Malignancies and Cellular Therapeutic (HMCT), University of Kansas Medical Center, USA.",
            "Division of Hematologic Malignancies and Cellular Therapeutic (HMCT), University of Kansas Medical Center, USA.",
            "Division of Hematologic Malignancies and Cellular Therapeutic (HMCT), University of Kansas Medical Center, USA."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "12",
                "Day": "19"
            }
        ]
    },
    {
        "ArticleTitle": "A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.",
        "AuthorList": [
            "Myron S Czuczman",
            "Marek Trněný",
            "Andrew Davies",
            "Simon Rule",
            "Kim M Linton",
            "Nina Wagner-Johnston",
            "Randy D Gascoyne",
            "Graham W Slack"
        ],
        "AffiliationList": [
            "Roswell Park Cancer Institute, Buffalo, New York. mczuczman@celgene.com.",
            "Department of Hematology, Charles University Hospital, Prague, Czech Republic.",
            "Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.",
            "Department of Haematology, Derriford Hospital, Plymouth, United Kingdom.",
            "Division of Molecular and Clinical Cancer Sciences, The Christie Foundation Trust, Manchester, United Kingdom.",
            "Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.",
            "Centre for Lymphoid Cancers, BC Cancer Agency, Vancouver, British Columbia, Canada.",
            "Centre for Lymphoid Cancers, BC Cancer Agency, Vancouver, British Columbia, Canada."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "04",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study.",
        "AuthorList": [
            "M Rieger",
            "A Österborg",
            "R Pettengell",
            "D White",
            "D Gill",
            "J Walewski",
            "E Kuhnt",
            "M Loeffler"
        ],
        "AffiliationList": [
            "Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany. Electronic address: michael.rieger@med.uni-heidelberg.de.",
            "Departments of Oncology, Haematology, Karolinska University Hospital, Stockholm, Sweden.",
            "St George's University of London, UK.",
            "Dalhousie University, Halifax, Nova Scotia for the NCIC Clinical Trials Group, Kingston, Ontario, Canada.",
            "Department of Haematology, Princess Alexandra Hospital, Queensland, Australia.",
            "Department of Lymphoma, Maria Sklodowska-Curie Institute and Oncology Centre, Warszawa, Poland.",
            "Clinical Trial Centre Leipzig, University of Leipzig, Leipzig.",
            "Institute of Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig."
        ],
        "Years": [
            {
                "Year": "2010",
                "Month": "08",
                "Day": "19"
            }
        ]
    },
    {
        "ArticleTitle": "[Clinical Efficiency and Safety of the First-line CHOP Regimen Containing PLD Applied to Treat Aged Patients with Advanced DLBCL].",
        "AuthorList": [
            "Zhi-Hui Li",
            "Ming-Tao Xing",
            "Yan-Pin Zhang",
            "Yu Wang",
            "Xin-Rong Zhan"
        ],
        "AffiliationList": [
            "Department of Hematology, Xinxiang Municipal Central Hospital, Xinxiang 453000, Henan Province, China. E-mail: zhihui060982@163.com.",
            "Department of Hematology, Xinxiang Municipal Central Hospital, Xinxiang 453000, Henan Province, China.",
            "Department of Hematology, Xinxiang Municipal Central Hospital, Xinxiang 453000, Henan Province, China.",
            "Department of Hematology, Xinxiang Municipal Central Hospital, Xinxiang 453000, Henan Province, China.",
            "Department of Hematology, Xinxiang Municipal Central Hospital, Xinxiang 453000, Henan Province, China."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.",
        "AuthorList": [
            "Matthew J Reilley",
            "Patricia McCoon",
            "Carl Cook",
            "Paul Lyne",
            "Razelle Kurzrock",
            "Youngsoo Kim",
            "Richard Woessner",
            "Anas Younes"
        ],
        "AffiliationList": [
            "Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA, USA.",
            "Oncology, IMED Biotech Unit, AstraZeneca Pharmaceuticals, Waltham, MA, USA.",
            "Oncology, IMED Biotech Unit, AstraZeneca Pharmaceuticals, Waltham, MA, USA.",
            "Oncology, IMED Biotech Unit, AstraZeneca Pharmaceuticals, Waltham, MA, USA.",
            "UC San Diego Moores Cancer Center, La Jolla, CA, USA.",
            "Department of Antisense Drug Discovery, Ionis Pharmaceuticals, Inc., Carlsbad, CA, USA.",
            "Oncology, IMED Biotech Unit, AstraZeneca Pharmaceuticals, Waltham, MA, USA.",
            "Memorial Sloan Kettering Cancer Center, New York, NY, USA."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "11",
                "Day": "16"
            }
        ]
    },
    {
        "ArticleTitle": "Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma.",
        "AuthorList": [
            "S-K Leivonen",
            "M Taskinen",
            "A Cervera",
            "M-L Karjalainen-Lindsberg",
            "J Delabie",
            "H Holte",
            "R Lehtonen",
            "S Hautaniemi"
        ],
        "AffiliationList": [
            "Research Program Unit, Medical Faculty, University of Helsinki, Helsinki, Finland.",
            "Research Program Unit, Medical Faculty, University of Helsinki, Helsinki, Finland.",
            "Research Program Unit, Medical Faculty, University of Helsinki, Helsinki, Finland.",
            "Department of Pathology, Haartman Institute, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.",
            "Department of Pathology, Oslo University Hospital, Oslo, Norway.",
            "Department of Oncology, Oslo University Hospital, Oslo, Norway.",
            "Research Program Unit, Medical Faculty, University of Helsinki, Helsinki, Finland.",
            "Research Program Unit, Medical Faculty, University of Helsinki, Helsinki, Finland."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "08",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis.",
        "AuthorList": [
            "Qiang Zeng",
            "Zhigang Liu",
            "Ting Liu"
        ],
        "AffiliationList": [
            "Department of Hematology, West China Hospital, Sichuan University, Chengdu, 610041, China.",
            "Department of Hematology, West China Hospital, Sichuan University, Chengdu, 610041, China.",
            "Department of Hematology, West China Hospital, Sichuan University, Chengdu, 610041, China. liuting@scu.edu.cn."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "01",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUV<sub>max</sub> Method.",
        "AuthorList": [
            "Jan Rekowski",
            "Andreas Hüttmann",
            "Christine Schmitz",
            "Stefan P Müller",
            "Lars Kurch",
            "Jörg Kotzerke",
            "Christiane Franzius",
            "Matthias Weckesser"
        ],
        "AffiliationList": [
            "Institut für Medizinische Informatik, Biometrie, und Epidemiologie, Universitätsklinikum, Essen, Germany jan.rekowski@uk-essen.de.",
            "Klinik für Hämatologie, Universitätsklinikum, Essen, Germany.",
            "Klinik für Hämatologie, Universitätsklinikum, Essen, Germany.",
            "Klinik für Nuklearmedizin, Universitätsklinikum, Essen, Germany.",
            "Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum, Leipzig, Germany.",
            "Klinik für Nuklearmedizin, Universitätsklinikum Carl Gustav Carus, Dresden, Germany.",
            "Zentrum für moderne Diagnostik (Zemodi), Zentrum für Nuklearmedizin und PET/CT, Bremen, Germany.",
            "Klinik für Nuklearmedizin, Universitätsklinikum, Münster, Germany."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "05",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "Deletion 20q12 is associated with histological transformation of nodal marginal zone lymphoma to diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Lei Qian",
            "Craig Soderquist",
            "April Schrank-Hacker",
            "Honore Strauser",
            "Vanessa Dupoux",
            "Chi Ngong Tang",
            "Jennifer R Smith",
            "Ang Sun"
        ],
        "AffiliationList": [
            "Department of Medical Genetics & Molecular Biochemistry, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania.",
            "Department of Pathology and Cell Biology, Columbia University Medical Center, New York, Pennsylvania.",
            "Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.",
            "Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.",
            "Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.",
            "Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.",
            "Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.",
            "Department of Biology, Temple University, Philadelphia, Pennsylvania."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "12",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "Inferior survival and frequent hepatic dysfunction in non-Hodgkin's lymphoma patients with HBV infection: a systematic review and meta-analysis.",
        "AuthorList": [
            "Min-Yue Zhang",
            "Fei Gao",
            "Yan-Wei Zhao",
            "Bei-Wen Ni",
            "Hong-Hui Huang",
            "Jian Hou"
        ],
        "AffiliationList": [
            "Division of Hematology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, People's Republic of China.",
            "State Key Laboratory of Southwestern Chinese Medicine Resources, College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.",
            "Division of Hospitalist, Shanghai Jiahui International Hospital, Shanghai, People's Republic of China.",
            "Division of Hematology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, People's Republic of China.",
            "Division of Hematology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, People's Republic of China.",
            "Division of Hematology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, People's Republic of China."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Geoffrey I Shapiro",
            "Patricia LoRusso",
            "Afshin Dowlati",
            "Khanh T Do",
            "Caron A Jacobson",
            "Ulka Vaishampayan",
            "Amy Weise",
            "Paolo F Caimi"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. geoffrey_shapiro@dfci.harvard.edu.",
            "Early Phase Clinical Trials Program, Yale University Medical Center, New Haven, CT, USA.",
            "Department of Medicine-Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.",
            "Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.",
            "Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.",
            "Department of Oncology, Karmanos Cancer Institute, Detroit, MI, USA.",
            "Medical Oncology, Karmanos Cancer Institute, Detroit, MI, USA.",
            "Department of Medicine-Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "12",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "Interobserver Agreement of Interim and End-of-Treatment <sup>18</sup>F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials.",
        "AuthorList": [
            "Coreline N Burggraaff",
            "Alexander C Cornelisse",
            "Otto S Hoekstra",
            "Pieternella J Lugtenburg",
            "Bart De Keizer",
            "Anne I J Arens",
            "Filiz Celik",
            "Julia E Huijbregts"
        ],
        "AffiliationList": [
            "Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.",
            "Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.",
            "Department of Radiology and Nuclear Medicine, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.",
            "Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.",
            "Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.",
            "Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.",
            "Department of Radiology and Nuclear Medicine, Deventer Ziekenhuis, Deventer, The Netherlands.",
            "Department of Radiology and Nuclear Medicine, Gelre Ziekenhuis, Apeldoorn, The Netherlands; and."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "05",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study.",
        "AuthorList": [
            "Jian-Qiu Wu",
            "Yong-Ping Song",
            "Li-Ping Su",
            "Ming-Zhi Zhang",
            "Wei Li",
            "Yu Hu",
            "Xiao-Hong Zhang",
            "Yu-Huan Gao"
        ],
        "AffiliationList": [
            "Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, Nanjing, Jiangsu 210008, China.",
            "Department of Hematology, Henan Cancer Hospital, Zhengzhou, Henan 450000, China.",
            "Department of Hematology, Shanxi Cancer Hospital, Taiyuan, Shanxi 030013, China.",
            "Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China.",
            "Department of Oncology, Jilin University First Affiliated Hospital, Changchun, Jilin 130000, China.",
            "Department of Hematology, Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430072, China.",
            "Department of Hematology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China.",
            "Department of Hematology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective studies.",
        "AuthorList": [
            "L Abar",
            "J G Sobiecki",
            "M Cariolou",
            "N Nanu",
            "A R Vieira",
            "C Stevens",
            "D Aune",
            "D C Greenwood"
        ],
        "AffiliationList": [
            "Department of Epidemiology and Biostatistics, Imperial College London, London. Electronic address: l.abar@imperial.ac.uk.",
            "Department of Epidemiology and Biostatistics, Imperial College London, London; Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge.",
            "Department of Epidemiology and Biostatistics, Imperial College London, London.",
            "Department of Epidemiology and Biostatistics, Imperial College London, London.",
            "Department of Epidemiology and Biostatistics, Imperial College London, London.",
            "Department of Epidemiology and Biostatistics, Imperial College London, London.",
            "Department of Epidemiology and Biostatistics, Imperial College London, London.",
            "School of Medicine, University of Leeds, Leeds, UK."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Prognostic significance of CD30 expression in diffuse large B-cell lymphoma: A systematic review with meta-analysis.",
        "AuthorList": [
            "Carla Isabelly Rodrigues-Fernandes",
            "Lucas Guimarães Abreu",
            "Raghu Radhakrishnan",
            "Danyel Elias da Cruz Perez",
            "Gleyson Kleber Amaral-Silva",
            "Rogério de Oliveira Gondak",
            "Siavash Rahimi",
            "Peter A Brennan"
        ],
        "AffiliationList": [
            "Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Piracicaba, Brazil.",
            "Department of Child's and Adolescent's Oral Health, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.",
            "Department of Oral Pathology, Manipal College of Dental Sciences, Manipal Academy of Higher Education, Manipal, India.",
            "Department of Clinical and Preventive Dentistry, School of Dentistry, Universidade Federal de Pernambuco, Recife, Brazil.",
            "Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Piracicaba, Brazil.",
            "Department of Pathology, Federal University of Santa Catarina, Florianópolis, Brazil.",
            "Department of Pathology, Queen Alexandra Hospital, Portsmouth, UK.",
            "Department of Oral and Maxillofacial Surgery, Queen Alexandra Hospital, Portsmouth, UK."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "06",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.",
        "AuthorList": [
            "Ho-Young Yhim",
            "Jin Seok Kim",
            "Hye Jin Kang",
            "Seok Jin Kim",
            "Won Seog Kim",
            "Chul Won Choi",
            "Hyeon Seok Eom",
            "Jeong-A Kim"
        ],
        "AffiliationList": [
            "Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "08",
                "Day": "30"
            }
        ]
    },
    {
        "ArticleTitle": "Polymorphism in IKZF1 gene affects clinical outcome in diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Marta Bielska",
            "Maciej Borowiec",
            "Dorota Jesionek-Kupnicka",
            "Marcin Braun",
            "Marcin Bojo",
            "Agata Pastorczak",
            "Ewa Kalinka-Warzocha",
            "Monika Prochorec-Sobieszek"
        ],
        "AffiliationList": [
            "Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, 36/50 Sporna St., 91-738, Lodz, Poland.",
            "Department of Clinical Genetics, Medical University of Lodz, Lodz, Poland.",
            "Chair of Oncology, Department of Pathology, Medical University of Lodz, Lodz, Poland.",
            "Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, 36/50 Sporna St., 91-738, Lodz, Poland.",
            "Department of Chemotherapy, Wojewódzki Szpital Specjalistyczny im. M. Kopernika, Lodz, Poland.",
            "Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, 36/50 Sporna St., 91-738, Lodz, Poland.",
            "Department of Chemotherapy, Wojewódzki Szpital Specjalistyczny im. M. Kopernika, Lodz, Poland.",
            "Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "09",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era.",
        "AuthorList": [
            "Nianhai Zhang",
            "Deming Xu",
            "Bo Liu",
            "Xi Shi",
            "Xianhe Xie",
            "Zili Wang"
        ],
        "AffiliationList": [
            "Department of Oncology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian 350000, China.",
            "Department of Oncology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian 350000, China.",
            "Department of Thoracic Surgery, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian 350000, China.",
            "Department of Oncology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian 350000, China.",
            "Department of Oncology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian 350000, China; Molecular Oncology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian 350000, China. Electronic address: xiexianhe@fjmu.edu.cn.",
            "Department of Oncology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian 350000, China. Electronic address: wangzili83@163.com."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "10",
                "Day": "17"
            }
        ]
    },
    {
        "ArticleTitle": "Hepatic dysfunction after radiotherapy for primary gastric lymphoma.",
        "AuthorList": [
            "Hidekazu Tanaka",
            "Shinya Hayashi",
            "Kazuhiro Ohtakara",
            "Hiroaki Hoshi"
        ],
        "AffiliationList": [
            "Department of Radiology, Gifu University Hospital, Yanagido 1-1, Gifu 501-1194, Japan. htanaka-gif@umin.ac.jp",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "07",
                "Day": "31"
            }
        ]
    },
    {
        "ArticleTitle": "Gene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma.",
        "AuthorList": [
            "Matthew A Care",
            "David R Westhead",
            "Reuben M Tooze"
        ],
        "AffiliationList": [
            "Section of Experimental Haematology, Wellcome Trust Brenner Building, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, LS9 7TF, UK.",
            "Bioinformatics Group, School of Molecular and Cellular Biology, University of Leeds, Leeds, UK.",
            "Section of Experimental Haematology, Wellcome Trust Brenner Building, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, LS9 7TF, UK. r.tooze@leeds.ac.uk."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "09",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas.",
        "AuthorList": [
            "Ayesha Tariq",
            "Muhammad Tahir Aziz",
            "Yasir Mehmood",
            "Shehroz Ali Asghar",
            "Azhar Khurshid"
        ],
        "AffiliationList": [
            "University of Central Punjab, Lahore, Pakistan.",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "05",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era.",
        "AuthorList": [
            "Haizhu Chen",
            "Qiaofeng Zhong",
            "Yu Zhou",
            "Yan Qin",
            "Jianliang Yang",
            "Peng Liu",
            "Xiaohui He",
            "Shengyu Zhou"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.",
            "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.",
            "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.",
            "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.",
            "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.",
            "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.",
            "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.",
            "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "05",
                "Day": "27"
            }
        ]
    },
    {
        "ArticleTitle": "Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study).",
        "AuthorList": [
            "Luigi Rigacci",
            "Roberta Battistini",
            "Sofia Kovalchuk",
            "Valerio Zoli",
            "Benedetta Puccini",
            "Andrea Evangelista",
            "Luca Arcaini",
            "Leonardo Flenghi"
        ],
        "AffiliationList": [
            "UOC Hematology and Stem Cell Transplantation, AO San Camillo Forlanini, Roma, Italy.",
            "UOC Hematology and Stem Cell Transplantation, AO San Camillo Forlanini, Roma, Italy.",
            "SOD Hematology, AOU Careggi, Firenze, Italy.",
            "UOC Hematology and Stem Cell Transplantation, AO San Camillo Forlanini, Roma, Italy.",
            "SOD Hematology, AOU Careggi, Firenze, Italy.",
            "Unit of Clinical Epidemiology, CPO Piemonte, AOU Città della Salute e della Scienza di Torino, Torino, Italy.",
            "Policlinico San Matteo Pavia Fondazione IRCCS, Pavia, Italy.",
            "Institute of Hematology, Ospedale S. Maria della Misericordia, University of Perugia, Perugia, Italy."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "06",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.",
        "AuthorList": [
            "Stephen M Ansell",
            "Monique C Minnema",
            "Peter Johnson",
            "John M Timmerman",
            "Philippe Armand",
            "Margaret A Shipp",
            "Scott J Rodig",
            "Azra H Ligon"
        ],
        "AffiliationList": [
            "1 Mayo Clinic, Rochester, MN.",
            "2 University Medical Center Utrecht Cancer Center, Utrecht, The Netherlands, on behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC.",
            "3 University of Southampton, Southampton, United Kingdom.",
            "4 University of California, Los Angeles, Los Angeles, CA.",
            "5 Dana-Farber Cancer Institute, Boston, MA.",
            "5 Dana-Farber Cancer Institute, Boston, MA.",
            "5 Dana-Farber Cancer Institute, Boston, MA.",
            "6 Brigham and Women's Hospital, Boston, MA."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "01",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial.",
        "AuthorList": [
            "Martina Broecker-Preuss",
            "Nina Becher-Boveleth",
            "Stefan P Müller",
            "Andreas Hüttmann",
            "Christine Hanoun",
            "Hong Grafe",
            "Julia Richter",
            "Wolfram Klapper"
        ],
        "AffiliationList": [
            "Klinik für Nuklearmedizin, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany. martina.broeckerp@uk-essen.de.",
            "Klinik für Nuklearmedizin, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany.",
            "Klinik für Nuklearmedizin, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany.",
            "Klinik für Hämatologie, Universitätsklinikum Essen, Essen, Germany.",
            "Klinik für Hämatologie, Universitätsklinikum Essen, Essen, Germany.",
            "Klinik für Nuklearmedizin, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany.",
            "Sektion für Hämatopathologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.",
            "Sektion für Hämatopathologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "10",
                "Day": "27"
            }
        ]
    },
    {
        "ArticleTitle": "FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Fen Liu",
            "Huirong Ding",
            "Xuan Jin",
            "Ning Ding",
            "Lijuan Deng",
            "Yan He",
            "Jun Zhu",
            "Yuqin Song"
        ],
        "AffiliationList": [
            "1 Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University , Beijing, China .",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "07",
                "Day": "22"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis.",
        "AuthorList": [
            "Lu Li",
            "Yanyan Li",
            "Ximei Que",
            "Xue Gao",
            "Qian Gao",
            "Mingxing Yu",
            "Kaili Ma",
            "Yanfeng Xi"
        ],
        "AffiliationList": [
            "Department of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan, 030001, China.",
            "Department of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan, 030001, China.",
            "Department of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan, 030001, China.",
            "Department of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan, 030001, China.",
            "Department of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan, 030001, China.",
            "Department of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan, 030001, China.",
            "Department of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan, 030001, China.",
            "Department of Pathology, Shanxi Tumor Hospital, Taiyuan, 030013, China."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "04",
                "Day": "19"
            }
        ]
    },
    {
        "ArticleTitle": "Outcomes after intensive care unit admission in newly diagnosed diffuse large B-cell lymphoma patients: A real-life study.",
        "AuthorList": [
            "Alexandra Zduniak",
            "Sorina-Dana Mihailescu",
            "Justine Lequesne",
            "Pascal Lenain",
            "Nathalie Contentin",
            "Louis-Ferdinand Pepin",
            "Anne-Lise Ménard",
            "Stéphane Leprêtre"
        ],
        "AffiliationList": [
            "Department of Hematology, Centre Henri Becquerel, Rouen, France.",
            "Department of Statistics and Clinical Research Unit, Centre Henri Becquerel, Rouen, France.",
            "Department of Statistics and Clinical Research Unit, Centre Henri Becquerel, Rouen, France.",
            "Department of Hematology, Centre Henri Becquerel, Rouen, France.",
            "Department of Hematology, Centre Henri Becquerel, Rouen, France.",
            "Department of Statistics and Clinical Research Unit, Centre Henri Becquerel, Rouen, France.",
            "Department of Hematology, Centre Henri Becquerel, Rouen, France.",
            "Department of Hematology, Centre Henri Becquerel, Rouen, France."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "03",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic and Clinicopathological Value of Survivin in Diffuse Large B-cell Lymphoma: A Meta-Analysis.",
        "AuthorList": [
            "Ya Zhang",
            "Jianhong Wang",
            "Xiaohui Sui",
            "Ying Li",
            "Kang Lu",
            "Xiaosheng Fang",
            "Yujie Jiang",
            "Xin Wang"
        ],
        "AffiliationList": [
            "From the Department of Hematology, Shandong Provincial Hospital affiliated to Shandong University (YZ, JW, XS, YL, KL, XF, YJ, XW); and Institute of Diagnostics, Shandong University School of Medicine, Jinan, Shandong, P.R. China (XW).",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.",
        "AuthorList": [
            "Wendy Cuccuini",
            "Josette Briere",
            "Nicolas Mounier",
            "Hans-Ullrich Voelker",
            "Andreas Rosenwald",
            "Christer Sundstrom",
            "Sergio Cogliatti",
            "Edouard Hirchaud"
        ],
        "AffiliationList": [
            "Hematologie biologique, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), 1 Ave. Claude Vellefaux, Paris, France.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "03",
                "Day": "09"
            }
        ]
    },
    {
        "ArticleTitle": "Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients.",
        "AuthorList": [
            "Pier Luigi Zinzani",
            "Alessandro Broccoli",
            "Vittorio Stefoni",
            "Gerardo Musuraca",
            "Elisabetta Abruzzese",
            "Amalia De Renzo",
            "Maria Cantonetti",
            "Francesco Bacci"
        ],
        "AffiliationList": [
            "Institute of Hematology and Medical Oncology L. e A. Seràgnoli, Policlinico Sant'Orsola-Malpighi, University of Bologna, Bologna, Italy. pierluigi.zinzani@unibo.it",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2010",
                "Month": "08",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "The impact of diagnostic wait time on the survival of patients with diffuse large B-cell lymphoma: effect modification by the International Prognostic Index.",
        "AuthorList": [
            "Shin Lee",
            "Kei Fujita",
            "Eiju Negoro",
            "Tetsuji Morishita",
            "Hideaki Yamauchi",
            "Kana Oiwa",
            "Takanori Ueda",
            "Takahiro Yamauchi"
        ],
        "AffiliationList": [
            "Department of Haematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.",
            "Department of Haematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.",
            "Department of Haematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.",
            "Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.",
            "Department of Haematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.",
            "Department of Haematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.",
            "Department of Haematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.",
            "Department of Haematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "06",
                "Day": "27"
            }
        ]
    },
    {
        "ArticleTitle": "Clinical significance of MYC expression and/or \"high-grade\" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study.",
        "AuthorList": [
            "James R Cook",
            "Bryan Goldman",
            "Raymond R Tubbs",
            "Lisa Rimsza",
            "Michael Leblanc",
            "Patrick Stiff",
            "Richard Fisher"
        ],
        "AffiliationList": [
            "*Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH †SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA ‡University of Arizona, Tucson, AZ §Fox Chase Cancer Center, Philadelphia, PA ∥Loyola University Medical Center, Maywood, IL.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Clinical characteristics and outcomes of primary adrenal diffuse large B cell lymphoma in a large contemporary cohort: a SEER-based analysis.",
        "AuthorList": [
            "Shu Li",
            "Zhan Wang",
            "Zhaoxing Wu",
            "Haifeng Zhuang",
            "Yang Xu"
        ],
        "AffiliationList": [
            "Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.",
            "Center for Orthopaedic Research, Orthopaedics Research Institute of Zhejiang University, Department of Orthopaedics, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.",
            "Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.",
            "Department of Hematology, the First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310009, China.",
            "Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China. yxu@zju.edu.cn."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "06",
                "Day": "21"
            }
        ]
    },
    {
        "ArticleTitle": "A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Steven I Park",
            "Natalie S Grover",
            "Oludamilola Olajide",
            "Adam S Asch",
            "James G Wall",
            "Kristy L Richards",
            "Anna L Sobol",
            "Allison M Deal"
        ],
        "AffiliationList": [
            "Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC, USA. sipark@med.unc.edu.",
            "Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC, USA.",
            "Rex Hematology Oncology Associates, Raleigh, NC, USA.",
            "Division of Hematology/Oncology, University of Oklahoma College of Medicine, Oklahoma City, OK, USA.",
            "Levine Cancer Institute, Concord, NC, USA.",
            "Division of Hematology/Oncology, Weill Cornell Medical College, New York, NY, USA.",
            "Seby B. Jones Regional Cancer Center, Boone, NC, USA.",
            "Division of Biostatistics and Data Management, University of North Carolina, Chapel Hill, NC, USA."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "07",
                "Day": "22"
            }
        ]
    },
    {
        "ArticleTitle": "Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Kohei Tada",
            "Sung-Won Kim",
            "Yoshitaka Asakura",
            "Nobuhiro Hiramoto",
            "Kimikazu Yakushijin",
            "Saiko Kurosawa",
            "Kinuko Tajima",
            "Shin-ichiro Mori"
        ],
        "AffiliationList": [
            "Department of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "05",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Exposure to glyphosate and risk of non-Hodgkin lymphoma and multiple myeloma: an updated meta-analysis.",
        "AuthorList": [
            "Francesca Donato",
            "Enrico Pira",
            "Catalina Ciocan",
            "Paolo Boffetta"
        ],
        "AffiliationList": [
            "department of pediatrics and public health, university of turin, italy. francesca.donato@unito.it.",
            "department of pediatrics and public health, university of turin, italy. enrico.pira@unito.it.",
            "department of pediatrics and public health, university of turin, italy. catalina.ciocan@unito.it.",
            ". paolo.boffetta@gmail.com."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "02",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.",
        "AuthorList": [
            "Jung Yong Hong",
            "Kyung Ju Ryu",
            "Chaehwa Park",
            "Mineui Hong",
            "Young Hyeh Ko",
            "Won Seog Kim",
            "Seok Jin Kim"
        ],
        "AffiliationList": [
            "Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.",
            "Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.",
            "Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.",
            "Department of Pathology, Kangnam Sacred Heart Hospital, Hallym University Medical Center, Seoul, Korea.",
            "Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.",
            "Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.",
            "Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Yi Xia",
            "Zhi-Ming Li",
            "Yan-Xia Shi",
            "Zhong-Jun Xia",
            "Wen-Qi Jiang",
            "Hui-Qiang Huang"
        ],
        "AffiliationList": [
            "State Key Laboratory of Oncology in South China, Department of Medical Oncology, Sun Yat-sen University, Guangzhou, Guangdong, PR China.",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2009",
                "Month": "02",
                "Day": "15"
            }
        ]
    },
    {
        "ArticleTitle": "Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and meta-analysis of cohort studies.",
        "AuthorList": [
            "Theodora Psaltopoulou",
            "Theodoros N Sergentanis",
            "Ioannis Ntanasis-Stathopoulos",
            "Ioannis-Georgios Tzanninis",
            "Elena Riza",
            "Meletios A Dimopoulos"
        ],
        "AffiliationList": [
            "Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.",
            "Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.",
            "Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.",
            "Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.",
            "Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.",
            "Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "02",
                "Day": "12"
            }
        ]
    },
    {
        "ArticleTitle": "Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study - JCOG0108A.",
        "AuthorList": [
            "Tomohiro Kinoshita",
            "Takashi Watanabe",
            "Kuniaki Itoh",
            "Kenichi Yoshimura",
            "Kensei Tobinai",
            "Michinori Ogura",
            "Motoko Yamaguchi",
            "Mitsutoshi Kurosawa"
        ],
        "AffiliationList": [
            "Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.",
            "Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.",
            "Division of Oncology and Hematology, National Cancer Center Hospital East, Kashiwa, Japan.",
            "Department of Biostatistics, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan.",
            "Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.",
            "Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan.",
            "Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.",
            "Department of Hematology, National Hospital Organization, Hokkaido Cancer Center, Sapporo, Japan."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.",
        "AuthorList": [
            "Jia Ruan",
            "Peter Martin",
            "Richard R Furman",
            "Shing M Lee",
            "Ken Cheung",
            "Julie M Vose",
            "Ann Lacasce",
            "Julia Morrison"
        ],
        "AffiliationList": [
            "Center for Lymphoma and Myeloma, Weill Cornell Medical College, 525 East 68th St, Starr 340, New York, NY 10065, USA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2010",
                "Month": "12",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "The international staging system improves the IPI risk stratification in patients with diffuse large B-cell lymphoma treated with R-CHOP.",
        "AuthorList": [
            "Xiaolei Wei",
            "Xiaoxiao Hao",
            "Lizhi Zhou",
            "Qi Wei",
            "Yuankun Zhang",
            "Weimin Huang",
            "Jialin Song",
            "Ru Feng"
        ],
        "AffiliationList": [
            "Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.",
            "Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.",
            "Department of Biostatistics, School of Public Health, Southern Medical University, Guangzhou, China.",
            "Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.",
            "Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.",
            "Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.",
            "Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.",
            "Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "10",
                "Day": "19"
            }
        ]
    },
    {
        "ArticleTitle": "Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.",
        "AuthorList": [
            "Annette M Staiger",
            "Marita Ziepert",
            "Heike Horn",
            "David W Scott",
            "Thomas F E Barth",
            "Heinz-Wolfram Bernd",
            "Alfred C Feller",
            "Wolfram Klapper"
        ],
        "AffiliationList": [
            "Annette M. Staiger, Heike Horn, and German Ott, Institute of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart; Annette M. Staiger and Heike Horn, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart; Annette M. Staiger and Heike Horn, University of Tuebingen, Tuebingen; Marita Ziepert and Markus Löffler, Institute for Medical Informatics, Statistics and Epidemiology, Universität Leipzig, Leipzig; Thomas F.E. Barth and Peter Möller, Institute of Pathology, Universitätsklinikum Ulm, Ulm; Heinz-Wolfram Bernd and Alfred C. Feller, Haematopathologie Luebeck, Luebeck; Wolfram Klapper and Monika Szczepanowski, Institute of Pathology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel; Monika Szczepanowski, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel; Michael Hummel and Dido Lenze, Institute of Pathology, Campus Benjamin Franklin, Charité Universitätsmedizin; Harald Stein, Pathodiagnostik Berlin, Berlin; Martin-Leo Hansmann and Sylvia Hartmann, Dr. Senckenberg Institute of Pathology, Goethe University Hospital, Frankfurt; Georg Lenz, Translational Oncology, Albert-Schweitzer-Campus 1, University Hospital Münster, and Cluster of Excellence EXC 1003, Cells in Motion, Münster; Lorenz Trümper, Georg-August Universität, Göttingen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg; Michael Pfreundschuh, Saarland University Medical School, Homburg/Saar; Andreas Rosenwald, Institute of Pathology, Universität Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany; David W. Scott, Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Sergio Cogliatti, Institute of Pathology, Kantonal Hospital St Gallen, St Gallen, Switzerland.",
            "Annette M. Staiger, Heike Horn, and German Ott, Institute of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart; Annette M. Staiger and Heike Horn, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart; Annette M. Staiger and Heike Horn, University of Tuebingen, Tuebingen; Marita Ziepert and Markus Löffler, Institute for Medical Informatics, Statistics and Epidemiology, Universität Leipzig, Leipzig; Thomas F.E. Barth and Peter Möller, Institute of Pathology, Universitätsklinikum Ulm, Ulm; Heinz-Wolfram Bernd and Alfred C. Feller, Haematopathologie Luebeck, Luebeck; Wolfram Klapper and Monika Szczepanowski, Institute of Pathology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel; Monika Szczepanowski, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel; Michael Hummel and Dido Lenze, Institute of Pathology, Campus Benjamin Franklin, Charité Universitätsmedizin; Harald Stein, Pathodiagnostik Berlin, Berlin; Martin-Leo Hansmann and Sylvia Hartmann, Dr. Senckenberg Institute of Pathology, Goethe University Hospital, Frankfurt; Georg Lenz, Translational Oncology, Albert-Schweitzer-Campus 1, University Hospital Münster, and Cluster of Excellence EXC 1003, Cells in Motion, Münster; Lorenz Trümper, Georg-August Universität, Göttingen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg; Michael Pfreundschuh, Saarland University Medical School, Homburg/Saar; Andreas Rosenwald, Institute of Pathology, Universität Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany; David W. Scott, Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Sergio Cogliatti, Institute of Pathology, Kantonal Hospital St Gallen, St Gallen, Switzerland.",
            "Annette M. Staiger, Heike Horn, and German Ott, Institute of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart; Annette M. Staiger and Heike Horn, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart; Annette M. Staiger and Heike Horn, University of Tuebingen, Tuebingen; Marita Ziepert and Markus Löffler, Institute for Medical Informatics, Statistics and Epidemiology, Universität Leipzig, Leipzig; Thomas F.E. Barth and Peter Möller, Institute of Pathology, Universitätsklinikum Ulm, Ulm; Heinz-Wolfram Bernd and Alfred C. Feller, Haematopathologie Luebeck, Luebeck; Wolfram Klapper and Monika Szczepanowski, Institute of Pathology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel; Monika Szczepanowski, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel; Michael Hummel and Dido Lenze, Institute of Pathology, Campus Benjamin Franklin, Charité Universitätsmedizin; Harald Stein, Pathodiagnostik Berlin, Berlin; Martin-Leo Hansmann and Sylvia Hartmann, Dr. Senckenberg Institute of Pathology, Goethe University Hospital, Frankfurt; Georg Lenz, Translational Oncology, Albert-Schweitzer-Campus 1, University Hospital Münster, and Cluster of Excellence EXC 1003, Cells in Motion, Münster; Lorenz Trümper, Georg-August Universität, Göttingen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg; Michael Pfreundschuh, Saarland University Medical School, Homburg/Saar; Andreas Rosenwald, Institute of Pathology, Universität Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany; David W. Scott, Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Sergio Cogliatti, Institute of Pathology, Kantonal Hospital St Gallen, St Gallen, Switzerland.",
            "Annette M. Staiger, Heike Horn, and German Ott, Institute of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart; Annette M. Staiger and Heike Horn, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart; Annette M. Staiger and Heike Horn, University of Tuebingen, Tuebingen; Marita Ziepert and Markus Löffler, Institute for Medical Informatics, Statistics and Epidemiology, Universität Leipzig, Leipzig; Thomas F.E. Barth and Peter Möller, Institute of Pathology, Universitätsklinikum Ulm, Ulm; Heinz-Wolfram Bernd and Alfred C. Feller, Haematopathologie Luebeck, Luebeck; Wolfram Klapper and Monika Szczepanowski, Institute of Pathology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel; Monika Szczepanowski, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel; Michael Hummel and Dido Lenze, Institute of Pathology, Campus Benjamin Franklin, Charité Universitätsmedizin; Harald Stein, Pathodiagnostik Berlin, Berlin; Martin-Leo Hansmann and Sylvia Hartmann, Dr. Senckenberg Institute of Pathology, Goethe University Hospital, Frankfurt; Georg Lenz, Translational Oncology, Albert-Schweitzer-Campus 1, University Hospital Münster, and Cluster of Excellence EXC 1003, Cells in Motion, Münster; Lorenz Trümper, Georg-August Universität, Göttingen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg; Michael Pfreundschuh, Saarland University Medical School, Homburg/Saar; Andreas Rosenwald, Institute of Pathology, Universität Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany; David W. Scott, Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Sergio Cogliatti, Institute of Pathology, Kantonal Hospital St Gallen, St Gallen, Switzerland.",
            "Annette M. Staiger, Heike Horn, and German Ott, Institute of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart; Annette M. Staiger and Heike Horn, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart; Annette M. Staiger and Heike Horn, University of Tuebingen, Tuebingen; Marita Ziepert and Markus Löffler, Institute for Medical Informatics, Statistics and Epidemiology, Universität Leipzig, Leipzig; Thomas F.E. Barth and Peter Möller, Institute of Pathology, Universitätsklinikum Ulm, Ulm; Heinz-Wolfram Bernd and Alfred C. Feller, Haematopathologie Luebeck, Luebeck; Wolfram Klapper and Monika Szczepanowski, Institute of Pathology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel; Monika Szczepanowski, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel; Michael Hummel and Dido Lenze, Institute of Pathology, Campus Benjamin Franklin, Charité Universitätsmedizin; Harald Stein, Pathodiagnostik Berlin, Berlin; Martin-Leo Hansmann and Sylvia Hartmann, Dr. Senckenberg Institute of Pathology, Goethe University Hospital, Frankfurt; Georg Lenz, Translational Oncology, Albert-Schweitzer-Campus 1, University Hospital Münster, and Cluster of Excellence EXC 1003, Cells in Motion, Münster; Lorenz Trümper, Georg-August Universität, Göttingen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg; Michael Pfreundschuh, Saarland University Medical School, Homburg/Saar; Andreas Rosenwald, Institute of Pathology, Universität Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany; David W. Scott, Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Sergio Cogliatti, Institute of Pathology, Kantonal Hospital St Gallen, St Gallen, Switzerland.",
            "Annette M. Staiger, Heike Horn, and German Ott, Institute of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart; Annette M. Staiger and Heike Horn, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart; Annette M. Staiger and Heike Horn, University of Tuebingen, Tuebingen; Marita Ziepert and Markus Löffler, Institute for Medical Informatics, Statistics and Epidemiology, Universität Leipzig, Leipzig; Thomas F.E. Barth and Peter Möller, Institute of Pathology, Universitätsklinikum Ulm, Ulm; Heinz-Wolfram Bernd and Alfred C. Feller, Haematopathologie Luebeck, Luebeck; Wolfram Klapper and Monika Szczepanowski, Institute of Pathology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel; Monika Szczepanowski, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel; Michael Hummel and Dido Lenze, Institute of Pathology, Campus Benjamin Franklin, Charité Universitätsmedizin; Harald Stein, Pathodiagnostik Berlin, Berlin; Martin-Leo Hansmann and Sylvia Hartmann, Dr. Senckenberg Institute of Pathology, Goethe University Hospital, Frankfurt; Georg Lenz, Translational Oncology, Albert-Schweitzer-Campus 1, University Hospital Münster, and Cluster of Excellence EXC 1003, Cells in Motion, Münster; Lorenz Trümper, Georg-August Universität, Göttingen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg; Michael Pfreundschuh, Saarland University Medical School, Homburg/Saar; Andreas Rosenwald, Institute of Pathology, Universität Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany; David W. Scott, Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Sergio Cogliatti, Institute of Pathology, Kantonal Hospital St Gallen, St Gallen, Switzerland.",
            "Annette M. Staiger, Heike Horn, and German Ott, Institute of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart; Annette M. Staiger and Heike Horn, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart; Annette M. Staiger and Heike Horn, University of Tuebingen, Tuebingen; Marita Ziepert and Markus Löffler, Institute for Medical Informatics, Statistics and Epidemiology, Universität Leipzig, Leipzig; Thomas F.E. Barth and Peter Möller, Institute of Pathology, Universitätsklinikum Ulm, Ulm; Heinz-Wolfram Bernd and Alfred C. Feller, Haematopathologie Luebeck, Luebeck; Wolfram Klapper and Monika Szczepanowski, Institute of Pathology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel; Monika Szczepanowski, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel; Michael Hummel and Dido Lenze, Institute of Pathology, Campus Benjamin Franklin, Charité Universitätsmedizin; Harald Stein, Pathodiagnostik Berlin, Berlin; Martin-Leo Hansmann and Sylvia Hartmann, Dr. Senckenberg Institute of Pathology, Goethe University Hospital, Frankfurt; Georg Lenz, Translational Oncology, Albert-Schweitzer-Campus 1, University Hospital Münster, and Cluster of Excellence EXC 1003, Cells in Motion, Münster; Lorenz Trümper, Georg-August Universität, Göttingen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg; Michael Pfreundschuh, Saarland University Medical School, Homburg/Saar; Andreas Rosenwald, Institute of Pathology, Universität Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany; David W. Scott, Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Sergio Cogliatti, Institute of Pathology, Kantonal Hospital St Gallen, St Gallen, Switzerland.",
            "Annette M. Staiger, Heike Horn, and German Ott, Institute of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart; Annette M. Staiger and Heike Horn, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart; Annette M. Staiger and Heike Horn, University of Tuebingen, Tuebingen; Marita Ziepert and Markus Löffler, Institute for Medical Informatics, Statistics and Epidemiology, Universität Leipzig, Leipzig; Thomas F.E. Barth and Peter Möller, Institute of Pathology, Universitätsklinikum Ulm, Ulm; Heinz-Wolfram Bernd and Alfred C. Feller, Haematopathologie Luebeck, Luebeck; Wolfram Klapper and Monika Szczepanowski, Institute of Pathology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel; Monika Szczepanowski, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel; Michael Hummel and Dido Lenze, Institute of Pathology, Campus Benjamin Franklin, Charité Universitätsmedizin; Harald Stein, Pathodiagnostik Berlin, Berlin; Martin-Leo Hansmann and Sylvia Hartmann, Dr. Senckenberg Institute of Pathology, Goethe University Hospital, Frankfurt; Georg Lenz, Translational Oncology, Albert-Schweitzer-Campus 1, University Hospital Münster, and Cluster of Excellence EXC 1003, Cells in Motion, Münster; Lorenz Trümper, Georg-August Universität, Göttingen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg; Michael Pfreundschuh, Saarland University Medical School, Homburg/Saar; Andreas Rosenwald, Institute of Pathology, Universität Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany; David W. Scott, Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Sergio Cogliatti, Institute of Pathology, Kantonal Hospital St Gallen, St Gallen, Switzerland."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "05",
                "Day": "19"
            }
        ]
    },
    {
        "ArticleTitle": "Functional Parameters of <sup>18</sup>F-FDG PET/CT in Patients with Primary Testicular Diffuse Large B-Cell Lymphoma.",
        "AuthorList": [
            "Jing Yang",
            "Sha Zhu",
            "Fuwen Pang",
            "Miao Xu",
            "Yiting Dong",
            "Jianqi Hao",
            "Xuelei Ma"
        ],
        "AffiliationList": [
            "State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China.",
            "West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.",
            "West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.",
            "Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.",
            "West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.",
            "West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.",
            "State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "09",
                "Day": "27"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic significance of neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma: A meta-analysis.",
        "AuthorList": [
            "Jin Wang",
            "Xu Zhou",
            "Yu Liu",
            "Zheng Li",
            "Xiang Li"
        ],
        "AffiliationList": [
            "Hematology Department of Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China.",
            "Hematology Department of Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China.",
            "Hematology Department of Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China.",
            "Hematology Department of Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China.",
            "Hematology Department of Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "04",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis.",
        "AuthorList": [
            "Sang Eun Yoon",
            "Seok Jin Kim",
            "Dok Hyun Yoon",
            "Youngil Koh",
            "Yeung-Chul Mun",
            "Young Rok Do",
            "Yoon Seok Choi",
            "Deok Hwan Yang"
        ],
        "AffiliationList": [
            "Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul, 06351, South Korea.",
            "Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul, 06351, South Korea.",
            "Department of Oncology, Asan Medical Center, Ulsan University College of Medicine, Seoul, South Korea.",
            "Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.",
            "Department of Hematology-Oncology, Ewha Womans University Mokdong Hospital, Seoul, South Korea.",
            "Department of Hematology-Oncology, Keimyung University School of Medicine, Daegu, South Korea.",
            "Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, South Korea.",
            "Division of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, South Korea."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "04",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma.",
        "AuthorList": [
            "Greg Hapgood",
            "Janey M Stone",
            "Diana Zannino",
            "Anup George",
            "Paula Marlton",
            "Henry Miles Prince",
            "Chi-Hung Hui",
            "Ian Prosser"
        ],
        "AffiliationList": [
            "a Department of Haematology , Princess Alexandra Hospital , Brisbane , Australia.",
            "b Australasian Leukaemia and Lymphoma Group , Melbourne , Australia.",
            "b Australasian Leukaemia and Lymphoma Group , Melbourne , Australia.",
            "c Wellington Blood and Cancer Centre , Wellington Regional Hospital , Wellington , New Zealand.",
            "a Department of Haematology , Princess Alexandra Hospital , Brisbane , Australia.",
            "e Epworth Healthcare and Peter MacCallum, Department of Oncology , University of Melbourne , Melbourne , Australia.",
            "f Department of Haematology , Adelaide Cancer Centre , Adelaide , Australia.",
            "g Department of Haematology , Canberra Hospital , Canberra , Australia."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "12",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Hideki Goto",
            "Shinichi Makita",
            "Koji Kato",
            "Kota Tokushige",
            "Taizo Fujita",
            "Koichi Akashi",
            "Koji Izutsu",
            "Takanori Teshima"
        ],
        "AffiliationList": [
            "Department of Hematology, Graduate School of Medicine, Hokkaido University Faculty of Medicine, Sapporo, Japan. hidekigt@med.hokudai.ac.jp.",
            "Department of Hematology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.",
            "Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.",
            "Novartis Pharma K.K., Toranomon Minato-ku, Tokyo, Japan.",
            "Novartis Pharma K.K., Toranomon Minato-ku, Tokyo, Japan.",
            "Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.",
            "Department of Hematology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.",
            "Department of Hematology, Graduate School of Medicine, Hokkaido University Faculty of Medicine, Sapporo, Japan."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "05",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial.",
        "AuthorList": [
            "Andrés J M Ferreri",
            "Teresa Calimeri",
            "Maurilio Ponzoni",
            "Flavio Curnis",
            "Gian Marco Conte",
            "Eloise Scarano",
            "Eltjona Rrapaj",
            "Daniela De Lorenzo"
        ],
        "AffiliationList": [
            "Lymphoma Unit, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy.",
            "Lymphoma Unit, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy.",
            "Università Vita-Salute San Raffaele, Milan, Italy.",
            "Division of Experimental Oncology, Tumor Biology and Vascular Targeting Unit.",
            "Neuroradiology Unit, and.",
            "Data Manager and Study Coordinator Office, Lymphoma Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.",
            "Division of Experimental Oncology, Tumor Biology and Vascular Targeting Unit.",
            "Data Manager and Study Coordinator Office, Lymphoma Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.",
        "AuthorList": [
            "Vincent Ribrag",
            "Seung Tae Lee",
            "David Rizzieri",
            "Martin J S Dyer",
            "Luis Fayad",
            "Razelle Kurzrock",
            "Leslie Andritsos",
            "Reda Bouabdallah"
        ],
        "AffiliationList": [
            "Department of Hematology, Early Drug Development, Institut Gustave Roussy, Villejuif, France. Electronic address: vincent.ribrag@igr.fr.",
            "Department of Medicine, University of Maryland, Baltimore, MD.",
            "Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC.",
            "The Ernest and Helen Scott Hematological Research Institute, University of Leicester, Leicester, UK.",
            "Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX.",
            "Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX.",
            "Division of Hematology/Oncology, University of New Mexico, Albuquerque, NM.",
            "Department of Hematology, Institut Paoli-Calmettes Unicancer, Paris, France."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "12",
                "Day": "17"
            }
        ]
    },
    {
        "ArticleTitle": "Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Luigi Marcheselli",
            "Raffaella Marcheselli",
            "Alessia Bari",
            "Eliana Valentina Liardo",
            "Fortunato Morabito",
            "Luca Baldini",
            "Maura Brugiatelli",
            "Francesco Merli"
        ],
        "AffiliationList": [
            "Department of Oncology and Hematology, University of Modena and Reggio Emilia, Policlinico, Modena, Italy.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "06",
                "Day": "12"
            }
        ]
    },
    {
        "ArticleTitle": "Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID).",
        "AuthorList": [
            "Kristina Drott",
            "Hans Hagberg",
            "Karin Papworth",
            "Thomas Relander",
            "Mats Jerkeman"
        ],
        "AffiliationList": [
            "Department of Oncology, Skåne University Hospital, Lund, Sweden.",
            "Department of Oncology, Akademiska, Uppsala University Hospital, Uppsala, Sweden; and.",
            "Department of Oncology, Norrland University Hospital, Umeå, Sweden.",
            "Department of Oncology, Skåne University Hospital, Lund, Sweden.",
            "Department of Oncology, Skåne University Hospital, Lund, Sweden."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Clinical characteristics and prognostic significance of EBER positivity in diffuse large B-cell lymphoma: A meta-analysis.",
        "AuthorList": [
            "Xiaojuan Gao",
            "Jia Li",
            "Yaqi Wang",
            "Shuai Liu",
            "Baohong Yue"
        ],
        "AffiliationList": [
            "Department of Laboratory Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China.",
            "Department of Laboratory Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China.",
            "Department of Laboratory Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China.",
            "Department of Laboratory Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China.",
            "Department of Laboratory Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "06",
                "Day": "19"
            }
        ]
    },
    {
        "ArticleTitle": "Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Nobuhiko Nakamura",
            "Takeshi Hara",
            "Yuhei Shibata",
            "Takuro Matsumoto",
            "Hiroshi Nakamura",
            "Soranobu Ninomiya",
            "Yusuke Kito",
            "Junichi Kitagawa"
        ],
        "AffiliationList": [
            "Department of Hematology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.",
            "Department of Hematology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.",
            "Department of Hematology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.",
            "Department of Hematology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.",
            "Department of Hematology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.",
            "Department of Hematology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.",
            "Department of Pathology and Translational Research, Gifu University Graduate School of Medicine, Gifu, Japan.",
            "Department of Hematology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "09",
                "Day": "19"
            }
        ]
    },
    {
        "ArticleTitle": "Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis.",
        "AuthorList": [
            "Xuan Zhou",
            "Tingting Ma",
            "Yichan Zhang",
            "Na Zhou",
            "Juan Li"
        ],
        "AffiliationList": [
            "Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Gulou District, Nanjing, China.",
            "Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Gulou District, Nanjing, China.",
            "Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Gulou District, Nanjing, China.",
            "Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Gulou District, Nanjing, China.",
            "Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Gulou District, Nanjing, China."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "03",
                "Day": "29"
            }
        ]
    },
    {
        "ArticleTitle": "Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses.",
        "AuthorList": [
            "Julien Broséus",
            "Gaili Chen",
            "Sébastien Hergalant",
            "Gérard Ramstein",
            "Nicolas Mounier",
            "Jean-Louis Guéant",
            "Pierre Feugier",
            "Christian Gisselbrecht"
        ],
        "AffiliationList": [
            "Inserm U954, Faculty of Medicine, Nancy, France.",
            "ZhongNan Hospital of Wuhan University, Wuhan, China.",
            "Inserm U954, Faculty of Medicine, Nancy, France.",
            "LINA DUKe, UMR 6241, Université de Nantes, Nantes, France.",
            "Hemato-oncology, University Hospital of l'Archet, Nice, France.",
            "Inserm U954, Faculty of Medicine, Nancy, France.",
            "Inserm U954, Faculty of Medicine, Nancy, France.",
            "APHP, Saint-Louis Hospital, Hemato-Oncology Department, Paris, France."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "A Pooled Analysis of The Clinical Utilities of Long Non-Coding RNA Based Molecular Signature for Diffuse Large B Cell Lymphoma.",
        "AuthorList": [
            "Pei Xu",
            "Xiaoli Chen",
            "Panke Su"
        ],
        "AffiliationList": [
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.",
        "AuthorList": [
            "Andrés J M Ferreri",
            "Marianna Sassone",
            "Francesco Zaja",
            "Alessandro Re",
            "Michele Spina",
            "Alice Di Rocco",
            "Alberto Fabbri",
            "Caterina Stelitano"
        ],
        "AffiliationList": [
            "Unit of Lymphoid Malignancies, Department of Onco-Hematology, Milan, Italy. Electronic address: ferreri.andres@hsr.it.",
            "Unit of Lymphoid Malignancies, Department of Onco-Hematology, Milan, Italy.",
            "Centro Trapianti e Terapie Cellulari \"Carlo Melzi\", A O Universitaria S. Maria Misericordia, Udine, Italy.",
            "Division of Hematology, Spedali Civili, Brescia, Italy.",
            "Division of Medical Oncology, National Cancer Institute, Aviano, Italy.",
            "Division of Hematology, University Sapienza, Rome, Italy.",
            "Azienda Ospedaliera Università Senese, Siena, Italy.",
            "Division of Hematology, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "02",
                "Day": "17"
            }
        ]
    },
    {
        "ArticleTitle": "Reduced-dose EPOCH-R chemotherapy for elderly patients with advanced stage diffuse large B cell lymphoma.",
        "AuthorList": [
            "Wen-Hao Zhang",
            "Gao-Yang Li",
            "Yu-Jie Ma",
            "Zhi-Chao Li",
            "Yang Zhu",
            "Jun Chang",
            "Si-Guo Hao",
            "Rong Tao"
        ],
        "AffiliationList": [
            "Department of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.",
            "Department of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.",
            "Department of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.",
            "Department of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.",
            "Department of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.",
            "Department of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.",
            "Department of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.",
            "Department of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China. taorong@xinhuamed.com.cn."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "05",
                "Day": "12"
            }
        ]
    },
    {
        "ArticleTitle": "Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma.",
        "AuthorList": [
            "Yucai Wang",
            "Matthew J Maurer",
            "Melissa C Larson",
            "Cristine Allmer",
            "Andrew L Feldman",
            "N Nora Bennani",
            "Carrie A Thompson",
            "Luis F Porrata"
        ],
        "AffiliationList": [
            "Division of Hematology, Mayo Clinic, Rochester, MN, USA.",
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.",
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.",
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.",
            "Division of Hematopathology, Mayo Clinic, Rochester, MN, USA.",
            "Division of Hematology, Mayo Clinic, Rochester, MN, USA.",
            "Division of Hematology, Mayo Clinic, Rochester, MN, USA.",
            "Division of Hematology, Mayo Clinic, Rochester, MN, USA."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "05",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Can the SUV<sub>max-liver</sub>-based interpretation improve prognostic accuracy of interim and posttreatment <sup>18</sup>F-FDG PET/CT in patients with diffuse large B-cell lymphoma?",
        "AuthorList": [
            "Yuewei Zhang",
            "Yang Fan",
            "Zhitao Ying",
            "Yuqin Song",
            "Jun Zhu",
            "Zhi Yang",
            "Xuejuan Wang"
        ],
        "AffiliationList": [
            "a Department of Nuclear Medicine, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education) , Peking University Cancer Hospital & Institute , Beijing, P.R. China.",
            "a Department of Nuclear Medicine, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education) , Peking University Cancer Hospital & Institute , Beijing, P.R. China.",
            "b Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education) , Peking University Cancer Hospital & Institute , Beijing, P.R. China.",
            "b Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education) , Peking University Cancer Hospital & Institute , Beijing, P.R. China.",
            "b Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education) , Peking University Cancer Hospital & Institute , Beijing, P.R. China.",
            "a Department of Nuclear Medicine, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education) , Peking University Cancer Hospital & Institute , Beijing, P.R. China.",
            "a Department of Nuclear Medicine, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education) , Peking University Cancer Hospital & Institute , Beijing, P.R. China."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "08",
                "Day": "03"
            }
        ]
    },
    {
        "ArticleTitle": "Methylenetetrahydrofolate reductase gene polymorphisms association with the risk of diffuse large B cell lymphoma: a meta-analysis.",
        "AuthorList": [
            "Yun-Yu Sun",
            "Li An",
            "Yu-Lan Xie",
            "Jing-Yan Xu",
            "Jing Wang"
        ],
        "AffiliationList": [
            "Department of Hematology, The Affiliated Zhong Da Hospital of Southeast University, 87# Dingjiaqiao, Nanjing, 210009, People's Republic of China, yunyusun66@163.com.",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "06",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial.",
        "AuthorList": [
            "Christine Schmitz",
            "Andreas Hüttmann",
            "Stefan P Müller",
            "Maher Hanoun",
            "Ronald Boellaard",
            "Marcus Brinkmann",
            "Karl-Heinz Jöckel",
            "Ulrich Dührsen"
        ],
        "AffiliationList": [
            "Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. Electronic address: christine.schmitz@uk-essen.de.",
            "Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.",
            "Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.",
            "Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.",
            "Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands.",
            "Center for Clinical Trials, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.",
            "Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.",
            "Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "11",
                "Day": "09"
            }
        ]
    },
    {
        "ArticleTitle": "Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.",
        "AuthorList": [
            "Margaret A Shipp",
            "Ken N Ross",
            "Pablo Tamayo",
            "Andrew P Weng",
            "Jeffery L Kutok",
            "Ricardo C T Aguiar",
            "Michelle Gaasenbeek",
            "Michael Angelo"
        ],
        "AffiliationList": [
            "Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA. margaret_shipp@dfci.harvard.edu",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi.",
        "AuthorList": [
            "Francesco Merli",
            "Federica Cavallo",
            "Flavia Salvi",
            "Alessandra Tucci",
            "Gerardo Musuraca",
            "Luca Nassi",
            "Michele Merli",
            "Monica Tani"
        ],
        "AffiliationList": [
            "Hematology Unit, Arcispedale S.Maria Nuova, Azienda Unità Sanitaria Locale - IRCCS, Reggio Emilia, Italy. Electronic address: merli.francesco@ausl.re.it.",
            "Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino/AOU \"Città della Salute e della Scienza di Torino\", Torino, Italy.",
            "Hematology Unit, Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy.",
            "Hematology, Spedali Civili Hospital, Brescia, Italy.",
            "Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.",
            "Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Azienda Ospedaliero-Universitaria Maggiore della Carità Novara, Italy.",
            "Division of Hematology, University Hospital Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi, Varese, Italy.",
            "Hematology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "07",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "R-mini CHP in ≥80-year-old Patients with Diffuse Large B-cell Lymphoma: A Multicenter, Open-label, Single-arm Phase II Trial Protocol.",
        "AuthorList": [
            "Yasuhiko Miyata",
            "Akiko M Saito",
            "Takahiro Yano",
            "Isao Yoshida",
            "Youko Suehiro",
            "Naoki Harada",
            "Hirokazu Nagai"
        ],
        "AffiliationList": [
            "Department of Hematology, Nagoya Medical Center, Nagoya 460-0001, Japan.miyatay@nnh.hosp.go.jp.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "R-CHOP compared to R-CHOP + X for newly diagnosed diffuse large B-cell lymphoma: a systematic review and meta-analysis.",
        "AuthorList": [
            "Oren Pasvolsky",
            "Alon Rozental",
            "Pia Raanani",
            "Anat Gafter-Gvili",
            "Ronit Gurion"
        ],
        "AffiliationList": [
            "Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.",
            "Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.",
            "Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.",
            "Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.",
            "Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "03",
                "Day": "18"
            }
        ]
    },
    {
        "ArticleTitle": "Non-Hodgkin lymphoma and gluten-sensitive enteropathy: estimate of risk using meta-analyses.",
        "AuthorList": [
            "Eleanor V Kane",
            "Rob Newton",
            "Eve Roman"
        ],
        "AffiliationList": [
            "Epidemiology and Genetics Unit, Department of Health Sciences, University of York, Seebohm Rowntree Building, Heslington, York, YO10 5DD, UK. eleanor.kane@egu.york.ac.uk",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "07",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial.",
        "AuthorList": [
            "Andrea Kühnl",
            "Clare Peckitt",
            "Bijal Patel",
            "Kirit M Ardeshna",
            "Marian P Macheta",
            "John Radford",
            "Rod Johnson",
            "Shankaranarayana Paneesha"
        ],
        "AffiliationList": [
            "Royal Marsden NHS Foundation Trust London and Surrey, Downs Road Sutton, Surrey, SM2 5PT, UK.",
            "Royal Marsden NHS Foundation Trust London and Surrey, Downs Road Sutton, Surrey, SM2 5PT, UK.",
            "Royal Marsden NHS Foundation Trust London and Surrey, Downs Road Sutton, Surrey, SM2 5PT, UK.",
            "University College London Hospital, London, UK.",
            "Blackpool Victoria Hospital, Blackpool, UK.",
            "University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.",
            "St James's Hospital, Leeds, UK.",
            "Heart of England NHS Foundation Trust, Birmingham, UK."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "11",
                "Day": "27"
            }
        ]
    },
    {
        "ArticleTitle": "Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.",
        "AuthorList": [
            "Renata de Oliveira Costa",
            "Abrahão Hallack Neto",
            "Sheila Siqueira",
            "Luis Alberto de Padua Covas Lage",
            "Henrique M de Paula",
            "Arthur M Coutinho",
            "Juliana Pereira"
        ],
        "AffiliationList": [
            "aMedical School of São Paulo University bNuclear Medicine Service of the Medical School of São Paulo University cLusiadas University Center, Santos, São Paulo dJuiz de Fora Federal University, Juiz de Fora, Minas Gerais eGoiás Federal University, Jatai, Goiás, Brazil.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Obesity is associated with increased relative risk of diffuse large B-cell lymphoma: a meta-analysis of observational studies.",
        "AuthorList": [
            "Jorge J Castillo",
            "Randall R Ingham",
            "John L Reagan",
            "Michael Furman",
            "Samir Dalia",
            "Joanna Mitri"
        ],
        "AffiliationList": [
            "Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA. Electronic address: jorgej_castillo@dfci.harvard.edu.",
            "Division of Hematology and Oncology, Rhode Island Hospital, Providence, RI.",
            "Division of Hematology and Oncology, Rhode Island Hospital, Providence, RI.",
            "Department of Medicine, Rhode Island Hospital, Providence, RI.",
            "Division of Hematology and Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL.",
            "Service of Endocrinology, Prima CARE, Fall River, MA."
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "11",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "Occupation and Risk of Non-Hodgkin Lymphoma and Its Subtypes: A Pooled Analysis from the InterLymph Consortium.",
        "AuthorList": [
            "Andrea 't Mannetje",
            "Anneclaire J De Roos",
            "Paolo Boffetta",
            "Roel Vermeulen",
            "Geza Benke",
            "Lin Fritschi",
            "Paul Brennan",
            "Lenka Foretova"
        ],
        "AffiliationList": [
            "Centre for Public Health Research, Massey University, Wellington Campus, Wellington, New Zealand.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "09",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Fang Bao",
            "Wei Wan",
            "Ting He",
            "Feifei Qi",
            "Guanghua Liu",
            "Kai Hu",
            "Xin-An Lu",
            "Ping Yang"
        ],
        "AffiliationList": [
            "Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, Haidian District, Beijing, 100191, China.",
            "Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, Haidian District, Beijing, 100191, China.",
            "Immunochina Pharmaceuticals Co., Ltd, Haidian District, Beijing, 100094, China.",
            "Immunochina Pharmaceuticals Co., Ltd, Haidian District, Beijing, 100094, China.",
            "Immunochina Pharmaceuticals Co., Ltd, Haidian District, Beijing, 100094, China.",
            "Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, Haidian District, Beijing, 100191, China.",
            "Immunochina Pharmaceuticals Co., Ltd, Haidian District, Beijing, 100094, China.",
            "Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, Haidian District, Beijing, 100191, China."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "01",
                "Day": "09"
            }
        ]
    },
    {
        "ArticleTitle": "Mobilization characteristics, blood graft composition, and outcome in diffuse large B-cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study.",
        "AuthorList": [
            "Anu Partanen",
            "Antti Turunen",
            "Jaakko Valtola",
            "Marja Pyörälä",
            "Kaija Vasala",
            "Outi Kuittinen",
            "Hanne Kuitunen",
            "Karri Penttilä"
        ],
        "AffiliationList": [
            "Department of Medicine, Kuopio University Hospital, Kuopio, Finland.",
            "Department of Medicine, Kuopio University Hospital, Kuopio, Finland.",
            "Department of Medicine, Kuopio University Hospital, Kuopio, Finland.",
            "Department of Medicine, Kuopio University Hospital, Kuopio, Finland.",
            "Department of Oncology, Central Hospital of Central Finland, Jyväskylä, Finland.",
            "Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.",
            "Department of Oncology, Oulu University Hospital, Oulu, Finland.",
            "Department of Medicine, Central Hospital of Savonlinna, Savonlinna, Finland."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "11",
                "Day": "27"
            }
        ]
    },
    {
        "ArticleTitle": "A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma.",
        "AuthorList": [
            "Ken Ohmachi",
            "Michinori Ogura",
            "Youko Suehiro",
            "Kiyoshi Ando",
            "Toshiki Uchida",
            "Ilseung Choi",
            "Yoshiaki Ogawa",
            "Miki Kobayashi"
        ],
        "AffiliationList": [
            "Department of Hematology and Oncology, Tokai University Hospital, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1143, Japan. 8jmmd004@is.icc.u-tokai.ac.jp.",
            "Kasugai Municipal Hospital, Kasugai, Japan.",
            "Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.",
            "Department of Hematology and Oncology, Tokai University Hospital, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1143, Japan.",
            "Department of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan.",
            "Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.",
            "Department of Hematology and Oncology, Tokai University Hospital, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1143, Japan.",
            "Department of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "03",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.",
        "AuthorList": [
            "Catherine Thieblemont",
            "Hervé Tilly",
            "Maria Gomes da Silva",
            "Rene-Olivier Casasnovas",
            "Christophe Fruchart",
            "Franck Morschhauser",
            "Corinne Haioun",
            "Julien Lazarovici"
        ],
        "AffiliationList": [
            "Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Diderot University, Sorbonne Paris-Cité; Catherine Thieblemont and Josette Briere, Descartes University; Josette Briere, Hôpital Necker, Paris; Hervé Tilly, University of Rouen, Institut National de la Santé et de la Recherche Médicale U1245, Rouen; Rene-Olivier Casasnovas, Centre Hospitalier Universitaire Dijon; Institut National de la Santé et de la Recherche Médicale UMR1231, Dijon; Christophe Fruchart, Institut d'Hématologie de Basse Normandie, Centre Hospitalier Universitaire, Caen; Franck Morschhauser, Centre Hospitalier Universitaire Régional de Lille, Lille; Corinne Haioun and Philippe Gaulard, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Mondor; Philippe Gaulard, Institut National de la Santé et de la Recherche Médicale U955; Université Paris-Est, Créteil; Julien Lazarovici, Gustave Roussy Cancer Center, Villejuif; Aurore Perrot, University Hospital, Vandoeuvre les Nancy; Catherine Sebban, Centre Leon Berard, University Claude Bernard Lyon 1; Gilles Salles, Hospices Civils de Lyon, Université Claude Bernard U1052, Lyon; Hugo Gonzalez, Centre Hospitalier René Dubos, Pontoise; Reda Bouabdallah, Institut Paoli Calmettes, Marseille; Lucie Oberic, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse; Bernadette Corront, Centre Hospitalier Régional Annecy, Annecy; Bachra Choufi, Centre Hospitalier Dr Duchenne, Boulogne-sur-mer; Gilles Salles and Bertrand Coiffier, Institut National de la Santé et de la Recherche Médicale U1052, Hospices Civils de Lyon, Pierre-Benite, France; Maria Gomes da Silva and Jose Cabeçadas, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal; Anida Grosicka, Medical University of Silesia, Katowice, Poland; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Concord; John Catalano, Frankston Hospital and Monash University, Frankston, Australia; Dolores Caballero, Hospital Universitario de Salamanca, Salamanca; Armando Lopez-Guillermo, Hospital Clinic Barcelona, Barcelona, Spain; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute; Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; Koen van Eygen, Algemeen Ziekenhuis Groeninge Hospital, President Kennedylaan 4, Kortrijk; Achiel Van Hoof, Algemeen Ziekenhuis Sint Jan AV, Brugge; Andre Bosly, UCL Mont Godinne, Yvoir, Belgium; and Amos M. Cohen, Rabin Medical Center, Beilinson Hospital, Davidoff Cancer Center, Tel-Aviv University, Ramat-Aviv, Israel.",
            "Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Diderot University, Sorbonne Paris-Cité; Catherine Thieblemont and Josette Briere, Descartes University; Josette Briere, Hôpital Necker, Paris; Hervé Tilly, University of Rouen, Institut National de la Santé et de la Recherche Médicale U1245, Rouen; Rene-Olivier Casasnovas, Centre Hospitalier Universitaire Dijon; Institut National de la Santé et de la Recherche Médicale UMR1231, Dijon; Christophe Fruchart, Institut d'Hématologie de Basse Normandie, Centre Hospitalier Universitaire, Caen; Franck Morschhauser, Centre Hospitalier Universitaire Régional de Lille, Lille; Corinne Haioun and Philippe Gaulard, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Mondor; Philippe Gaulard, Institut National de la Santé et de la Recherche Médicale U955; Université Paris-Est, Créteil; Julien Lazarovici, Gustave Roussy Cancer Center, Villejuif; Aurore Perrot, University Hospital, Vandoeuvre les Nancy; Catherine Sebban, Centre Leon Berard, University Claude Bernard Lyon 1; Gilles Salles, Hospices Civils de Lyon, Université Claude Bernard U1052, Lyon; Hugo Gonzalez, Centre Hospitalier René Dubos, Pontoise; Reda Bouabdallah, Institut Paoli Calmettes, Marseille; Lucie Oberic, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse; Bernadette Corront, Centre Hospitalier Régional Annecy, Annecy; Bachra Choufi, Centre Hospitalier Dr Duchenne, Boulogne-sur-mer; Gilles Salles and Bertrand Coiffier, Institut National de la Santé et de la Recherche Médicale U1052, Hospices Civils de Lyon, Pierre-Benite, France; Maria Gomes da Silva and Jose Cabeçadas, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal; Anida Grosicka, Medical University of Silesia, Katowice, Poland; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Concord; John Catalano, Frankston Hospital and Monash University, Frankston, Australia; Dolores Caballero, Hospital Universitario de Salamanca, Salamanca; Armando Lopez-Guillermo, Hospital Clinic Barcelona, Barcelona, Spain; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute; Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; Koen van Eygen, Algemeen Ziekenhuis Groeninge Hospital, President Kennedylaan 4, Kortrijk; Achiel Van Hoof, Algemeen Ziekenhuis Sint Jan AV, Brugge; Andre Bosly, UCL Mont Godinne, Yvoir, Belgium; and Amos M. Cohen, Rabin Medical Center, Beilinson Hospital, Davidoff Cancer Center, Tel-Aviv University, Ramat-Aviv, Israel.",
            "Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Diderot University, Sorbonne Paris-Cité; Catherine Thieblemont and Josette Briere, Descartes University; Josette Briere, Hôpital Necker, Paris; Hervé Tilly, University of Rouen, Institut National de la Santé et de la Recherche Médicale U1245, Rouen; Rene-Olivier Casasnovas, Centre Hospitalier Universitaire Dijon; Institut National de la Santé et de la Recherche Médicale UMR1231, Dijon; Christophe Fruchart, Institut d'Hématologie de Basse Normandie, Centre Hospitalier Universitaire, Caen; Franck Morschhauser, Centre Hospitalier Universitaire Régional de Lille, Lille; Corinne Haioun and Philippe Gaulard, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Mondor; Philippe Gaulard, Institut National de la Santé et de la Recherche Médicale U955; Université Paris-Est, Créteil; Julien Lazarovici, Gustave Roussy Cancer Center, Villejuif; Aurore Perrot, University Hospital, Vandoeuvre les Nancy; Catherine Sebban, Centre Leon Berard, University Claude Bernard Lyon 1; Gilles Salles, Hospices Civils de Lyon, Université Claude Bernard U1052, Lyon; Hugo Gonzalez, Centre Hospitalier René Dubos, Pontoise; Reda Bouabdallah, Institut Paoli Calmettes, Marseille; Lucie Oberic, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse; Bernadette Corront, Centre Hospitalier Régional Annecy, Annecy; Bachra Choufi, Centre Hospitalier Dr Duchenne, Boulogne-sur-mer; Gilles Salles and Bertrand Coiffier, Institut National de la Santé et de la Recherche Médicale U1052, Hospices Civils de Lyon, Pierre-Benite, France; Maria Gomes da Silva and Jose Cabeçadas, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal; Anida Grosicka, Medical University of Silesia, Katowice, Poland; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Concord; John Catalano, Frankston Hospital and Monash University, Frankston, Australia; Dolores Caballero, Hospital Universitario de Salamanca, Salamanca; Armando Lopez-Guillermo, Hospital Clinic Barcelona, Barcelona, Spain; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute; Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; Koen van Eygen, Algemeen Ziekenhuis Groeninge Hospital, President Kennedylaan 4, Kortrijk; Achiel Van Hoof, Algemeen Ziekenhuis Sint Jan AV, Brugge; Andre Bosly, UCL Mont Godinne, Yvoir, Belgium; and Amos M. Cohen, Rabin Medical Center, Beilinson Hospital, Davidoff Cancer Center, Tel-Aviv University, Ramat-Aviv, Israel.",
            "Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Diderot University, Sorbonne Paris-Cité; Catherine Thieblemont and Josette Briere, Descartes University; Josette Briere, Hôpital Necker, Paris; Hervé Tilly, University of Rouen, Institut National de la Santé et de la Recherche Médicale U1245, Rouen; Rene-Olivier Casasnovas, Centre Hospitalier Universitaire Dijon; Institut National de la Santé et de la Recherche Médicale UMR1231, Dijon; Christophe Fruchart, Institut d'Hématologie de Basse Normandie, Centre Hospitalier Universitaire, Caen; Franck Morschhauser, Centre Hospitalier Universitaire Régional de Lille, Lille; Corinne Haioun and Philippe Gaulard, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Mondor; Philippe Gaulard, Institut National de la Santé et de la Recherche Médicale U955; Université Paris-Est, Créteil; Julien Lazarovici, Gustave Roussy Cancer Center, Villejuif; Aurore Perrot, University Hospital, Vandoeuvre les Nancy; Catherine Sebban, Centre Leon Berard, University Claude Bernard Lyon 1; Gilles Salles, Hospices Civils de Lyon, Université Claude Bernard U1052, Lyon; Hugo Gonzalez, Centre Hospitalier René Dubos, Pontoise; Reda Bouabdallah, Institut Paoli Calmettes, Marseille; Lucie Oberic, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse; Bernadette Corront, Centre Hospitalier Régional Annecy, Annecy; Bachra Choufi, Centre Hospitalier Dr Duchenne, Boulogne-sur-mer; Gilles Salles and Bertrand Coiffier, Institut National de la Santé et de la Recherche Médicale U1052, Hospices Civils de Lyon, Pierre-Benite, France; Maria Gomes da Silva and Jose Cabeçadas, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal; Anida Grosicka, Medical University of Silesia, Katowice, Poland; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Concord; John Catalano, Frankston Hospital and Monash University, Frankston, Australia; Dolores Caballero, Hospital Universitario de Salamanca, Salamanca; Armando Lopez-Guillermo, Hospital Clinic Barcelona, Barcelona, Spain; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute; Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; Koen van Eygen, Algemeen Ziekenhuis Groeninge Hospital, President Kennedylaan 4, Kortrijk; Achiel Van Hoof, Algemeen Ziekenhuis Sint Jan AV, Brugge; Andre Bosly, UCL Mont Godinne, Yvoir, Belgium; and Amos M. Cohen, Rabin Medical Center, Beilinson Hospital, Davidoff Cancer Center, Tel-Aviv University, Ramat-Aviv, Israel.",
            "Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Diderot University, Sorbonne Paris-Cité; Catherine Thieblemont and Josette Briere, Descartes University; Josette Briere, Hôpital Necker, Paris; Hervé Tilly, University of Rouen, Institut National de la Santé et de la Recherche Médicale U1245, Rouen; Rene-Olivier Casasnovas, Centre Hospitalier Universitaire Dijon; Institut National de la Santé et de la Recherche Médicale UMR1231, Dijon; Christophe Fruchart, Institut d'Hématologie de Basse Normandie, Centre Hospitalier Universitaire, Caen; Franck Morschhauser, Centre Hospitalier Universitaire Régional de Lille, Lille; Corinne Haioun and Philippe Gaulard, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Mondor; Philippe Gaulard, Institut National de la Santé et de la Recherche Médicale U955; Université Paris-Est, Créteil; Julien Lazarovici, Gustave Roussy Cancer Center, Villejuif; Aurore Perrot, University Hospital, Vandoeuvre les Nancy; Catherine Sebban, Centre Leon Berard, University Claude Bernard Lyon 1; Gilles Salles, Hospices Civils de Lyon, Université Claude Bernard U1052, Lyon; Hugo Gonzalez, Centre Hospitalier René Dubos, Pontoise; Reda Bouabdallah, Institut Paoli Calmettes, Marseille; Lucie Oberic, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse; Bernadette Corront, Centre Hospitalier Régional Annecy, Annecy; Bachra Choufi, Centre Hospitalier Dr Duchenne, Boulogne-sur-mer; Gilles Salles and Bertrand Coiffier, Institut National de la Santé et de la Recherche Médicale U1052, Hospices Civils de Lyon, Pierre-Benite, France; Maria Gomes da Silva and Jose Cabeçadas, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal; Anida Grosicka, Medical University of Silesia, Katowice, Poland; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Concord; John Catalano, Frankston Hospital and Monash University, Frankston, Australia; Dolores Caballero, Hospital Universitario de Salamanca, Salamanca; Armando Lopez-Guillermo, Hospital Clinic Barcelona, Barcelona, Spain; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute; Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; Koen van Eygen, Algemeen Ziekenhuis Groeninge Hospital, President Kennedylaan 4, Kortrijk; Achiel Van Hoof, Algemeen Ziekenhuis Sint Jan AV, Brugge; Andre Bosly, UCL Mont Godinne, Yvoir, Belgium; and Amos M. Cohen, Rabin Medical Center, Beilinson Hospital, Davidoff Cancer Center, Tel-Aviv University, Ramat-Aviv, Israel.",
            "Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Diderot University, Sorbonne Paris-Cité; Catherine Thieblemont and Josette Briere, Descartes University; Josette Briere, Hôpital Necker, Paris; Hervé Tilly, University of Rouen, Institut National de la Santé et de la Recherche Médicale U1245, Rouen; Rene-Olivier Casasnovas, Centre Hospitalier Universitaire Dijon; Institut National de la Santé et de la Recherche Médicale UMR1231, Dijon; Christophe Fruchart, Institut d'Hématologie de Basse Normandie, Centre Hospitalier Universitaire, Caen; Franck Morschhauser, Centre Hospitalier Universitaire Régional de Lille, Lille; Corinne Haioun and Philippe Gaulard, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Mondor; Philippe Gaulard, Institut National de la Santé et de la Recherche Médicale U955; Université Paris-Est, Créteil; Julien Lazarovici, Gustave Roussy Cancer Center, Villejuif; Aurore Perrot, University Hospital, Vandoeuvre les Nancy; Catherine Sebban, Centre Leon Berard, University Claude Bernard Lyon 1; Gilles Salles, Hospices Civils de Lyon, Université Claude Bernard U1052, Lyon; Hugo Gonzalez, Centre Hospitalier René Dubos, Pontoise; Reda Bouabdallah, Institut Paoli Calmettes, Marseille; Lucie Oberic, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse; Bernadette Corront, Centre Hospitalier Régional Annecy, Annecy; Bachra Choufi, Centre Hospitalier Dr Duchenne, Boulogne-sur-mer; Gilles Salles and Bertrand Coiffier, Institut National de la Santé et de la Recherche Médicale U1052, Hospices Civils de Lyon, Pierre-Benite, France; Maria Gomes da Silva and Jose Cabeçadas, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal; Anida Grosicka, Medical University of Silesia, Katowice, Poland; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Concord; John Catalano, Frankston Hospital and Monash University, Frankston, Australia; Dolores Caballero, Hospital Universitario de Salamanca, Salamanca; Armando Lopez-Guillermo, Hospital Clinic Barcelona, Barcelona, Spain; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute; Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; Koen van Eygen, Algemeen Ziekenhuis Groeninge Hospital, President Kennedylaan 4, Kortrijk; Achiel Van Hoof, Algemeen Ziekenhuis Sint Jan AV, Brugge; Andre Bosly, UCL Mont Godinne, Yvoir, Belgium; and Amos M. Cohen, Rabin Medical Center, Beilinson Hospital, Davidoff Cancer Center, Tel-Aviv University, Ramat-Aviv, Israel.",
            "Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Diderot University, Sorbonne Paris-Cité; Catherine Thieblemont and Josette Briere, Descartes University; Josette Briere, Hôpital Necker, Paris; Hervé Tilly, University of Rouen, Institut National de la Santé et de la Recherche Médicale U1245, Rouen; Rene-Olivier Casasnovas, Centre Hospitalier Universitaire Dijon; Institut National de la Santé et de la Recherche Médicale UMR1231, Dijon; Christophe Fruchart, Institut d'Hématologie de Basse Normandie, Centre Hospitalier Universitaire, Caen; Franck Morschhauser, Centre Hospitalier Universitaire Régional de Lille, Lille; Corinne Haioun and Philippe Gaulard, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Mondor; Philippe Gaulard, Institut National de la Santé et de la Recherche Médicale U955; Université Paris-Est, Créteil; Julien Lazarovici, Gustave Roussy Cancer Center, Villejuif; Aurore Perrot, University Hospital, Vandoeuvre les Nancy; Catherine Sebban, Centre Leon Berard, University Claude Bernard Lyon 1; Gilles Salles, Hospices Civils de Lyon, Université Claude Bernard U1052, Lyon; Hugo Gonzalez, Centre Hospitalier René Dubos, Pontoise; Reda Bouabdallah, Institut Paoli Calmettes, Marseille; Lucie Oberic, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse; Bernadette Corront, Centre Hospitalier Régional Annecy, Annecy; Bachra Choufi, Centre Hospitalier Dr Duchenne, Boulogne-sur-mer; Gilles Salles and Bertrand Coiffier, Institut National de la Santé et de la Recherche Médicale U1052, Hospices Civils de Lyon, Pierre-Benite, France; Maria Gomes da Silva and Jose Cabeçadas, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal; Anida Grosicka, Medical University of Silesia, Katowice, Poland; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Concord; John Catalano, Frankston Hospital and Monash University, Frankston, Australia; Dolores Caballero, Hospital Universitario de Salamanca, Salamanca; Armando Lopez-Guillermo, Hospital Clinic Barcelona, Barcelona, Spain; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute; Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; Koen van Eygen, Algemeen Ziekenhuis Groeninge Hospital, President Kennedylaan 4, Kortrijk; Achiel Van Hoof, Algemeen Ziekenhuis Sint Jan AV, Brugge; Andre Bosly, UCL Mont Godinne, Yvoir, Belgium; and Amos M. Cohen, Rabin Medical Center, Beilinson Hospital, Davidoff Cancer Center, Tel-Aviv University, Ramat-Aviv, Israel.",
            "Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Diderot University, Sorbonne Paris-Cité; Catherine Thieblemont and Josette Briere, Descartes University; Josette Briere, Hôpital Necker, Paris; Hervé Tilly, University of Rouen, Institut National de la Santé et de la Recherche Médicale U1245, Rouen; Rene-Olivier Casasnovas, Centre Hospitalier Universitaire Dijon; Institut National de la Santé et de la Recherche Médicale UMR1231, Dijon; Christophe Fruchart, Institut d'Hématologie de Basse Normandie, Centre Hospitalier Universitaire, Caen; Franck Morschhauser, Centre Hospitalier Universitaire Régional de Lille, Lille; Corinne Haioun and Philippe Gaulard, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Mondor; Philippe Gaulard, Institut National de la Santé et de la Recherche Médicale U955; Université Paris-Est, Créteil; Julien Lazarovici, Gustave Roussy Cancer Center, Villejuif; Aurore Perrot, University Hospital, Vandoeuvre les Nancy; Catherine Sebban, Centre Leon Berard, University Claude Bernard Lyon 1; Gilles Salles, Hospices Civils de Lyon, Université Claude Bernard U1052, Lyon; Hugo Gonzalez, Centre Hospitalier René Dubos, Pontoise; Reda Bouabdallah, Institut Paoli Calmettes, Marseille; Lucie Oberic, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse; Bernadette Corront, Centre Hospitalier Régional Annecy, Annecy; Bachra Choufi, Centre Hospitalier Dr Duchenne, Boulogne-sur-mer; Gilles Salles and Bertrand Coiffier, Institut National de la Santé et de la Recherche Médicale U1052, Hospices Civils de Lyon, Pierre-Benite, France; Maria Gomes da Silva and Jose Cabeçadas, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal; Anida Grosicka, Medical University of Silesia, Katowice, Poland; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Concord; John Catalano, Frankston Hospital and Monash University, Frankston, Australia; Dolores Caballero, Hospital Universitario de Salamanca, Salamanca; Armando Lopez-Guillermo, Hospital Clinic Barcelona, Barcelona, Spain; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute; Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; Koen van Eygen, Algemeen Ziekenhuis Groeninge Hospital, President Kennedylaan 4, Kortrijk; Achiel Van Hoof, Algemeen Ziekenhuis Sint Jan AV, Brugge; Andre Bosly, UCL Mont Godinne, Yvoir, Belgium; and Amos M. Cohen, Rabin Medical Center, Beilinson Hospital, Davidoff Cancer Center, Tel-Aviv University, Ramat-Aviv, Israel."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "04",
                "Day": "20"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic Significance of MiRNA in Patients with Diffuse Large B-Cell Lymphoma: a Meta-Analysis.",
        "AuthorList": [
            "Zhuojun Zheng",
            "Xiaodong Li",
            "Yuandong Zhu",
            "Weiying Gu",
            "Xiaobao Xie",
            "Jingting Jiang"
        ],
        "AffiliationList": [
            "Department of Hematology, The Third Affiliated Hospital, Soochow University, Changzhou, China.",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "10",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.",
        "AuthorList": [
            "Victor Yazbeck",
            "Danielle Shafer",
            "Edward B Perkins",
            "Domenico Coppola",
            "Lubomir Sokol",
            "Kristy L Richards",
            "Thomas Shea",
            "Jia Ruan"
        ],
        "AffiliationList": [
            "Massey Cancer Center, Virginia Commonwealth University, Richmond, VA.",
            "Massey Cancer Center, Virginia Commonwealth University, Richmond, VA.",
            "Massey Cancer Center, Virginia Commonwealth University, Richmond, VA; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA.",
            "Department of Pathology, H. Lee Moffitt Cancer Center, Tampa, FL.",
            "Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.",
            "Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.",
            "Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.",
            "Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "06",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "Transient adrenal insufficiency in diffuse large B cell lymphoma patients after chemotherapy with short-course, high-dose corticosteroids.",
        "AuthorList": [
            "Weerapat Owattanapanich",
            "Sirinart Sirinvaravong",
            "Kittima Suphadirekkul",
            "Taweesak Wannachalee"
        ],
        "AffiliationList": [
            "Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700, Thailand. weerapato36733@gmail.com.",
            "Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.",
            "Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700, Thailand.",
            "Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "08",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach.",
        "AuthorList": [
            "Myrna Candelaria",
            "Derlis Gonzalez",
            "Francisco Javier Fernández Gómez",
            "Alexandra Paravisini",
            "Ana Del Campo García",
            "Luis Pérez",
            "Bernardo Miguel-Lillo",
            "Susana Millán"
        ],
        "AffiliationList": [
            "Instituto Nacional de Cancerología, Av. San Fernando No. 22, Tlalpan, Sección XVI, Mexico, DF, Mexico.",
            "Instituto Privado de Hematología e Investigación Clínica (IPHIC), Mariano Roque Alonso 1450, Asunción, Paraguay.",
            "mAbxience Research S.L., Manuel Pombo Angulo 28, 28050, Madrid, Spain. javierfergo@outlook.com.",
            "mAbxience Research S.L., Manuel Pombo Angulo 28, 28050, Madrid, Spain.",
            "mAbxience Research S.L., Manuel Pombo Angulo 28, 28050, Madrid, Spain.",
            "mAbxience Research S.L., Manuel Pombo Angulo 28, 28050, Madrid, Spain.",
            "SGS Exprimo NV, Mechelen, Belgium.",
            "mAbxience Research S.L., Manuel Pombo Angulo 28, 28050, Madrid, Spain."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "01",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "Expression of p63 in reactive hyperplasias and malignant lymphomas.",
        "AuthorList": [
            "Chan-Kum Park",
            "Young-Ha Oh"
        ],
        "AffiliationList": [
            "Department of Pathology, College of Medicine, Hanyang University, Seoul, Korea.",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Prognostic significance of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in diffuse large B cell lymphoma.",
        "AuthorList": [
            "Yan-Li Li",
            "Zhi-Hu Shi",
            "Xian Wang",
            "Kang-Sheng Gu",
            "Zhi-Min Zhai"
        ],
        "AffiliationList": [
            "Department of Pathology, Anhui Medical University, Hefei, Anhui, 230032, People's Republic of China.",
            "Department of Pathology, Anhui Ji Min Cancer Hospital, Hefei, Anhui, 230012, People's Republic of China.",
            "Department of Pathology, Anhui Medical University, Hefei, Anhui, 230032, People's Republic of China.",
            "Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, People's Republic of China.",
            "Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, People's Republic of China. zzzm889@163.com."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "10",
                "Day": "29"
            }
        ]
    },
    {
        "ArticleTitle": "Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Minna Taskinen",
            "Riku Louhimo",
            "Satu Koivula",
            "Ping Chen",
            "Ville Rantanen",
            "Harald Holte",
            "Jan Delabie",
            "Marja-Liisa Karjalainen-Lindsberg"
        ],
        "AffiliationList": [
            "Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland; Genome Scale Biology Program, University of Helsinki, Helsinki, Finland.",
            "Genome Scale Biology Program, University of Helsinki, Helsinki, Finland.",
            "Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland; Genome Scale Biology Program, University of Helsinki, Helsinki, Finland.",
            "Genome Scale Biology Program, University of Helsinki, Helsinki, Finland.",
            "Genome Scale Biology Program, University of Helsinki, Helsinki, Finland.",
            "Department of Oncology, Oslo University Hospital, Oslo, Norway.",
            "Department of Pathology, Oslo University Hospital, Oslo, Norway.",
            "Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "03",
                "Day": "13"
            }
        ]
    },
    {
        "ArticleTitle": "Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL).",
        "AuthorList": [
            "Hye J Kang",
            "Seung S Lee",
            "Kyeong M Kim",
            "Tae H Choi",
            "Gi J Cheon",
            "Won S Kim",
            "Cheolwon Suh",
            "Sung H Yang"
        ],
        "AffiliationList": [
            "Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Republic of Korea.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.",
        "AuthorList": [
            "Sydney Dubois",
            "Pierre-Julien Viailly",
            "Sylvain Mareschal",
            "Elodie Bohers",
            "Philippe Bertrand",
            "Philippe Ruminy",
            "Catherine Maingonnat",
            "Jean-Philippe Jais"
        ],
        "AffiliationList": [
            "Inserm U918, Centre Henri Becquerel, Université de Rouen, IRIB, Rouen, France.",
            "Inserm U918, Centre Henri Becquerel, Université de Rouen, IRIB, Rouen, France. LITIS EA 4108, Normandie Université, Rouen, France.",
            "Inserm U918, Centre Henri Becquerel, Université de Rouen, IRIB, Rouen, France.",
            "Inserm U918, Centre Henri Becquerel, Université de Rouen, IRIB, Rouen, France.",
            "Inserm U918, Centre Henri Becquerel, Université de Rouen, IRIB, Rouen, France.",
            "Inserm U918, Centre Henri Becquerel, Université de Rouen, IRIB, Rouen, France.",
            "Inserm U918, Centre Henri Becquerel, Université de Rouen, IRIB, Rouen, France.",
            "Inserm UMRS 872, AP-HP Hôpital Necker, Paris, France."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "01",
                "Day": "27"
            }
        ]
    },
    {
        "ArticleTitle": "Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection.",
        "AuthorList": [
            "Rui Cui",
            "Cuicui Lyu",
            "Qing Li",
            "Yanyu Jiang",
            "Nan Mou",
            "Zhenxing Yang",
            "Xuxiang Liu",
            "Qi Deng"
        ],
        "AffiliationList": [
            "Department of Hematology, Tianjin First Central Hospital, Tianjin, China.",
            "Department of Hematology, Tianjin First Central Hospital, Tianjin, China.",
            "Department of Hematology, Tianjin First Central Hospital, Tianjin, China.",
            "Department of Hematology, Tianjin First Central Hospital, Tianjin, China.",
            "Department of Gene Therapy, Shanghai Genbase Biotechnology Co., Ltd, Shanghai, China.",
            "Department of Gene Therapy, Shanghai Genbase Biotechnology Co., Ltd, Shanghai, China.",
            "Department of Pathology, City of Hope National Medical Center, Duarte, California, USA.",
            "Department of Hematology, Tianjin First Central Hospital, Tianjin, China."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "10",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Novel risk stratification of de novo diffuse large B cell lymphoma based on tumour-infiltrating T lymphocytes evaluated by flow cytometry.",
        "AuthorList": [
            "Zihang Chen",
            "Xueqin Deng",
            "Yunxia Ye",
            "Limin Gao",
            "Wenyan Zhang",
            "Weiping Liu",
            "Sha Zhao"
        ],
        "AffiliationList": [
            "Department of Pathology, West China Hospital, Sichuan University, No. 37 GuoXue Xiang, Chengdu, 610041, Sichuan, China.",
            "Department of Pathology, West China Hospital, Sichuan University, No. 37 GuoXue Xiang, Chengdu, 610041, Sichuan, China.",
            "Department of Pathology, West China Hospital, Sichuan University, No. 37 GuoXue Xiang, Chengdu, 610041, Sichuan, China.",
            "Department of Pathology, West China Hospital, Sichuan University, No. 37 GuoXue Xiang, Chengdu, 610041, Sichuan, China.",
            "Department of Pathology, West China Hospital, Sichuan University, No. 37 GuoXue Xiang, Chengdu, 610041, Sichuan, China.",
            "Department of Pathology, West China Hospital, Sichuan University, No. 37 GuoXue Xiang, Chengdu, 610041, Sichuan, China.",
            "Department of Pathology, West China Hospital, Sichuan University, No. 37 GuoXue Xiang, Chengdu, 610041, Sichuan, China. hxblzhaosha@126.com."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "10",
                "Day": "30"
            }
        ]
    },
    {
        "ArticleTitle": "The distinct clinical features and prognosis of the CD10⁺MUM1⁺ and CD10⁻Bcl6⁻MUM1⁻ diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Ting-Xun Lu",
            "Yi Miao",
            "Jia-Zhu Wu",
            "Qi-Xing Gong",
            "Jin-Hua Liang",
            "Zhen Wang",
            "Li Wang",
            "Lei Fan"
        ],
        "AffiliationList": [
            "Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.",
            "Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.",
            "Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.",
            "Department of Pathology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.",
            "Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.",
            "Department of Pathology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.",
            "Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.",
            "Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "02",
                "Day": "09"
            }
        ]
    },
    {
        "ArticleTitle": "Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.",
        "AuthorList": [
            "Umberto Vitolo",
            "Marek Trněný",
            "David Belada",
            "John M Burke",
            "Angelo Michele Carella",
            "Neil Chua",
            "Pau Abrisqueta",
            "Judit Demeter"
        ],
        "AffiliationList": [
            "Umberto Vitolo, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin; Angelo Michele Carella, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliera e Universitaria San Martino-IST, Genoa; Antonio Pinto, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples; Maurizio Martelli, Sapienza University, Rome, Italy; Marek Trněný, Charles University, General Hospital, Prague; David Belada, Charles University Hospital, Hradec Králové, Czech Republic; John M. Burke, Rocky Mountain Cancer Centers, Aurora, CO; US Oncology Research, The Woodlands, TX; Neil Chua, Cross Cancer Institute, University of Alberta, Edmonton, Alberta; Laurie H. Sehn, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada; Pau Abrisqueta, University Hospital Vall d'Hebron, Barcelona, Spain; Judit Demeter, Semmelweiss University, Budapest, Hungary; Ian Flinn, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Xiaonan Hong, Fudan University Shanghai Cancer Center, Shanghai; Yuan-Kai Shi, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China; Won Seog Kim, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, Republic of Korea; Yoichi Tatsumi, Kinki University Hospital, Osaka, Japan; Mikkel Z. Oestergaard, Günter Fingerle-Rowson, Olivier Catalani, and Tina Nielsen, F. Hoffman-La Roche, Basel, Switzerland; and Michael Wenger, Genentech, South San Francisco, CA.",
            "Umberto Vitolo, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin; Angelo Michele Carella, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliera e Universitaria San Martino-IST, Genoa; Antonio Pinto, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples; Maurizio Martelli, Sapienza University, Rome, Italy; Marek Trněný, Charles University, General Hospital, Prague; David Belada, Charles University Hospital, Hradec Králové, Czech Republic; John M. Burke, Rocky Mountain Cancer Centers, Aurora, CO; US Oncology Research, The Woodlands, TX; Neil Chua, Cross Cancer Institute, University of Alberta, Edmonton, Alberta; Laurie H. Sehn, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada; Pau Abrisqueta, University Hospital Vall d'Hebron, Barcelona, Spain; Judit Demeter, Semmelweiss University, Budapest, Hungary; Ian Flinn, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Xiaonan Hong, Fudan University Shanghai Cancer Center, Shanghai; Yuan-Kai Shi, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China; Won Seog Kim, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, Republic of Korea; Yoichi Tatsumi, Kinki University Hospital, Osaka, Japan; Mikkel Z. Oestergaard, Günter Fingerle-Rowson, Olivier Catalani, and Tina Nielsen, F. Hoffman-La Roche, Basel, Switzerland; and Michael Wenger, Genentech, South San Francisco, CA.",
            "Umberto Vitolo, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin; Angelo Michele Carella, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliera e Universitaria San Martino-IST, Genoa; Antonio Pinto, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples; Maurizio Martelli, Sapienza University, Rome, Italy; Marek Trněný, Charles University, General Hospital, Prague; David Belada, Charles University Hospital, Hradec Králové, Czech Republic; John M. Burke, Rocky Mountain Cancer Centers, Aurora, CO; US Oncology Research, The Woodlands, TX; Neil Chua, Cross Cancer Institute, University of Alberta, Edmonton, Alberta; Laurie H. Sehn, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada; Pau Abrisqueta, University Hospital Vall d'Hebron, Barcelona, Spain; Judit Demeter, Semmelweiss University, Budapest, Hungary; Ian Flinn, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Xiaonan Hong, Fudan University Shanghai Cancer Center, Shanghai; Yuan-Kai Shi, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China; Won Seog Kim, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, Republic of Korea; Yoichi Tatsumi, Kinki University Hospital, Osaka, Japan; Mikkel Z. Oestergaard, Günter Fingerle-Rowson, Olivier Catalani, and Tina Nielsen, F. Hoffman-La Roche, Basel, Switzerland; and Michael Wenger, Genentech, South San Francisco, CA.",
            "Umberto Vitolo, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin; Angelo Michele Carella, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliera e Universitaria San Martino-IST, Genoa; Antonio Pinto, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples; Maurizio Martelli, Sapienza University, Rome, Italy; Marek Trněný, Charles University, General Hospital, Prague; David Belada, Charles University Hospital, Hradec Králové, Czech Republic; John M. Burke, Rocky Mountain Cancer Centers, Aurora, CO; US Oncology Research, The Woodlands, TX; Neil Chua, Cross Cancer Institute, University of Alberta, Edmonton, Alberta; Laurie H. Sehn, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada; Pau Abrisqueta, University Hospital Vall d'Hebron, Barcelona, Spain; Judit Demeter, Semmelweiss University, Budapest, Hungary; Ian Flinn, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Xiaonan Hong, Fudan University Shanghai Cancer Center, Shanghai; Yuan-Kai Shi, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China; Won Seog Kim, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, Republic of Korea; Yoichi Tatsumi, Kinki University Hospital, Osaka, Japan; Mikkel Z. Oestergaard, Günter Fingerle-Rowson, Olivier Catalani, and Tina Nielsen, F. Hoffman-La Roche, Basel, Switzerland; and Michael Wenger, Genentech, South San Francisco, CA.",
            "Umberto Vitolo, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin; Angelo Michele Carella, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliera e Universitaria San Martino-IST, Genoa; Antonio Pinto, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples; Maurizio Martelli, Sapienza University, Rome, Italy; Marek Trněný, Charles University, General Hospital, Prague; David Belada, Charles University Hospital, Hradec Králové, Czech Republic; John M. Burke, Rocky Mountain Cancer Centers, Aurora, CO; US Oncology Research, The Woodlands, TX; Neil Chua, Cross Cancer Institute, University of Alberta, Edmonton, Alberta; Laurie H. Sehn, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada; Pau Abrisqueta, University Hospital Vall d'Hebron, Barcelona, Spain; Judit Demeter, Semmelweiss University, Budapest, Hungary; Ian Flinn, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Xiaonan Hong, Fudan University Shanghai Cancer Center, Shanghai; Yuan-Kai Shi, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China; Won Seog Kim, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, Republic of Korea; Yoichi Tatsumi, Kinki University Hospital, Osaka, Japan; Mikkel Z. Oestergaard, Günter Fingerle-Rowson, Olivier Catalani, and Tina Nielsen, F. Hoffman-La Roche, Basel, Switzerland; and Michael Wenger, Genentech, South San Francisco, CA.",
            "Umberto Vitolo, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin; Angelo Michele Carella, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliera e Universitaria San Martino-IST, Genoa; Antonio Pinto, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples; Maurizio Martelli, Sapienza University, Rome, Italy; Marek Trněný, Charles University, General Hospital, Prague; David Belada, Charles University Hospital, Hradec Králové, Czech Republic; John M. Burke, Rocky Mountain Cancer Centers, Aurora, CO; US Oncology Research, The Woodlands, TX; Neil Chua, Cross Cancer Institute, University of Alberta, Edmonton, Alberta; Laurie H. Sehn, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada; Pau Abrisqueta, University Hospital Vall d'Hebron, Barcelona, Spain; Judit Demeter, Semmelweiss University, Budapest, Hungary; Ian Flinn, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Xiaonan Hong, Fudan University Shanghai Cancer Center, Shanghai; Yuan-Kai Shi, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China; Won Seog Kim, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, Republic of Korea; Yoichi Tatsumi, Kinki University Hospital, Osaka, Japan; Mikkel Z. Oestergaard, Günter Fingerle-Rowson, Olivier Catalani, and Tina Nielsen, F. Hoffman-La Roche, Basel, Switzerland; and Michael Wenger, Genentech, South San Francisco, CA.",
            "Umberto Vitolo, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin; Angelo Michele Carella, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliera e Universitaria San Martino-IST, Genoa; Antonio Pinto, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples; Maurizio Martelli, Sapienza University, Rome, Italy; Marek Trněný, Charles University, General Hospital, Prague; David Belada, Charles University Hospital, Hradec Králové, Czech Republic; John M. Burke, Rocky Mountain Cancer Centers, Aurora, CO; US Oncology Research, The Woodlands, TX; Neil Chua, Cross Cancer Institute, University of Alberta, Edmonton, Alberta; Laurie H. Sehn, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada; Pau Abrisqueta, University Hospital Vall d'Hebron, Barcelona, Spain; Judit Demeter, Semmelweiss University, Budapest, Hungary; Ian Flinn, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Xiaonan Hong, Fudan University Shanghai Cancer Center, Shanghai; Yuan-Kai Shi, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China; Won Seog Kim, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, Republic of Korea; Yoichi Tatsumi, Kinki University Hospital, Osaka, Japan; Mikkel Z. Oestergaard, Günter Fingerle-Rowson, Olivier Catalani, and Tina Nielsen, F. Hoffman-La Roche, Basel, Switzerland; and Michael Wenger, Genentech, South San Francisco, CA.",
            "Umberto Vitolo, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin; Angelo Michele Carella, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliera e Universitaria San Martino-IST, Genoa; Antonio Pinto, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples; Maurizio Martelli, Sapienza University, Rome, Italy; Marek Trněný, Charles University, General Hospital, Prague; David Belada, Charles University Hospital, Hradec Králové, Czech Republic; John M. Burke, Rocky Mountain Cancer Centers, Aurora, CO; US Oncology Research, The Woodlands, TX; Neil Chua, Cross Cancer Institute, University of Alberta, Edmonton, Alberta; Laurie H. Sehn, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada; Pau Abrisqueta, University Hospital Vall d'Hebron, Barcelona, Spain; Judit Demeter, Semmelweiss University, Budapest, Hungary; Ian Flinn, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Xiaonan Hong, Fudan University Shanghai Cancer Center, Shanghai; Yuan-Kai Shi, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China; Won Seog Kim, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, Republic of Korea; Yoichi Tatsumi, Kinki University Hospital, Osaka, Japan; Mikkel Z. Oestergaard, Günter Fingerle-Rowson, Olivier Catalani, and Tina Nielsen, F. Hoffman-La Roche, Basel, Switzerland; and Michael Wenger, Genentech, South San Francisco, CA."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "08",
                "Day": "10"
            }
        ]
    },
    {
        "ArticleTitle": "Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.",
        "AuthorList": [
            "Grzegorz S Nowakowski",
            "Betsy LaPlant",
            "William R Macon",
            "Craig B Reeder",
            "James M Foran",
            "Garth D Nelson",
            "Carrie A Thompson",
            "Candido E Rivera"
        ],
        "AffiliationList": [
            "Grzegorz S. Nowakowski, Betsy LaPlant, William R. Macon, Garth D. Nelson, Carrie A. Thompson, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Thomas M. Habermann, and Thomas E. Witzig, Mayo Clinic, Rochester, MN; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, BC, Canada; Craig B. Reeder, Mayo Clinic, Scottsdale, AZ; and James M. Foran and Candido E. Rivera, Mayo Clinic, Jacksonville, FL. nowakowski.grzegorz@mayo.edu.",
            "Grzegorz S. Nowakowski, Betsy LaPlant, William R. Macon, Garth D. Nelson, Carrie A. Thompson, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Thomas M. Habermann, and Thomas E. Witzig, Mayo Clinic, Rochester, MN; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, BC, Canada; Craig B. Reeder, Mayo Clinic, Scottsdale, AZ; and James M. Foran and Candido E. Rivera, Mayo Clinic, Jacksonville, FL.",
            "Grzegorz S. Nowakowski, Betsy LaPlant, William R. Macon, Garth D. Nelson, Carrie A. Thompson, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Thomas M. Habermann, and Thomas E. Witzig, Mayo Clinic, Rochester, MN; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, BC, Canada; Craig B. Reeder, Mayo Clinic, Scottsdale, AZ; and James M. Foran and Candido E. Rivera, Mayo Clinic, Jacksonville, FL.",
            "Grzegorz S. Nowakowski, Betsy LaPlant, William R. Macon, Garth D. Nelson, Carrie A. Thompson, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Thomas M. Habermann, and Thomas E. Witzig, Mayo Clinic, Rochester, MN; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, BC, Canada; Craig B. Reeder, Mayo Clinic, Scottsdale, AZ; and James M. Foran and Candido E. Rivera, Mayo Clinic, Jacksonville, FL.",
            "Grzegorz S. Nowakowski, Betsy LaPlant, William R. Macon, Garth D. Nelson, Carrie A. Thompson, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Thomas M. Habermann, and Thomas E. Witzig, Mayo Clinic, Rochester, MN; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, BC, Canada; Craig B. Reeder, Mayo Clinic, Scottsdale, AZ; and James M. Foran and Candido E. Rivera, Mayo Clinic, Jacksonville, FL.",
            "Grzegorz S. Nowakowski, Betsy LaPlant, William R. Macon, Garth D. Nelson, Carrie A. Thompson, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Thomas M. Habermann, and Thomas E. Witzig, Mayo Clinic, Rochester, MN; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, BC, Canada; Craig B. Reeder, Mayo Clinic, Scottsdale, AZ; and James M. Foran and Candido E. Rivera, Mayo Clinic, Jacksonville, FL.",
            "Grzegorz S. Nowakowski, Betsy LaPlant, William R. Macon, Garth D. Nelson, Carrie A. Thompson, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Thomas M. Habermann, and Thomas E. Witzig, Mayo Clinic, Rochester, MN; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, BC, Canada; Craig B. Reeder, Mayo Clinic, Scottsdale, AZ; and James M. Foran and Candido E. Rivera, Mayo Clinic, Jacksonville, FL.",
            "Grzegorz S. Nowakowski, Betsy LaPlant, William R. Macon, Garth D. Nelson, Carrie A. Thompson, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Thomas M. Habermann, and Thomas E. Witzig, Mayo Clinic, Rochester, MN; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, BC, Canada; Craig B. Reeder, Mayo Clinic, Scottsdale, AZ; and James M. Foran and Candido E. Rivera, Mayo Clinic, Jacksonville, FL."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "08",
                "Day": "18"
            }
        ]
    },
    {
        "ArticleTitle": "Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.",
        "AuthorList": [
            "Xueying Li",
            "He Huang",
            "Bing Xu",
            "Hongqiang Guo",
            "Yingcheng Lin",
            "Sheng Ye",
            "Jiqun Yi",
            "Wenyu Li"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.",
            "Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.",
            "Department of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen, China.",
            "Department of Medical Oncology, Henan Cancer Hospital, Zhengzhou, China.",
            "Department of Medical Oncology, Cancer Hospital, Shantou University Medical College, Shantou, China.",
            "Department of Medical Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.",
            "Department of Medical Oncology, Red Cross Hospital of Guangzhou, Guangzhou, China.",
            "Department of Lymphoma, Guangdong General Hospital, Guangzhou, China."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "10",
                "Day": "02"
            }
        ]
    },
    {
        "ArticleTitle": "Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?",
        "AuthorList": [
            "Charlott Mörth",
            "Antonios Valachis",
            "Amal Abu Sabaa",
            "Daniel Molin",
            "Max Flogegård",
            "Gunilla Enblad"
        ],
        "AffiliationList": [
            "Centre for Clinical Research Sörmland, Uppsala University, Uppsala, Sweden. charlott.morth@dll.se.",
            "Centre for Clinical Research Sörmland, Uppsala University, Uppsala, Sweden.",
            "Department of Immunology, Genetics, and Pathology, Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden.",
            "Department of Immunology, Genetics, and Pathology, Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden.",
            "Department of Internal Medicine, Falun General Hospital, Falun, Sweden.",
            "Department of Immunology, Genetics, and Pathology, Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "08",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study.",
        "AuthorList": [
            "Jianqiu Wu",
            "Yongping Song",
            "Liping Su",
            "Li Xu",
            "Tingchao Chen",
            "Zhiyun Zhao",
            "Mingzhi Zhang",
            "Wei Li"
        ],
        "AffiliationList": [
            "Jiangsu Cancer Hospital, Nanjing, 210000, China.",
            "Henan Cancer Hospital, Zhengzhou, China.",
            "Shanxi Cancer Hospital, Taiyuan, China.",
            "Shanghai Roche Pharmaceuticals Ltd, Shanghai, China.",
            "Shanghai Roche Pharmaceuticals Ltd, Shanghai, China.",
            "Shanghai Roche Pharmaceuticals Ltd, Shanghai, China.",
            "The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.",
            "Jilin University First Affiliated Hospital, Changchun, China."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "07",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "Comparative randomized trial evaluating the effect of proton pump inhibitor versus histamine 2 receptor antagonist as an adjuvant therapy in diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Sahar K Hegazy",
            "Sahar M El-Haggar",
            "Suzan A Alhassanin",
            "Eman I El-Berri"
        ],
        "AffiliationList": [
            "Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, El-Guiesh Street, El-Gharbia Government, Tanta, 31527, Egypt.",
            "Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, El-Guiesh Street, El-Gharbia Government, Tanta, 31527, Egypt.",
            "Oncology and Nuclear Medicine Department, Faculty of Medicine, Menoufia University, Yassin Abdel Ghaffar St-from Gamal Abdel Anasar St, Shibin Elkom, Menoufia, 32511, Egypt.",
            "Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, El-Guiesh Street, El-Gharbia Government, Tanta, 31527, Egypt. Eman.elberri@pharm.tanta.edu.eg."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "01",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma.",
        "AuthorList": [
            "Hanne Kuitunen",
            "Elina Kaprio",
            "Peeter Karihtala",
            "Ville Makkonen",
            "Saila Kauppila",
            "Kirsi-Maria Haapasaari",
            "Milla Kuusisto",
            "Esa Jantunen"
        ],
        "AffiliationList": [
            "Medical Research Center, Department of Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, Kajaanintie 50, P.O. Box 5000, 900l4, Oulu, Finland.",
            "Medical Research Center, Department of Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, Kajaanintie 50, P.O. Box 5000, 900l4, Oulu, Finland. elina.kaprio@fimnet.fi.",
            "Medical Research Center, Department of Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, Kajaanintie 50, P.O. Box 5000, 900l4, Oulu, Finland.",
            "Medical Research Center, Department of Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, Kajaanintie 50, P.O. Box 5000, 900l4, Oulu, Finland.",
            "Cancer and Translational Medicine Research Unit, University of Oulu, Kajaanintie 50, P.O. Box 5000, 900l4, Oulu, Finland.",
            "Cancer and Translational Medicine Research Unit, University of Oulu, Kajaanintie 50, P.O. Box 5000, 900l4, Oulu, Finland.",
            "Medical Research Center, Department of Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, Kajaanintie 50, P.O. Box 5000, 900l4, Oulu, Finland.",
            "Department of Medicine, Kuopio University Hospital, Puijonlaaksontie 2, 70210, Kuopio, Finland."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "06",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma-data from the prospective German Tumour Registry Lymphatic Neoplasms.",
        "AuthorList": [
            "Wolfgang Knauf",
            "Wolfgang Abenhardt",
            "Johannes Mohm",
            "Jacqueline Rauh",
            "Johanna Harde",
            "Anja Kaiser-Osterhues",
            "Martina Jänicke",
            "Norbert Marschner"
        ],
        "AffiliationList": [
            "Centrum Hämatologie/Onkologie Bethanien, Frankfurt, Germany.",
            "MVZ Onkologie im Elisenhof, München, Germany.",
            "Onkologische Gemeinschaftspraxis, Dresden, Germany.",
            "GIM Gemeinschaftspraxis, Innere Medizin, Witten, Germany.",
            "Statistics, iOMEDICO, Freiburg, Germany.",
            "Medical Department, iOMEDICO, Freiburg, Germany.",
            "Clinical Epidemiology and Health Economics, iOMEDICO, Freiburg, Germany.",
            "Praxis für Interdisziplinäre Onkologie und Hämatologie, Freiburg, Germany."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "09",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP.",
        "AuthorList": [
            "Jorge J Castillo",
            "Brady E Beltran",
            "Moo-Kon Song",
            "Ivana Ilic",
            "Sirpa Leppa",
            "Heidi Nurmi",
            "Ritsuko Seki",
            "Silvia Uccella"
        ],
        "AffiliationList": [
            "Division of Hematology and Oncology, The Warren Alpert Medical School of Brown University, The Miriam Hospital, Providence, RI 02906, USA. jcastillo@lifespan.org",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "01",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "High-dose etoposide could discriminate the benefit from autologous peripheral blood stem cell transplantation in the patients with refractory diffuse large B cell lymphoma.",
        "AuthorList": [
            "Yu Cai",
            "Liping Wan",
            "Juan Yang",
            "Jun Zhu",
            "Jieling Jiang",
            "Su Li",
            "Xianmin Song",
            "Chun Wang"
        ],
        "AffiliationList": [
            "Department of Hematology, Shanghai General Hospital affiliated to Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, People's Republic of China.",
            "Department of Hematology, Shanghai General Hospital affiliated to Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, People's Republic of China.",
            "Department of Hematology, Shanghai General Hospital affiliated to Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, People's Republic of China.",
            "Department of Hematology, Shanghai General Hospital affiliated to Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, People's Republic of China.",
            "Department of Hematology, Shanghai General Hospital affiliated to Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, People's Republic of China.",
            "Department of Hematology, Shanghai General Hospital affiliated to Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, People's Republic of China.",
            "Department of Hematology, Shanghai General Hospital affiliated to Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, People's Republic of China. shongxm@139.com.",
            "Department of Hematology, Shanghai General Hospital affiliated to Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, People's Republic of China. wangchunsgh@126.com."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "02",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.",
        "AuthorList": [
            "Ching Soon Teoh",
            "Soo Yin Lee",
            "Su Kien Chiang",
            "Teng Keat Chew",
            "Ai Sim Goh"
        ],
        "AffiliationList": [
            "Haematology Unit, Department of Internal Medicine, Hospital Pulau Pinang, Penang, Malaysia.  Email: csteoh20@yahoo.com",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "05",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.",
        "AuthorList": [
            "Darius Juskevicius",
            "David Jucker",
            "Dirk Klingbiel",
            "Christoph Mamot",
            "Stephan Dirnhofer",
            "Alexandar Tzankov"
        ],
        "AffiliationList": [
            "Institute of Pathology, University of Basel and University Hospital Basel, Schoenbeinstrasse 40, CH-4031, Basel, Switzerland.",
            "Institute of Pathology, University of Basel and University Hospital Basel, Schoenbeinstrasse 40, CH-4031, Basel, Switzerland.",
            "Swiss Group for Clinical Cancer Research (SAKK), Effingerstrasse 40, CH-3008, Bern, Switzerland.",
            "Department of Biomedicine, University Hospital Basel, Hebelstrasse 20, CH-4031, Basel, Switzerland.",
            "Institute of Pathology, University of Basel and University Hospital Basel, Schoenbeinstrasse 40, CH-4031, Basel, Switzerland.",
            "Institute of Pathology, University of Basel and University Hospital Basel, Schoenbeinstrasse 40, CH-4031, Basel, Switzerland. alexandar.tzankov@usb.ch."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "03",
                "Day": "17"
            }
        ]
    },
    {
        "ArticleTitle": "Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities.",
        "AuthorList": [
            "Norina Tanaka",
            "Yoichi Imai",
            "Kentaro Yoshinaga",
            "Masayuki Shiseki",
            "Junji Tanaka"
        ],
        "AffiliationList": [
            "Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.",
            "Department of Hematology/Oncology, Research Hospital, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan. imaiyo-tky@umin.ac.jp.",
            "Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.",
            "Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.",
            "Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "09",
                "Day": "18"
            }
        ]
    },
    {
        "ArticleTitle": "Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP - the PLRG report.",
        "AuthorList": [
            "Joanna Drozd-Sokolowska",
            "Jan Maciej Zaucha",
            "Przemyslaw Biecek",
            "Agnieszka Giza",
            "Katarzyna Kobylinska",
            "Monika Joks",
            "Tomasz Wrobel",
            "Beata Kumiega"
        ],
        "AffiliationList": [
            "Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Banacha 1a Str, 02-097, Warszawa, Poland.",
            "Department of Hematology and Transplantology, Medical University of Gdansk, Smoluchowskiego 17 Str., 80-214, Gdansk, Poland. jzaucha@gumed.edu.pl.",
            "Faculty of Mathematics and Information Science, Warsaw University of Technology, Koszykowa 75 Str., 00-662, Warszawa, Poland.",
            "Department of Hematology, Jagiellonian University, Mikołaja Kopernika 17 Str., 30-501, Krakow, Poland.",
            "Faculty of Mathematics and Information Science, Warsaw University of Technology, Koszykowa 75 Str., 00-662, Warszawa, Poland.",
            "Department of Hematology, University of Medical Sciences of Poznan, Szamarzewskiego 84 Str., 60-569, Poznan, Poland.",
            "Department of Hematology, Wroclaw Medical University, Wybrzeże L. Pasteura 4 Str., 50-367, Wroclaw, Poland.",
            "Department of Hematooncology, Markiewicz Memorial Oncology Center Brzozow, Ks. Bielawskiego 18 Str., 36-200, Brzozow, Poland."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "02",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "Relationship between IL-10 gene polymorphisms and the risk of non-Hodgkin lymphoma: A meta-analysis.",
        "AuthorList": [
            "Gang Li",
            "Danqing Li"
        ],
        "AffiliationList": [
            "College of Mathematics, South China University of Technology, Guangzhou, Guangdong, China; Guangzhou E-Government Center, Guangzhou, China. Electronic address: lg@gz.gov.cn.",
            "Cancer Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "03",
                "Day": "19"
            }
        ]
    },
    {
        "ArticleTitle": "Prevalence of Cytoplasmic Actin Mutations in Diffuse Large B-Cell Lymphoma and Multiple Myeloma: A Functional Assessment Based on Actin Three-Dimensional Structures.",
        "AuthorList": [
            "Laura Witjes",
            "Marleen Van Troys",
            "Bruno Verhasselt",
            "Christophe Ampe"
        ],
        "AffiliationList": [
            "Department of Biomolecular Medicine, Ghent University, Albert Baertsoenkaai 3, B-9000 Ghent, Belgium.",
            "Department of Biomolecular Medicine, Ghent University, Albert Baertsoenkaai 3, B-9000 Ghent, Belgium.",
            "Department of Diagnostic Sciences, Ghent University Hospital, Ghent University, Corneel Heymanslaan 10, B-9000 Ghent, Belgium.",
            "Department of Biomolecular Medicine, Ghent University, Albert Baertsoenkaai 3, B-9000 Ghent, Belgium."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "04",
                "Day": "27"
            }
        ]
    },
    {
        "ArticleTitle": "Anthropometrics and prognosis in diffuse large B-cell lymphoma: a multicentre study of 653 patients.",
        "AuthorList": [
            "Mette Dahl Bendtsen",
            "Peter Svenssen Munksgaard",
            "Marianne Tang Severinsen",
            "Eric Bekric",
            "Christian Brieghel",
            "Kristina Buchardi Nielsen",
            "Peter de Nully Brown",
            "Karen Dybkaer"
        ],
        "AffiliationList": [
            "Department of Haematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.",
            "Department of Haematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.",
            "Department of Haematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.",
            "Department of Haematology, Odense University Hospital, Odense, Denmark.",
            "Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.",
            "Department of Haematology, Holstebro Hospital, Holstebro, Denmark.",
            "Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.",
            "Department of Haematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "01",
                "Day": "31"
            }
        ]
    },
    {
        "ArticleTitle": "Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Xin Hu",
            "Min Zeng",
            "Shun-E Yang",
            "Xiao Liang",
            "Shan-Shan Ding",
            "Li Guo",
            "Shan Li",
            "Shu-Juan Wen"
        ],
        "AffiliationList": [
            "Department of Lymphoma Department of Chest Radiotherapy, Affiliated Tumor Hospital of Xinjiang Medical University, Xinjiang, Urumqi, China.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Yoshihiro Kameoka",
            "Tomoaki Akagi",
            "Kazunori Murai",
            "Hideyoshi Noji",
            "Yuichi Kato",
            "Osamu Sasaki",
            "Shigeki Ito",
            "Kenichi Ishizawa"
        ],
        "AffiliationList": [
            "Department of Hematology, Nephrology and Rheumatology, Akita University, 44-2 Hasunuma Hiroomote, Akita city, Akita, 010-0041, Japan. ykameoka@doc.med.akita-u.ac.jp.",
            "Department of Hematology, Aomori Prefectural Central Hospital, Aomori, Japan.",
            "Department of Hematology and Oncology, Iwate Medical University, Morioka, Iwate, Japan.",
            "Department of Cardiology and Hematology, Fukushima Medical University, Fukushima, Japan.",
            "Department of Hematology, Yamagata University, Yamagata, Japan.",
            "Department of Hematology, Miyagi Cancer Center, Natori, Miyagi, Japan.",
            "Department of Hematology and Oncology, Iwate Medical University, Morioka, Iwate, Japan.",
            "Department of Hematology, Yamagata University, Yamagata, Japan."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "07",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "The role of maintenance therapy in patients with diffuse large B cell lymphoma: A systematic review and meta-analysis.",
        "AuthorList": [
            "Alon Rozental",
            "Anat Gafter-Gvili",
            "Liat Vidal",
            "Pia Raanani",
            "Ronit Gurion"
        ],
        "AffiliationList": [
            "Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.",
            "Department of Internal Medicine A, Rabin Medical Center, Petah Tikva, Israel.",
            "Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.",
            "Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.",
            "Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "10",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial.",
        "AuthorList": [
            "Takeshi Hara",
            "Takeshi Yoshikawa",
            "Hideko Goto",
            "Michio Sawada",
            "Toshiki Yamada",
            "Kenji Fukuno",
            "Senji Kasahara",
            "Yuhei Shibata"
        ],
        "AffiliationList": [
            "First Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.",
            "First Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.",
            "Division of Hematology, Gifu Municipal Hospital, Gifu, Japan.",
            "Department of Hematology, Gifu Red-Cross Hospital, Gifu, Japan.",
            "Department of Hematology, Gifu Prefectural General Medical Center, Gifu, Japan.",
            "First Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.",
            "Division of Hematology, Gifu Municipal Hospital, Gifu, Japan.",
            "First Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "06",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "Body fatness at a young age and risks of eight types of cancer: systematic review and meta-analysis of observational studies.",
        "AuthorList": [
            "K Hidayat",
            "X Du",
            "B-M Shi"
        ],
        "AffiliationList": [
            "Department of Endocrinology and Metabolism, The First Affiliated Hospital of Soochow University, Suzhou, China.",
            "Department of Endocrinology and Metabolism, The First Affiliated Hospital of Soochow University, Suzhou, China.",
            "Department of Endocrinology and Metabolism, The First Affiliated Hospital of Soochow University, Suzhou, China."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "07",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling.",
        "AuthorList": [
            "Ebrahim Sakhinia",
            "Caroline Glennie",
            "Judith A Hoyland",
            "Lia P Menasce",
            "Gerard Brady",
            "Crispin Miller",
            "John A Radford",
            "Richard J Byers"
        ],
        "AffiliationList": [
            "Division of Regenerative Medicine, School of Medicine, Faculty of Medical and Human Sciences, The University of Manchester, Oxford Road, Manchester, UK.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2007",
                "Month": "01",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis.",
        "AuthorList": [
            "Coreline N Burggraaff",
            "Antoinette de Jong",
            "Otto S Hoekstra",
            "Nikie J Hoetjes",
            "Rutger A J Nievelstein",
            "Elise P Jansma",
            "Martijn W Heymans",
            "Henrica C W de Vet"
        ],
        "AffiliationList": [
            "Department of Hematology, VU University Medical Center, Cancer Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.",
            "Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.",
            "Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.",
            "Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.",
            "Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.",
            "Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.",
            "Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.",
            "Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "08",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the <i>Fondazione Italiana Linfomi</i>.",
        "AuthorList": [
            "Sergio Storti",
            "Michele Spina",
            "Emanuela Anna Pesce",
            "Flavia Salvi",
            "Michele Merli",
            "Alessia Ruffini",
            "Giuseppina Cabras",
            "Annalisa Chiappella"
        ],
        "AffiliationList": [
            "Department of Hematology, Universita' Cattolica Sacro Cuore Campobasso, Italy.",
            "Division of Oncology A, National Cancer Institute Aviano, Italy.",
            "Fondazione Italiana Linfomi Onlus, Italy.",
            "Hematology Unit, Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy.",
            "Department of Hematology, Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi, Varese, Italy.",
            "GRADE -Gruppo Amici Dell'Ematologia, Italy.",
            "Unit of Hematology Ospedale Businco, Cagliari, Italy.",
            "Department of Hematology, Città della Salute Hospital and University, Torino, Italy."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "05",
                "Day": "10"
            }
        ]
    },
    {
        "ArticleTitle": "Evaluation of diffuse large B-cell lymphoma patients with 64-slice multidetector computed tomography versus <sup>18</sup>FDG positron emission tomography/computed tomography in initial staging and restaging after treatment.",
        "AuthorList": [
            "Nieves Gómez León",
            "Gema Vega",
            "Beatriz Rodríguez-Vigil Junco",
            "Carlos Suevos Ballesteros"
        ],
        "AffiliationList": [
            "Instituto de Investigación, Servicio de Radiología del Hospital Universitario de la Princesa, Madrid, España; Universidad Autónoma de Madrid, Madrid, España.",
            "Instituto de Investigación, Servicio de Radiología del Hospital Universitario de la Princesa, Madrid, España; Servicio de Medicina Intensiva del Universitario de la Princesa, Madrid, España.",
            "Osatek RM. Hospital Universitario de Álava, Vitoria, España. Electronic address: beatrizrodriguezvigil@yahoo.es.",
            "Instituto de Investigación, Servicio de Radiología del Hospital Universitario de la Princesa, Madrid, España; Universidad Autónoma de Madrid, Madrid, España."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "04",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.",
        "AuthorList": [
            "John M Burke",
            "Andrei Shustov",
            "James Essell",
            "Dipti Patel-Donnelly",
            "Jay Yang",
            "Robert Chen",
            "Wei Ye",
            "Wen Shi"
        ],
        "AffiliationList": [
            "Rocky Mountain Cancer Centers, The US Oncology Network, Aurora, CO. Electronic address: John.Burke@USOncology.com.",
            "University of Washington School of Medicine, Seattle, WA.",
            "Oncology Hematology Care, Inc, Cincinnati, OH.",
            "Virginia Cancer Specialists, The US Oncology Network, Fairfax, VA.",
            "Karmanos Cancer Institute, Wayne State University, Detroit, MI.",
            "City of Hope, Duarte, CA.",
            "Gilead Sciences, Inc, Foster City, CA.",
            "Gilead Sciences, Inc, Foster City, CA."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "06",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "Predictive Modelling of Overall Survival in Adult Patients with Primary Diffuse Large B-cell Lymphoma of the Breast Using the Surveillance, Epidemiology, and End Results (SEER) Database.",
        "AuthorList": [
            "Yishuai Liu",
            "Haifeng Han",
            "Hong Wei",
            "Xinlong Wang",
            "Zhaotang Luan",
            "Kun Jiang"
        ],
        "AffiliationList": [
            "Department of Clinical Laboratory, Weifang Traditional Chinese Hospital, Weifang, China.",
            "Department of Clinical Laboratory, Weifang People's Hospital, Weifang, China.",
            "Department of Clinical Laboratory, Weifang Traditional Chinese Hospital, Weifang, China.",
            "Department of Clinical Laboratory, Weifang Traditional Chinese Hospital, Weifang, China.",
            "Department of Clinical Laboratory, Weifang Traditional Chinese Hospital, Weifang, China.",
            "Department of Clinical Laboratory, Weifang People's Hospital, Weifang, China."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Clinicopathological characteristics of diffuse large B-cell lymphoma involving small and large intestines: an analysis of 126 patients.",
        "AuthorList": [
            "Akiko Miyagi Maeshima",
            "Hirokazu Taniguchi",
            "Yuta Ito",
            "Shunsuke Hatta",
            "Tomotaka Suzuki",
            "Sayako Yuda",
            "Shinichi Makita",
            "Suguru Fukuhara"
        ],
        "AffiliationList": [
            "Pathology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. akmaeshi@ncc.go.jp.",
            "Pathology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.",
            "Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.",
            "Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.",
            "Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.",
            "Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.",
            "Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.",
            "Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "06",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation.",
        "AuthorList": [
            "Andrés J M Ferreri",
            "Marianna Sassone",
            "Piera Angelillo",
            "Francesco Zaja",
            "Alessandro Re",
            "Alice Di Rocco",
            "Michele Spina",
            "Alberto Fabbri"
        ],
        "AffiliationList": [
            "Lymphoma Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.",
            "Lymphoma Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.",
            "Lymphoma Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.",
            "SC Ematologia, Azienda Sanitaria Universitaria Integrata, Trieste, Italy.",
            "Division of Hematology, Spedali Civili, Brescia, Italy.",
            "Division of Hematology, University \"La Sapienza\", Rome, Italy.",
            "Division of Medical Oncology, National Cancer Institute, Aviano, Italy.",
            "Division of Hematology, Azienda Ospedaliera Università Senese, Siena, Italy."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "05",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12.",
        "AuthorList": [
            "John Kuruvilla",
            "David A MacDonald",
            "C Tom Kouroukis",
            "Matthew Cheung",
            "Harold J Olney",
            "A Robert Turner",
            "Peter Anglin",
            "Matthew Seftel"
        ],
        "AffiliationList": [
            "Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada;",
            "Hematology, Queen Elizabeth II Health Sciences Centre, Halifax, Canada;",
            "Hematology, Juravinski Cancer Centre, Hamilton, Canada;",
            "Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada;",
            "Hematologic Oncology, Centre hospitalier de l'université de Montréal-Hôpital Notre-Dame, Montreal, Canada;",
            "Department of Oncology, Cross Cancer Institute, Edmonton, Canada;",
            "Medical Oncology, Stronach Regional Cancer Centre, Newmarket, Canada;",
            "Hematologic Oncology, Cancer Care Manitoba, Winnipeg, Canada;"
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "06",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "Metabolic fingerprinting of fresh lymphoma samples used to discriminate between follicular and diffuse large B-cell lymphomas.",
        "AuthorList": [
            "Ignasi Barba",
            "Carolina Sanz",
            "Angels Barbera",
            "Gustavo Tapia",
            "José-Luis Mate",
            "David Garcia-Dorado",
            "Josep-Maria Ribera",
            "Albert Oriol"
        ],
        "AffiliationList": [
            "Laboratory of Experimental Cardiology, Heart Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2009",
                "Month": "08",
                "Day": "29"
            }
        ]
    },
    {
        "ArticleTitle": "Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis.",
        "AuthorList": [
            "Francesca Merchionne",
            "Giovanni Quintana",
            "Francesco Gaudio",
            "Carla Minoia",
            "Giorgina Specchia",
            "Attilio Guarini",
            "Giovanni Quarta",
            "Vincenzo Pavone"
        ],
        "AffiliationList": [
            "Hematology and Bone Marrow Transplantation Unit, Antonio Perrino Hospital, Brindisi, Italy. Electronic address: framerk@hotmail.com.",
            "Hematology and Bone Marrow Transplantation Unit, Antonio Perrino Hospital, Brindisi, Italy.",
            "Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari Medical School, Bari, Italy.",
            "Hematology Unit, Department of Medical and Experimental Oncology, IRCCS National Cancer Research Centre \"Giovanni Paolo II\", Bari, Italy.",
            "Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari Medical School, Bari, Italy.",
            "Hematology Unit, Department of Medical and Experimental Oncology, IRCCS National Cancer Research Centre \"Giovanni Paolo II\", Bari, Italy.",
            "Hematology and Bone Marrow Transplantation Unit, Antonio Perrino Hospital, Brindisi, Italy.",
            "Hematology Unit, Foundation Hospital Cardinal \"G. Panico\", Tricase, Lecce, Italy."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "10",
                "Day": "22"
            }
        ]
    },
    {
        "ArticleTitle": "Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.",
        "AuthorList": [
            "James R Cerhan",
            "Anne Kricker",
            "Ora Paltiel",
            "Christopher R Flowers",
            "Sophia S Wang",
            "Alain Monnereau",
            "Aaron Blair",
            "Luigino Dal Maso"
        ],
        "AffiliationList": [
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN (JRC, SLS); Sydney School of Public Health, The University of Sydney, Sydney, Australia (AK); Department of Entomology, The Robert H. Smith Faculty of Agriculture, Koret School of Veterinary Medicine Veterinary Teaching Hospital, Hebrew University of Jerusalem, Jerusalem, Israel (OP); Winship Cancer Institute, Emory University, Atlanta, GA (CRF); Department of Cancer Etiology, Beckman Research Institute of the City of Hope, Duarte, CA (SSW, LB); Inserm, Centre for Research in Epidemiology and Population Health (CESP), U1018, Environmental Epidemiology of Cancer Group, F-94805, and Univ Paris Sud, UMRS 1018, F-94805, Villejuif, France (AM, JC); Registry of Hematological Malignancies in Gironde, Bergonié Institute, Bordeaux, France (AM); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD (AB, NR, JNS, LMM); Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy (LDM); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Center for Chronic Immunodeficiency (CCI), University Medical Center Freiburg, Freiburg, Germany (AN); Department of Cancer Biology, Mayo Clinic Cancer Center, Jacksonville, FL (JMF); Unit of Occupational and Environmental Epidemiology, Cancer Prevention and Research Institute ISPO Florence, Florence, Italy (LM); Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL (CFS). cerhan.james@mayo.edu.",
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN (JRC, SLS); Sydney School of Public Health, The University of Sydney, Sydney, Australia (AK); Department of Entomology, The Robert H. Smith Faculty of Agriculture, Koret School of Veterinary Medicine Veterinary Teaching Hospital, Hebrew University of Jerusalem, Jerusalem, Israel (OP); Winship Cancer Institute, Emory University, Atlanta, GA (CRF); Department of Cancer Etiology, Beckman Research Institute of the City of Hope, Duarte, CA (SSW, LB); Inserm, Centre for Research in Epidemiology and Population Health (CESP), U1018, Environmental Epidemiology of Cancer Group, F-94805, and Univ Paris Sud, UMRS 1018, F-94805, Villejuif, France (AM, JC); Registry of Hematological Malignancies in Gironde, Bergonié Institute, Bordeaux, France (AM); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD (AB, NR, JNS, LMM); Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy (LDM); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Center for Chronic Immunodeficiency (CCI), University Medical Center Freiburg, Freiburg, Germany (AN); Department of Cancer Biology, Mayo Clinic Cancer Center, Jacksonville, FL (JMF); Unit of Occupational and Environmental Epidemiology, Cancer Prevention and Research Institute ISPO Florence, Florence, Italy (LM); Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL (CFS).",
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN (JRC, SLS); Sydney School of Public Health, The University of Sydney, Sydney, Australia (AK); Department of Entomology, The Robert H. Smith Faculty of Agriculture, Koret School of Veterinary Medicine Veterinary Teaching Hospital, Hebrew University of Jerusalem, Jerusalem, Israel (OP); Winship Cancer Institute, Emory University, Atlanta, GA (CRF); Department of Cancer Etiology, Beckman Research Institute of the City of Hope, Duarte, CA (SSW, LB); Inserm, Centre for Research in Epidemiology and Population Health (CESP), U1018, Environmental Epidemiology of Cancer Group, F-94805, and Univ Paris Sud, UMRS 1018, F-94805, Villejuif, France (AM, JC); Registry of Hematological Malignancies in Gironde, Bergonié Institute, Bordeaux, France (AM); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD (AB, NR, JNS, LMM); Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy (LDM); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Center for Chronic Immunodeficiency (CCI), University Medical Center Freiburg, Freiburg, Germany (AN); Department of Cancer Biology, Mayo Clinic Cancer Center, Jacksonville, FL (JMF); Unit of Occupational and Environmental Epidemiology, Cancer Prevention and Research Institute ISPO Florence, Florence, Italy (LM); Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL (CFS).",
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN (JRC, SLS); Sydney School of Public Health, The University of Sydney, Sydney, Australia (AK); Department of Entomology, The Robert H. Smith Faculty of Agriculture, Koret School of Veterinary Medicine Veterinary Teaching Hospital, Hebrew University of Jerusalem, Jerusalem, Israel (OP); Winship Cancer Institute, Emory University, Atlanta, GA (CRF); Department of Cancer Etiology, Beckman Research Institute of the City of Hope, Duarte, CA (SSW, LB); Inserm, Centre for Research in Epidemiology and Population Health (CESP), U1018, Environmental Epidemiology of Cancer Group, F-94805, and Univ Paris Sud, UMRS 1018, F-94805, Villejuif, France (AM, JC); Registry of Hematological Malignancies in Gironde, Bergonié Institute, Bordeaux, France (AM); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD (AB, NR, JNS, LMM); Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy (LDM); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Center for Chronic Immunodeficiency (CCI), University Medical Center Freiburg, Freiburg, Germany (AN); Department of Cancer Biology, Mayo Clinic Cancer Center, Jacksonville, FL (JMF); Unit of Occupational and Environmental Epidemiology, Cancer Prevention and Research Institute ISPO Florence, Florence, Italy (LM); Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL (CFS).",
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN (JRC, SLS); Sydney School of Public Health, The University of Sydney, Sydney, Australia (AK); Department of Entomology, The Robert H. Smith Faculty of Agriculture, Koret School of Veterinary Medicine Veterinary Teaching Hospital, Hebrew University of Jerusalem, Jerusalem, Israel (OP); Winship Cancer Institute, Emory University, Atlanta, GA (CRF); Department of Cancer Etiology, Beckman Research Institute of the City of Hope, Duarte, CA (SSW, LB); Inserm, Centre for Research in Epidemiology and Population Health (CESP), U1018, Environmental Epidemiology of Cancer Group, F-94805, and Univ Paris Sud, UMRS 1018, F-94805, Villejuif, France (AM, JC); Registry of Hematological Malignancies in Gironde, Bergonié Institute, Bordeaux, France (AM); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD (AB, NR, JNS, LMM); Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy (LDM); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Center for Chronic Immunodeficiency (CCI), University Medical Center Freiburg, Freiburg, Germany (AN); Department of Cancer Biology, Mayo Clinic Cancer Center, Jacksonville, FL (JMF); Unit of Occupational and Environmental Epidemiology, Cancer Prevention and Research Institute ISPO Florence, Florence, Italy (LM); Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL (CFS).",
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN (JRC, SLS); Sydney School of Public Health, The University of Sydney, Sydney, Australia (AK); Department of Entomology, The Robert H. Smith Faculty of Agriculture, Koret School of Veterinary Medicine Veterinary Teaching Hospital, Hebrew University of Jerusalem, Jerusalem, Israel (OP); Winship Cancer Institute, Emory University, Atlanta, GA (CRF); Department of Cancer Etiology, Beckman Research Institute of the City of Hope, Duarte, CA (SSW, LB); Inserm, Centre for Research in Epidemiology and Population Health (CESP), U1018, Environmental Epidemiology of Cancer Group, F-94805, and Univ Paris Sud, UMRS 1018, F-94805, Villejuif, France (AM, JC); Registry of Hematological Malignancies in Gironde, Bergonié Institute, Bordeaux, France (AM); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD (AB, NR, JNS, LMM); Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy (LDM); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Center for Chronic Immunodeficiency (CCI), University Medical Center Freiburg, Freiburg, Germany (AN); Department of Cancer Biology, Mayo Clinic Cancer Center, Jacksonville, FL (JMF); Unit of Occupational and Environmental Epidemiology, Cancer Prevention and Research Institute ISPO Florence, Florence, Italy (LM); Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL (CFS).",
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN (JRC, SLS); Sydney School of Public Health, The University of Sydney, Sydney, Australia (AK); Department of Entomology, The Robert H. Smith Faculty of Agriculture, Koret School of Veterinary Medicine Veterinary Teaching Hospital, Hebrew University of Jerusalem, Jerusalem, Israel (OP); Winship Cancer Institute, Emory University, Atlanta, GA (CRF); Department of Cancer Etiology, Beckman Research Institute of the City of Hope, Duarte, CA (SSW, LB); Inserm, Centre for Research in Epidemiology and Population Health (CESP), U1018, Environmental Epidemiology of Cancer Group, F-94805, and Univ Paris Sud, UMRS 1018, F-94805, Villejuif, France (AM, JC); Registry of Hematological Malignancies in Gironde, Bergonié Institute, Bordeaux, France (AM); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD (AB, NR, JNS, LMM); Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy (LDM); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Center for Chronic Immunodeficiency (CCI), University Medical Center Freiburg, Freiburg, Germany (AN); Department of Cancer Biology, Mayo Clinic Cancer Center, Jacksonville, FL (JMF); Unit of Occupational and Environmental Epidemiology, Cancer Prevention and Research Institute ISPO Florence, Florence, Italy (LM); Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL (CFS).",
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN (JRC, SLS); Sydney School of Public Health, The University of Sydney, Sydney, Australia (AK); Department of Entomology, The Robert H. Smith Faculty of Agriculture, Koret School of Veterinary Medicine Veterinary Teaching Hospital, Hebrew University of Jerusalem, Jerusalem, Israel (OP); Winship Cancer Institute, Emory University, Atlanta, GA (CRF); Department of Cancer Etiology, Beckman Research Institute of the City of Hope, Duarte, CA (SSW, LB); Inserm, Centre for Research in Epidemiology and Population Health (CESP), U1018, Environmental Epidemiology of Cancer Group, F-94805, and Univ Paris Sud, UMRS 1018, F-94805, Villejuif, France (AM, JC); Registry of Hematological Malignancies in Gironde, Bergonié Institute, Bordeaux, France (AM); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD (AB, NR, JNS, LMM); Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy (LDM); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Center for Chronic Immunodeficiency (CCI), University Medical Center Freiburg, Freiburg, Germany (AN); Department of Cancer Biology, Mayo Clinic Cancer Center, Jacksonville, FL (JMF); Unit of Occupational and Environmental Epidemiology, Cancer Prevention and Research Institute ISPO Florence, Florence, Italy (LM); Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL (CFS)."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis.",
        "AuthorList": [
            "Xin He",
            "Zhigang Chen",
            "Tao Fu",
            "Xueli Jin",
            "Teng Yu",
            "Yun Liang",
            "Xiaoying Zhao",
            "Liansheng Huang"
        ],
        "AffiliationList": [
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. hlsdoctor@126.com."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "03",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trials.",
        "AuthorList": [
            "Nazik Rayman",
            "King H Lam",
            "Bronno van der Holt",
            "Clara Koss",
            "Dennis Veldhuizen",
            "Leo M Budel",
            "Andries H Mulder",
            "Leo F Verdonck"
        ],
        "AffiliationList": [
            "Department of Hematology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands. n.rayman@erasmusmc.nl",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial.",
        "AuthorList": [
            "Yasuhiro Oki",
            "Kevin R Kelly",
            "Ian Flinn",
            "Manish R Patel",
            "Robert Gharavi",
            "Anna Ma",
            "Jefferson Parker",
            "Amir Hafeez"
        ],
        "AffiliationList": [
            "Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.",
            "Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California, Los Angeles, CA, USA.",
            "Sarah Cannon Research Institute, Nashville, TN, USA.",
            "Sarah Cannon Research Institute, Nashville, TN, USA.",
            "Curis Inc., Lexington, MA, USA rgharavi@curis.com.",
            "Curis Inc., Lexington, MA, USA.",
            "Curis Inc., Lexington, MA, USA.",
            "Curis Inc., Lexington, MA, USA."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "08",
                "Day": "31"
            }
        ]
    },
    {
        "ArticleTitle": "High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study.",
        "AuthorList": [
            "Emmanuel Gyan",
            "Diane Damotte",
            "Stéphane Courby",
            "Delphine Sénécal",
            "Philippe Quittet",
            "Aline Schmidt-Tanguy",
            "Anne Banos",
            "Steven Le Gouill"
        ],
        "AffiliationList": [
            "Department of Haematology and Cell Therapy, CHRU de Tours, Tours, France.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "05",
                "Day": "21"
            }
        ]
    },
    {
        "ArticleTitle": "A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.",
        "AuthorList": [
            "Soham D Puvvada",
            "Hongli Li",
            "Lisa M Rimsza",
            "Steven H Bernstein",
            "Richard I Fisher",
            "Michael LeBlanc",
            "Monika Schmelz",
            "Betty Glinsmann-Gibson"
        ],
        "AffiliationList": [
            "a University of Arizona Cancer Center , Tucson , AZ , USA ;",
            "b SWOG Statistical Center , Seattle , WA , USA ;",
            "c Department of Pathology , University of Arizona , Tucson , AZ , USA ;",
            "d Wilmot Cancer Center , University of Rochester , Rochester , NY , USA ;",
            "e Fox Chase Cancer Center - Temple Health , Philadelphia , PA , USA ;",
            "b SWOG Statistical Center , Seattle , WA , USA ;",
            "c Department of Pathology , University of Arizona , Tucson , AZ , USA ;",
            "c Department of Pathology , University of Arizona , Tucson , AZ , USA ;"
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "01",
                "Day": "12"
            }
        ]
    },
    {
        "ArticleTitle": "The effect of biweekly CHOP and standard CHOP in different subgroups of diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Qingyuan Zhang",
            "Jingxuan Wang",
            "Zhengyan Yu",
            "Yongzhi Zhuang",
            "Wenjie Ma",
            "Shi Jin",
            "Shu Zhao"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, The Affiliated Tumor Hospital of Harbin Medicial University, Daqing Oilfield General Hospital, China. wjxwsci@126.com",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2009",
                "Month": "11",
                "Day": "20"
            }
        ]
    },
    {
        "ArticleTitle": "Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.",
        "AuthorList": [
            "E Van Den Neste",
            "N Schmitz",
            "N Mounier",
            "D Gill",
            "D Linch",
            "M Trneny",
            "R Bouadballah",
            "J Radford"
        ],
        "AffiliationList": [
            "Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium.",
            "AsklepiosKlinik St Georg, AbteilungHämatologie und Stammzelltransplantation, Hamburg, Germany.",
            "CHU de l'Archet, route de St Antoine-Ginestiere, Nice, France.",
            "Princess Alexandra Hospital, Woodville, South Australia, Australia.",
            "University College London, Cancer Institute, London, UK.",
            "Charles University and General Hospital, Praha, Czech Republic.",
            "Institut Paoli Calmette Département d'Onco-Hématologie, Institut Paoli-Calmettes, Marseille, France.",
            "University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "09",
                "Day": "19"
            }
        ]
    },
    {
        "ArticleTitle": "Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.",
        "AuthorList": [
            "Soranobu Ninomiya",
            "Takeshi Hara",
            "Hisashi Tsurumi",
            "Masato Hoshi",
            "Nobuhiro Kanemura",
            "Naoe Goto",
            "Senji Kasahara",
            "Masahito Shimizu"
        ],
        "AffiliationList": [
            "First Department of Internal Medicine, Gifu University Graduate School of Medicine, and Gifu Municipal Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2010",
                "Month": "10",
                "Day": "12"
            }
        ]
    },
    {
        "ArticleTitle": "Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Thomas M Habermann",
            "Edie A Weller",
            "Vicki A Morrison",
            "Randy D Gascoyne",
            "Peter A Cassileth",
            "Jeffrey B Cohn",
            "Shaker R Dakhil",
            "Bruce Woda"
        ],
        "AffiliationList": [
            "Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. habermann.thomas@mayo.edu",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2006",
                "Month": "06",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma.",
        "AuthorList": [
            "S Wöhrer",
            "A Püspök",
            "J Drach",
            "M Hejna",
            "A Chott",
            "M Raderer"
        ],
        "AffiliationList": [
            "Department of Internal Medicine I, Division of Oncology, Center of Excellence in Clinical and Experimental Oncology (CLEXO), University of Vienna, Vienna, Austria.",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.",
        "AuthorList": [
            "Franck Andre Morschhauser",
            "Guillaume Cartron",
            "Catherine Thieblemont",
            "Philippe Solal-Céligny",
            "Corinne Haioun",
            "Reda Bouabdallah",
            "Pierre Feugier",
            "Krimo Bouabdallah"
        ],
        "AffiliationList": [
            "Hematology Department, EA 4481 GRIIOT, Centre Hospitalier Régional Universitaire de Lille, Lille, France. franck.morschhauser@chru-lille.fr",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "07",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404).",
        "AuthorList": [
            "Daniel R Greenwald",
            "Hailun Li",
            "Selina M Luger",
            "Ronald S Go",
            "David King",
            "Taral Patel",
            "Randy D Gascoyne",
            "Jill Kolesar"
        ],
        "AffiliationList": [
            "Stanford University, Stanford, CA, USA. dgreenwald@ccsb.org",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "07",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group.",
        "AuthorList": [
            "Rena Buckstein",
            "John Kuruvilla",
            "Neil Chua",
            "Christina Lee",
            "David A Macdonald",
            "Abdulwahab J Al-Tourah",
            "Alison H Foo",
            "Wendy Walsh"
        ],
        "AffiliationList": [
            "Sunnybrook Health Sciences Center, Toronto, ON, Canada. Rena.buckstein@sunnybrook.ca",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "04",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Randomized, placebo-controlled, double-blinded chemoimmunotherapy clinical trial in a pet dog model of diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Laura Marconato",
            "Patrick Frayssinet",
            "Nicole Rouquet",
            "Stefano Comazzi",
            "Vito Ferdinando Leone",
            "Paola Laganga",
            "Federica Rossi",
            "Massimo Vignoli"
        ],
        "AffiliationList": [
            "Authors' Affiliations: Centro Oncologico Veterinario, Sasso Marconi, Bologna; Department of Veterinary Sciences and Public Health, University of Milan; Department of Comparative Biomedicine and Food Science, University of Padova, Italy; Urodelia, St Lys, France; and Epidemiology advisor, London, United Kingdom.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "12",
                "Day": "03"
            }
        ]
    },
    {
        "ArticleTitle": "Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? Results from a multicentre, retrospective study.",
        "AuthorList": [
            "Vanja Zeremski",
            "Kathleen Jentsch-Ullrich",
            "Christoph Kahl",
            "Martin Mohren",
            "Judith Eberhardt",
            "Thomas Fischer",
            "Enrico Schalk"
        ],
        "AffiliationList": [
            "Department of Haematology and Oncology, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany. vanja.zeremski@med.ovgu.de.",
            "Private Practice for Haematology and Oncology, Magdeburg, Germany.",
            "Department of Haematology, Oncology and Palliative Care, Klinikum Magdeburg, Magdeburg, Germany.",
            "Department of Hematology and Oncology, Johanniter Krankenhaus, Stendal, Germany.",
            "Department of Haematology and Oncology, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.",
            "Department of Haematology and Oncology, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.",
            "Department of Haematology and Oncology, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "11",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "Abnormal vascular endothelial growth factor protein expression may be correlated with poor prognosis in diffuse large B-cell lymphoma: A meta-analysis.",
        "AuthorList": [
            "Li Jiang",
            "Jiang Hong Sun",
            "Li-Na Quan",
            "Yu-Yang Tian",
            "Chui-Ming Jia",
            "Zhi-Qiang Liu",
            "Ai-Chun Liu"
        ],
        "AffiliationList": [
            "Department of Hematology, Harbin Medical University Cancer Hospital, Harbin 150000, P. R. China.",
            "Department of Radiology, Harbin Medical University Cancer Hospital, Harbin 150000, P. R. China.",
            "Department of Hematology, Harbin Medical University Cancer Hospital, Harbin 150000, P. R. China.",
            "Department of Hematology, Harbin Medical University Cancer Hospital, Harbin 150000, P. R. China.",
            "Department of Hematology, Harbin Medical University Cancer Hospital, Harbin 150000, P. R. China.",
            "Department of Hematology, Harbin Medical University Cancer Hospital, Harbin 150000, P. R. China.",
            "Department of Hematology, Harbin Medical University Cancer Hospital, Harbin 150000, P. R. China."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).",
        "AuthorList": [
            "N Ketterer",
            "B Coiffier",
            "C Thieblemont",
            "C Fermé",
            "J Brière",
            "O Casasnovas",
            "S Bologna",
            "B Christian"
        ],
        "AffiliationList": [
            "Department of Oncology, University Hospital, Lausanne, Switzerland. nicolas.ketterer@hirslanden.ch",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "12",
                "Day": "12"
            }
        ]
    },
    {
        "ArticleTitle": "A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402.",
        "AuthorList": [
            "Thomas E Witzig",
            "Fangxin Hong",
            "Ivana N Micallef",
            "Randy D Gascoyne",
            "Ahmet Dogan",
            "Henry Wagner",
            "Brad S Kahl",
            "Ranjana H Advani"
        ],
        "AffiliationList": [
            "Mayo Clinic, Rochester, MN, USA.",
            "Dana Farber Cancer Institute, Boston, MA, USA.",
            "Mayo Clinic, Rochester, MN, USA.",
            "British Columbia Cancer Agency, Centre for Lymphoid Cancer, Vancouver, BC, Canada.",
            "Mayo Clinic, Rochester, MN, USA.",
            "Penn State Cancer Institute, Hershey, PA, USA.",
            "University of Wisconsin, Madison, WI, USA.",
            "Stanford University, Stanford, CA, USA."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "05",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "A Phase II Exploratory Study of PXD-101 (Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma.",
        "AuthorList": [
            "Soham D Puvvada",
            "José M Guillén-Rodríguez",
            "Xavier I Rivera",
            "Kara Heard",
            "Lora Inclan",
            "Monika Schmelz",
            "Jonathan H Schatz",
            "Daniel O Persky"
        ],
        "AffiliationList": [
            "Division of Hematology-Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, AZ, USA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "09",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.",
        "AuthorList": [
            "Matthew Mei",
            "Marielle J Wondergem",
            "Joycelynne M Palmer",
            "Avichai Shimoni",
            "Justin Hasenkamp",
            "Ni-Chun Tsai",
            "Jennifer Simpson",
            "Auayporn Nademanee"
        ],
        "AffiliationList": [
            "Department of Hematology/HCT, City of Hope, Duarte, California.",
            "Department of Haematology, VU University Medical Centre, Amsterdam, The Netherlands.",
            "Department of Biostatistics, City of Hope, Duarte, California.",
            "Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Aviv, Israel.",
            "Department of Hematology and Oncology, University Medical Center Göttingen, Göttingen, Germany.",
            "Department of Haematology, VU University Medical Centre, Amsterdam, The Netherlands.",
            "Department of Radiation Oncology, City of Hope, Duarte, California.",
            "Department of Hematology/HCT, City of Hope, Duarte, California."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "07",
                "Day": "29"
            }
        ]
    },
    {
        "ArticleTitle": "Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Douglas A Stewart",
            "Reinhard Kloiber",
            "Carolyn Owen",
            "Nizar J Bahlis",
            "Peter Duggan",
            "Adnan Mansoor",
            "Isabelle Bence-Bruckler"
        ],
        "AffiliationList": [
            "Medicine and Oncology, University of Calgary , Calgary , Canada.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "02",
                "Day": "17"
            }
        ]
    },
    {
        "ArticleTitle": "FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.",
        "AuthorList": [
            "Hervé Ghesquières",
            "Beth R Larrabee",
            "Corinne Haioun",
            "Brian K Link",
            "Aurélie Verney",
            "Susan L Slager",
            "Nicolas Ketterer",
            "Stephen M Ansell"
        ],
        "AffiliationList": [
            "Department of Hematology, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.",
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.",
            "Lymphoid Malignancies Unit, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP) and University Paris Est, Créteil, France.",
            "Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.",
            "Centre de Recherche en Cancérologie de Lyon - INSERM U 1052/CNRS UMR 5286/Centre Léon Bérard, Lyon, France.",
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.",
            "Department of Oncology, University Hospital, Lausanne, Switzerland.",
            "Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "06",
                "Day": "10"
            }
        ]
    },
    {
        "ArticleTitle": "The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Sarah Park",
            "Jeeyun Lee",
            "Young Hyeh Ko",
            "Arum Han",
            "Hyun Jung Jun",
            "Sang Chul Lee",
            "In Gyu Hwang",
            "Yeon Hee Park"
        ],
        "AffiliationList": [
            "Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-dong Kangnam-ku, Seoul 135-710, Korea.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2007",
                "Month": "03",
                "Day": "30"
            }
        ]
    },
    {
        "ArticleTitle": "Long-term outcomes with HLX01 (HanliKang<sup>®</sup>), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.",
        "AuthorList": [
            "Yan Qin",
            "Yongping Song",
            "Dong Wang",
            "Ou Bai",
            "Jifeng Feng",
            "Xiuhua Sun",
            "Lihua Qiu",
            "Jianmin Yang"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, 100021, Beijing, China.",
            "Department of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.",
            "Department of Oncology, Army Characteristic Medical Center, Chongqing, China.",
            "Department of Hematology, Cancer Center, the First Hospital of Jilin University, Changchun, China.",
            "Department of Oncology, Jiangsu Cancer Hospital, the Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Institute of Cancer Research, Nanjing, China.",
            "Department of Medical Oncology, the Second Affiliated Hospital of Dalian Medical University, Dalian, China.",
            "Department of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin, China.",
            "Department of Hematology, Changhai Hospital, Naval Medical University, Shanghai, China."
        ],
        "Years": [
            {
                "Year": "2024",
                "Month": "01",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Sarit E Assouline",
            "Torsten Holm Nielsen",
            "Stephen Yu",
            "Miguel Alcaide",
            "Lauren Chong",
            "David MacDonald",
            "Axel Tosikyan",
            "Vishal Kukreti"
        ],
        "AffiliationList": [
            "Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada;",
            "Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada;",
            "Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada;",
            "Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada;",
            "Centre for Lymphoid Cancer, Department of Experimental Therapeutics, University of British Columbia, Vancouver, BC, Canada;",
            "Hematology, QEII Health Sciences Centre, Halifax, NS, Canada;",
            "Departement d'oncologie et hematologie, Hopital Sacre-Coeur, Montreal, QC, Canada;",
            "Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada;"
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "05",
                "Day": "10"
            }
        ]
    },
    {
        "ArticleTitle": "Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab).",
        "AuthorList": [
            "M Rummel",
            "T M Kim",
            "F Aversa",
            "W Brugger",
            "E Capochiani",
            "C Plenteda",
            "F Re",
            "P Trask"
        ],
        "AffiliationList": [
            "Department of Hematology & Oncology, University Hospital Giessen, Giessen, Germany.",
            "Division of Hematology & Medical Oncology, Seoul National University Hospital, Seoul, South Korea.",
            "University of Parma, Parma, Italy.",
            "Schwarzwald-Baar Clinic Villingen-Schwenningen, Academic Teaching Hospital, University of Freiburg, Freiburg, Germany.",
            "Center for Hematology, Livorno, Italy.",
            "University of Parma, Parma, Italy.",
            "University Hospital Parma, Parma, Italy.",
            "Genentech Inc., South San Francisco, USA."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis.",
        "AuthorList": [
            "Jianhong Wang",
            "Xiaohui Duan",
            "Lijie Yang",
            "Xiangxiang Liu",
            "Caixia Hao",
            "Hongjuan Dong",
            "Hongtao Gu",
            "Hailong Tang"
        ],
        "AffiliationList": [
            "Department of Hematology, Xijing Hospital, Fourth Military Medical University, Shaanxi Province, Xi'an, China.",
            "Department of Hematology, Xijing Hospital, Fourth Military Medical University, Shaanxi Province, Xi'an, China.",
            "Department of Hematology, Xijing Hospital, Fourth Military Medical University, Shaanxi Province, Xi'an, China.",
            "Department of Hematology, Xijing Hospital, Fourth Military Medical University, Shaanxi Province, Xi'an, China.",
            "Department of Hematology, Xijing Hospital, Fourth Military Medical University, Shaanxi Province, Xi'an, China.",
            "Department of Hematology, Xijing Hospital, Fourth Military Medical University, Shaanxi Province, Xi'an, China.",
            "Department of Hematology, Xijing Hospital, Fourth Military Medical University, Shaanxi Province, Xi'an, China.",
            "Department of Hematology, Xijing Hospital, Fourth Military Medical University, Shaanxi Province, Xi'an, China."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Tatyana Feldman",
            "Anthony R Mato",
            "Kar F Chow",
            "Ewelina A Protomastro",
            "Kara M L Yannotti",
            "Pritish Bhattacharyya",
            "Xiao Yang",
            "Michele L Donato"
        ],
        "AffiliationList": [
            "John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "03",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.",
        "AuthorList": [
            "Christian Gisselbrecht",
            "Norbert Schmitz",
            "Nicolas Mounier",
            "Devinder Singh Gill",
            "David C Linch",
            "Marek Trneny",
            "Andre Bosly",
            "Noel J Milpied"
        ],
        "AffiliationList": [
            "Hôpital Saint Louis, Paris, France. christian.gisselbrecht@sls.aphp.fr",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "10",
                "Day": "22"
            }
        ]
    },
    {
        "ArticleTitle": "Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP.",
        "AuthorList": [
            "Guoqi Song",
            "William C Cho",
            "Ling Gu",
            "Bangshun He",
            "Yuqin Pan",
            "Shukui Wang"
        ],
        "AffiliationList": [
            "Medical School of Southeast University, Nanjing, 210009, Jiangsu Province, China.",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "06",
                "Day": "13"
            }
        ]
    },
    {
        "ArticleTitle": "Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma.",
        "AuthorList": [
            "Shaker Dakhil",
            "Robert Hermann",
            "Marshall T Schreeder",
            "Stephanie A Gregory",
            "Marc Monte",
            "Kevin S Windsor",
            "Deborah Hurst",
            "Akiko Chai"
        ],
        "AffiliationList": [
            "Cancer Center of Kansas , Wichita, KS , USA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "03",
                "Day": "07"
            }
        ]
    },
    {
        "ArticleTitle": "Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Enrico Derenzini",
            "Vittorio Stefoni",
            "Cinzia Pellegrini",
            "Maria Paola Fina",
            "Alessandro Broccoli",
            "Filippo Venturini",
            "Letizia Gandolfi",
            "Stefano A Pileri"
        ],
        "AffiliationList": [
            "Institute of Haematology and Medical Oncology L. & A. Seràgnoli, University of Bologna, Bologna, Italy. enrico.derenzini@libero.it",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "De novo CD5 positive diffuse large B-cell lymphomas with bone marrow involvement in Korean.",
        "AuthorList": [
            "Sun-Young Kong",
            "Eun Hae Cho",
            "Hee Yeon Woo",
            "Qeuhn Park",
            "Young Hyeh Ko",
            "Sun-Hee Kim"
        ],
        "AffiliationList": [
            "Departments of Laboratory Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy.",
        "AuthorList": [
            "Jeffrey L Halaas",
            "Craig H Moskowitz",
            "Steven Horwitz",
            "Carol Portlock",
            "Ariela Noy",
            "David Straus",
            "Owen A O'Connor",
            "Joachim Yahalom"
        ],
        "AffiliationList": [
            "Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Dong Hwan Kim",
            "Hee Du Jung",
            "Jong Gwang Kim",
            "Je-Jung Lee",
            "Deok-Hwan Yang",
            "Yeon Hee Park",
            "Young Rok Do",
            "Ho Jin Shin"
        ],
        "AffiliationList": [
            "Department of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Ilwon-dong 50, Kangnam-gu, Seoul, Korea 135-710. drkiim@medimail.co.kr",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2006",
                "Month": "04",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "Long-term impact of prior rituximab therapy and early lymphocyte recovery on auto-SCT outcome for diffuse large B-cell lymphoma.",
        "AuthorList": [
            "D G Stover",
            "V K Reddy",
            "Y Shyr",
            "B N Savani",
            "N Reddy"
        ],
        "AffiliationList": [
            "Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN 37232-5505, USA.",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "02",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Infused autograft lymphocyte to monocyte ratio and survival in diffuse large B cell lymphoma.",
        "AuthorList": [
            "Luis F Porrata",
            "David J Inwards",
            "Stephen M Ansell",
            "Ivana N Micallef",
            "Patrick B Johnston",
            "William J Hogan",
            "Svetomir N Markovic"
        ],
        "AffiliationList": [
            "Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: porrata.luis@mayo.edu.",
            "Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.",
            "Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.",
            "Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.",
            "Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.",
            "Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.",
            "Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "07",
                "Day": "17"
            }
        ]
    },
    {
        "ArticleTitle": "Association between tumor necrosis factor-α gene polymorphisms and diffuse large B-cell lymphoma in Chinese Han population: evidence from two center case-control study and a meta-analysis.",
        "AuthorList": [
            "Cui Yang",
            "Wanling Wang",
            "Youmei Zi",
            "Xiaolin Han",
            "Xiaoxue Qin",
            "Jingdong Li",
            "Honggang Ren"
        ],
        "AffiliationList": [
            "Department of Hematology, First Affiliated Hospital of Xinxiang Medical University 88 Jiankang Road, Weihui 453100, Henan Province, China.",
            "Department of Hematology, First Affiliated Hospital of Xinxiang Medical University 88 Jiankang Road, Weihui 453100, Henan Province, China.",
            "Department of Hematology, First Affiliated Hospital of Xinxiang Medical University 88 Jiankang Road, Weihui 453100, Henan Province, China.",
            "Department of Hematology, First Affiliated Hospital of Xinxiang Medical University 88 Jiankang Road, Weihui 453100, Henan Province, China.",
            "Department of Hematology, First Affiliated Hospital of Xinxiang Medical University 88 Jiankang Road, Weihui 453100, Henan Province, China.",
            "Department of Hematology, First Affiliated Hospital of Xinxiang Medical University 88 Jiankang Road, Weihui 453100, Henan Province, China.",
            "Medical Center, Vanderbilt University School of Medicine Nashville, TN 37212, USA."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "10",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies.",
        "AuthorList": [
            "Aurélie Cabannes-Hamy",
            "Frederic Peyrade",
            "Fabrice Jardin",
            "Jean-François Emile",
            "Vincent Delwail",
            "Nicolas Mounier",
            "Corinne Haioun",
            "Aurore Perrot"
        ],
        "AffiliationList": [
            "APHP, Hôpital Saint-Louis, Hemato-Oncologie, Paris, France.",
            "Centre Antoine Lacassagne, Hematologie, Nice, France.",
            "Department of Hematology, Centre Henri Becquerel, UNIROUEN, INSERMU1245, Rouen, France.",
            "APHP, Hôpital universitaire Ambroise Paré, Service d'anatomie pathologique, Boulogne, France.",
            "Department of Oncology-Hematology and Cell Therapy, University Hospital, CIC INSERM 1402, Poitiers, France.",
            "Onco Hématologie, CHU L'archet, Nice, France.",
            "Lymphoid Malignancies Unit, AP-HP, Groupe Hospitalier Mondor, Créteil, France.",
            "Hematology Department, University Hospital, Vandoeuvre Les Nancy, France."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "02",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas.",
        "AuthorList": [
            "Bruce D Cheson",
            "Jeanette Crawford"
        ],
        "AffiliationList": [
            "Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA.",
            "null"
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "03",
                "Day": "07"
            }
        ]
    },
    {
        "ArticleTitle": "Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.",
        "AuthorList": [
            "Carlos Panizo",
            "Anny Jaramillo Rodríguez",
            "Gonzalo Gutiérrez",
            "Francisco Javier Díaz",
            "Eva González-Barca",
            "Raquel de Oña",
            "Carlos Grande",
            "Juan Manuel Sancho"
        ],
        "AffiliationList": [
            "Clínica Universidad de Navarra, Pamplona, Spain. Electronic address: cpanizo@unav.es.",
            "Hospital Vall d' Hebrón, Barcelona, Spain.",
            "Hospital Clínico de Barcelona, Barcelona, Spain.",
            "Hospital Clínico Universitario, Valladolid, Spain.",
            "Institut Catalá d'Oncología-Hospital Duran i Reynals, Barcelona, Spain.",
            "M.D. Anderson, Madrid, Spain.",
            "Hospital Universitario 12 de Octubre, Madrid, Spain.",
            "Hospital German Trias I Pujol, Badalona, Spain."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "03",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "[Efficacy of conservative treatment of gastric lymphosarcoma].",
        "AuthorList": [
            "E E Zvonkov",
            "A M Kremenetskaia",
            "S K Kravchenko",
            "V A Makhinia",
            "I B Kaplanskaia",
            "T N Obukhova",
            "R S Samoĭlova",
            "A A Shevelev"
        ],
        "AffiliationList": [
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium.",
        "AuthorList": [
            "Christine F Skibola",
            "Paige M Bracci",
            "Alexandra Nieters",
            "Angela Brooks-Wilson",
            "Silvia de Sanjosé",
            "Ann Maree Hughes",
            "James R Cerhan",
            "Danica R Skibola"
        ],
        "AffiliationList": [
            "237A Hildebrand Hall, School of Public Health, University of California, Berkeley, Berkeley, CA 94720-7360, USA. chrisfs@berkeley.edu",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2010",
                "Month": "01",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.",
        "AuthorList": [
            "Stephen M Ansell",
            "Matthew J Maurer",
            "Steven C Ziesmer",
            "Susan L Slager",
            "Thomas M Habermann",
            "Brian K Link",
            "Thomas E Witzig",
            "William R Macon"
        ],
        "AffiliationList": [
            "Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. ansell.ansell.stephen@mayo.edu",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "06",
                "Day": "03"
            }
        ]
    },
    {
        "ArticleTitle": "Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial.",
        "AuthorList": [
            "Mathias Witzens-Harig",
            "Axel Benner",
            "Fabienne McClanahan",
            "Jennifer Klemmer",
            "Julia Brandt",
            "Elke Brants",
            "Michael Rieger",
            "Julia Meissner"
        ],
        "AffiliationList": [
            "Internal Medicine V, University of Heidelberg, Heidelberg, Germany.",
            "Division of Biostatistics, German Cancer Research Centre, Heidelberg, Germany.",
            "Centre for Haemato-Oncology, Barts Cancer Institute - a CR-UK Centre of Excellence, London, UK.",
            "Internal Medicine V, University of Heidelberg, Heidelberg, Germany.",
            "Internal Medicine V, University of Heidelberg, Heidelberg, Germany.",
            "Internal Medicine V, University of Heidelberg, Heidelberg, Germany.",
            "Onkologische Schwerpunktpraxis Darmstadt, Darmstadt, Germany.",
            "Internal Medicine V, University of Heidelberg, Heidelberg, Germany."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "10",
                "Day": "09"
            }
        ]
    },
    {
        "ArticleTitle": "Concurrent administration of rituximab and CHOP chemotherapeutic agents for outpatients with CD20-positive lymphoma.",
        "AuthorList": [
            "Yoshihiro Yakushijin",
            "Tomiko Tatsukawa",
            "Takumi Yamaguchi",
            "Takashi Egawa",
            "Noriaki Hidaka",
            "Keiko Ido",
            "Katsuya Suemaru",
            "Masaki Yasukawa"
        ],
        "AffiliationList": [
            "Cancer Center, Ehime University Hospital, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 7910295, Japan. yoshiyak@m.ehime-u.ac.jp",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma.",
        "AuthorList": [
            "Jennifer E Amengual",
            "Sean Clark-Garvey",
            "Matko Kalac",
            "Luigi Scotto",
            "Enrica Marchi",
            "Ellen Neylon",
            "Paul Johannet",
            "Ying Wei"
        ],
        "AffiliationList": [
            "Center for Lymphoid Malignancies, Columbia University, New York, NY;",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "08",
                "Day": "02"
            }
        ]
    },
    {
        "ArticleTitle": "Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants.",
        "AuthorList": [
            "Mixue Xie",
            "Kefei Wu",
            "Yan Liu",
            "Qi Jiang",
            "Yanhui Xie"
        ],
        "AffiliationList": [
            "Department of Hematology, Huadong Hospital Affiliated to Fudan University, West Yan'an Road 221#, Shanghai, 200030, China, 281515835@qq.com.",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "12",
                "Day": "16"
            }
        ]
    },
    {
        "ArticleTitle": "Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms.",
        "AuthorList": [
            "Jay A Read",
            "Jean L Koff",
            "Loretta J Nastoupil",
            "Jessica N Williams",
            "Jonathon B Cohen",
            "Christopher R Flowers"
        ],
        "AffiliationList": [
            "Emory University School of Medicine, Atlanta, GA.",
            "Emory University School of Medicine, Atlanta, GA.",
            "The University of Texas M.D. Anderson Cancer Center, Houston, TX.",
            "Emory University School of Medicine, Atlanta, GA.",
            "Emory University School of Medicine, Atlanta, GA.",
            "Emory University School of Medicine, Atlanta, GA. Electronic address: crflowe@emory.edu."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "06",
                "Day": "12"
            }
        ]
    },
    {
        "ArticleTitle": "Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly \"fit\" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.",
        "AuthorList": [
            "Francesco Merli",
            "Stefano Luminari",
            "Giuseppe Rossi",
            "Caterina Mammi",
            "Luigi Marcheselli",
            "Alessandra Tucci",
            "Fiorella Ilariucci",
            "Annalisa Chiappella"
        ],
        "AffiliationList": [
            "Oncology Department, Azienda Ospedaliera Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Argentina. merli.francesco@asmn.re.it",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "11",
                "Day": "15"
            }
        ]
    },
    {
        "ArticleTitle": "Efficacy of palliative low-dose involved-field radiation therapy in advanced lymphoma: a phase II study.",
        "AuthorList": [
            "Vedang Murthy",
            "Karen Thomas",
            "Kerwyn Foo",
            "David Cunningham",
            "Bernadette Johnson",
            "Andrew Norman",
            "Alan Horwich"
        ],
        "AffiliationList": [
            "Academic Unit of Radiotherapy and Oncology, The Royal Marsden NHS Foundation Trust, Surrey, UK.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.",
        "AuthorList": [
            "M Jerkeman",
            "P Aman",
            "E Cavallin-Stahl",
            "E Torlakovic",
            "M Akerman",
            "F Mitelman",
            "T Fioretos"
        ],
        "AffiliationList": [
            "Department of Oncology, Lund University Hospital, SE-221 85 Lund, Sweden. mats.jerkeman@onk.lu.se",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "One-carbon metabolism gene polymorphisms and risk of non-Hodgkin lymphoma in Australia.",
        "AuthorList": [
            "Kyoung-Mu Lee",
            "Qing Lan",
            "Anne Kricker",
            "Mark P Purdue",
            "Andrew E Grulich",
            "Claire M Vajdic",
            "Jennifer Turner",
            "Denise Whitby"
        ],
        "AffiliationList": [
            "Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, 6120 Executive Blvd. EPS 8118, Bethesda, MD 20892-7240, USA. leekyou@mail.nih.gov",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2007",
                "Month": "09",
                "Day": "21"
            }
        ]
    },
    {
        "ArticleTitle": "Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.",
        "AuthorList": [
            "Noelia Purroy",
            "Juan Bergua",
            "Laura Gallur",
            "Julio Prieto",
            "Luis A Lopez",
            "Juan M Sancho",
            "Jose A García-Marco",
            "Josep Castellví"
        ],
        "AffiliationList": [
            "Department of Haematology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "12",
                "Day": "18"
            }
        ]
    },
    {
        "ArticleTitle": "A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Nina D Wagner-Johnston",
            "Andrè Goy",
            "Maria A Rodriguez",
            "W Christopher Ehmann",
            "Paul A Hamlin",
            "John Radford",
            "Catherine Thieblemont",
            "Cheolwon Suh"
        ],
        "AffiliationList": [
            "a Washington University School of Medicine , St Louis , MO , USA.",
            "b The Cancer Center at Hackensack University Medical Center , Hackensack , NJ , USA.",
            "c University of Texas MD Anderson Cancer Center , Houston , TX , USA.",
            "d Penn State Hershey Cancer Institute , Hershey , PA , USA.",
            "e Memorial Sloan Kettering Cancer Center , New York , NY , USA.",
            "f The University of Manchester and The Christie NHS Foundation Trust , Manchester , UK.",
            "g Hospital Saint Louis , Paris , France.",
            "h Asan Medical Center, University of Ulsan College of Medicine , Seoul , Korea."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "03",
                "Day": "29"
            }
        ]
    },
    {
        "ArticleTitle": "Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09).",
        "AuthorList": [
            "Dok Hyun Yoon",
            "Byeong Seok Sohn",
            "Sung Yong Oh",
            "Won-Sik Lee",
            "Sang Min Lee",
            "Deok-Hwan Yang",
            "Jooryung Huh",
            "Cheolwon Suh"
        ],
        "AffiliationList": [
            "Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.",
            "Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea.",
            "Department of Internal Medicine, Dong-A University Hospital, Busan, Korea.",
            "Department of Hemato-Oncology, Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.",
            "Department of Hemato-Oncology, Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.",
            "Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.",
            "Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.",
            "Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era.",
        "AuthorList": [
            "Moo-Kon Song",
            "Joo-Seop Chung",
            "Gyeong-Won Lee",
            "Su-Hee Cho",
            "Junshik Hong",
            "Dong-Yeop Shin",
            "Ho-Jin Shin"
        ],
        "AffiliationList": [
            "Department of Hematology-Oncology, Pusan National University Hospital Medical Research Institute, Busan, Republic of Korea.",
            "Department of Hematology-Oncology, Pusan National University Hospital Medical Research Institute, Busan, Republic of Korea. Electronic address: Hemon@pusan.ac.kr.",
            "Department of Hematology, Gyeong-Sang National University Hospital, School of Medicine, Gyeong-Sang National University, Jinju, Republic of Korea.",
            "Department of Hematology-Oncology, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.",
            "Department of Hematology, Gachon University Gil Medical Center, Incheon, Republic of Korea.",
            "Department of Hematology, Korea Cancer Center Hospital, Seoul, Republic of Korea.",
            "Department of Hematology-Oncology, Pusan National University Hospital Medical Research Institute, Busan, Republic of Korea."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "12",
                "Day": "09"
            }
        ]
    },
    {
        "ArticleTitle": "Localized primary gastrointestinal diffuse large B cell lymphoma received a surgical approach: an analysis of prognostic factors and comparison of staging systems in 101 patients from a single institution.",
        "AuthorList": [
            "Shengting Zhang",
            "Li Wang",
            "Dong Yu",
            "Yang Shen",
            "Shu Cheng",
            "Li Zhang",
            "Ying Qian",
            "Zhixiang Shen"
        ],
        "AffiliationList": [
            "State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. annezhang1001@gmail.com.",
            "State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. wl_wangdong@126.com.",
            "State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zinic_yu84@yahoo.com.",
            "State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. shen_yang@126.com.",
            "State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. orenge@medmail.com.cn.",
            "State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. dr-lisa@hotmail.com.",
            "State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. ljj10395502@163.com.",
            "State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. drshenzx@yahoo.com."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "08",
                "Day": "15"
            }
        ]
    },
    {
        "ArticleTitle": "SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.",
        "AuthorList": [
            "René-Olivier Casasnovas",
            "Michel Meignan",
            "Alina Berriolo-Riedinger",
            "Stéphane Bardet",
            "Anne Julian",
            "Catherine Thieblemont",
            "Pierre Vera",
            "Serge Bologna"
        ],
        "AffiliationList": [
            "Hopital Le Bocage, Dijon, France. casasnovas@chu-dijon.fr",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "04",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Bruce D Cheson",
            "Nancy L Bartlett",
            "Julie M Vose",
            "Andres Lopez-Hernandez",
            "Amanda L Seiz",
            "Anne T Keating",
            "Setareh Shamsili",
            "Kyriakos P Papadopoulos"
        ],
        "AffiliationList": [
            "Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA. bdc4@georgetown.edu",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "10",
                "Day": "17"
            }
        ]
    },
    {
        "ArticleTitle": "Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi.",
        "AuthorList": [
            "Francesco Merli",
            "Stefano Luminari",
            "Giuseppe Rossi",
            "Caterina Mammi",
            "Luigi Marcheselli",
            "Angela Ferrari",
            "Michele Spina",
            "Alessandra Tucci"
        ],
        "AffiliationList": [
            "Hematology Unit, Arcispedale Santa Maria Nuova, Istituto di Ricovero e Cura a Carattere Scientifico , Reggio Emilia , Italy.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "04",
                "Day": "30"
            }
        ]
    },
    {
        "ArticleTitle": "Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Danielle Brander",
            "David Rizzieri",
            "Jon Gockerman",
            "Louis Diehl",
            "Thomas Charles Shea",
            "Carlos Decastro",
            "Joseph O Moore",
            "Anne Beaven"
        ],
        "AffiliationList": [
            "Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke Cancer Institute , Durham, NC , USA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "04",
                "Day": "19"
            }
        ]
    },
    {
        "ArticleTitle": "Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapy.",
        "AuthorList": [
            "Yuki Nakajima",
            "Naoto Tomita",
            "Megumi Itabashi",
            "Kazuho Miyashita",
            "Reina Watanabe",
            "Takuya Miyazaki",
            "Takayoshi Tachibana",
            "Hirotaka Takasaki"
        ],
        "AffiliationList": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan. Electronic address: yuki1234@yokohama-cu.ac.jp.",
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan.",
            "Department of Hematology, Yokohama City University, Medical Center, Yokohama, Japan.",
            "Department of Hematology/Immunology, Fujisawa City Hospital, Fujisawa, Japan.",
            "Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.",
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan.",
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan.",
            "Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "12",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome.",
        "AuthorList": [
            "M J Terol",
            "M Tormo",
            "J A Martinez-Climent",
            "I Marugan",
            "I Benet",
            "A Ferrandez",
            "A Teruel",
            "R Ferrer"
        ],
        "AffiliationList": [
            "Department of Hematology and Medical Oncology, Hospital Clínico Universitario, University of Valencia, Valencia, Spain. terol39@mail.ono.es",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.",
        "AuthorList": [
            "Pier Luigi Zinzani",
            "Cinzia Pellegrini",
            "Letizia Gandolfi",
            "Vittorio Stefoni",
            "Federica Quirini",
            "Enrico Derenzini",
            "Alessandro Broccoli",
            "Lisa Argnani"
        ],
        "AffiliationList": [
            "Institute of Haematology and Medical Oncology \"L. e A. Seràgnoli,\" University of Bologna, Italy. pierluigi.zinzani@unibo.it",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "05",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Red meat intake and risk of non-Hodgkin lymphoma: a meta-analysis.",
        "AuthorList": [
            "Hosein Fallahzadeh",
            "Maria Cheraghi",
            "Neda Amoori",
            "Mehrangiz Alaf"
        ],
        "AffiliationList": [
            "Department of Biostatistics and Epidemiology, Research Center of Prevention and Epidemiology of Non-Communicable Disease, Faculty of Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran E-mail : Epidemiology2012@gmail.com.",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis.",
        "AuthorList": [
            "Ulrich J M Mey",
            "Attilio Olivieri",
            "Katjana S Orlopp",
            "Christian Rabe",
            "John W Strehl",
            "Marcus Gorschlueter",
            "Manfred Hensel",
            "Dimitri Flieger"
        ],
        "AffiliationList": [
            "Department of Internal Medicine I, University of Bonn, Germany. mey@uni-bonn.de",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era.",
        "AuthorList": [
            "Gonzalo Gutiérrez-García",
            "Lluis Colomo",
            "Neus Villamor",
            "Leonor Arenillas",
            "Antonio Martínez",
            "Teresa Cardesa",
            "Adriana García-Herrera",
            "Xavier Setoain"
        ],
        "AffiliationList": [
            "Department of Hematology, Hospital Clínic, Institut de Recerca Biomèdica August Pi i Sunyer, Barcelona, Spain.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma.",
        "AuthorList": [
            "C Haioun",
            "N Mounier",
            "J F Emile",
            "D Ranta",
            "B Coiffier",
            "H Tilly",
            "C Récher",
            "C Fermé"
        ],
        "AffiliationList": [
            "Service d'Hématologie Clinique, Centre Hospitalier Universitaire, Groupe Hospitalier Henri Mondor-Chenevier, Assistance Publique-Hôpitaux de Paris et Université Paris XII, Créteil, France. corinne.haioun@hmn.aphp.fr",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2009",
                "Month": "06",
                "Day": "30"
            }
        ]
    },
    {
        "ArticleTitle": "Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma.",
        "AuthorList": [
            "Takeshi Hara",
            "Hisashi Tsurumi",
            "Naoe Goto",
            "Jun-ichi Kitagawa",
            "Nobuhiro Kanemura",
            "Takeshi Yoshikawa",
            "Senji Kasahara",
            "Hideko Goto"
        ],
        "AffiliationList": [
            "First Department of Internal Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).",
        "AuthorList": [
            "Sung-Hoon Jung",
            "Je-Jung Lee",
            "Won Seog Kim",
            "Won-Sik Lee",
            "Young Rok Do",
            "Sung Yong Oh",
            "Min Kyoung Kim",
            "Yeung-Chul Mun"
        ],
        "AffiliationList": [
            "Department of Hemato-Oncology, Chonnam National University Hwasun Hospital, Jeollanam-do, Korea.",
            "Department of Hemato-Oncology, Chonnam National University Hwasun Hospital, Jeollanam-do, Korea.",
            "Department of Hemato-Oncology, Samsung Medical Center, Seoul, Korea.",
            "Department of Hemato-Oncology, Busan Paik Hospital, Inje University, Busan, Korea.",
            "Department of Hemato-Oncology, Keimyung University Dongsan Medical Center, Daegu, Korea.",
            "Department of Hemato-Oncology, Dong-A Medical Center, Busan, Korea.",
            "Department of Hemato-Oncology, Yeungnam University College of Medicine, Taegu, Korea.",
            "Department of Hemato-Oncology, Ewha Womans University Hospital, Seoul, Korea."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "11",
                "Day": "21"
            }
        ]
    },
    {
        "ArticleTitle": "Relationships between VEGF protein expression and pathological characteristics of diffuse large B cell lymphoma: a meta-analysis.",
        "AuthorList": [
            "Lu Sui",
            "Kun Liu",
            "Wei Shen",
            "Liang Zhang"
        ],
        "AffiliationList": [
            "Department of Pathophysiology, Shenyang Medical College, Huanghe North Avenue No.146, Shenyang, 110034, People's Republic of China, suilu312@126.com.",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "06",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "[Clinical features of rituximab plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma].",
        "AuthorList": [
            "Jifeng Feng",
            "Jianqiu Wu",
            "Yongping Song",
            "Liping Su",
            "Mingzhi Zhang",
            "Wei Li",
            "Yu Hu",
            "Xiaohong Zhang"
        ],
        "AffiliationList": [
            "Jiangsu Cancer Hospital, Nanjing 210000, China.",
            "Jiangsu Cancer Hospital, Nanjing 210000, China.",
            "Jiangsu Cancer Hospital, Nanjing 210000, China.",
            "Jiangsu Cancer Hospital, Nanjing 210000, China.",
            "Jiangsu Cancer Hospital, Nanjing 210000, China.",
            "Jiangsu Cancer Hospital, Nanjing 210000, China.",
            "Jiangsu Cancer Hospital, Nanjing 210000, China.",
            "Jiangsu Cancer Hospital, Nanjing 210000, China."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Menstrual and reproductive factors, and hormonal contraception use: associations with non-Hodgkin lymphoma in a pooled analysis of InterLymph case-control studies.",
        "AuthorList": [
            "E V Kane",
            "E Roman",
            "N Becker",
            "L Bernstein",
            "P Boffetta",
            "P M Bracci",
            "J R Cerhan",
            "B C-H Chiu"
        ],
        "AffiliationList": [
            "Epidemiology and Genetics Unit, Department of Health Sciences, University of York, York, UK. Electronic address: eleanor.kane@egu.york.ac.uk.",
            "Epidemiology and Genetics Unit, Department of Health Sciences, University of York, York, UK.",
            "Division of Cancer Epidemiology German Cancer Research Centre, Heidelberg, Germany.",
            "Division of Cancer Etiology, Department of Population Sciences, Beckham Research Institute of the City of Hope Duarte, USA.",
            "Institute for Translational Epidemiology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, USA; International Prevention Research Institute, Lyon, France.",
            "Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco.",
            "Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester.",
            "Division of Biological Sciences, Department of Health Studies, University of Chicago, Chicago, USA."
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "07",
                "Day": "10"
            }
        ]
    },
    {
        "ArticleTitle": "High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy.",
        "AuthorList": [
            "Sari Riihijärvi",
            "Heidi Nurmi",
            "Harald Holte",
            "Magnus Björkholm",
            "Oystein Fluge",
            "Lars Møller Pedersen",
            "Karin Rydström",
            "Mats Jerkeman"
        ],
        "AffiliationList": [
            "Department of Oncology, Helsinki University Central Hospital, Finland.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "09",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Senji Kasahara",
            "Takeshi Hara",
            "Hisashi Tsurumi",
            "Naoe Goto",
            "Jun-Ichi Kitagawa",
            "Nobuhiro Kanemura",
            "Takeshi Yoshikawa",
            "Hideko Goto"
        ],
        "AffiliationList": [
            "First Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Different role of tumor necrosis factor-α polymorphism in non-Hodgkin lymphomas among Caucasian and Asian populations: a meta-analysis.",
        "AuthorList": [
            "Kan Zhai",
            "Jie Ding",
            "Yan Zhou"
        ],
        "AffiliationList": [
            "Medical Research Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China. kan_zhai@sina.com.",
            "Medical Research Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China. ding201cy@sina.com.",
            "Medical Research Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China. abi373a@sohu.com."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "05",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma.",
        "AuthorList": [
            "Tomáš Papajík",
            "Miroslav Mysliveček",
            "Zuzana Sedová",
            "Eva Buriánková",
            "Vít Procházka",
            "Pavel Koranda",
            "Luděk Raida",
            "Zuzana Kubová"
        ],
        "AffiliationList": [
            "Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic. tomas.papajik@fnol.cz",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2010",
                "Month": "11",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.",
        "AuthorList": [
            "M Jerkeman",
            "H Anderson",
            "M Dictor",
            "S Kvaløy",
            "M Akerman",
            "E Cavallin-Ståhl"
        ],
        "AffiliationList": [
            "Department of Oncology, Jubileum Institute, Lund University Hospital, Sweden. mats.jerkeman@onk.lu.se",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2004",
                "Month": "04",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Andreas Viardot",
            "Marie-Elisabeth Goebeler",
            "Georg Hess",
            "Svenja Neumann",
            "Michael Pfreundschuh",
            "Nicole Adrian",
            "Florian Zettl",
            "Martin Libicher"
        ],
        "AffiliationList": [
            "Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany;",
            "Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany;",
            "Department of Hematology, Oncology, and Pneumology, Johannes Gutenberg-University, Mainz, Germany;",
            "Medical Department II, University Hospital Schleswig Holstein Campus Kiel, Kiel, Germany;",
            "Klinik für Innere Medizin I, Saarland University Medical School, Homburg (Saar), Germany;",
            "Klinik für Innere Medizin I, Saarland University Medical School, Homburg (Saar), Germany;",
            "University Hospital Göttingen, Göttingen, Germany;",
            "Department of Radiology, Diakoniekrankenhaus Schwäbisch-Hall, Schwäbisch-Hall, Germany;"
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "01",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Mixue Xie",
            "Weihao Zhai",
            "Shiyu Cheng",
            "Hongdi Zhang",
            "Yanhui Xie",
            "Wei He"
        ],
        "AffiliationList": [
            "a Department of Hematology , Huadong Hospital Affiliated to Fudan University , Shanghai 200030 , China.",
            "b Department of Nuclear Medicine , Huadong Hospital Affiliated to Fudan University , Shanghai 200030 , China.",
            "a Department of Hematology , Huadong Hospital Affiliated to Fudan University , Shanghai 200030 , China.",
            "a Department of Hematology , Huadong Hospital Affiliated to Fudan University , Shanghai 200030 , China.",
            "a Department of Hematology , Huadong Hospital Affiliated to Fudan University , Shanghai 200030 , China.",
            "b Department of Nuclear Medicine , Huadong Hospital Affiliated to Fudan University , Shanghai 200030 , China."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "07",
                "Day": "17"
            }
        ]
    },
    {
        "ArticleTitle": "Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.",
        "AuthorList": [
            "M Crump",
            "B Coiffier",
            "E D Jacobsen",
            "L Sun",
            "J L Ricker",
            "H Xie",
            "S R Frankel",
            "S S Randolph"
        ],
        "AffiliationList": [
            "Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada. michael.crump@uhn.on.ca",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2008",
                "Month": "02",
                "Day": "21"
            }
        ]
    },
    {
        "ArticleTitle": "Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series.",
        "AuthorList": [
            "Enrico Derenzini",
            "Beatrice Casadei",
            "Cinzia Pellegrini",
            "Lisa Argnani",
            "Stefano Pileri",
            "Pier Luigi Zinzani"
        ],
        "AffiliationList": [
            "Institute of Hematology and Medical Oncology \"L. & A. Seràgnoli\", University of Bologna, Bologna, Italy. ederenzini@gmail.com",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "12",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.",
        "AuthorList": [
            "Pieternella Lugtenburg",
            "Antonio Salar Silvestre",
            "Francesca G Rossi",
            "Lucien Noens",
            "Wanda Krall",
            "Kate Bendall",
            "Zsolt Szabo",
            "Ulrich Jaeger"
        ],
        "AffiliationList": [
            "Department of Hematology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. p.lugtenburg@erasmusmc.nl",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Cancer diagnosis in a cohort of patients with Sjogren's syndrome and rheumatoid arthritis: a single-center experience and review of the literature.",
        "AuthorList": [
            "Stergios Boussios",
            "George Pentheroudakis",
            "George Somarakis",
            "Theodora E Markatseli",
            "Alexandros A Drosos",
            "Nicholas Pavlidis"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece.",
            "Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece.",
            "Department of Internal Medicine-Division of Rheumatology, Ioannina University Hospital, Ioannina, Greece.",
            "Department of Internal Medicine-Division of Rheumatology, Ioannina University Hospital, Ioannina, Greece.",
            "Department of Internal Medicine-Division of Rheumatology, Ioannina University Hospital, Ioannina, Greece.",
            "Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece npavlid@uoi.gr."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma.",
        "AuthorList": [
            "Trond Hagtvedt",
            "Therese Seierstad",
            "Kjersti V Lund",
            "Ayca M Løndalen",
            "Trond V Bogsrud",
            "Hans-Jørgen Smith",
            "Oliver M Geier",
            "Harald Holte"
        ],
        "AffiliationList": [
            "Department of Radiology and Nuclear Medicine, Oslo University Hospital, Norway University of Oslo, Norway.",
            "Department of Radiology and Nuclear Medicine, Oslo University Hospital, Norway.",
            "Department of Radiology and Nuclear Medicine, Oslo University Hospital, Norway.",
            "Department of Radiology and Nuclear Medicine, Oslo University Hospital, Norway.",
            "Department of Radiology and Nuclear Medicine, Oslo University Hospital, Norway Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus, Denmark.",
            "Department of Radiology and Nuclear Medicine, Oslo University Hospital, Norway University of Oslo, Norway.",
            "The Intervention Centre, Oslo University Hospital, Norway.",
            "Department of Oncology, Division of Cancer Medicine, Surgery and Transplantation, Oslo University Hospital, Norway."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "02",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone.",
        "AuthorList": [
            "Seok Jin Kim",
            "Hye Jin Kang",
            "Jin Seok Kim",
            "Sung Yong Oh",
            "Chul Won Choi",
            "Soon Il Lee",
            "Jong Ho Won",
            "Min Kyoung Kim"
        ],
        "AffiliationList": [
            "Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2010",
                "Month": "12",
                "Day": "09"
            }
        ]
    },
    {
        "ArticleTitle": "Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.",
        "AuthorList": [
            "M Wang",
            "N Fowler",
            "N Wagner-Bartak",
            "L Feng",
            "J Romaguera",
            "S S Neelapu",
            "F Hagemeister",
            "M Fanale"
        ],
        "AffiliationList": [
            "Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. miwang@mdanderson.org",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "04",
                "Day": "02"
            }
        ]
    },
    {
        "ArticleTitle": "A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial.",
        "AuthorList": [
            "Mathias Witzens-Harig",
            "Marie Luise Memmer",
            "Martin Dreyling",
            "Georg Hess"
        ],
        "AffiliationList": [
            "Department of Internal Medicine V, University of Heidelberg, INF 410, 69120, Heidelberg, Germany. Mathias.Witzens-Harig@med.uni-heidelberg.de",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "06",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.",
        "AuthorList": [
            "Luis Fayad",
            "Fritz Offner",
            "Mitchell R Smith",
            "Gregor Verhoef",
            "Peter Johnson",
            "Jonathan L Kaufman",
            "Ama Rohatiner",
            "Anjali Advani"
        ],
        "AffiliationList": [
            "Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA. lefayad@mdanderson.org",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "01",
                "Day": "07"
            }
        ]
    },
    {
        "ArticleTitle": "Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Nozomi Niitsu",
            "Mika Kohuri",
            "Masaaki Higashihara",
            "Masami Bessho"
        ],
        "AffiliationList": [
            "Hematology Division Department of Internal Medicine, Saitama Medical University, 38 Morohongo, Saitama 350-0495, Japan. nniitsu@saitama-med.ac.jp",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2006",
                "Month": "06",
                "Day": "29"
            }
        ]
    },
    {
        "ArticleTitle": "Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers.",
        "AuthorList": [
            "Nozomi Niitsu",
            "Miyuki Hayama",
            "Tadashi Yoshino",
            "Shigeo Nakamura",
            "Jun-Ichi Tamaru",
            "Hirokazu Nakamine",
            "Masataka Okamoto"
        ],
        "AffiliationList": [
            "Department of Haematology, International Medical Centre, Saitama Medical University, Saitama Adult Lymphoma Treatment Study Group, Nagoya, Japan. nniitsu@saitama-med.ac.jp",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "04",
                "Day": "15"
            }
        ]
    },
    {
        "ArticleTitle": "Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study.",
        "AuthorList": [
            "Dongmei Ji",
            "Qiu Li",
            "Junning Cao",
            "Ye Guo",
            "Fangfang Lv",
            "Xiaojian Liu",
            "Biyun Wang",
            "Leiping Wang"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.",
            "Department of Medical Oncology, West China Hospital of Medicine, Sichuan University, Chengdu 610041, P.R. China.",
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.",
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.",
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.",
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.",
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.",
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.",
        "AuthorList": [
            "Frédéric Peyrade",
            "Serge Bologna",
            "Vincent Delwail",
            "Jean François Emile",
            "Laurent Pascal",
            "Christophe Fermé",
            "Jean-Marc Schiano",
            "Bertrand Coiffier"
        ],
        "AffiliationList": [
            "Centre Antoine Lacassagne, Nice, France. Electronic address: frederic.peyrade@nice.unicancer.fr.",
            "Centre Hospitalier Nancy-Brabois, Vandoeuvre, France.",
            "Hematology, University Hospital, Poitiers, France.",
            "Pathology Department, Hôpital Ambroise Paré, Boulogne, France.",
            "Hôpital Saint-Vincent de Paul, Lille, France.",
            "Institut Gustave Roussy, Villejuif, France.",
            "Institut Paoli Calmettes, Marseille, France.",
            "Hematology Department, Centre Hospitalier Lyon-Sud, Pierre-Benite Cedex, France."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy.",
        "AuthorList": [
            "Moo-Kon Song",
            "Joo-Seop Chung",
            "Oh Sung-Yong",
            "Gyeong-Won Lee",
            "Seung-Geun Kim",
            "Young-Mi Seol",
            "Ho-Jin Shin",
            "Young-Jin Choi"
        ],
        "AffiliationList": [
            "Department of Hematology-Oncology, Busan National Cancer Center, Pusan National University Hospital Medical Research Institute, South Korea.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2010",
                "Month": "04",
                "Day": "29"
            }
        ]
    },
    {
        "ArticleTitle": "Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study.",
        "AuthorList": [
            "Marie-Sarah Dilhuydy",
            "Thierry Lamy",
            "Charles Foussard",
            "Remy Gressin",
            "Philippe Casassus",
            "Eric Deconninck",
            "Christine Le Maignan",
            "Diane Damotte"
        ],
        "AffiliationList": [
            "Department of Hematology, Hôpital Haut Lévèque, CHU de Bordeaux, Bordeaux, France.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2010",
                "Month": "01",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.",
        "AuthorList": [
            "Josep-Maria Ribera",
            "Albert Oriol",
            "Mireia Morgades",
            "Eva González-Barca",
            "Pilar Miralles",
            "Armando López-Guillermo",
            "Santiago Gardella",
            "Andres López"
        ],
        "AffiliationList": [
            "Haematology Department, Institut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol, Badalona, Spain. jribera@iconcologia.net",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2007",
                "Month": "12",
                "Day": "19"
            }
        ]
    },
    {
        "ArticleTitle": "Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients.",
        "AuthorList": [
            "Pier Luigi Zinzani",
            "Giuseppe Rossi",
            "Silvia Franceschetti",
            "Barbara Botto",
            "Alice Di Rocco",
            "Maria Giuseppina Cabras",
            "Maria Concetta Petti",
            "Vittorio Stefoni"
        ],
        "AffiliationList": [
            "Institute of Hematology and Medical Oncology L. e A. Seràgnoli, Policlinico Sant'Orsola-Malpighi, University of Bologna, Via Massarenti 9, Bologna, Italy. pierluigi.zinzani@unibo.it",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2010",
                "Month": "06",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.",
        "AuthorList": [
            "P L Zinzani",
            "M Tani",
            "S Fanti",
            "V Stefoni",
            "G Musuraca",
            "P Castellucci",
            "E Marchi",
            "M Farsad"
        ],
        "AffiliationList": [
            "Institute of Hematology and Medical Oncology 'L. & A. Seràgnoli', University of Bologna, Bologna, Italy. plzinzo@med.unibo.it",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2008",
                "Month": "02",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "Gastrointestinal Lymphoma in Southwest China: Subtype Distribution of 1,010 Cases Using the WHO (2008) Classification in a Single Institution.",
        "AuthorList": [
            "Wenshuang Ding",
            "Sha Zhao",
            "Jianchao Wang",
            "Qunpei Yang",
            "Hong Sun",
            "Jiaqi Yan",
            "Limin Gao",
            "Wenqing Yao"
        ],
        "AffiliationList": [
            "Department of Pathology, West China Hospital of Sichuan University, Chengdu, PR China.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "08",
                "Day": "15"
            }
        ]
    },
    {
        "ArticleTitle": "Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Michael J Robertson",
            "Brad S Kahl",
            "Julie M Vose",
            "Sven de Vos",
            "Mary Laughlin",
            "Patrick J Flynn",
            "Kendrith Rowland",
            "Jose C Cruz"
        ],
        "AffiliationList": [
            "Indiana University Medical Center, Indianapolis, IN, USA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2007",
                "Month": "03",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study.",
        "AuthorList": [
            "Jean-Marie Michot",
            "Danielle Canioni",
            "Henda Driss",
            "Laurent Alric",
            "Patrice Cacoub",
            "Felipe Suarez",
            "David Sibon",
            "Catherine Thieblemont"
        ],
        "AffiliationList": [
            "Department of Internal Medicine and Clinical Immunology, Paris Sud University, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "11",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Ken Ohmachi",
            "Nozomi Niitsu",
            "Toshiki Uchida",
            "Seok Jin Kim",
            "Kiyoshi Ando",
            "Naoki Takahashi",
            "Naoto Takahashi",
            "Naokuni Uike"
        ],
        "AffiliationList": [
            "Yokohama City University Hospital, Kanagawa, Japan.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "05",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.",
        "AuthorList": [
            "German Ott",
            "Marita Ziepert",
            "Wolfram Klapper",
            "Heike Horn",
            "Monika Szczepanowski",
            "Heinz-Wolfram Bernd",
            "Christoph Thorns",
            "Alfred C Feller"
        ],
        "AffiliationList": [
            "Institute of Pathology, University of Würzburg, Würzburg, Germany. german.ott@rbk.de",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2010",
                "Month": "08",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.",
        "AuthorList": [
            "Fredrick Hagemeister",
            "Maria Alma Rodriguez",
            "Steven R Deitcher",
            "Anas Younes",
            "Luis Fayad",
            "Andre Goy",
            "Nam H Dang",
            "Arthur Forman"
        ],
        "AffiliationList": [
            "University of Texas M. D. Anderson Cancer Center (UTMDACC), Houston, TX 77030, USA. fhagemei@mdanderson.org",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "06",
                "Day": "27"
            }
        ]
    },
    {
        "ArticleTitle": "Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab.",
        "AuthorList": [
            "Jörg Thomas Bittenbring",
            "Frank Neumann",
            "Bettina Altmann",
            "Marina Achenbach",
            "Jörg Reichrath",
            "Marita Ziepert",
            "Jürgen Geisel",
            "Evi Regitz"
        ],
        "AffiliationList": [
            "Jörg Thomas Bittenbring, Frank Neumann, Marina Achenbach, Jörg Reichrath, Jürgen Geisel, Evi Regitz, Gerhard Held, and Michael Pfreundschuh, Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg; and Bettina Altmann and Marita Ziepert, University Leipzig, Leipzig, Germany.",
            "Jörg Thomas Bittenbring, Frank Neumann, Marina Achenbach, Jörg Reichrath, Jürgen Geisel, Evi Regitz, Gerhard Held, and Michael Pfreundschuh, Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg; and Bettina Altmann and Marita Ziepert, University Leipzig, Leipzig, Germany.",
            "Jörg Thomas Bittenbring, Frank Neumann, Marina Achenbach, Jörg Reichrath, Jürgen Geisel, Evi Regitz, Gerhard Held, and Michael Pfreundschuh, Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg; and Bettina Altmann and Marita Ziepert, University Leipzig, Leipzig, Germany.",
            "Jörg Thomas Bittenbring, Frank Neumann, Marina Achenbach, Jörg Reichrath, Jürgen Geisel, Evi Regitz, Gerhard Held, and Michael Pfreundschuh, Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg; and Bettina Altmann and Marita Ziepert, University Leipzig, Leipzig, Germany.",
            "Jörg Thomas Bittenbring, Frank Neumann, Marina Achenbach, Jörg Reichrath, Jürgen Geisel, Evi Regitz, Gerhard Held, and Michael Pfreundschuh, Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg; and Bettina Altmann and Marita Ziepert, University Leipzig, Leipzig, Germany.",
            "Jörg Thomas Bittenbring, Frank Neumann, Marina Achenbach, Jörg Reichrath, Jürgen Geisel, Evi Regitz, Gerhard Held, and Michael Pfreundschuh, Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg; and Bettina Altmann and Marita Ziepert, University Leipzig, Leipzig, Germany.",
            "Jörg Thomas Bittenbring, Frank Neumann, Marina Achenbach, Jörg Reichrath, Jürgen Geisel, Evi Regitz, Gerhard Held, and Michael Pfreundschuh, Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg; and Bettina Altmann and Marita Ziepert, University Leipzig, Leipzig, Germany.",
            "Jörg Thomas Bittenbring, Frank Neumann, Marina Achenbach, Jörg Reichrath, Jürgen Geisel, Evi Regitz, Gerhard Held, and Michael Pfreundschuh, Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg; and Bettina Altmann and Marita Ziepert, University Leipzig, Leipzig, Germany."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "08",
                "Day": "18"
            }
        ]
    },
    {
        "ArticleTitle": "Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Deok-Hwan Yang",
            "Won Seog Kim",
            "Seok Jin Kim",
            "Jin Seok Kim",
            "Jae-Yong Kwak",
            "Joo Seop Chung",
            "Sung Yong Oh",
            "Cheolwon Suh"
        ],
        "AffiliationList": [
            "Chonnam National University Hwasun Hospital, Jeollanam-do, Korea.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "12",
                "Day": "07"
            }
        ]
    },
    {
        "ArticleTitle": "Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Paul A Hamlin",
            "Andrew D Zelenetz",
            "Tarun Kewalramani",
            "Jing Qin",
            "Jaya M Satagopan",
            "David Verbel",
            "Ariela Noy",
            "Carol S Portlock"
        ],
        "AffiliationList": [
            "Lymphoma and Hematology Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Box 350, 1275 York Ave, New York, NY, 10021.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2003",
                "Month": "04",
                "Day": "03"
            }
        ]
    },
    {
        "ArticleTitle": "Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma.",
        "AuthorList": [
            "A Plonquet",
            "C Haioun",
            "J-P Jais",
            "A-L Debard",
            "G Salles",
            "M-C Bene",
            "P Feugier",
            "C Rabian"
        ],
        "AffiliationList": [
            "Service d'Immunologie Biologique, Institut National de la Santé et de la Recherche Médicale, U617, Créteil, France.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2007",
                "Month": "05",
                "Day": "12"
            }
        ]
    },
    {
        "ArticleTitle": "Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma.",
        "AuthorList": [
            "Christophe Fruchart",
            "Hervé Tilly",
            "Franck Morschhauser",
            "Hervé Ghesquières",
            "Marie Bouteloup",
            "Christophe Fermé",
            "Eric Van Den Neste",
            "Dominique Bordessoule"
        ],
        "AffiliationList": [
            "Centre François Baclesse, Department of Hematology, Caen, France. Electronic address: c.fruchart@baclesse.fr.",
            "Centre Henri Becquerel, Rouen, France.",
            "CHU, Lille, France.",
            "Centre Léon Bérard, Lyon, France.",
            "Hospices Civils de Lyon, France.",
            "Institut Gustave Roussy, Villejuif, France.",
            "A.Z St. Jan, Brugge, Belgium.",
            "CHU, Limoges, France."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "07",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.",
        "AuthorList": [
            "Sandra J Strauss",
            "Frank Morschhauser",
            "Juergen Rech",
            "Roland Repp",
            "Philippe Solal-Celigny",
            "Pier L Zinzani",
            "Andreas Engert",
            "Bernard Coiffier"
        ],
        "AffiliationList": [
            "Cancer Research United Kingdom Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2006",
                "Month": "07",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04).",
        "AuthorList": [
            "Tohru Murayama",
            "Takahiro Fukuda",
            "Hirokazu Okumura",
            "Kazutaka Sunami",
            "Aiko Sawazaki",
            "Yoshinobu Maeda",
            "Hisashi Tsurumi",
            "Naokuni Uike"
        ],
        "AffiliationList": [
            "Department of Hematology, Hyogo Cancer Center, 13-70, Kita-oji, Akashi, Hyogo, 673-8558, Japan. tmurayam@hp.pref.hyogo.jp.",
            "Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.",
            "Hematology Department, Toyama Prefectural Central Hospital, Toyama, Japan.",
            "Division of Hematology, Department of Internal Medicine National Hospital Organization, Okayama Medical Center, Okayama, Japan.",
            "Department of Hematology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.",
            "Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.",
            "First Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.",
            "Department of Hematology, National Kyushu Cancer Center, Fukuoka, Japan."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "03",
                "Day": "21"
            }
        ]
    },
    {
        "ArticleTitle": "Phase II study of CHOP-GR therapy in diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Sachiya Takemura",
            "Naoto Tomita",
            "Hideyuki Koharazawa",
            "Katsumichi Fujimaki",
            "Hiroshi Harano",
            "Rie Hyo",
            "Etsuko Yamazaki",
            "Chizuko Hashimoto"
        ],
        "AffiliationList": [
            "Department of Internal Medicine, Yokohama Ekisaikai Hospital, Yokohama, Japan.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "06",
                "Day": "10"
            }
        ]
    },
    {
        "ArticleTitle": "Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.",
        "AuthorList": [
            "Sarah J Nagle",
            "Kaitlin Woo",
            "Stephen J Schuster",
            "Sunita D Nasta",
            "Edward Stadtmauer",
            "Rosemarie Mick",
            "Jakub Svoboda"
        ],
        "AffiliationList": [
            "Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "08",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma.",
        "AuthorList": [
            "Ulrich J M Mey",
            "Anna Maier",
            "Ingo G H Schmidt-Wolf",
            "Carsten Ziske",
            "Helmut Forstbauer",
            "Gamal-Andre Banat",
            "Michael Reber",
            "John W Strehl"
        ],
        "AffiliationList": [
            "Department of Internal Medicine I, University of Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany. mey@uni-bonn.de",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial.",
        "AuthorList": [
            "N Schoof",
            "F von Bonin",
            "S Zeynalova",
            "M Ziepert",
            "W Jung",
            "M Loeffler",
            "M Pfreundschuh",
            "L Trümper"
        ],
        "AffiliationList": [
            "Department of Hematology and Oncology, Medical Center of the Georg-August-University of Göttingen, Göttingen. Electronic address: nschoof@gwdg.de.",
            "Department of Hematology and Oncology, Medical Center of the Georg-August-University of Göttingen, Göttingen.",
            "Department of Statistics and Epidemiology, Institute of Medical Informatics, University of Leipzig, Leipzig.",
            "Department of Statistics and Epidemiology, Institute of Medical Informatics, University of Leipzig, Leipzig.",
            "Department of Hematology and Oncology, Medical Center of the Georg-August-University of Göttingen, Göttingen.",
            "Department of Statistics and Epidemiology, Institute of Medical Informatics, University of Leipzig, Leipzig.",
            "Department of Internal Medicine I, Saarland University, Homburg/Saar, Germany for the DSHNHL (German High-Grade Non-Hodgkin's Lymphoma Study Group).",
            "Department of Hematology and Oncology, Medical Center of the Georg-August-University of Göttingen, Göttingen."
        ],
        "Years": [
            {
                "Year": "2009",
                "Month": "06",
                "Day": "10"
            }
        ]
    },
    {
        "ArticleTitle": "Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapy.",
        "AuthorList": [
            "Lawrence D Kaplan",
            "Steven R Deitcher",
            "Jeffrey A Silverman",
            "Gareth Morgan"
        ],
        "AffiliationList": [
            "University of California, San Francisco, CA.",
            "Talon Therapeutics, South San Francisco, CA.",
            "Talon Therapeutics, South San Francisco, CA. Electronic address: silvermanja@gmail.com.",
            "The Institute of Cancer Research, Royal Cancer Hospital, London, UK."
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "10",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Hisashi Tsurumi",
            "Takeshi Hara",
            "Naoe Goto",
            "Nobuhiro Kanemura",
            "Senji Kasahara",
            "Michio Sawada",
            "Ichiro Yasuda",
            "Toshiki Yamada"
        ],
        "AffiliationList": [
            "First Department of Internal Medicine, Gifu University School of Medicine, Gifu, Japan. htsuru@cc.gifu-ac.jp",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.",
        "AuthorList": [
            "Eva González-Barca",
            "Miguel Canales",
            "Montse Cortés",
            "M Jesus Vidal",
            "Antonio Salar",
            "Albert Oriol",
            "Joan Bargay",
            "José L Bello"
        ],
        "AffiliationList": [
            "Department of Hematology, Institut Català d'Oncologia, Hospital Duran i Reynals, Spain. e.gonzalez@iconcologia.net",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.",
        "AuthorList": [
            "Kristie A Blum",
            "Mehdi Hamadani",
            "Gary S Phillips",
            "Gerard Lozanski",
            "Amy J Johnson",
            "David M Lucas",
            "Lisa L Smith",
            "Robert Baiocchi"
        ],
        "AffiliationList": [
            "Division of Hematology-Oncology, Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA. kristie.blum@osumc.edu",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "[Combination of rituximab with autologous peripheral blood stem cell transplantation for treatment of diffuse large B-cell lymphoma: a single-center experience].",
        "AuthorList": [
            "Ze-yin Liang",
            "Xi-nan Cen",
            "Zhi-xiang Qiu",
            "Jin-ping Ou",
            "Wen-sheng Wang",
            "Wei-lin Xu",
            "Yuan Li",
            "Mang-ju Wang"
        ],
        "AffiliationList": [
            "Department of Hematology, Peking University First Hospital, Beijing 100034, China.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.",
        "AuthorList": [
            "Wyndham H Wilson",
            "Kieron Dunleavy",
            "Stefania Pittaluga",
            "Upendra Hegde",
            "Nicole Grant",
            "Seth M Steinberg",
            "Mark Raffeld",
            "Martin Gutierrez"
        ],
        "AffiliationList": [
            "Metabolism Branch, National Cancer Institute, Building 10, 9000 Rockville Pike, Bethesda, MD 20892, USA. wilsonw@mail.nih.gov",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2008",
                "Month": "03",
                "Day": "31"
            }
        ]
    },
    {
        "ArticleTitle": "Evaluation of interphase fluorescence in situ hybridization for the t(14;18)(q32;q21) translocation in the diagnosis of follicular lymphoma on fine-needle aspirates: a comparison with flow cytometry immunophenotyping.",
        "AuthorList": [
            "Yun Gong",
            "Nancy Caraway",
            "Jun Gu",
            "Tanweer Zaidi",
            "Ricardo Fernandez",
            "Xiaoping Sun",
            "Yang O Huh",
            "Ruth L Katz"
        ],
        "AffiliationList": [
            "Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.",
        "AuthorList": [
            "Patrick B Johnston",
            "Betsy LaPlant",
            "Ellen McPhail",
            "Thomas M Habermann",
            "David J Inwards",
            "Ivana N Micallef",
            "Joseph P Colgan",
            "Grzegorz S Nowakowski"
        ],
        "AffiliationList": [
            "Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN, USA.",
            "Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN, USA.",
            "Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN, USA.",
            "Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN, USA.",
            "Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN, USA.",
            "Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN, USA.",
            "Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN, USA.",
            "Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN, USA."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "06",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "[A phase II multicenter study to investigate R-ICE as a salvage therapy for relapsed diffuse large B-cell lymphoma].",
        "AuthorList": [
            "Ye Guo",
            "Yu Chen",
            "Xiaonan Hong",
            "Li Yu",
            "Jun Ma",
            "Yuankai Shi",
            "Ting Liu",
            "Wenqi Jiang"
        ],
        "AffiliationList": [
            "Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.",
            "Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.",
            "Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.",
            "Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.",
            "Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.",
            "Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.",
            "Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.",
            "Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity.",
        "AuthorList": [
            "Ercole Brusamolino",
            "Chiara Rusconi",
            "Luigi Montalbetti",
            "Livio Gargantini",
            "Lilj Uziel",
            "Graziella Pinotti",
            "Sergio Fava",
            "Luigi Rigacci"
        ],
        "AffiliationList": [
            "Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Italy. ebrusa@smatteo.pv.it",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2006",
                "Month": "03",
                "Day": "15"
            }
        ]
    },
    {
        "ArticleTitle": "Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation.",
        "AuthorList": [
            "Franck Morschhauser",
            "Tim Illidge",
            "Damien Huglo",
            "Giovanni Martinelli",
            "Giovanni Paganelli",
            "Pier Luigi Zinzani",
            "Simon Rule",
            "Anna Marina Liberati"
        ],
        "AffiliationList": [
            "Department of Hematology, Centre Hospitalier Universitaire, Lille, France.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2007",
                "Month": "03",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: results of a multi center phase II study and quality of life evaluation.",
        "AuthorList": [
            "Yeon Hee Park",
            "Se-Hoon Lee",
            "Won Seog Kim",
            "Soo-Mee Bang",
            "Baek-Yeol Ryoo",
            "Sung Hyun Yang",
            "Seung-Sook Lee",
            "Mi Sook Kim"
        ],
        "AffiliationList": [
            "Department of Hematology-Oncology, Korea Institute of Radiological & Medical Sciences, Seoul, Korea.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "A phase II study of high-dose celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma.",
        "AuthorList": [
            "Naser Abd El Bary",
            "Tarek Hashem",
            "Hasan Metwally",
            "Ashraf Abd Ghany",
            "Hager Abd El Mageed"
        ],
        "AffiliationList": [
            "Menoufia Faculty of Medicine, Egypt. kushia@ngha.med.sa",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology.",
        "AuthorList": [
            "Amrita Y Krishnan",
            "Joycelynne Palmer",
            "Auayporn P Nademanee",
            "Robert Chen",
            "Leslie L Popplewell",
            "Ni-Chun Tsai",
            "James F Sanchez",
            "Jennifer Simpson"
        ],
        "AffiliationList": [
            "Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, California; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California. Electronic address: akrishnan@coh.org.",
            "Department of Information Sciences, City of Hope, Duarte, California.",
            "Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.",
            "Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.",
            "Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.",
            "Department of Information Sciences, City of Hope, Duarte, California.",
            "Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.",
            "Clinical Trials Office, City of Hope, Duarte, California."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "03",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).",
        "AuthorList": [
            "Graham M Mead",
            "Sharon L Barrans",
            "Wendi Qian",
            "Jan Walewski",
            "John A Radford",
            "Max Wolf",
            "Simon M Clawson",
            "Sally P Stenning"
        ],
        "AffiliationList": [
            "Southampton University Hospitals Trust, Southampton, United Kingdom.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2008",
                "Month": "07",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Ho-Jin Shin",
            "Joo Seop Chung",
            "Moo-Kon Song",
            "Seon-Kyeong Kim",
            "Sangmin Choe",
            "Goon-Jae Cho"
        ],
        "AffiliationList": [
            "Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, 1-10, Ami-Dong, Seo-Gu, Busan, Korea.",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "01",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Clinical outcomes of post-remission therapy using (90)yttrium ibritumomab tiuxetan (Zevalin®) for high-risk patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Eun Ji Han",
            "Sung-Eun Lee",
            "Sung Hoon Kim",
            "Hyung Sun Sohn",
            "Seung Eun Jung",
            "Gyeongsin Park",
            "Byung-Ock Choi",
            "Sang-Nam Lee"
        ],
        "AffiliationList": [
            "Department of Radiology, Catholic Lymphoma Study Group, The Catholic University of Korea College of Medicine, Seoul, South Korea.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "02",
                "Day": "19"
            }
        ]
    },
    {
        "ArticleTitle": "MicroRNA profiling of low-grade and transformed nodal marginal zone lymphoma reveals a similar signature pattern distinct from diffuse large B cell lymphoma.",
        "AuthorList": [
            "Niklas Gebauer",
            "Christoph Thorns",
            "Veronica Bernard",
            "Andrea Senft",
            "Arne Schillert",
            "Hartmut Merz",
            "Alfred C Feller",
            "Heinz-Wolfram Bernd"
        ],
        "AffiliationList": [
            "Department of Pathology, Reference Centre for Lymph Node Pathology and Hematopathology, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "11",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Nozomi Niitsu",
            "Mika Kohri",
            "Yuki Hagiwara",
            "Ken Tanae",
            "Naoki Takahashi",
            "Masami Bessho",
            "Masataka Okamoto"
        ],
        "AffiliationList": [
            "Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan. nniitsu@saitama-med.ac.jp",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "[Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].",
        "AuthorList": [
            "Zhi-xiang Cheng",
            "Shan-hua Zou",
            "Feng Li",
            "Jun-min Li",
            "Jian-min Wang",
            "Fang-yuan Chen",
            "Jun-ning Cao",
            "Chun Wang"
        ],
        "AffiliationList": [
            "Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "[Comparison between efficacy and safety of rituximab plus CHOP regimen and CHOP regimen for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].",
        "AuthorList": [
            "Wei Xu",
            "Jian-Yong Li",
            "Zhi-Hong Zhang",
            "Hong-Xia Qiu",
            "Si-Xuan Qian",
            "Han-Xin Wu",
            "Hua Lu",
            "Rui-Lan Sheng"
        ],
        "AffiliationList": [
            "Department of Hematology, The First Hospital of Nanjing Medical University, Jiangsu Province People Hospital, Nanjing 210029, Jiangsu Province, China.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Favourable outcomes in children with diffuse large B-cell lymphoma treated by a short-term ALL-like regimen: a report on the NHL960 study from the Japanese Childhood Cancer and Leukemia Study Group.",
        "AuthorList": [
            "Masahito Tsurusawa",
            "Takashi Taga",
            "Yasuo Horikoshi",
            "Atsushi Ogawa",
            "Atsushi Kikuta",
            "Hirokazu Kanegane",
            "Takeji Matsushita",
            "Nobuyuki Hyakuna"
        ],
        "AffiliationList": [
            "Department of Paediatrics, Aichi Medical University, Aichi, Japan. mtsuru@aichi-med-u.ac.jp",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma.",
        "AuthorList": [
            "M Binn",
            "A Ruskoné-Fourmestraux",
            "E Lepage",
            "C Haioun",
            "A Delmer",
            "P Aegerter",
            "A Lavergne",
            "C Guettier"
        ],
        "AffiliationList": [
            "Hôpital Henri Mondor, Gastroentérologie, Créteil, Val de Marne, France.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "[Diffuse large B-cell lymphoma with primary involvement of mediastinal lymph nodes: diagnosis and treatment].",
        "AuthorList": [
            "Ia K Mangasarova",
            "A U Magomedova",
            "S K Kravchenko",
            "E E Zvonkov",
            "A M Kremenetskaia",
            "V I Vorob'ev",
            "D S Mar'in",
            "A V Gubkin"
        ],
        "AffiliationList": [
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "[Late cardiotoxicity of high-dose chemotherapy according to the modified NHL-BFM-90 program in adult patients with diffuse large B-cell lymphoma].",
        "AuthorList": [
            "E I Dorokhina",
            "A U Magomedova",
            "A A Shevelev",
            "S M Kulikov",
            "M K Gitis",
            "A V Vedernikov",
            "A I Vorobyev",
            "S K Kravchenko"
        ],
        "AffiliationList": [
            "Hematology Research Center, Ministry of Health of Russia, Moscow, Russia.",
            "Hematology Research Center, Ministry of Health of Russia, Moscow, Russia.",
            "Hematology Research Center, Ministry of Health of Russia, Moscow, Russia.",
            "Hematology Research Center, Ministry of Health of Russia, Moscow, Russia.",
            "Hematology Research Center, Ministry of Health of Russia, Moscow, Russia.",
            "Hematology Research Center, Ministry of Health of Russia, Moscow, Russia.",
            "Hematology Research Center, Ministry of Health of Russia, Moscow, Russia.",
            "Hematology Research Center, Ministry of Health of Russia, Moscow, Russia."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "[The modified program NHL-BFM-90 in the treatment of patients with diffuse large B-cell lymphosarcoma].",
        "AuthorList": [
            "A U Magomedova",
            "S K Kravchenko",
            "A M Kremenetskaia",
            "E E Zvonkov",
            "E A Bariakh",
            "O V Margolin",
            "I B Kaplanskaia",
            "I A Vorob'ev"
        ],
        "AffiliationList": [
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Efficacy and safety of lenalidomide in diffuse large B-cell lymphoma: a meta-analysis of randomized controlled trials.",
        "AuthorList": [
            "Jia Liu",
            "Ruihua Mi",
            "Lin Chen",
            "Xiaoli Guo",
            "Taotao Liang",
            "Qingsong Yin"
        ],
        "AffiliationList": [
            "The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.",
            "The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.",
            "The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.",
            "The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.",
            "The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.",
            "The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China. jnyinqingsong@163.com."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "10",
                "Day": "31"
            }
        ]
    },
    {
        "ArticleTitle": "Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma.",
        "AuthorList": [
            "Nieves Gómez León",
            "Roberto C Delgado-Bolton",
            "Lourdes Del Campo Del Val",
            "Beatriz Cabezas",
            "Reyes Arranz",
            "Marta García",
            "Jimena Cannata",
            "Saturnino González Ortega"
        ],
        "AffiliationList": [
            "From the *University Hospital Research Institute, Department of Radiology, University Hospital La Princesa, Madrid; †Autonomous University of Madrid, Madrid; ‡Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, San Pedro Hospital and Centre for Biomedical Research of La Rioja (CIBIR), University of La Rioja, Logroño, La Rioja; Departments of §Nuclear Medicine, and ∥Radiology, University Hospital Clínico San Carlos, Madrid; ¶Department of Haematology, University Hospital la Princesa of Madrid, Madrid; Departments of **Haematology, and ††Radiology, University Hospital Fundación Jiménez Díaz, Madrid; ‡‡Department of Radiology, University Hospital Txagorritxu, Vitoria; §§Department of Haematology, University Hospital Clínico San Carlos, Madrid, Spain; ∥∥Department of Radiology, University of Southern California, Los Angeles, CA; and ¶¶Department of Nuclear Medicine, Imaging and Clinical Pathology, Santa Maria della Misericordia Hospital, Rovigo, Italy.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.",
        "AuthorList": [
            "E Van Den Neste",
            "N Schmitz",
            "N Mounier",
            "D Gill",
            "D Linch",
            "M Trneny",
            "N Milpied",
            "J Radford"
        ],
        "AffiliationList": [
            "Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium.",
            "AsklepiosKlinik St Georg, AbteilungHämatologie und Stammzelltransplantation, Hamburg, Germany.",
            "CHU de l'Archet, Nice, France.",
            "Princess Alexandra Hospital, Woodville, SA, Australia.",
            "University College London, Cancer Institute, London, UK.",
            "Charles Univ. General Hosp., Praha, Czech Republic.",
            "Hématologie Clinique et thérapie cellulaire, Hôpital Haut-Lévêque, Pessac, France.",
            "University of Manchester, c/o Department of Medical Oncology, Christie Hospital NHS, Manchester, UK."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "09",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.",
        "AuthorList": [
            "D Coso",
            "C Sebban",
            "O Boulat",
            "P Biron",
            "J Rey",
            "T Aurran",
            "C Chabannon",
            "L Xerri"
        ],
        "AffiliationList": [
            "Department of Hematology, Cancer Center Institut J Paoli - I Calmettes, Marseille Cedex, France.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2006",
                "Month": "06",
                "Day": "12"
            }
        ]
    },
    {
        "ArticleTitle": "Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study.",
        "AuthorList": [
            "Gareth P Gregory",
            "Shaji Kumar",
            "Ding Wang",
            "Daruka Mahadevan",
            "Patricia Walker",
            "Nina Wagner-Johnston",
            "Carolina Escobar",
            "Rajat Bannerji"
        ],
        "AffiliationList": [
            "Department of Hematology, School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC, Australia.",
            "Department of Hematology and Oncology, Mayo Clinic, Rochester, MN.",
            "Department of Medical Oncology, Henry Ford Cancer Institute, Detroit, MI.",
            "Division of Hematology/Medical Oncology, UT Health San Antonio, San Antonio, TX.",
            "Department of Hematology, Peninsula Health and Peninsula Private Hospitals, Frankston, VIC, Australia.",
            "Division of Oncology, Johns Hopkins Medical Institution, Baltimore, MD.",
            "Department of Hematology and Oncology, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX.",
            "Section of Hematologic Malignancies, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study.",
        "AuthorList": [
            "Karim Labreche",
            "Mailys Daniau",
            "Amit Sud",
            "Philip J Law",
            "Louis Royer-Perron",
            "Amy Holroyd",
            "Peter Broderick",
            "Molly Went"
        ],
        "AffiliationList": [
            "Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, Surrey, UK.",
            "(i) National Institute of Health and Medical Research (Inserm) U 1127, Paris, France, (ii) National Center for Scientific Research, Joint Research Unit 7225, Paris, France, (iii) Brain and Spine Institute (ICM), Paris, France, and (iv) Sorbonne University, Pierre and Marie Curie University, Paris 6, Paris, France.",
            "Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, Surrey, UK.",
            "Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, Surrey, UK.",
            "(i) National Institute of Health and Medical Research (Inserm) U 1127, Paris, France, (ii) National Center for Scientific Research, Joint Research Unit 7225, Paris, France, (iii) Brain and Spine Institute (ICM), Paris, France, and (iv) Sorbonne University, Pierre and Marie Curie University, Paris 6, Paris, France.",
            "Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, Surrey, UK.",
            "Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, Surrey, UK.",
            "Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, Surrey, UK."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.",
        "AuthorList": [
            "Michael Pfreundschuh",
            "Niels Murawski",
            "Samira Zeynalova",
            "Marita Ziepert",
            "M Loeffler",
            "Matthias Hänel",
            "Judith Dierlamm",
            "Ulrich Keller"
        ],
        "AffiliationList": [
            "Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg, Germany.",
            "Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg, Germany.",
            "IMISE, Leipzig University, Leipzig, Germany.",
            "IMISE, Leipzig University, Leipzig, Germany.",
            "IMISE, Leipzig University, Leipzig, Germany.",
            "Städtisches Klinikum Chemnitz, Chemnitz, Germany.",
            "Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.",
            "Medizinische Klinik III, Klinikum rechts der Isar, Technische Universität, Munich, Germany."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "10",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.",
        "AuthorList": [
            "Gustaaf W van Imhoff",
            "Andrew McMillan",
            "Matthew J Matasar",
            "John Radford",
            "Kirit M Ardeshna",
            "Kazimierz Kuliczkowski",
            "WonSeog Kim",
            "Xiaonan Hong"
        ],
        "AffiliationList": [
            "Gustaaf W. van Imhoff, University Medical Center, University of Groningen; Bronno van der Holt, University Medical Center, Rotterdam; Anton Hagenbeek, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Andrew McMillan, Nottingham University Hospital, Nottingham; John Radford and Kirit M. Ardeshna, Christie Hospital NHS Trust, Manchester; Andrew Davies, University of Southampton, Southampton, United Kingdom; Matthew J. Matasar, Memorial Sloan Kettering Cancer Center, New York, NY; Kazimierz Kuliczkowski, Wroclaw Medical University, Wroclaw, Poland; WonSeog Kim, Sungkyunkwan University School of Medicine, Seoul, Korea; Xiaonan Hong, Fudan University, Shanghai, China; Jette Soenderskov Goerloev, Rigshospitalet; Steen Lisby, Genmab A/S, Copenhagen, Denmark; María Dolores Caballero Barrigón, Hospital Universitario de Salamanca, Salamanca, Spain; Michinori Ogura, Nagoya Daini Red Cross Hospital, Nagoya; Michinori Ogura, Tokai Central Hospital, Kakamigahara, Japan; Sirpa Leppä, Helsinki University Central Hospital Cancer Center, Helsinki, Finland; and Michael Fennessy and Qiming Liao, Novartis AG, Basel, Switzerland.",
            "Gustaaf W. van Imhoff, University Medical Center, University of Groningen; Bronno van der Holt, University Medical Center, Rotterdam; Anton Hagenbeek, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Andrew McMillan, Nottingham University Hospital, Nottingham; John Radford and Kirit M. Ardeshna, Christie Hospital NHS Trust, Manchester; Andrew Davies, University of Southampton, Southampton, United Kingdom; Matthew J. Matasar, Memorial Sloan Kettering Cancer Center, New York, NY; Kazimierz Kuliczkowski, Wroclaw Medical University, Wroclaw, Poland; WonSeog Kim, Sungkyunkwan University School of Medicine, Seoul, Korea; Xiaonan Hong, Fudan University, Shanghai, China; Jette Soenderskov Goerloev, Rigshospitalet; Steen Lisby, Genmab A/S, Copenhagen, Denmark; María Dolores Caballero Barrigón, Hospital Universitario de Salamanca, Salamanca, Spain; Michinori Ogura, Nagoya Daini Red Cross Hospital, Nagoya; Michinori Ogura, Tokai Central Hospital, Kakamigahara, Japan; Sirpa Leppä, Helsinki University Central Hospital Cancer Center, Helsinki, Finland; and Michael Fennessy and Qiming Liao, Novartis AG, Basel, Switzerland.",
            "Gustaaf W. van Imhoff, University Medical Center, University of Groningen; Bronno van der Holt, University Medical Center, Rotterdam; Anton Hagenbeek, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Andrew McMillan, Nottingham University Hospital, Nottingham; John Radford and Kirit M. Ardeshna, Christie Hospital NHS Trust, Manchester; Andrew Davies, University of Southampton, Southampton, United Kingdom; Matthew J. Matasar, Memorial Sloan Kettering Cancer Center, New York, NY; Kazimierz Kuliczkowski, Wroclaw Medical University, Wroclaw, Poland; WonSeog Kim, Sungkyunkwan University School of Medicine, Seoul, Korea; Xiaonan Hong, Fudan University, Shanghai, China; Jette Soenderskov Goerloev, Rigshospitalet; Steen Lisby, Genmab A/S, Copenhagen, Denmark; María Dolores Caballero Barrigón, Hospital Universitario de Salamanca, Salamanca, Spain; Michinori Ogura, Nagoya Daini Red Cross Hospital, Nagoya; Michinori Ogura, Tokai Central Hospital, Kakamigahara, Japan; Sirpa Leppä, Helsinki University Central Hospital Cancer Center, Helsinki, Finland; and Michael Fennessy and Qiming Liao, Novartis AG, Basel, Switzerland.",
            "Gustaaf W. van Imhoff, University Medical Center, University of Groningen; Bronno van der Holt, University Medical Center, Rotterdam; Anton Hagenbeek, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Andrew McMillan, Nottingham University Hospital, Nottingham; John Radford and Kirit M. Ardeshna, Christie Hospital NHS Trust, Manchester; Andrew Davies, University of Southampton, Southampton, United Kingdom; Matthew J. Matasar, Memorial Sloan Kettering Cancer Center, New York, NY; Kazimierz Kuliczkowski, Wroclaw Medical University, Wroclaw, Poland; WonSeog Kim, Sungkyunkwan University School of Medicine, Seoul, Korea; Xiaonan Hong, Fudan University, Shanghai, China; Jette Soenderskov Goerloev, Rigshospitalet; Steen Lisby, Genmab A/S, Copenhagen, Denmark; María Dolores Caballero Barrigón, Hospital Universitario de Salamanca, Salamanca, Spain; Michinori Ogura, Nagoya Daini Red Cross Hospital, Nagoya; Michinori Ogura, Tokai Central Hospital, Kakamigahara, Japan; Sirpa Leppä, Helsinki University Central Hospital Cancer Center, Helsinki, Finland; and Michael Fennessy and Qiming Liao, Novartis AG, Basel, Switzerland.",
            "Gustaaf W. van Imhoff, University Medical Center, University of Groningen; Bronno van der Holt, University Medical Center, Rotterdam; Anton Hagenbeek, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Andrew McMillan, Nottingham University Hospital, Nottingham; John Radford and Kirit M. Ardeshna, Christie Hospital NHS Trust, Manchester; Andrew Davies, University of Southampton, Southampton, United Kingdom; Matthew J. Matasar, Memorial Sloan Kettering Cancer Center, New York, NY; Kazimierz Kuliczkowski, Wroclaw Medical University, Wroclaw, Poland; WonSeog Kim, Sungkyunkwan University School of Medicine, Seoul, Korea; Xiaonan Hong, Fudan University, Shanghai, China; Jette Soenderskov Goerloev, Rigshospitalet; Steen Lisby, Genmab A/S, Copenhagen, Denmark; María Dolores Caballero Barrigón, Hospital Universitario de Salamanca, Salamanca, Spain; Michinori Ogura, Nagoya Daini Red Cross Hospital, Nagoya; Michinori Ogura, Tokai Central Hospital, Kakamigahara, Japan; Sirpa Leppä, Helsinki University Central Hospital Cancer Center, Helsinki, Finland; and Michael Fennessy and Qiming Liao, Novartis AG, Basel, Switzerland.",
            "Gustaaf W. van Imhoff, University Medical Center, University of Groningen; Bronno van der Holt, University Medical Center, Rotterdam; Anton Hagenbeek, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Andrew McMillan, Nottingham University Hospital, Nottingham; John Radford and Kirit M. Ardeshna, Christie Hospital NHS Trust, Manchester; Andrew Davies, University of Southampton, Southampton, United Kingdom; Matthew J. Matasar, Memorial Sloan Kettering Cancer Center, New York, NY; Kazimierz Kuliczkowski, Wroclaw Medical University, Wroclaw, Poland; WonSeog Kim, Sungkyunkwan University School of Medicine, Seoul, Korea; Xiaonan Hong, Fudan University, Shanghai, China; Jette Soenderskov Goerloev, Rigshospitalet; Steen Lisby, Genmab A/S, Copenhagen, Denmark; María Dolores Caballero Barrigón, Hospital Universitario de Salamanca, Salamanca, Spain; Michinori Ogura, Nagoya Daini Red Cross Hospital, Nagoya; Michinori Ogura, Tokai Central Hospital, Kakamigahara, Japan; Sirpa Leppä, Helsinki University Central Hospital Cancer Center, Helsinki, Finland; and Michael Fennessy and Qiming Liao, Novartis AG, Basel, Switzerland.",
            "Gustaaf W. van Imhoff, University Medical Center, University of Groningen; Bronno van der Holt, University Medical Center, Rotterdam; Anton Hagenbeek, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Andrew McMillan, Nottingham University Hospital, Nottingham; John Radford and Kirit M. Ardeshna, Christie Hospital NHS Trust, Manchester; Andrew Davies, University of Southampton, Southampton, United Kingdom; Matthew J. Matasar, Memorial Sloan Kettering Cancer Center, New York, NY; Kazimierz Kuliczkowski, Wroclaw Medical University, Wroclaw, Poland; WonSeog Kim, Sungkyunkwan University School of Medicine, Seoul, Korea; Xiaonan Hong, Fudan University, Shanghai, China; Jette Soenderskov Goerloev, Rigshospitalet; Steen Lisby, Genmab A/S, Copenhagen, Denmark; María Dolores Caballero Barrigón, Hospital Universitario de Salamanca, Salamanca, Spain; Michinori Ogura, Nagoya Daini Red Cross Hospital, Nagoya; Michinori Ogura, Tokai Central Hospital, Kakamigahara, Japan; Sirpa Leppä, Helsinki University Central Hospital Cancer Center, Helsinki, Finland; and Michael Fennessy and Qiming Liao, Novartis AG, Basel, Switzerland.",
            "Gustaaf W. van Imhoff, University Medical Center, University of Groningen; Bronno van der Holt, University Medical Center, Rotterdam; Anton Hagenbeek, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Andrew McMillan, Nottingham University Hospital, Nottingham; John Radford and Kirit M. Ardeshna, Christie Hospital NHS Trust, Manchester; Andrew Davies, University of Southampton, Southampton, United Kingdom; Matthew J. Matasar, Memorial Sloan Kettering Cancer Center, New York, NY; Kazimierz Kuliczkowski, Wroclaw Medical University, Wroclaw, Poland; WonSeog Kim, Sungkyunkwan University School of Medicine, Seoul, Korea; Xiaonan Hong, Fudan University, Shanghai, China; Jette Soenderskov Goerloev, Rigshospitalet; Steen Lisby, Genmab A/S, Copenhagen, Denmark; María Dolores Caballero Barrigón, Hospital Universitario de Salamanca, Salamanca, Spain; Michinori Ogura, Nagoya Daini Red Cross Hospital, Nagoya; Michinori Ogura, Tokai Central Hospital, Kakamigahara, Japan; Sirpa Leppä, Helsinki University Central Hospital Cancer Center, Helsinki, Finland; and Michael Fennessy and Qiming Liao, Novartis AG, Basel, Switzerland."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "12",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients.",
        "AuthorList": [
            "Eva González-Barca",
            "Miguel A Canales",
            "Antonio Salar",
            "Secundino Ferrer",
            "Eva Domingo-Domenech",
            "María-Jesús Vidal",
            "Carlos Grande",
            "Joan Bargay"
        ],
        "AffiliationList": [
            "Institut Catalx00E0; d'Oncologia, Hospital Duran i Reynals, IDIBELL, Barcelona, Spain.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "05",
                "Day": "18"
            }
        ]
    },
    {
        "ArticleTitle": "Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.",
        "AuthorList": [
            "Colm Keane",
            "Frank Vari",
            "Mark Hertzberg",
            "Kim-Anh Lê Cao",
            "Michael R Green",
            "Erica Han",
            "John F Seymour",
            "Rodney J Hicks"
        ],
        "AffiliationList": [
            "University of Queensland Diamantina Institute, Translational Research Institute, University of Queensland, Brisbane, QLD, Australia; Princess Alexandra Hospital, Brisbane, QLD, Australia; Genomics Research Centre, Griffith University, Southport, QLD, Australia.",
            "University of Queensland Diamantina Institute, Translational Research Institute, University of Queensland, Brisbane, QLD, Australia.",
            "Department of Haematology, Prince of Wales Hospital, Sydney, NSW, Australia.",
            "University of Queensland Diamantina Institute, Translational Research Institute, University of Queensland, Brisbane, QLD, Australia.",
            "Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA.",
            "University of Queensland Diamantina Institute, Translational Research Institute, University of Queensland, Brisbane, QLD, Australia.",
            "Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia.",
            "Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "10",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Development of a radiomic-clinical nomogram for prediction of survival in patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T cells.",
        "AuthorList": [
            "Yeye Zhou",
            "Bin Zhang",
            "Jiangqin Han",
            "Na Dai",
            "Tongtong Jia",
            "Haiwen Huang",
            "Shengming Deng",
            "Shibiao Sang"
        ],
        "AffiliationList": [
            "Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.",
            "Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.",
            "Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.",
            "Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.",
            "Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.",
            "Institute of Blood and Marrow Transplantation, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, Jiangsu, China. hhaiwen111@163.com.",
            "Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. dshming@163.com.",
            "Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. sshibiao@163.com."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "07",
                "Day": "03"
            }
        ]
    },
    {
        "ArticleTitle": "Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.",
        "AuthorList": [
            "Lihua E Budde",
            "David Wu",
            "Daniel B Martin",
            "Mary Philip",
            "Andrei R Shustov",
            "Stephen D Smith",
            "Ted A Gooley",
            "Tara L Chen"
        ],
        "AffiliationList": [
            "Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.",
            "Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.",
            "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.",
            "Department of Medicine, Divisions of Medical Oncology and Hematology, University of Washington, Seattle, WA, USA.",
            "Department of Medicine, Divisions of Medical Oncology and Hematology, University of Washington, Seattle, WA, USA.",
            "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.",
            "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.",
            "Department of Medicine, Divisions of Medical Oncology and Hematology, University of Washington, Seattle, WA, USA."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "09",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study.",
        "AuthorList": [
            "Julie E Chang",
            "Songwong Seo",
            "Kyungmann M Kim",
            "Jae E Werndli",
            "Wayne A Bottner",
            "Gilberto A Rodrigues",
            "Federico A Sanchez",
            "Thomas J Saphner"
        ],
        "AffiliationList": [
            "Department of Medicine, University of Wisconsin School of Medicine and Public Health and UW Carbone Cancer Center, Madison, WI, USA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.",
        "AuthorList": [
            "Christiane Copie-Bergman",
            "Philippe Gaulard",
            "Karen Leroy",
            "Josette Briere",
            "Maryse Baia",
            "Jean-Philippe Jais",
            "Gilles A Salles",
            "Françoise Berger"
        ],
        "AffiliationList": [
            "Assistance Publique-Hôpitaux de Paris, Groupe Henri Mondor-Albert Chenevier, L'Institut National de la Santé et de la Recherche Médicale, Unité 955, Institut Mondor de Recherche Biomédicale; Université Paris 12, Faculté de médecine, Créteil. christiane.copie@hmn.aphp.fr",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2009",
                "Month": "09",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study.",
        "AuthorList": [
            "Guido Gini",
            "Monica Tani",
            "Alessandra Tucci",
            "Luigi Marcheselli",
            "Marina Cesaretti",
            "Monica Bellei",
            "Anna Pascarella",
            "Filippo Ballerini"
        ],
        "AffiliationList": [
            "Struttura Organizzativa Dipartimentale di Clinica Ematologica, Azienda Ospedaliero Universitaria delle Marche, Università Politecnica delle Marche, Ancona, Italy.",
            "Unità di Ematologia, Ospedale Santa Maria delle Croci, Ravenna, Italy.",
            "Unità di Ematologia, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia, Italy.",
            "Uffici Studi Fondazione Italiana Linfomi, sede di Modena, Modena, Italy.",
            "Uffici Studi Fondazione Italiana Linfomi, sede di Modena, Modena, Italy.",
            "Uffici Studi Fondazione Italiana Linfomi, sede di Modena, Modena, Italy.",
            "Unità Operativa Complessa di Ematologia, Ospedale dell'Angelo, Venice-Mestre, Italy.",
            "Clinica Ematologica, IRCCS Ospedale Policlinico San Martino, Università di Genova, Genoa, Italy."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.",
        "AuthorList": [
            "Mary Gleeson",
            "Nicholas Counsell",
            "David Cunningham",
            "Anthony Lawrie",
            "Laura Clifton-Hadley",
            "Eliza Hawkes",
            "Andrew McMillan",
            "Kirit M Ardeshna"
        ],
        "AffiliationList": [
            "The Royal Marsden Hospital, London and Surrey, London, UK.",
            "Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.",
            "The Royal Marsden Hospital, London and Surrey, London, UK.",
            "Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.",
            "Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.",
            "Department of Oncology and Clinical Haematology, Austin Health, Heidelberg, Melbourne, Australia.",
            "Nottingham City Hospital, Nottingham, UK.",
            "University College London, London, UK."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "05",
                "Day": "20"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic Value of microRNA-224 in Various Cancers: A Meta-analysis.",
        "AuthorList": [
            "Yue Zhang",
            "Cong-Cong Guo",
            "Dong-Hui Guan",
            "Chuan-Hua Yang",
            "Yue-Hua Jiang"
        ],
        "AffiliationList": [
            "First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People's Republic of China.",
            "First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People's Republic of China.",
            "Department of Orthopedics, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People's Republic of China.",
            "Department of Cardiology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People's Republic of China.",
            "Central Laboratory, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People's Republic of China. Electronic address: jiang_yuehua@hotmail.com."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "11",
                "Day": "10"
            }
        ]
    },
    {
        "ArticleTitle": "[Aidi Injection-Asisted R-CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma].",
        "AuthorList": [
            "Guo-Quan Lu",
            "Xiao-Hong Zhou",
            "Hong Chen",
            "Jian-Ping Tan"
        ],
        "AffiliationList": [
            "Department of Oncology, Anshun People's Hospital, Anshun 561000, Guizhou Province, China.",
            "Department of Oncology, Anshun People's Hospital, Anshun 561000, Guizhou Province, China. E-mail: 229794192@qq.com.",
            "Department of Oncology, Anshun People's Hospital, Anshun 561000, Guizhou Province, China.",
            "Department of Oncology, Anshun People's Hospital, Anshun 561000, Guizhou Province, China."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Pre-transplant (18)F-fluorodeoxyglucose positron emission tomography-based survival model in patients with aggressive lymphoma undergoing high-dose chemotherapy and autologous SCT.",
        "AuthorList": [
            "S Akhtar",
            "A S Al-Sugair",
            "M Abouzied",
            "Y Alkadhi",
            "M Dingle",
            "M Abdelsalam",
            "H Soudy",
            "A Darwish"
        ],
        "AffiliationList": [
            "King Faisal Specialist Hospital and Research Center, Oncology Center, Riyadh, Saudi Arabia. sakhtar@kfshrc.edu.sa",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "09",
                "Day": "10"
            }
        ]
    },
    {
        "ArticleTitle": "Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.",
        "AuthorList": [
            "Paolo F Caimi",
            "Weiyun Ai",
            "Juan Pablo Alderuccio",
            "Kirit M Ardeshna",
            "Mehdi Hamadani",
            "Brian Hess",
            "Brad S Kahl",
            "John Radford"
        ],
        "AffiliationList": [
            "University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA. Electronic address: paolo.caimi@case.edu.",
            "Division of Haematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.",
            "Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.",
            "Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.",
            "Blood and Marrow Transplant and Cellular Therapy Programme, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.",
            "Division of Haematology and Medical Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.",
            "Department of Medicine, Oncology Division, Washington University, St Louis, MO, USA.",
            "National Institute for Health Research Manchester Clinical Research Facility, University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "05",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-cell lymphomas.",
        "AuthorList": [
            "Paolo F Caimi",
            "Weiyun Ai",
            "Juan Pablo Alderuccio",
            "Kirit M Ardeshna",
            "Mehdi Hamadani",
            "Brian Hess",
            "Brad S Kahl",
            "John Radford"
        ],
        "AffiliationList": [
            "University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA. Electronic address: paolo.caimi@case.edu.",
            "Division of Haematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.",
            "Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.",
            "Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.",
            "Blood and Marrow Transplant and Cellular Therapy Programme, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.",
            "Division of Haematology and Medical Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.",
            "Department of Medicine, Oncology Division, Washington University, St Louis, MO, USA.",
            "National Institute for Health Research Manchester Clinical Research Facility, University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2.",
        "AuthorList": [
            "P Morel",
            "P Gaulard",
            "C Gisselbrecht",
            "C Ferme",
            "G Salles",
            "H Tilly",
            "J Brière",
            "M C Copin"
        ],
        "AffiliationList": [
            "Service d'Hématologie Clinique, Hôpital Schaffner, Lens, France.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2007",
                "Month": "12",
                "Day": "19"
            }
        ]
    },
    {
        "ArticleTitle": "Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.",
        "AuthorList": [
            "John P Leonard",
            "Morton Coleman",
            "Jamie Ketas",
            "Michelle Ashe",
            "Jennifer M Fiore",
            "Richard R Furman",
            "Ruben Niesvizky",
            "Tsiporah Shore"
        ],
        "AffiliationList": [
            "Center for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY 10021, USA. jpleonar@med.cornell.edu",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2005",
                "Month": "06",
                "Day": "13"
            }
        ]
    },
    {
        "ArticleTitle": "N-acetyltransferase polymorphisms are associated with risk of lymphoma subtypes.",
        "AuthorList": [
            "Pierluigi Cocco",
            "Mariagrazia Zucca",
            "Sonia Sanna",
            "Giannina Satta",
            "Tinucia Nonne",
            "Emanuele Angelucci",
            "Attilio Gabbas",
            "Marco Rais"
        ],
        "AffiliationList": [
            "Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Monserrato, Cagliari, Italy.",
            "Department of Biomedical Sciences, Cytomorphology Section, University of Cagliari, Monserrato, Cagliari, Italy.",
            "Department of Biomedical Sciences, Cytomorphology Section, University of Cagliari, Monserrato, Cagliari, Italy.",
            "Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Monserrato, Cagliari, Italy.",
            "Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Monserrato, Cagliari, Italy.",
            "Unit of Haematology, A. Businco Oncology Hospital, Cagliari, Italy.",
            "Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Monserrato, Cagliari, Italy.",
            "Cagliari, Italy."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "02",
                "Day": "17"
            }
        ]
    },
    {
        "ArticleTitle": "Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306).",
        "AuthorList": [
            "Ruth Pettengell",
            "Monika Długosz-Danecka",
            "David Andorsky",
            "David Belada",
            "Pencho Georgiev",
            "Donald Quick",
            "Jack W Singer",
            "Simran B Singh"
        ],
        "AffiliationList": [
            "St. George's Hospital, London, UK.",
            "Department of Haematology, Jagiellonian University, Krakow, Poland.",
            "Rocky Mountain Cancer Centers, US Oncology Research, Boulder, CO, USA.",
            "Clinical Haematology, 4th Department of Internal Medicine, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.",
            "Clinic of Oncology and Haematology, University Multiprofile Hospital for Active Treatment \"Sveti Georgi\" and Medical University, Plovdiv, Bulgaria.",
            "Joe Arrington Cancer Research Treatment Center, Lubbock, TX, USA.",
            "CTI Biopharma, Seattle, WA, USA.",
            "CTI Biopharma, Seattle, WA, USA."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "12",
                "Day": "27"
            }
        ]
    },
    {
        "ArticleTitle": "A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Yuankai Shi",
            "Yongping Song",
            "Yan Qin",
            "Qingyuan Zhang",
            "Xiaohong Han",
            "Xiaonan Hong",
            "Dong Wang",
            "Wei Li"
        ],
        "AffiliationList": [
            "National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. syuankai@cicams.ac.cn.",
            "Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.",
            "National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.",
            "Harbin Medical University Cancer Hospital, Harbin, China.",
            "National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.",
            "Fudan University Shanghai Cancer Center, Shanghai, China.",
            "Daping Hospital, Third Affiliated Hospital of the Army Medical University, Chongqing, China.",
            "The First Bethune Hospital of Jilin University, Changchun, China."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "04",
                "Day": "16"
            }
        ]
    },
    {
        "ArticleTitle": "Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.",
        "AuthorList": [
            "David Belada",
            "Katerina Kopeckova",
            "Juan Miguel Bergua Burgues",
            "Don Stevens",
            "Marc André",
            "Ernesto Perez Persona",
            "Petra Pichler",
            "Philipp B Staber"
        ],
        "AffiliationList": [
            "4th Department of Internal Medicine-Hematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.",
            "Department of Oncology of the 2nd Faculty of Medicine of Charles University and University Hospital in Motol, Prague, Czech Republic.",
            "Department of Hematology, Hospital San Pedro de Alcantara, Cáceres, Spain.",
            "Norton Cancer Institute-St. Matthews Campus, Louisville, KY.",
            "Department of Hematology, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium.",
            "Bioaraba (Onco-hematology Research Group), Vitoria-Gasteiz, Spain.",
            "Department of Internal Medicine, University Hospital of St. Pölten, St. Pölten, Austria.",
            "Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.",
        "AuthorList": [
            "Reid W Merryman",
            "Robert Redd",
            "Erin Jeter",
            "Jeff L Wong",
            "Kristin McHugh",
            "Carol Reynolds",
            "Matthew Nazzaro",
            "Aine Varden"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address: Reid_merryman@dfci.harvard.edu.",
            "Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.",
            "Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.",
            "Laboratory of Molecular Genetics and Immunology, Rockefeller University, New York, New York; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, New York.",
            "Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.",
            "Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.",
            "Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.",
            "Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "10",
                "Day": "17"
            }
        ]
    },
    {
        "ArticleTitle": "Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Ivana N M Micallef",
            "Matthew J Maurer",
            "Gregory A Wiseman",
            "Daniel A Nikcevich",
            "Paul J Kurtin",
            "Michael W Cannon",
            "Domingo G Perez",
            "Gamini S Soori"
        ],
        "AffiliationList": [
            "Mayo Clinic Rochester, Rochester, MN, USA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "06",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.",
        "AuthorList": [
            "Frederick L Locke",
            "Sattva S Neelapu",
            "Nancy L Bartlett",
            "Tanya Siddiqi",
            "Julio C Chavez",
            "Chitra M Hosing",
            "Armin Ghobadi",
            "Lihua E Budde"
        ],
        "AffiliationList": [
            "Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612, USA. Electronic address: frederick.locke@moffitt.org.",
            "Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.",
            "Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA.",
            "Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA.",
            "Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 33612, USA.",
            "Division of Cancer Medicine, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.",
            "Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA.",
            "Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "01",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Ukihide Tateishi",
            "Mitsuaki Tatsumi",
            "Takashi Terauchi",
            "Kiyoshi Ando",
            "Nozomi Niitsu",
            "Won Seog Kim",
            "Cheolwon Suh",
            "Michinori Ogura"
        ],
        "AffiliationList": [
            "Department of Diagnostic Radiology and Nuclear Medicine, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "02",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.",
        "AuthorList": [
            "Jeffrey L Vacirca",
            "Peter I Acs",
            "Imad A Tabbara",
            "Peter J Rosen",
            "Peter Lee",
            "Eric Lynam"
        ],
        "AffiliationList": [
            "North Shore Hematology and Oncology Associates, 235 N Belle Mead Road, East Setauket, NY, 11733-3456, USA, Jvacirca@yahoo.com.",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "08",
                "Day": "17"
            }
        ]
    },
    {
        "ArticleTitle": "Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.",
        "AuthorList": [
            "Ajay Major",
            "Justin Kline",
            "Theodore G Karrison",
            "Paul A S Fishkin",
            "Amy S Kimball",
            "Adam M Petrich",
            "Sreenivasa Nattam",
            "Krishna Rao"
        ],
        "AffiliationList": [
            "University of Chicago, Chicago, IL.",
            "University of Chicago, Chicago, IL.",
            "University of Chicago, Chicago, IL.",
            "Illinois Cancer Care, Peoria, IL.",
            "University of Maryland School of Medicine and Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Amgen Inc., Thousand Oaks, CA.",
            "Northwestern University, Chicago, IL, USA; Daiichi-Sankyo, Basking Ridge, NJ.",
            "Fort Wayne Oncology/Hematology, Fort Wayne, IN.",
            "Southern Illinois University, Springfield, IL."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "07",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study.",
        "AuthorList": [
            "Myrna Candelaria",
            "Derlis E González",
            "Marcia Torresan Delamain",
            "Daniel Oscar Bär",
            "Surender Kumar Beniwal",
            "Lokanatha Dasappa",
            "David Hugo Flores",
            "John Querol"
        ],
        "AffiliationList": [
            "Instituto Nacional de Cancerologia, Tlalpan, Mexico City, Mexico.",
            "Instituto Privado de Hematología E Investigación Clínica (IPHIC), Asunción, Paraguay.",
            "Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil.",
            "Hospital J.B. Iturraspe, Santa Fe, Argentina.",
            "Acharya Tulsi Regional Cancer Treatment and Research Institute (RCC), S. P. Medical College and AG of Hospitals, Bikaner, India.",
            "HCG Care Centre, Bangalore, India.",
            "Hospital Ángel Padilla, Tucumán, Argentina.",
            "Veterans Memorial Medical Center (VMMC), Quezon City, Philippines."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "07",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Comparison of Three Chemotherapy Regimens in Elderly Patients with Diffuse Large B Cell Lymphoma: Experience at a Single National Reference Center in Mexico.",
        "AuthorList": [
            "Diana Nolasco-Medina",
            "Nancy Reynoso-Noveron",
            "Alejandro Mohar-Betancourt",
            "Alejandro Aviles-Salas",
            "Osvaldo García-Perez",
            "Myrna Candelaria"
        ],
        "AffiliationList": [
            "Hematology Department, Instituto Nacional de Cancerología, 14080 Mexico City, DF, Mexico.",
            "Clinical Research Division, Instituto Nacional de Cancerología, 14080 Mexico City, DF, Mexico.",
            "Clinical Research Division, Instituto Nacional de Cancerología, 14080 Mexico City, DF, Mexico; Instituto de Investigaciones Biomédicas, UNAM, 04510 Mexico City, DF, Mexico.",
            "Pathology Department, Instituto Nacional de Cancerología, 14080 Mexico City, DF, Mexico.",
            "Nuclear Medicine Department, Instituto Nacional de Cancerología, 14080 Mexico City, DF, Mexico.",
            "Clinical Research Division, Instituto Nacional de Cancerología, 14080 Mexico City, DF, Mexico."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "07",
                "Day": "10"
            }
        ]
    },
    {
        "ArticleTitle": "[Nine-year experience in the treatment of patients with diffuse large B-cell lymphosarcoma].",
        "AuthorList": [
            "A U Magomedova",
            "S K Kravchenko",
            "A M Kremenetskaia",
            "E A Zvonkov",
            "E A Bariakh",
            "Ia K Mangasarova",
            "I B Kaplanskaia",
            "R S Samoĭlova"
        ],
        "AffiliationList": [
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy.",
        "AuthorList": [
            "Gaetano Corazzelli",
            "Ferdinando Frigeri",
            "Manuela Arcamone",
            "Anna Lucania",
            "Maria Rosariavilla",
            "Emanuela Morelli",
            "Alfonso Amore",
            "Gaetana Capobianco"
        ],
        "AffiliationList": [
            "Haematology-Oncology and Stem Cell Transplantation Unit, National Cancer Institute, Fondazione G. Pascale, IRCCS, Naples, Italy. g.corazzelli@istitutotumori.na.it",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "06",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Clinicopathological features of 171 cases of primary thyroid lymphoma: a long-term study involving 24553 patients with Hashimoto's disease.",
        "AuthorList": [
            "Natsuko Watanabe",
            "Jaeduk Y Noh",
            "Hiroto Narimatsu",
            "Kengo Takeuchi",
            "Takuhiro Yamaguchi",
            "Kaori Kameyama",
            "Kazuhiko Kobayashi",
            "Masahiro Kami"
        ],
        "AffiliationList": [
            "Ito Hospital, 4-3-6 Jingumae, Shibuya-ku,Tokyo, Japan. n-watanabe@ito-hospital.jp",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "03",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial.",
        "AuthorList": [
            "Ken Ohmachi",
            "Tomohiro Kinoshita",
            "Kensei Tobinai",
            "Gakuto Ogawa",
            "Tomonori Mizutani",
            "Nobuhiko Yamauchi",
            "Noriko Fukuhara",
            "Toshiki Uchida"
        ],
        "AffiliationList": [
            "Department of Hematology and Oncology, Tokai University School of Medicine, Kanagawa, Japan.",
            "Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Aichi, Japan.",
            "Department of Hematology and.",
            "Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.",
            "Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.",
            "Department of Hematology, National Cancer Center Hospital East, Chiba, Japan.",
            "Department of Hematology, Tohoku University Hospital, Miyagi, Japan.",
            "Department of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Aichi, Japan."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.",
        "AuthorList": [
            "Deborah M Stephens",
            "Hongli Li",
            "Michael L LeBlanc",
            "Soham D Puvvada",
            "Daniel Persky",
            "Jonathan W Friedberg",
            "Sonali M Smith"
        ],
        "AffiliationList": [
            "Deborah M. Stephens, University of Utah, Salt Lake City, UT; Hongli Li and Michael L. LeBlanc, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Soham D. Puvvada and Daniel Persky, University of Arizona, Tucson, AZ; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; and Sonali M. Smith, University of Chicago, Chicago, IL.",
            "Deborah M. Stephens, University of Utah, Salt Lake City, UT; Hongli Li and Michael L. LeBlanc, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Soham D. Puvvada and Daniel Persky, University of Arizona, Tucson, AZ; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; and Sonali M. Smith, University of Chicago, Chicago, IL.",
            "Deborah M. Stephens, University of Utah, Salt Lake City, UT; Hongli Li and Michael L. LeBlanc, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Soham D. Puvvada and Daniel Persky, University of Arizona, Tucson, AZ; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; and Sonali M. Smith, University of Chicago, Chicago, IL.",
            "Deborah M. Stephens, University of Utah, Salt Lake City, UT; Hongli Li and Michael L. LeBlanc, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Soham D. Puvvada and Daniel Persky, University of Arizona, Tucson, AZ; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; and Sonali M. Smith, University of Chicago, Chicago, IL.",
            "Deborah M. Stephens, University of Utah, Salt Lake City, UT; Hongli Li and Michael L. LeBlanc, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Soham D. Puvvada and Daniel Persky, University of Arizona, Tucson, AZ; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; and Sonali M. Smith, University of Chicago, Chicago, IL.",
            "Deborah M. Stephens, University of Utah, Salt Lake City, UT; Hongli Li and Michael L. LeBlanc, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Soham D. Puvvada and Daniel Persky, University of Arizona, Tucson, AZ; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; and Sonali M. Smith, University of Chicago, Chicago, IL.",
            "Deborah M. Stephens, University of Utah, Salt Lake City, UT; Hongli Li and Michael L. LeBlanc, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Soham D. Puvvada and Daniel Persky, University of Arizona, Tucson, AZ; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; and Sonali M. Smith, University of Chicago, Chicago, IL. smsmith@medicine.bsd.uchicago.edu."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "07",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis.",
        "AuthorList": [
            "Catherine Thieblemont",
            "Bettina Altmann",
            "Fabian Frontzek",
            "Loïc Renaud",
            "Loic Chartier",
            "Nicolas Ketterer",
            "Christian Récher",
            "Viola Poeschel"
        ],
        "AffiliationList": [
            "Université de Paris, Assistance Publique-Hôpitaux de Paris (APHP), Hemato-oncologie, Saint-Louis Hôpital, Paris, France.",
            "Institute for Medical Informatics, Statistics, and Epidemiology, University of Leipzig, Leipzig, Germany.",
            "Department of Medicine A, Hematology, Oncology, and Pneumonology, Münster University Hospital, Münster, Germany.",
            "Université de Paris, Assistance Publique-Hôpitaux de Paris (APHP), Hemato-oncologie, Saint-Louis Hôpital, Paris, France.",
            "Statistique, Lymphoma Academic Research Organisation, Pierre-Benite, France.",
            "Centre d'Oncologie-Hématologie, Bois-Cerf Clinique, Lausanne, Switzerland.",
            "Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université Toulouse III Paul Sabatier, Toulouse, France.",
            "Department of Internal Medicine I, Medical School, Saarland University, Homburg/Saar, Germany."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.",
        "AuthorList": [
            "Raul Cordoba",
            "Thibaud Prawitz",
            "Tracy Westley",
            "Anuj Sharma",
            "Sumeet Ambarkhane",
            "Venediktos Kapetanakis",
            "Lorenzo Sabatelli"
        ],
        "AffiliationList": [
            "Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain.",
            "Evidera Inc., Paris, France.",
            "Evidera Inc., Montreal, QC, Canada.",
            "Evidera Inc., Montreal, QC, Canada.",
            "MorphoSys AG, Planegg, Germany.",
            "Evidera Inc., London, UK.",
            "Incyte Biosciences International Sàrl, Morges, Switzerland. lsabatelli@incyte.com."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "04",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group.",
        "AuthorList": [
            "Juan-Manuel Sancho",
            "Rubén Fernández-Alvarez",
            "Francisco Gual-Capllonch",
            "Esther González-García",
            "Carlos Grande",
            "Norma Gutiérrez",
            "María-Jesús Peñarrubia",
            "Ana Batlle-López"
        ],
        "AffiliationList": [
            "Hematology Department, ICO-IJC-Hospital Germans Trias i Pujol, Badalona, Spain.",
            "Hematology Department, Hospital de Cabueñes, Gijón, Spain.",
            "Cardiology Department of Hospital Germans Trias i Pujol, Badalona, Spain.",
            "Hematology Department, Hospital de Cabueñes, Gijón, Spain.",
            "Hematology Department, Hospital Doce de Octubre, Madrid, Spain.",
            "Hematology Department, Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain.",
            "Hematology Department, Hospital Clínico de Valladolid, Valladolid, Spain.",
            "Hematology Department, Hospital Marqués de Valdecilla, Santander, Spain."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "01",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.",
        "AuthorList": [
            "Laurie H Sehn",
            "Alex F Herrera",
            "Christopher R Flowers",
            "Manali K Kamdar",
            "Andrew McMillan",
            "Mark Hertzberg",
            "Sarit Assouline",
            "Tae Min Kim"
        ],
        "AffiliationList": [
            "BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, British Columbia, Canada.",
            "City of Hope, Duarte, CA.",
            "Winship Cancer Institute of Emory University, Atlanta, GA.",
            "University of Colorado, Aurora, CO.",
            "Nottingham University Hospitals, Nottingham, United Kingdom.",
            "Prince of Wales Hospital and University of NSW, Sydney, NSW, Australia.",
            "Jewish General Hospital, Montreal, Quebec, Canada.",
            "Seoul National University Hospital, Seoul, South Korea."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "11",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.",
        "AuthorList": [
            "Jonathan W Friedberg",
            "Daruka Mahadevan",
            "Erin Cebula",
            "Daniel Persky",
            "Izidore Lossos",
            "Amit B Agarwal",
            "Jungah Jung",
            "Richard Burack"
        ],
        "AffiliationList": [
            "Jonathan W. Friedberg, Erin Cebula, Richard Burack, and Steven H. Bernstein, University of Rochester Wilmot Cancer Center, Rochester, NY; Daruka Mahadevan, West Clinic and University of Tennessee Health Sciences Center, Memphis, TN; Daniel Persky, Yale University, New Haven, CT; Izidore Lossos, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Amit G. Agarwal, University of Arizona Cancer Center, Tucson, AZ; and JungAh Jung, Xiaofei Zhou, E. Jane Leonard, Howard Fingert, and Hadi Danaee, Millennium Pharmaceuticals, Cambridge, MA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "09",
                "Day": "16"
            }
        ]
    },
    {
        "ArticleTitle": "Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.",
        "AuthorList": [
            "John P Leonard",
            "Kathryn S Kolibaba",
            "James A Reeves",
            "Anil Tulpule",
            "Ian W Flinn",
            "Tatjana Kolevska",
            "Robert Robles",
            "Christopher R Flowers"
        ],
        "AffiliationList": [
            "John P. Leonard, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY; Kathryn S. Kolibaba, Compass Oncology, Vancouver, WA; Kathryn S. Kolibaba and Nicholas J. DiBella, US Oncology Research, The Woodlands; Robert Collins, University of Texas Southwestern Medical Center, Dallas, TX; James A. Reeves, Florida Cancer Specialists, Fort Myers; Julio Hajdenberg, University of Florida Health Cancer Center at Orlando Health, Orlando, FL; Anil Tulpule, Keck Medicine of University of Southern California; Sven de Vos, University of California at Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles; Tatjana Kolevska, Kaiser Permanente Medical Center Northern California, Vallejo; Robert Robles, Bay Area Cancer Research Group (Diablo Valley Medical Group), Pleasant Hill; Andrew Horodner, Cancer Care Associates Medical Group, Redondo Beach, CA; Ian W. Flinn, Sarah Cannon Research Institute, Nashville, TN; Christopher R. Flowers, Winship Cancer Institute of Emory University, Atlanta, GA; Nicholas J. DiBella, Rocky Mountain Cancer Centers, Aurora, CO; Steven W. Papish, Summit Medical Group MD Anderson Cancer Center, Camden, NJ; Parameswaran Venugopal, Rush University Medical Center, Chicago, IL; Amir Tabatabai, York Cancer Center/Cancer Care Associates of York, York, PA; and Jaehong Park, Rachel Neuwirth, George Mulligan, Kaveri Suryanarayan, and Dixie-Lee Esseltine, Millennium Pharmaceuticals, Cambridge, MA.",
            "John P. Leonard, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY; Kathryn S. Kolibaba, Compass Oncology, Vancouver, WA; Kathryn S. Kolibaba and Nicholas J. DiBella, US Oncology Research, The Woodlands; Robert Collins, University of Texas Southwestern Medical Center, Dallas, TX; James A. Reeves, Florida Cancer Specialists, Fort Myers; Julio Hajdenberg, University of Florida Health Cancer Center at Orlando Health, Orlando, FL; Anil Tulpule, Keck Medicine of University of Southern California; Sven de Vos, University of California at Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles; Tatjana Kolevska, Kaiser Permanente Medical Center Northern California, Vallejo; Robert Robles, Bay Area Cancer Research Group (Diablo Valley Medical Group), Pleasant Hill; Andrew Horodner, Cancer Care Associates Medical Group, Redondo Beach, CA; Ian W. Flinn, Sarah Cannon Research Institute, Nashville, TN; Christopher R. Flowers, Winship Cancer Institute of Emory University, Atlanta, GA; Nicholas J. DiBella, Rocky Mountain Cancer Centers, Aurora, CO; Steven W. Papish, Summit Medical Group MD Anderson Cancer Center, Camden, NJ; Parameswaran Venugopal, Rush University Medical Center, Chicago, IL; Amir Tabatabai, York Cancer Center/Cancer Care Associates of York, York, PA; and Jaehong Park, Rachel Neuwirth, George Mulligan, Kaveri Suryanarayan, and Dixie-Lee Esseltine, Millennium Pharmaceuticals, Cambridge, MA.",
            "John P. Leonard, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY; Kathryn S. Kolibaba, Compass Oncology, Vancouver, WA; Kathryn S. Kolibaba and Nicholas J. DiBella, US Oncology Research, The Woodlands; Robert Collins, University of Texas Southwestern Medical Center, Dallas, TX; James A. Reeves, Florida Cancer Specialists, Fort Myers; Julio Hajdenberg, University of Florida Health Cancer Center at Orlando Health, Orlando, FL; Anil Tulpule, Keck Medicine of University of Southern California; Sven de Vos, University of California at Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles; Tatjana Kolevska, Kaiser Permanente Medical Center Northern California, Vallejo; Robert Robles, Bay Area Cancer Research Group (Diablo Valley Medical Group), Pleasant Hill; Andrew Horodner, Cancer Care Associates Medical Group, Redondo Beach, CA; Ian W. Flinn, Sarah Cannon Research Institute, Nashville, TN; Christopher R. Flowers, Winship Cancer Institute of Emory University, Atlanta, GA; Nicholas J. DiBella, Rocky Mountain Cancer Centers, Aurora, CO; Steven W. Papish, Summit Medical Group MD Anderson Cancer Center, Camden, NJ; Parameswaran Venugopal, Rush University Medical Center, Chicago, IL; Amir Tabatabai, York Cancer Center/Cancer Care Associates of York, York, PA; and Jaehong Park, Rachel Neuwirth, George Mulligan, Kaveri Suryanarayan, and Dixie-Lee Esseltine, Millennium Pharmaceuticals, Cambridge, MA.",
            "John P. Leonard, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY; Kathryn S. Kolibaba, Compass Oncology, Vancouver, WA; Kathryn S. Kolibaba and Nicholas J. DiBella, US Oncology Research, The Woodlands; Robert Collins, University of Texas Southwestern Medical Center, Dallas, TX; James A. Reeves, Florida Cancer Specialists, Fort Myers; Julio Hajdenberg, University of Florida Health Cancer Center at Orlando Health, Orlando, FL; Anil Tulpule, Keck Medicine of University of Southern California; Sven de Vos, University of California at Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles; Tatjana Kolevska, Kaiser Permanente Medical Center Northern California, Vallejo; Robert Robles, Bay Area Cancer Research Group (Diablo Valley Medical Group), Pleasant Hill; Andrew Horodner, Cancer Care Associates Medical Group, Redondo Beach, CA; Ian W. Flinn, Sarah Cannon Research Institute, Nashville, TN; Christopher R. Flowers, Winship Cancer Institute of Emory University, Atlanta, GA; Nicholas J. DiBella, Rocky Mountain Cancer Centers, Aurora, CO; Steven W. Papish, Summit Medical Group MD Anderson Cancer Center, Camden, NJ; Parameswaran Venugopal, Rush University Medical Center, Chicago, IL; Amir Tabatabai, York Cancer Center/Cancer Care Associates of York, York, PA; and Jaehong Park, Rachel Neuwirth, George Mulligan, Kaveri Suryanarayan, and Dixie-Lee Esseltine, Millennium Pharmaceuticals, Cambridge, MA.",
            "John P. Leonard, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY; Kathryn S. Kolibaba, Compass Oncology, Vancouver, WA; Kathryn S. Kolibaba and Nicholas J. DiBella, US Oncology Research, The Woodlands; Robert Collins, University of Texas Southwestern Medical Center, Dallas, TX; James A. Reeves, Florida Cancer Specialists, Fort Myers; Julio Hajdenberg, University of Florida Health Cancer Center at Orlando Health, Orlando, FL; Anil Tulpule, Keck Medicine of University of Southern California; Sven de Vos, University of California at Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles; Tatjana Kolevska, Kaiser Permanente Medical Center Northern California, Vallejo; Robert Robles, Bay Area Cancer Research Group (Diablo Valley Medical Group), Pleasant Hill; Andrew Horodner, Cancer Care Associates Medical Group, Redondo Beach, CA; Ian W. Flinn, Sarah Cannon Research Institute, Nashville, TN; Christopher R. Flowers, Winship Cancer Institute of Emory University, Atlanta, GA; Nicholas J. DiBella, Rocky Mountain Cancer Centers, Aurora, CO; Steven W. Papish, Summit Medical Group MD Anderson Cancer Center, Camden, NJ; Parameswaran Venugopal, Rush University Medical Center, Chicago, IL; Amir Tabatabai, York Cancer Center/Cancer Care Associates of York, York, PA; and Jaehong Park, Rachel Neuwirth, George Mulligan, Kaveri Suryanarayan, and Dixie-Lee Esseltine, Millennium Pharmaceuticals, Cambridge, MA.",
            "John P. Leonard, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY; Kathryn S. Kolibaba, Compass Oncology, Vancouver, WA; Kathryn S. Kolibaba and Nicholas J. DiBella, US Oncology Research, The Woodlands; Robert Collins, University of Texas Southwestern Medical Center, Dallas, TX; James A. Reeves, Florida Cancer Specialists, Fort Myers; Julio Hajdenberg, University of Florida Health Cancer Center at Orlando Health, Orlando, FL; Anil Tulpule, Keck Medicine of University of Southern California; Sven de Vos, University of California at Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles; Tatjana Kolevska, Kaiser Permanente Medical Center Northern California, Vallejo; Robert Robles, Bay Area Cancer Research Group (Diablo Valley Medical Group), Pleasant Hill; Andrew Horodner, Cancer Care Associates Medical Group, Redondo Beach, CA; Ian W. Flinn, Sarah Cannon Research Institute, Nashville, TN; Christopher R. Flowers, Winship Cancer Institute of Emory University, Atlanta, GA; Nicholas J. DiBella, Rocky Mountain Cancer Centers, Aurora, CO; Steven W. Papish, Summit Medical Group MD Anderson Cancer Center, Camden, NJ; Parameswaran Venugopal, Rush University Medical Center, Chicago, IL; Amir Tabatabai, York Cancer Center/Cancer Care Associates of York, York, PA; and Jaehong Park, Rachel Neuwirth, George Mulligan, Kaveri Suryanarayan, and Dixie-Lee Esseltine, Millennium Pharmaceuticals, Cambridge, MA.",
            "John P. Leonard, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY; Kathryn S. Kolibaba, Compass Oncology, Vancouver, WA; Kathryn S. Kolibaba and Nicholas J. DiBella, US Oncology Research, The Woodlands; Robert Collins, University of Texas Southwestern Medical Center, Dallas, TX; James A. Reeves, Florida Cancer Specialists, Fort Myers; Julio Hajdenberg, University of Florida Health Cancer Center at Orlando Health, Orlando, FL; Anil Tulpule, Keck Medicine of University of Southern California; Sven de Vos, University of California at Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles; Tatjana Kolevska, Kaiser Permanente Medical Center Northern California, Vallejo; Robert Robles, Bay Area Cancer Research Group (Diablo Valley Medical Group), Pleasant Hill; Andrew Horodner, Cancer Care Associates Medical Group, Redondo Beach, CA; Ian W. Flinn, Sarah Cannon Research Institute, Nashville, TN; Christopher R. Flowers, Winship Cancer Institute of Emory University, Atlanta, GA; Nicholas J. DiBella, Rocky Mountain Cancer Centers, Aurora, CO; Steven W. Papish, Summit Medical Group MD Anderson Cancer Center, Camden, NJ; Parameswaran Venugopal, Rush University Medical Center, Chicago, IL; Amir Tabatabai, York Cancer Center/Cancer Care Associates of York, York, PA; and Jaehong Park, Rachel Neuwirth, George Mulligan, Kaveri Suryanarayan, and Dixie-Lee Esseltine, Millennium Pharmaceuticals, Cambridge, MA.",
            "John P. Leonard, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY; Kathryn S. Kolibaba, Compass Oncology, Vancouver, WA; Kathryn S. Kolibaba and Nicholas J. DiBella, US Oncology Research, The Woodlands; Robert Collins, University of Texas Southwestern Medical Center, Dallas, TX; James A. Reeves, Florida Cancer Specialists, Fort Myers; Julio Hajdenberg, University of Florida Health Cancer Center at Orlando Health, Orlando, FL; Anil Tulpule, Keck Medicine of University of Southern California; Sven de Vos, University of California at Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles; Tatjana Kolevska, Kaiser Permanente Medical Center Northern California, Vallejo; Robert Robles, Bay Area Cancer Research Group (Diablo Valley Medical Group), Pleasant Hill; Andrew Horodner, Cancer Care Associates Medical Group, Redondo Beach, CA; Ian W. Flinn, Sarah Cannon Research Institute, Nashville, TN; Christopher R. Flowers, Winship Cancer Institute of Emory University, Atlanta, GA; Nicholas J. DiBella, Rocky Mountain Cancer Centers, Aurora, CO; Steven W. Papish, Summit Medical Group MD Anderson Cancer Center, Camden, NJ; Parameswaran Venugopal, Rush University Medical Center, Chicago, IL; Amir Tabatabai, York Cancer Center/Cancer Care Associates of York, York, PA; and Jaehong Park, Rachel Neuwirth, George Mulligan, Kaveri Suryanarayan, and Dixie-Lee Esseltine, Millennium Pharmaceuticals, Cambridge, MA."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "09",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms.",
        "AuthorList": [
            "Hee Sang Hwang",
            "Dok Hyun Yoon",
            "Jung Yong Hong",
            "Chan-Sik Park",
            "Yoon Se Lee",
            "Young Hyeh Ko",
            "Seok Jin Kim",
            "Won Seog Kim"
        ],
        "AffiliationList": [
            "Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.",
            "Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.",
            "Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.",
            "Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.",
            "Department of Otorhinolaryngology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.",
            "Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.",
            "Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.",
            "Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "08",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic role of peripheral blood lymphocyte/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: a meta-analysis.",
        "AuthorList": [
            "Baochai Lin",
            "Cuie Chen",
            "Yan Qian",
            "Jianhua Feng"
        ],
        "AffiliationList": [
            "a Division of Radiation Oncology and Chemotherapy, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou , P. R. China.",
            "b Division of Pediatrics, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou , P. R. China.",
            "b Division of Pediatrics, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou , P. R. China.",
            "c Division of Pediatric Hematology-Oncology, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou , P. R. China."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "03",
                "Day": "03"
            }
        ]
    },
    {
        "ArticleTitle": "Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Michele Spina",
            "Monica Balzarotti",
            "Lilj Uziel",
            "Andrés José Marìa Ferreri",
            "Lucia Fratino",
            "Massimo Magagnoli",
            "Renato Talamini",
            "Annalisa Giacalone"
        ],
        "AffiliationList": [
            "Division of Medical Oncology A, National Cancer Institute, Via Franco Gallini 2, Aviano, PN, Italy. mspina@cro.it",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "05",
                "Day": "18"
            }
        ]
    },
    {
        "ArticleTitle": "A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Ivana N M Micallef",
            "Brad S Kahl",
            "Matthew J Maurer",
            "Ahmet Dogan",
            "Stephen M Ansell",
            "Joseph P Colgan",
            "Susan Geyer",
            "David J Inwards"
        ],
        "AffiliationList": [
            "Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA. micallef.ivana@mayo.edu",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Monica Balzarotti",
            "Massimo Magagnoli",
            "Miguel Ángel Canales",
            "Paolo Corradini",
            "Carlos Grande",
            "Juan-Manuel Sancho",
            "Francesco Zaja",
            "Anne-Marie Quinson"
        ],
        "AffiliationList": [
            "Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milano, Italy.",
            "Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milano, Italy.",
            "Servicio de Hematologia, Hospital Universitario La Paz, Madrid, Spain.",
            "University of Milan, Milan, Italy.",
            "Hospital Universitario 12 de Octubre, Madrid, Spain.",
            "Clinical Hematology Department, ICO-IJC-Hospital Germans Trias i Pujol, Badalona, Spain.",
            "University of Trieste, Ospedale Maggiore, Piazza dell'Ospitale 1, Trieste, Italy.",
            "Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "02",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis.",
        "AuthorList": [
            "Andreas M Schmitt",
            "Amanda K Herbrand",
            "Christopher P Fox",
            "Katerina Bakunina",
            "Jacoline E C Bromberg",
            "Kate Cwynarski",
            "Jeanette K Doorduijn",
            "Andrés J M Ferreri"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, University Hospital Basel and University of Basel, Basel, Switzerland.",
            "Department of Medical Oncology, University Hospital Basel and University of Basel, Basel, Switzerland.",
            "Department of Clinical Haematology, Nottingham Hospitals NHS Trust, Nottingham, UK.",
            "HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.",
            "Department of Neuro-Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.",
            "Department of Haematology, University College London Hospital, London, UK.",
            "Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.",
            "Lymphoma Unit, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "10",
                "Day": "09"
            }
        ]
    },
    {
        "ArticleTitle": "Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.",
        "AuthorList": [
            "Andrew D Zelenetz",
            "Gilles Salles",
            "Kylie D Mason",
            "Carla Casulo",
            "Steven Le Gouill",
            "Laurie H Sehn",
            "Herve Tilly",
            "Guillaume Cartron"
        ],
        "AffiliationList": [
            "Memorial Sloan Kettering Cancer Center, New York, NY.",
            "Hospices Civils de Lyon, Lyon, France.",
            "Royal Melbourne Hospital, Melbourne, VIC, Australia.",
            "Wilmot Cancer Institute, University of Rochester, Rochester, NY.",
            "Service d'Hématologie, CHU de Nantes, Nantes, France.",
            "Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada.",
            "Centre Henri Becquerel, Rouen, France.",
            "Department of Hematology, University of Montpellier, Montpellier, France."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "03",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.",
        "AuthorList": [
            "Jane N Winter",
            "Edie A Weller",
            "Sandra J Horning",
            "Maryla Krajewska",
            "Daina Variakojis",
            "Thomas M Habermann",
            "Richard I Fisher",
            "Paul J Kurtin"
        ],
        "AffiliationList": [
            "Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. j-winter@northwestern.edu",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2006",
                "Month": "01",
                "Day": "31"
            }
        ]
    },
    {
        "ArticleTitle": "Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study.",
        "AuthorList": [
            "Maria Lia Palomba",
            "Guillaume Cartron",
            "Leslie Popplewell",
            "Vincent Ribrag",
            "Jason Westin",
            "Ling-Yuh Huw",
            "Shefali Agarwal",
            "Mahesh Shivhare"
        ],
        "AffiliationList": [
            "Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.",
            "Department of Clinical Hematology, University Hospital Center of Montpellier, Montpellier, France.",
            "Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.",
            "DITEP, Institut Gustave Roussy, Villejuif, France.",
            "Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX, USA.",
            "Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.",
            "Epizyme, Cambridge, MA, USA.",
            "Roche Products, Welwyn Garden City, UK."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "12",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "Experience with provisional WHO-entities large B-cell lymphoma with IRF4-rearrangement and Burkitt-like lymphoma with 11q aberration in paediatric patients of the NHL-BFM group.",
        "AuthorList": [
            "Rex K H Au-Yeung",
            "Laura Arias Padilla",
            "Martin Zimmermann",
            "Ilske Oschlies",
            "Reiner Siebert",
            "Wilhelm Woessmann",
            "Birgit Burkhardt",
            "Wolfram Klapper"
        ],
        "AffiliationList": [
            "Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Christian-Albrecht-University of Kiel, Kiel, Germany.",
            "Department of Paediatric Haematology and Oncology, University Children's Hospital, Münster, Germany.",
            "Department of Paediatric Haematology and Oncology, Hannover Medical School, Hanover, Germany.",
            "Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Christian-Albrecht-University of Kiel, Kiel, Germany.",
            "Institute of Human Genetics, Ulm University & Ulm University Medical Center, Ulm, Germany.",
            "Department of Paediatric Haematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.",
            "Department of Paediatric Haematology and Oncology, University Children's Hospital, Münster, Germany.",
            "Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Christian-Albrecht-University of Kiel, Kiel, Germany."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "04",
                "Day": "02"
            }
        ]
    },
    {
        "ArticleTitle": "Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Tove Wästerlid",
            "Sara Harrysson",
            "Therese M-L Andersson",
            "Sara Ekberg",
            "Gunilla Enblad",
            "Per-Ola Andersson",
            "Mats Jerkeman",
            "Sandra Eloranta"
        ],
        "AffiliationList": [
            "Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.",
            "Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.",
            "Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.",
            "Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.",
            "Department of Oncology, Akademiska University Hospital, Uppsala, Sweden.",
            "Department of Hematology, South Älvsborg Hospital, Borås, Sweden.",
            "Department of Oncology and Pathology, Institute of Clinical Sciences, Lund University, Lund, Sweden.",
            "Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "04",
                "Day": "03"
            }
        ]
    },
    {
        "ArticleTitle": "Disease characteristics of diffuse large B-cell lymphoma predicting relapse and survival after autologous stem cell transplantation: A single institution experience.",
        "AuthorList": [
            "Daria Gaut",
            "Tahmineh Romero",
            "David Oveisi",
            "Grant Howell",
            "Gary Schiller"
        ],
        "AffiliationList": [
            "Deparment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.",
            "Division of General Internal Medicine and Health Services Research, Department of Medicine Statistics Core, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.",
            "Deparment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.",
            "David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.",
            "Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "12",
                "Day": "03"
            }
        ]
    },
    {
        "ArticleTitle": "Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Valentina Bozzoli",
            "Maria C Tisi",
            "Elena Maiolo",
            "Eleonora Alma",
            "Silvia Bellesi",
            "Francesco D'Alo'",
            "Maria T Voso",
            "Giuseppe Leone"
        ],
        "AffiliationList": [
            "Institute of Haematology, Catholic University S. Cuore, Rome, Italy.",
            "Institute of Haematology, Catholic University S. Cuore, Rome, Italy.",
            "Institute of Haematology, Catholic University S. Cuore, Rome, Italy.",
            "Institute of Haematology, Catholic University S. Cuore, Rome, Italy.",
            "Institute of Haematology, Catholic University S. Cuore, Rome, Italy.",
            "Institute of Haematology, Catholic University S. Cuore, Rome, Italy.",
            "Institute of Haematology, Catholic University S. Cuore, Rome, Italy.",
            "Institute of Haematology, Catholic University S. Cuore, Rome, Italy."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "03",
                "Day": "29"
            }
        ]
    },
    {
        "ArticleTitle": "Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial.",
        "AuthorList": [
            "Luis Fayad",
            "Stephen M Ansell",
            "Ranjana Advani",
            "Bertrand Coiffier",
            "Robert Stuart",
            "Nancy L Bartlett",
            "Andres Forero-Torres",
            "Kazimierz Kuliczkowski"
        ],
        "AffiliationList": [
            "a M. D. Anderson Cancer Center , Houston , TX , USA.",
            "b Mayo Clinic , Rochester , MN , USA.",
            "c Stanford Cancer Center , Stanford , CA , USA.",
            "d Centre Hospitalier Lyon Sud , Pierre Benite , France.",
            "e Medical University of South Carolina , Charleston , SC , USA.",
            "f Washington University School of Medicine , St. Louis , MO , USA.",
            "g University of Alabama , Birmingham , AL , USA.",
            "h Samodzielny Publiczny Szpital Kliniczny , Wroclaw , Poland."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "02",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy.",
        "AuthorList": [
            "Mary Gerrard",
            "Ian M Waxman",
            "Richard Sposto",
            "Anne Auperin",
            "Sherrie L Perkins",
            "Stanton Goldman",
            "Lauren Harrison",
            "Ross Pinkerton"
        ],
        "AffiliationList": [
            "Sheffield Children's Hospital, Sheffield, United Kingdom.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "11",
                "Day": "13"
            }
        ]
    },
    {
        "ArticleTitle": "Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma.",
        "AuthorList": [
            "Julie M Vose",
            "Philip J Bierman",
            "Fausto R Loberiza",
            "Charles Enke",
            "Jordan Hankins",
            "Robert G Bociek",
            "Wing C Chan",
            "Dennis D Weisenburger"
        ],
        "AffiliationList": [
            "Department of Internal Medicine, Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, Nebraska 68198-7680, USA. jmvose@unmc.edu",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "08",
                "Day": "29"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: results from a prospective cohort study.",
        "AuthorList": [
            "Hyun Ae Jung",
            "Silvia Park",
            "Jin Hyun Cho",
            "Seonwoo Kim",
            "Young Hyeh Ko",
            "Seok Jin Kim",
            "Won Seog Kim"
        ],
        "AffiliationList": [
            "Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, Korea.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "06",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium.",
        "AuthorList": [
            "Gilles Salles",
            "Daphne de Jong",
            "Wanling Xie",
            "Andreas Rosenwald",
            "Mukesh Chhanabhai",
            "Philippe Gaulard",
            "Wolfram Klapper",
            "Maria Calaminici"
        ],
        "AffiliationList": [
            "Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Lyon, France. gilles.salles@chu-lyon.fr",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "05",
                "Day": "02"
            }
        ]
    },
    {
        "ArticleTitle": "[Long-term results of rituximab-based salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma].",
        "AuthorList": [
            "Xiao-xiao Wang",
            "Hui-qiang Huang",
            "Zhong-jun Xia",
            "Xu-bin Lin",
            "Qing-qing Cai",
            "Yan Gao",
            "Ze-xiao Lin",
            "Tong-yu Lin"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, Cancer Center/State Key Laboratory of Oncology in South China/Sun Yat-sen Institute of Hematology, Sun Yat-sen University, Guangzhou 510060, China. 996xiaoxiao@163.com",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study.",
        "AuthorList": [
            "Paolo F Caimi",
            "Weiyun Z Ai",
            "Juan Pablo Alderuccio",
            "Kirit M Ardeshna",
            "Mehdi Hamadani",
            "Brian Hess",
            "Brad S Kahl",
            "John Radford"
        ],
        "AffiliationList": [
            "Cleveland Clinic Taussig Cancer Center, Cleveland, OH. caimip@ccf.org.",
            "Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.",
            "Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL.",
            "University College London Hospitals NHS Foundation Trust, London, United Kingdom.",
            "Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI.",
            "Medical University of South Carolina, Charleston, SC.",
            "Washington University, St. Louis, MO.",
            "NIHR Clinical Research Facility, University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom."
        ],
        "Years": [
            {
                "Year": "2024",
                "Month": "04",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.",
        "AuthorList": [
            "Jinchul Kim",
            "Jinhyun Cho",
            "Sang Eun Yoon",
            "Won Seog Kim",
            "Seok Jin Kim"
        ],
        "AffiliationList": [
            "Department of Hematology-Oncology, Inha University College of Medicine, Incheon, Korea.",
            "Department of Hematology-Oncology, Inha University College of Medicine, Incheon, Korea.",
            "Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.",
            "Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.",
            "Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "03",
                "Day": "13"
            }
        ]
    },
    {
        "ArticleTitle": "Upfront autologous stem cell transplantation for untreated diffuse large B cell lymphoma patients in rituximab era: a systematic review and meta-analysis.",
        "AuthorList": [
            "Shu-Yun Ma",
            "Xiao-Peng Tian",
            "Jun Cai",
            "Guang-Zheng Zhong",
            "Xu Chen",
            "Hui-Qiang Huang",
            "Tong-Yu Lin",
            "Zhi-Ming Li"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, People's Republic of China.",
            "Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, People's Republic of China.",
            "Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, People's Republic of China.",
            "Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.",
            "Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.",
            "Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, People's Republic of China.",
            "Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, People's Republic of China.",
            "Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, People's Republic of China."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "04",
                "Day": "13"
            }
        ]
    },
    {
        "ArticleTitle": "Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.",
        "AuthorList": [
            "Andrés J M Ferreri",
            "Marta Bruno-Ventre",
            "Giovanni Donadoni",
            "Maurilio Ponzoni",
            "Giovanni Citterio",
            "Marco Foppoli",
            "Alessandro Vignati",
            "Lydia Scarfò"
        ],
        "AffiliationList": [
            "Division of Onco-Haematological Medicine, Department of Onco-Haematology, Unit of Lymphoid Malignancies, Milan, Italy.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "10",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.",
        "AuthorList": [
            "Matthew J Matasar",
            "Myron S Czuczman",
            "Maria Alma Rodriguez",
            "Michael Fennessy",
            "Thomas C Shea",
            "Gary Spitzer",
            "Izidore S Lossos",
            "Mohamed A Kharfan-Dabaja"
        ],
        "AffiliationList": [
            "Lymphoma and Adult Bone Marrow Transplant Services, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. matasarm@mskcc.org",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "05",
                "Day": "21"
            }
        ]
    },
    {
        "ArticleTitle": "An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.",
        "AuthorList": [
            "T E Witzig",
            "J M Vose",
            "P L Zinzani",
            "C B Reeder",
            "R Buckstein",
            "J A Polikoff",
            "R Bouabdallah",
            "C Haioun"
        ],
        "AffiliationList": [
            "Department of Medicine, Division of Hematology, Mayo Clinic, Rochester. Electronic address: witzig@mayo.edu.",
            "Section of Hematology/Oncology, University of Nebraska, Omaha, USA.",
            "Institute of Hematology and Oncology Seragnoli, University of Bologna, Bologna, Italy.",
            "Department of Medicine, Division of Hematology, Mayo Clinic, Scottsdale, USA.",
            "Department of Hematology, Sunnybrook Odette Cancer Center, Toronto, Canada.",
            "Department of Hematology/Oncology, Kaiser Permanente Medical Group, San Diego, USA.",
            "Department of Hematology, Institut Paoli Calmettes, Marseilles.",
            "Department of Hôpital Henri Mondor-AP-HP, Créteil."
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "01",
                "Day": "12"
            }
        ]
    },
    {
        "ArticleTitle": "Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.",
        "AuthorList": [
            "Antonino Musolino",
            "Daniela Boggiani",
            "Michele Panebianco",
            "Giovanna Vasini",
            "Stefania Salvagni",
            "Vittorio Franciosi",
            "Andrea Ardizzoni"
        ],
        "AffiliationList": [
            "Medical Oncology Unit, University Hospital of Parma, Parma, Italy. antoninomusolino@hotmail.com",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2010",
                "Month": "10",
                "Day": "19"
            }
        ]
    },
    {
        "ArticleTitle": "Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.",
        "AuthorList": [
            "Tadeusz Robak",
            "Ewa Lech-Maranda",
            "Agnieszka Janus",
            "Jerzy Blonski",
            "Agnieszka Wierzbowska",
            "Joanna Gora-Tybor"
        ],
        "AffiliationList": [
            "Department of Hematology, Medical University of Lodz, Poland. robaktad@csk.am.lodz.pl",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients.",
        "AuthorList": [
            "J M Li",
            "L Wang",
            "Y Shen",
            "Z G Xia",
            "Y Chen",
            "Q S Chen",
            "Y Chen",
            "X Y Zeng"
        ],
        "AffiliationList": [
            "Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China. lijunmin@medmail.com.cn",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2007",
                "Month": "06",
                "Day": "16"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic value of pre-therapy C-reactive protein level in diffuse large B-cell lymphoma: a meta-analysis.",
        "AuthorList": [
            "Wenqiong Qin",
            "Qiang Yuan",
            "Jingkui Wu",
            "Haonan Yu",
            "Ying Wang",
            "Qiusong Chen"
        ],
        "AffiliationList": [
            "a Department of PET/CT Diagnostic , Tianjin Medical University General Hospital , Heping District , Tianjin , China.",
            "b Department of Urology , The Second People's Hospital of Three Gorges University , Xiling District , Yichang , China.",
            "c Department of Traditional Chinese Medicine , Tianjin Medical University General Hospital , Heping District , Tianjin , China.",
            "a Department of PET/CT Diagnostic , Tianjin Medical University General Hospital , Heping District , Tianjin , China.",
            "a Department of PET/CT Diagnostic , Tianjin Medical University General Hospital , Heping District , Tianjin , China.",
            "a Department of PET/CT Diagnostic , Tianjin Medical University General Hospital , Heping District , Tianjin , China."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "07",
                "Day": "22"
            }
        ]
    },
    {
        "ArticleTitle": "[Pharmacological characteristics and clinical outcomes of Epcoritamab (recombinant) (Epkinly<sup>®</sup> subcutaneous injection ) for malignant lymphoma].",
        "AuthorList": [
            "Kana Takaura",
            "Hiroshi Ando",
            "Edward Ramirez Ganoza"
        ],
        "AffiliationList": [
            "Medical Affairs, Genmab K. K.",
            "Medical Affairs, Genmab K. K.",
            "Medical Affairs, Genmab K. K."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.",
        "AuthorList": [
            "Anas Younes",
            "Jesus G Berdeja",
            "Manish R Patel",
            "Ian Flinn",
            "John F Gerecitano",
            "Sattva S Neelapu",
            "Kevin R Kelly",
            "Amanda R Copeland"
        ],
        "AffiliationList": [
            "Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: younesa@mskcc.org.",
            "Sarah Cannon Research Institute, Nashville, TN, USA.",
            "Sarah Cannon Research Institute, Nashville, TN, USA; Florida Cancer Specialists, Sarasota, FL, USA.",
            "Sarah Cannon Research Institute, Nashville, TN, USA.",
            "Memorial Sloan Kettering Cancer Center, New York, NY, USA.",
            "Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.",
            "Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California, Los Angeles, CA, USA.",
            "Memorial Sloan Kettering Cancer Center, New York, NY, USA."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "03",
                "Day": "31"
            }
        ]
    },
    {
        "ArticleTitle": "Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.",
        "AuthorList": [
            "A Kühnl",
            "D Cunningham",
            "N Counsell",
            "E A Hawkes",
            "W Qian",
            "P Smith",
            "N Chadwick",
            "A Lawrie"
        ],
        "AffiliationList": [
            "Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey.",
            "Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey.",
            "Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.",
            "Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey.",
            "Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge.",
            "Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.",
            "Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.",
            "Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.",
        "AuthorList": [
            "Xinran Ma",
            "Ling Li",
            "Lei Zhang",
            "Xiaorui Fu",
            "Xin Li",
            "Xinhua Wang",
            "Jingjing Wu",
            "Zhenchang Sun"
        ],
        "AffiliationList": [
            "Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China.",
            "Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China.",
            "Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China.",
            "Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China.",
            "Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China.",
            "Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China.",
            "Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China.",
            "Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "01",
                "Day": "22"
            }
        ]
    },
    {
        "ArticleTitle": "Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.",
        "AuthorList": [
            "Michael Crump",
            "Sirpa Leppä",
            "Luis Fayad",
            "Je Jung Lee",
            "Alice Di Rocco",
            "Michinori Ogura",
            "Hans Hagberg",
            "Frederick Schnell"
        ],
        "AffiliationList": [
            "Michael Crump, Princess Margaret Cancer Centre, Toronto, Ontario; Kerry J. Savage, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Sirpa Leppä, Helsinki University Hospital Cancer Center, Helsinki, Finland; Luis Fayad, The University of Texas MD Anderson Cancer Center, Houston, TX; Frederick Schnell, Central Georgia Cancer Care, Macon, GA; Robert Rifkin, US Oncology Research Network and Rocky Mountain Cancer Centers, Denver, CO; Lauren Pinter-Brown, University of California at Los Angeles, Santa Monica, CA; Sonali Smith, University of Chicago, Chicago, IL; Eric D. Hsi, Cleveland Clinic, Cleveland, OH; Tuan Nguyen, Peipei Shi, Marjo Hahka-Kemppinen, Don Thornton, and Boris Lin, Eli Lilly and Company, Indianapolis, IN; Brad Kahl, University of Wisconsin, Madison, WI; Thomas Habermann, Mayo Clinic Cancer Research Consortium, Rochester, NY; Je Jung Lee, Chonnam National University Hwasun Hospital, Gwangju, South Korea; Alice Di Rocco, Sapienza University, Rome, Italy; Michinori Ogura, Tokai Central Hospital, Kakamigahara; Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan; Hans Hagberg, Akademiska Sjukhuset, Onkologkliniken, Uppsala, Sweden; Andreas Mackensen, University of Erlangen, Erlangen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg, Germany; Fritz Offner, University of Gent, Gent, Belgium; and Su-Peng Yeh, China Medical University Hospital, Taichung, Republic of China. michael.crump@uhn.ca.",
            "Michael Crump, Princess Margaret Cancer Centre, Toronto, Ontario; Kerry J. Savage, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Sirpa Leppä, Helsinki University Hospital Cancer Center, Helsinki, Finland; Luis Fayad, The University of Texas MD Anderson Cancer Center, Houston, TX; Frederick Schnell, Central Georgia Cancer Care, Macon, GA; Robert Rifkin, US Oncology Research Network and Rocky Mountain Cancer Centers, Denver, CO; Lauren Pinter-Brown, University of California at Los Angeles, Santa Monica, CA; Sonali Smith, University of Chicago, Chicago, IL; Eric D. Hsi, Cleveland Clinic, Cleveland, OH; Tuan Nguyen, Peipei Shi, Marjo Hahka-Kemppinen, Don Thornton, and Boris Lin, Eli Lilly and Company, Indianapolis, IN; Brad Kahl, University of Wisconsin, Madison, WI; Thomas Habermann, Mayo Clinic Cancer Research Consortium, Rochester, NY; Je Jung Lee, Chonnam National University Hwasun Hospital, Gwangju, South Korea; Alice Di Rocco, Sapienza University, Rome, Italy; Michinori Ogura, Tokai Central Hospital, Kakamigahara; Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan; Hans Hagberg, Akademiska Sjukhuset, Onkologkliniken, Uppsala, Sweden; Andreas Mackensen, University of Erlangen, Erlangen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg, Germany; Fritz Offner, University of Gent, Gent, Belgium; and Su-Peng Yeh, China Medical University Hospital, Taichung, Republic of China.",
            "Michael Crump, Princess Margaret Cancer Centre, Toronto, Ontario; Kerry J. Savage, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Sirpa Leppä, Helsinki University Hospital Cancer Center, Helsinki, Finland; Luis Fayad, The University of Texas MD Anderson Cancer Center, Houston, TX; Frederick Schnell, Central Georgia Cancer Care, Macon, GA; Robert Rifkin, US Oncology Research Network and Rocky Mountain Cancer Centers, Denver, CO; Lauren Pinter-Brown, University of California at Los Angeles, Santa Monica, CA; Sonali Smith, University of Chicago, Chicago, IL; Eric D. Hsi, Cleveland Clinic, Cleveland, OH; Tuan Nguyen, Peipei Shi, Marjo Hahka-Kemppinen, Don Thornton, and Boris Lin, Eli Lilly and Company, Indianapolis, IN; Brad Kahl, University of Wisconsin, Madison, WI; Thomas Habermann, Mayo Clinic Cancer Research Consortium, Rochester, NY; Je Jung Lee, Chonnam National University Hwasun Hospital, Gwangju, South Korea; Alice Di Rocco, Sapienza University, Rome, Italy; Michinori Ogura, Tokai Central Hospital, Kakamigahara; Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan; Hans Hagberg, Akademiska Sjukhuset, Onkologkliniken, Uppsala, Sweden; Andreas Mackensen, University of Erlangen, Erlangen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg, Germany; Fritz Offner, University of Gent, Gent, Belgium; and Su-Peng Yeh, China Medical University Hospital, Taichung, Republic of China.",
            "Michael Crump, Princess Margaret Cancer Centre, Toronto, Ontario; Kerry J. Savage, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Sirpa Leppä, Helsinki University Hospital Cancer Center, Helsinki, Finland; Luis Fayad, The University of Texas MD Anderson Cancer Center, Houston, TX; Frederick Schnell, Central Georgia Cancer Care, Macon, GA; Robert Rifkin, US Oncology Research Network and Rocky Mountain Cancer Centers, Denver, CO; Lauren Pinter-Brown, University of California at Los Angeles, Santa Monica, CA; Sonali Smith, University of Chicago, Chicago, IL; Eric D. Hsi, Cleveland Clinic, Cleveland, OH; Tuan Nguyen, Peipei Shi, Marjo Hahka-Kemppinen, Don Thornton, and Boris Lin, Eli Lilly and Company, Indianapolis, IN; Brad Kahl, University of Wisconsin, Madison, WI; Thomas Habermann, Mayo Clinic Cancer Research Consortium, Rochester, NY; Je Jung Lee, Chonnam National University Hwasun Hospital, Gwangju, South Korea; Alice Di Rocco, Sapienza University, Rome, Italy; Michinori Ogura, Tokai Central Hospital, Kakamigahara; Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan; Hans Hagberg, Akademiska Sjukhuset, Onkologkliniken, Uppsala, Sweden; Andreas Mackensen, University of Erlangen, Erlangen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg, Germany; Fritz Offner, University of Gent, Gent, Belgium; and Su-Peng Yeh, China Medical University Hospital, Taichung, Republic of China.",
            "Michael Crump, Princess Margaret Cancer Centre, Toronto, Ontario; Kerry J. Savage, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Sirpa Leppä, Helsinki University Hospital Cancer Center, Helsinki, Finland; Luis Fayad, The University of Texas MD Anderson Cancer Center, Houston, TX; Frederick Schnell, Central Georgia Cancer Care, Macon, GA; Robert Rifkin, US Oncology Research Network and Rocky Mountain Cancer Centers, Denver, CO; Lauren Pinter-Brown, University of California at Los Angeles, Santa Monica, CA; Sonali Smith, University of Chicago, Chicago, IL; Eric D. Hsi, Cleveland Clinic, Cleveland, OH; Tuan Nguyen, Peipei Shi, Marjo Hahka-Kemppinen, Don Thornton, and Boris Lin, Eli Lilly and Company, Indianapolis, IN; Brad Kahl, University of Wisconsin, Madison, WI; Thomas Habermann, Mayo Clinic Cancer Research Consortium, Rochester, NY; Je Jung Lee, Chonnam National University Hwasun Hospital, Gwangju, South Korea; Alice Di Rocco, Sapienza University, Rome, Italy; Michinori Ogura, Tokai Central Hospital, Kakamigahara; Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan; Hans Hagberg, Akademiska Sjukhuset, Onkologkliniken, Uppsala, Sweden; Andreas Mackensen, University of Erlangen, Erlangen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg, Germany; Fritz Offner, University of Gent, Gent, Belgium; and Su-Peng Yeh, China Medical University Hospital, Taichung, Republic of China.",
            "Michael Crump, Princess Margaret Cancer Centre, Toronto, Ontario; Kerry J. Savage, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Sirpa Leppä, Helsinki University Hospital Cancer Center, Helsinki, Finland; Luis Fayad, The University of Texas MD Anderson Cancer Center, Houston, TX; Frederick Schnell, Central Georgia Cancer Care, Macon, GA; Robert Rifkin, US Oncology Research Network and Rocky Mountain Cancer Centers, Denver, CO; Lauren Pinter-Brown, University of California at Los Angeles, Santa Monica, CA; Sonali Smith, University of Chicago, Chicago, IL; Eric D. Hsi, Cleveland Clinic, Cleveland, OH; Tuan Nguyen, Peipei Shi, Marjo Hahka-Kemppinen, Don Thornton, and Boris Lin, Eli Lilly and Company, Indianapolis, IN; Brad Kahl, University of Wisconsin, Madison, WI; Thomas Habermann, Mayo Clinic Cancer Research Consortium, Rochester, NY; Je Jung Lee, Chonnam National University Hwasun Hospital, Gwangju, South Korea; Alice Di Rocco, Sapienza University, Rome, Italy; Michinori Ogura, Tokai Central Hospital, Kakamigahara; Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan; Hans Hagberg, Akademiska Sjukhuset, Onkologkliniken, Uppsala, Sweden; Andreas Mackensen, University of Erlangen, Erlangen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg, Germany; Fritz Offner, University of Gent, Gent, Belgium; and Su-Peng Yeh, China Medical University Hospital, Taichung, Republic of China.",
            "Michael Crump, Princess Margaret Cancer Centre, Toronto, Ontario; Kerry J. Savage, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Sirpa Leppä, Helsinki University Hospital Cancer Center, Helsinki, Finland; Luis Fayad, The University of Texas MD Anderson Cancer Center, Houston, TX; Frederick Schnell, Central Georgia Cancer Care, Macon, GA; Robert Rifkin, US Oncology Research Network and Rocky Mountain Cancer Centers, Denver, CO; Lauren Pinter-Brown, University of California at Los Angeles, Santa Monica, CA; Sonali Smith, University of Chicago, Chicago, IL; Eric D. Hsi, Cleveland Clinic, Cleveland, OH; Tuan Nguyen, Peipei Shi, Marjo Hahka-Kemppinen, Don Thornton, and Boris Lin, Eli Lilly and Company, Indianapolis, IN; Brad Kahl, University of Wisconsin, Madison, WI; Thomas Habermann, Mayo Clinic Cancer Research Consortium, Rochester, NY; Je Jung Lee, Chonnam National University Hwasun Hospital, Gwangju, South Korea; Alice Di Rocco, Sapienza University, Rome, Italy; Michinori Ogura, Tokai Central Hospital, Kakamigahara; Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan; Hans Hagberg, Akademiska Sjukhuset, Onkologkliniken, Uppsala, Sweden; Andreas Mackensen, University of Erlangen, Erlangen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg, Germany; Fritz Offner, University of Gent, Gent, Belgium; and Su-Peng Yeh, China Medical University Hospital, Taichung, Republic of China.",
            "Michael Crump, Princess Margaret Cancer Centre, Toronto, Ontario; Kerry J. Savage, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Sirpa Leppä, Helsinki University Hospital Cancer Center, Helsinki, Finland; Luis Fayad, The University of Texas MD Anderson Cancer Center, Houston, TX; Frederick Schnell, Central Georgia Cancer Care, Macon, GA; Robert Rifkin, US Oncology Research Network and Rocky Mountain Cancer Centers, Denver, CO; Lauren Pinter-Brown, University of California at Los Angeles, Santa Monica, CA; Sonali Smith, University of Chicago, Chicago, IL; Eric D. Hsi, Cleveland Clinic, Cleveland, OH; Tuan Nguyen, Peipei Shi, Marjo Hahka-Kemppinen, Don Thornton, and Boris Lin, Eli Lilly and Company, Indianapolis, IN; Brad Kahl, University of Wisconsin, Madison, WI; Thomas Habermann, Mayo Clinic Cancer Research Consortium, Rochester, NY; Je Jung Lee, Chonnam National University Hwasun Hospital, Gwangju, South Korea; Alice Di Rocco, Sapienza University, Rome, Italy; Michinori Ogura, Tokai Central Hospital, Kakamigahara; Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan; Hans Hagberg, Akademiska Sjukhuset, Onkologkliniken, Uppsala, Sweden; Andreas Mackensen, University of Erlangen, Erlangen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg, Germany; Fritz Offner, University of Gent, Gent, Belgium; and Su-Peng Yeh, China Medical University Hospital, Taichung, Republic of China."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "05",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study.",
        "AuthorList": [
            "Adam J Olszewski",
            "Tycel J Phillips",
            "Marc S Hoffmann",
            "Philippe Armand",
            "Tae Min Kim",
            "Dok Hyun Yoon",
            "Amitkumar Mehta",
            "Richard Greil"
        ],
        "AffiliationList": [
            "Lifespan Cancer Institute, Warren Alpert Medical School of Brown University, Providence, RI.",
            "Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI.",
            "Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Kansas City, KS.",
            "Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.",
            "Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.",
            "Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.",
            "Division of Hematology and Oncology, University of Alabama School of Medicine, Birmingham, AL.",
            "IIIrd Medical Department, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT), Paracelsus Medical University, Salzburg, Austria."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.",
        "AuthorList": [
            "James N Kochenderfer",
            "Mark E Dudley",
            "Sadik H Kassim",
            "Robert P T Somerville",
            "Robert O Carpenter",
            "Maryalice Stetler-Stevenson",
            "James C Yang",
            "Giao Q Phan"
        ],
        "AffiliationList": [
            "James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim, Robert P.T. Somerville, Robert O. Carpenter, Maryalice Stetler-Stevenson, James C. Yang, Q. Phan, Marybeth S. Hughes, Richard M. Sherry, Mark Raffeld, Steven Feldman, Lily Lu, Yong F. Li, Lien T. Ngo, Debbie-Ann N. Nathan, Kathleen E. Morton, Mary Ann Toomey, and Steven A. Rosenberg, National Cancer Institute; Clara C. Chen, Clinical Center, National Institutes of Health (NIH); Sarah M. Kranick and Avindra Nath, National Institutes of Neurologic Disorders and Stroke, NIH, Bethesda, MD; Andre Goy and Tatyana Feldman, Hackensack University Medical Center, Hackensack, NJ; David E. Spaner, Sunybrook Odette Cancer Center, Toronto, Ontario, Canada; and Michael L. Wang, MD Anderson Cancer Center, Houston, TX. kochendj@mail.nih.gov.",
            "James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim, Robert P.T. Somerville, Robert O. Carpenter, Maryalice Stetler-Stevenson, James C. Yang, Q. Phan, Marybeth S. Hughes, Richard M. Sherry, Mark Raffeld, Steven Feldman, Lily Lu, Yong F. Li, Lien T. Ngo, Debbie-Ann N. Nathan, Kathleen E. Morton, Mary Ann Toomey, and Steven A. Rosenberg, National Cancer Institute; Clara C. Chen, Clinical Center, National Institutes of Health (NIH); Sarah M. Kranick and Avindra Nath, National Institutes of Neurologic Disorders and Stroke, NIH, Bethesda, MD; Andre Goy and Tatyana Feldman, Hackensack University Medical Center, Hackensack, NJ; David E. Spaner, Sunybrook Odette Cancer Center, Toronto, Ontario, Canada; and Michael L. Wang, MD Anderson Cancer Center, Houston, TX.",
            "James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim, Robert P.T. Somerville, Robert O. Carpenter, Maryalice Stetler-Stevenson, James C. Yang, Q. Phan, Marybeth S. Hughes, Richard M. Sherry, Mark Raffeld, Steven Feldman, Lily Lu, Yong F. Li, Lien T. Ngo, Debbie-Ann N. Nathan, Kathleen E. Morton, Mary Ann Toomey, and Steven A. Rosenberg, National Cancer Institute; Clara C. Chen, Clinical Center, National Institutes of Health (NIH); Sarah M. Kranick and Avindra Nath, National Institutes of Neurologic Disorders and Stroke, NIH, Bethesda, MD; Andre Goy and Tatyana Feldman, Hackensack University Medical Center, Hackensack, NJ; David E. Spaner, Sunybrook Odette Cancer Center, Toronto, Ontario, Canada; and Michael L. Wang, MD Anderson Cancer Center, Houston, TX.",
            "James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim, Robert P.T. Somerville, Robert O. Carpenter, Maryalice Stetler-Stevenson, James C. Yang, Q. Phan, Marybeth S. Hughes, Richard M. Sherry, Mark Raffeld, Steven Feldman, Lily Lu, Yong F. Li, Lien T. Ngo, Debbie-Ann N. Nathan, Kathleen E. Morton, Mary Ann Toomey, and Steven A. Rosenberg, National Cancer Institute; Clara C. Chen, Clinical Center, National Institutes of Health (NIH); Sarah M. Kranick and Avindra Nath, National Institutes of Neurologic Disorders and Stroke, NIH, Bethesda, MD; Andre Goy and Tatyana Feldman, Hackensack University Medical Center, Hackensack, NJ; David E. Spaner, Sunybrook Odette Cancer Center, Toronto, Ontario, Canada; and Michael L. Wang, MD Anderson Cancer Center, Houston, TX.",
            "James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim, Robert P.T. Somerville, Robert O. Carpenter, Maryalice Stetler-Stevenson, James C. Yang, Q. Phan, Marybeth S. Hughes, Richard M. Sherry, Mark Raffeld, Steven Feldman, Lily Lu, Yong F. Li, Lien T. Ngo, Debbie-Ann N. Nathan, Kathleen E. Morton, Mary Ann Toomey, and Steven A. Rosenberg, National Cancer Institute; Clara C. Chen, Clinical Center, National Institutes of Health (NIH); Sarah M. Kranick and Avindra Nath, National Institutes of Neurologic Disorders and Stroke, NIH, Bethesda, MD; Andre Goy and Tatyana Feldman, Hackensack University Medical Center, Hackensack, NJ; David E. Spaner, Sunybrook Odette Cancer Center, Toronto, Ontario, Canada; and Michael L. Wang, MD Anderson Cancer Center, Houston, TX.",
            "James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim, Robert P.T. Somerville, Robert O. Carpenter, Maryalice Stetler-Stevenson, James C. Yang, Q. Phan, Marybeth S. Hughes, Richard M. Sherry, Mark Raffeld, Steven Feldman, Lily Lu, Yong F. Li, Lien T. Ngo, Debbie-Ann N. Nathan, Kathleen E. Morton, Mary Ann Toomey, and Steven A. Rosenberg, National Cancer Institute; Clara C. Chen, Clinical Center, National Institutes of Health (NIH); Sarah M. Kranick and Avindra Nath, National Institutes of Neurologic Disorders and Stroke, NIH, Bethesda, MD; Andre Goy and Tatyana Feldman, Hackensack University Medical Center, Hackensack, NJ; David E. Spaner, Sunybrook Odette Cancer Center, Toronto, Ontario, Canada; and Michael L. Wang, MD Anderson Cancer Center, Houston, TX.",
            "James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim, Robert P.T. Somerville, Robert O. Carpenter, Maryalice Stetler-Stevenson, James C. Yang, Q. Phan, Marybeth S. Hughes, Richard M. Sherry, Mark Raffeld, Steven Feldman, Lily Lu, Yong F. Li, Lien T. Ngo, Debbie-Ann N. Nathan, Kathleen E. Morton, Mary Ann Toomey, and Steven A. Rosenberg, National Cancer Institute; Clara C. Chen, Clinical Center, National Institutes of Health (NIH); Sarah M. Kranick and Avindra Nath, National Institutes of Neurologic Disorders and Stroke, NIH, Bethesda, MD; Andre Goy and Tatyana Feldman, Hackensack University Medical Center, Hackensack, NJ; David E. Spaner, Sunybrook Odette Cancer Center, Toronto, Ontario, Canada; and Michael L. Wang, MD Anderson Cancer Center, Houston, TX.",
            "James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim, Robert P.T. Somerville, Robert O. Carpenter, Maryalice Stetler-Stevenson, James C. Yang, Q. Phan, Marybeth S. Hughes, Richard M. Sherry, Mark Raffeld, Steven Feldman, Lily Lu, Yong F. Li, Lien T. Ngo, Debbie-Ann N. Nathan, Kathleen E. Morton, Mary Ann Toomey, and Steven A. Rosenberg, National Cancer Institute; Clara C. Chen, Clinical Center, National Institutes of Health (NIH); Sarah M. Kranick and Avindra Nath, National Institutes of Neurologic Disorders and Stroke, NIH, Bethesda, MD; Andre Goy and Tatyana Feldman, Hackensack University Medical Center, Hackensack, NJ; David E. Spaner, Sunybrook Odette Cancer Center, Toronto, Ontario, Canada; and Michael L. Wang, MD Anderson Cancer Center, Houston, TX."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "08",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.",
        "AuthorList": [
            "Michael J Dickinson",
            "Carmelo Carlo-Stella",
            "Franck Morschhauser",
            "Emmanuel Bachy",
            "Paolo Corradini",
            "Gloria Iacoboni",
            "Cyrus Khan",
            "Tomasz Wróbel"
        ],
        "AffiliationList": [
            "From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and the University of Melbourne, Melbourne, VIC (M.J.D.), and Prince of Wales Hospital and the University of New South Wales, Sydney (M. Hertzberg) - all in Australia; Humanitas University and Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital (C.C.-S.), and Università degli Studi di Milano and Fondazione IRCCS Istituto Nazionale dei Tumori (P.C.) - all in Milan; Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, Unité Labellisée de Recherche 7365, Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille (F.M.), Centre Hospitalier Lyon Sud, Lyon (E.B.), and CHU de Montpellier, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5535, Montpellier (G.C.) - all in France; Vall d'Hebron University Hospital (G.I.) and Institut Català d'Oncologia Hospitalet, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona (A.S.) - both in Barcelona; the Allegheny Health Network Cancer Institute, Pittsburgh (C.K.); Uniwersytet Medyczny we Wrocławiu, Wroclaw, Poland (T.W.); Universitair Ziekenhuis Gent, Ghent, Belgium (F.O.); the First Faculty of Medicine, Charles University Hospital, Prague, Czech Republic (M.T.); National Taiwan University Hospital, Taipei (S.-J.W.); F. Hoffmann-La Roche, Basel, Switzerland (D.P.-C., L.L.); Roche Products, Welwyn Garden City, United Kingdom (J.R., M.D., E.C., K.H.); and Rigshospitalet, Copenhagen (M. Hutchings).",
            "From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and the University of Melbourne, Melbourne, VIC (M.J.D.), and Prince of Wales Hospital and the University of New South Wales, Sydney (M. Hertzberg) - all in Australia; Humanitas University and Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital (C.C.-S.), and Università degli Studi di Milano and Fondazione IRCCS Istituto Nazionale dei Tumori (P.C.) - all in Milan; Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, Unité Labellisée de Recherche 7365, Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille (F.M.), Centre Hospitalier Lyon Sud, Lyon (E.B.), and CHU de Montpellier, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5535, Montpellier (G.C.) - all in France; Vall d'Hebron University Hospital (G.I.) and Institut Català d'Oncologia Hospitalet, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona (A.S.) - both in Barcelona; the Allegheny Health Network Cancer Institute, Pittsburgh (C.K.); Uniwersytet Medyczny we Wrocławiu, Wroclaw, Poland (T.W.); Universitair Ziekenhuis Gent, Ghent, Belgium (F.O.); the First Faculty of Medicine, Charles University Hospital, Prague, Czech Republic (M.T.); National Taiwan University Hospital, Taipei (S.-J.W.); F. Hoffmann-La Roche, Basel, Switzerland (D.P.-C., L.L.); Roche Products, Welwyn Garden City, United Kingdom (J.R., M.D., E.C., K.H.); and Rigshospitalet, Copenhagen (M. Hutchings).",
            "From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and the University of Melbourne, Melbourne, VIC (M.J.D.), and Prince of Wales Hospital and the University of New South Wales, Sydney (M. Hertzberg) - all in Australia; Humanitas University and Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital (C.C.-S.), and Università degli Studi di Milano and Fondazione IRCCS Istituto Nazionale dei Tumori (P.C.) - all in Milan; Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, Unité Labellisée de Recherche 7365, Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille (F.M.), Centre Hospitalier Lyon Sud, Lyon (E.B.), and CHU de Montpellier, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5535, Montpellier (G.C.) - all in France; Vall d'Hebron University Hospital (G.I.) and Institut Català d'Oncologia Hospitalet, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona (A.S.) - both in Barcelona; the Allegheny Health Network Cancer Institute, Pittsburgh (C.K.); Uniwersytet Medyczny we Wrocławiu, Wroclaw, Poland (T.W.); Universitair Ziekenhuis Gent, Ghent, Belgium (F.O.); the First Faculty of Medicine, Charles University Hospital, Prague, Czech Republic (M.T.); National Taiwan University Hospital, Taipei (S.-J.W.); F. Hoffmann-La Roche, Basel, Switzerland (D.P.-C., L.L.); Roche Products, Welwyn Garden City, United Kingdom (J.R., M.D., E.C., K.H.); and Rigshospitalet, Copenhagen (M. Hutchings).",
            "From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and the University of Melbourne, Melbourne, VIC (M.J.D.), and Prince of Wales Hospital and the University of New South Wales, Sydney (M. Hertzberg) - all in Australia; Humanitas University and Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital (C.C.-S.), and Università degli Studi di Milano and Fondazione IRCCS Istituto Nazionale dei Tumori (P.C.) - all in Milan; Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, Unité Labellisée de Recherche 7365, Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille (F.M.), Centre Hospitalier Lyon Sud, Lyon (E.B.), and CHU de Montpellier, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5535, Montpellier (G.C.) - all in France; Vall d'Hebron University Hospital (G.I.) and Institut Català d'Oncologia Hospitalet, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona (A.S.) - both in Barcelona; the Allegheny Health Network Cancer Institute, Pittsburgh (C.K.); Uniwersytet Medyczny we Wrocławiu, Wroclaw, Poland (T.W.); Universitair Ziekenhuis Gent, Ghent, Belgium (F.O.); the First Faculty of Medicine, Charles University Hospital, Prague, Czech Republic (M.T.); National Taiwan University Hospital, Taipei (S.-J.W.); F. Hoffmann-La Roche, Basel, Switzerland (D.P.-C., L.L.); Roche Products, Welwyn Garden City, United Kingdom (J.R., M.D., E.C., K.H.); and Rigshospitalet, Copenhagen (M. Hutchings).",
            "From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and the University of Melbourne, Melbourne, VIC (M.J.D.), and Prince of Wales Hospital and the University of New South Wales, Sydney (M. Hertzberg) - all in Australia; Humanitas University and Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital (C.C.-S.), and Università degli Studi di Milano and Fondazione IRCCS Istituto Nazionale dei Tumori (P.C.) - all in Milan; Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, Unité Labellisée de Recherche 7365, Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille (F.M.), Centre Hospitalier Lyon Sud, Lyon (E.B.), and CHU de Montpellier, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5535, Montpellier (G.C.) - all in France; Vall d'Hebron University Hospital (G.I.) and Institut Català d'Oncologia Hospitalet, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona (A.S.) - both in Barcelona; the Allegheny Health Network Cancer Institute, Pittsburgh (C.K.); Uniwersytet Medyczny we Wrocławiu, Wroclaw, Poland (T.W.); Universitair Ziekenhuis Gent, Ghent, Belgium (F.O.); the First Faculty of Medicine, Charles University Hospital, Prague, Czech Republic (M.T.); National Taiwan University Hospital, Taipei (S.-J.W.); F. Hoffmann-La Roche, Basel, Switzerland (D.P.-C., L.L.); Roche Products, Welwyn Garden City, United Kingdom (J.R., M.D., E.C., K.H.); and Rigshospitalet, Copenhagen (M. Hutchings).",
            "From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and the University of Melbourne, Melbourne, VIC (M.J.D.), and Prince of Wales Hospital and the University of New South Wales, Sydney (M. Hertzberg) - all in Australia; Humanitas University and Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital (C.C.-S.), and Università degli Studi di Milano and Fondazione IRCCS Istituto Nazionale dei Tumori (P.C.) - all in Milan; Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, Unité Labellisée de Recherche 7365, Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille (F.M.), Centre Hospitalier Lyon Sud, Lyon (E.B.), and CHU de Montpellier, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5535, Montpellier (G.C.) - all in France; Vall d'Hebron University Hospital (G.I.) and Institut Català d'Oncologia Hospitalet, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona (A.S.) - both in Barcelona; the Allegheny Health Network Cancer Institute, Pittsburgh (C.K.); Uniwersytet Medyczny we Wrocławiu, Wroclaw, Poland (T.W.); Universitair Ziekenhuis Gent, Ghent, Belgium (F.O.); the First Faculty of Medicine, Charles University Hospital, Prague, Czech Republic (M.T.); National Taiwan University Hospital, Taipei (S.-J.W.); F. Hoffmann-La Roche, Basel, Switzerland (D.P.-C., L.L.); Roche Products, Welwyn Garden City, United Kingdom (J.R., M.D., E.C., K.H.); and Rigshospitalet, Copenhagen (M. Hutchings).",
            "From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and the University of Melbourne, Melbourne, VIC (M.J.D.), and Prince of Wales Hospital and the University of New South Wales, Sydney (M. Hertzberg) - all in Australia; Humanitas University and Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital (C.C.-S.), and Università degli Studi di Milano and Fondazione IRCCS Istituto Nazionale dei Tumori (P.C.) - all in Milan; Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, Unité Labellisée de Recherche 7365, Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille (F.M.), Centre Hospitalier Lyon Sud, Lyon (E.B.), and CHU de Montpellier, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5535, Montpellier (G.C.) - all in France; Vall d'Hebron University Hospital (G.I.) and Institut Català d'Oncologia Hospitalet, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona (A.S.) - both in Barcelona; the Allegheny Health Network Cancer Institute, Pittsburgh (C.K.); Uniwersytet Medyczny we Wrocławiu, Wroclaw, Poland (T.W.); Universitair Ziekenhuis Gent, Ghent, Belgium (F.O.); the First Faculty of Medicine, Charles University Hospital, Prague, Czech Republic (M.T.); National Taiwan University Hospital, Taipei (S.-J.W.); F. Hoffmann-La Roche, Basel, Switzerland (D.P.-C., L.L.); Roche Products, Welwyn Garden City, United Kingdom (J.R., M.D., E.C., K.H.); and Rigshospitalet, Copenhagen (M. Hutchings).",
            "From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and the University of Melbourne, Melbourne, VIC (M.J.D.), and Prince of Wales Hospital and the University of New South Wales, Sydney (M. Hertzberg) - all in Australia; Humanitas University and Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital (C.C.-S.), and Università degli Studi di Milano and Fondazione IRCCS Istituto Nazionale dei Tumori (P.C.) - all in Milan; Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, Unité Labellisée de Recherche 7365, Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille (F.M.), Centre Hospitalier Lyon Sud, Lyon (E.B.), and CHU de Montpellier, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5535, Montpellier (G.C.) - all in France; Vall d'Hebron University Hospital (G.I.) and Institut Català d'Oncologia Hospitalet, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona (A.S.) - both in Barcelona; the Allegheny Health Network Cancer Institute, Pittsburgh (C.K.); Uniwersytet Medyczny we Wrocławiu, Wroclaw, Poland (T.W.); Universitair Ziekenhuis Gent, Ghent, Belgium (F.O.); the First Faculty of Medicine, Charles University Hospital, Prague, Czech Republic (M.T.); National Taiwan University Hospital, Taipei (S.-J.W.); F. Hoffmann-La Roche, Basel, Switzerland (D.P.-C., L.L.); Roche Products, Welwyn Garden City, United Kingdom (J.R., M.D., E.C., K.H.); and Rigshospitalet, Copenhagen (M. Hutchings)."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "12",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.",
        "AuthorList": [
            "Nagesh Kalakonda",
            "Marie Maerevoet",
            "Federica Cavallo",
            "George Follows",
            "Andre Goy",
            "Joost S P Vermaat",
            "Olivier Casasnovas",
            "Nada Hamad"
        ],
        "AffiliationList": [
            "University of Liverpool, Liverpool, UK. Electronic address: nagesh.kalakonda@liverpool.ac.uk.",
            "Institut Jules Bordet, Brussels, Belgium.",
            "Department of Molecular Biotechnologies and Health Sciences, Division of Hematology, University of Torino, Turin, Italy.",
            "Addenbrooke's Hospital, Cambridge, UK.",
            "John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.",
            "Leiden University Medical Center, Leiden, Netherlands.",
            "Hématologie Clinique, Dijon, France.",
            "St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Iñigo Espinosa",
            "Javier Briones",
            "Ramon Bordes",
            "Salut Brunet",
            "Rodrigo Martino",
            "Ana Sureda",
            "Jaime Prat",
            "Jorge Sierra"
        ],
        "AffiliationList": [
            "Department of Pathology, Hospital de la Santa Creu i Sant Pau, Universidad Autónoma de Barcelona, Barcelona, Spain.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2006",
                "Month": "07",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.",
        "AuthorList": [
            "Philippe Armand",
            "Arnon Nagler",
            "Edie A Weller",
            "Steven M Devine",
            "David E Avigan",
            "Yi-Bin Chen",
            "Mark S Kaminski",
            "H Kent Holland"
        ],
        "AffiliationList": [
            "Philippe Armand and Edie Weller, Dana-Farber Cancer Institute; David E. Avigan, Beth Israel Deaconess Medical Center; Yi-Bin Chen, Massachusetts General Hospital, Boston, MA; Arnon Nagler, Chaim Sheba Medical Center, Tel-Hashomer; Reuven Or, Hadassah Medical Center, Jerusalem; Rinat Rotem-Yehudar, CureTech, Yavne, Israel; Steven M. Devine, The Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus; Hillard M. Lazarus, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH; Mark S. Kaminski, University of Michigan, Ann Arbor, MI; H. Kent Holland, Northside Hospital; Edmund K. Waller, Winship Cancer Institute, Emory University, Atlanta, GA; Jane N. Winter and Leo I. Gordon, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine; Stephanie A. Gregory, Rush Medical Center, Chicago, IL; James R. Mason, Scripps Clinic; Edward D. Ball, Moores University of California at San Diego Cancer Center, University of California, San Diego; John M. Timmerman and David Andorsky, University of California, Los Angeles, Los Angeles, CA; Joseph W. Fay, Baylor Research Institute, Baylor University Medical Center, Dallas; Chitra M. Hosing, The University of Texas MD Anderson Cancer Center, Houston, TX; David A. Rizzieri, Duke Cancer Center, Durham, NC; Joseph P. Uberti, Karmanos Cancer Institute, Detroit, MI; Markus Y. Mapara, University of Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, PA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "10",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial.",
        "AuthorList": [
            "Julie M Vose",
            "Shelly Carter",
            "Linda J Burns",
            "Ernesto Ayala",
            "Oliver W Press",
            "Craig H Moskowitz",
            "Edward A Stadtmauer",
            "Shin Mineshi"
        ],
        "AffiliationList": [
            "Section of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE 68198-7680, USA. jmvose@unmc.edu",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "03",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL.",
        "AuthorList": [
            "Annette M Staiger",
            "Michael Altenbuchinger",
            "Marita Ziepert",
            "Christian Kohler",
            "Heike Horn",
            "Michael Huttner",
            "Katrin S Hüttl",
            "Gunther Glehr"
        ],
        "AffiliationList": [
            "Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.",
            "Statistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, Regensburg, Germany.",
            "Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.",
            "Statistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, Regensburg, Germany.",
            "Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, University of Tuebingen, Stuttgart, Germany.",
            "Statistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, Regensburg, Germany.",
            "Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.",
            "Statistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, Regensburg, Germany."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "09",
                "Day": "17"
            }
        ]
    },
    {
        "ArticleTitle": "Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy.",
        "AuthorList": [
            "Ian W Flinn",
            "Jack Erter",
            "Davey B Daniel",
            "Joseph R Mace",
            "Jesus G Berdeja"
        ],
        "AffiliationList": [
            "Sarah Cannon Research Institute, Nashville, Tennessee, USA iflinn@tnonc.com.",
            "Sarah Cannon Research Institute, Nashville, Tennessee, USA.",
            "Sarah Cannon Research Institute, Nashville, Tennessee, USA.",
            "Florida Cancer Specialists, St. Petersburg, Florida, USA.",
            "Sarah Cannon Research Institute, Nashville, Tennessee, USA."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "05",
                "Day": "09"
            }
        ]
    },
    {
        "ArticleTitle": "Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.",
        "AuthorList": [
            "Alejandro Martín",
            "Alba M Redondo",
            "Iván Dlouhy",
            "Antonio Salar",
            "Eva González-Barca",
            "Miguel Canales",
            "Santiago Montes-Moreno",
            "Enrique M Ocio"
        ],
        "AffiliationList": [
            "Department of Haematology, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain.",
            "Department of Haematology, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain.",
            "Department of Haematology, Hospital Clinic, Barcelona, Spain.",
            "Department of Haematology, Hospital del Mar, Barcelona, Spain.",
            "Department of Haematology, Institut Català D'Oncologia Duran I Reynals, L'Hospitalet de Llobregat, Spain.",
            "Department of Haematology, Hospital Universitario La Paz, Madrid, Spain.",
            "Department of Pathology, Hospital Universitario Marqués de Valdecilla, IFIMAV, Santander, Spain.",
            "Department of Haematology, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "02",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera<sup>®</sup> ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial.",
        "AuthorList": [
            "Yuankai Shi",
            "Qingyuan Zhang",
            "Xiaonan Hong",
            "Zhen Wang",
            "Yuhuan Gao",
            "Liqun Zou",
            "Hong Cen",
            "Lin Gui"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.",
            "Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.",
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.",
            "Department of Oncology, Linyi Cancer Hospital, Linyi, Shandong, China.",
            "Department of Hematology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.",
            "Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.",
            "Department of Hematology/Oncology, Guangxi Medical University Affiliated Cancer Hospital, Nanning, Guangxi, China.",
            "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "08",
                "Day": "12"
            }
        ]
    },
    {
        "ArticleTitle": "Lack of association between using aspirin and development of non-Hodgkins lymphoma: a meta-analysis.",
        "AuthorList": [
            "Neda Amoori",
            "Maria Cheraghi",
            "Hosein Fallahzadeh",
            "Hossein Rahmani"
        ],
        "AffiliationList": [
            "null",
            "Social Determinants of Heath Research Center, School of Public Heath, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran E-mail : Epidemiology2012@gmail.com.",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Diagnostic utility of SOX11 immunohistochemistry in differentiating cutaneous spread of mantle cell lymphoma from primary cutaneous B-cell lymphomas.",
        "AuthorList": [
            "Andy C Hsi",
            "M Yadira Hurley",
            "Sena J Lee",
            "Ilana S Rosman",
            "Xiaofan Pang",
            "Alejandro Gru",
            "András Schaffer"
        ],
        "AffiliationList": [
            "Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, USA.",
            "Department of Dermatology, Saint Louis University School of Medicine, Saint Louis, MO, USA.",
            "Division of Dermatology, Washington University School of Medicine, Saint Louis, MO, USA.",
            "Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, USA.",
            "Department of Biology, Washington University in St. Louis, Saint Louis, MO, USA.",
            "Department of Pathology, The Ohio State University Medical Center, Columbus, OH, USA.",
            "Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, USA."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "02",
                "Day": "10"
            }
        ]
    },
    {
        "ArticleTitle": "Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.",
        "AuthorList": [
            "Sara Rattotti",
            "Virginia Valeria Ferretti",
            "Chiara Rusconi",
            "Andrea Rossi",
            "Stefano Fogazzi",
            "Luca Baldini",
            "Pietro Pioltelli",
            "Monica Balzarotti"
        ],
        "AffiliationList": [
            "Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.",
            "Department of Molecular Medicine, University of Pavia, Pavia, Italy.",
            "Division of Hematology, Ospedale Niguarda Ca' Granda, Milan, Italy.",
            "Division of Hematology, Ospedali Riuniti, Bergamo, Italy.",
            "Division of Hematology, Spedali Civili, Brescia, Italy.",
            "Division of Hematology, Fondazione IRCCS Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.",
            "Division of Hematology, Ospedale S. Gerardo, Monza, Italy.",
            "Division of Hematology, Humanitas Cancer Center, Milan, Italy."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "02",
                "Day": "22"
            }
        ]
    },
    {
        "ArticleTitle": "Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.",
        "AuthorList": [
            "David J Straus",
            "Paul A Hamlin",
            "Matthew J Matasar",
            "Maria Lia Palomba",
            "Pamela R Drullinsky",
            "Andrew D Zelenetz",
            "John F Gerecitano",
            "Ariela Noy"
        ],
        "AffiliationList": [
            "Memorial Sloan-Kettering Cancer Center, Division of Hematologic Oncology, Lymphoma Service, New York, NY, USA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "10",
                "Day": "15"
            }
        ]
    },
    {
        "ArticleTitle": "Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma.",
        "AuthorList": [
            "Paul M Barr",
            "Thomas P Miller",
            "Jonathan W Friedberg",
            "Derick R Peterson",
            "Andrea M Baran",
            "Megan Herr",
            "Catherine M Spier",
            "Haiyan Cui"
        ],
        "AffiliationList": [
            "University of Rochester, Wilmot Cancer Center, Rochester, NY;",
            "University of Arizona Cancer Center, Tucson, AZ;",
            "University of Rochester, Wilmot Cancer Center, Rochester, NY;",
            "University of Rochester, Wilmot Cancer Center, Rochester, NY;",
            "University of Rochester, Wilmot Cancer Center, Rochester, NY;",
            "University of Rochester, Wilmot Cancer Center, Rochester, NY;",
            "Department of Pathology, University of Arizona, Tucson, AZ;",
            "University of Arizona Cancer Center, Tucson, AZ;"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "07",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma.",
        "AuthorList": [
            "R Herbrecht",
            "P Cernohous",
            "A Engert",
            "S Le Gouill",
            "D Macdonald",
            "C Machida",
            "H Myint",
            "A Saleh"
        ],
        "AffiliationList": [
            "Department of Oncology and Hematology, Hôpital de Hautepierre, Strasbourg, France. Electronic address: raoul.herbrecht@chru-strasbourg.fr.",
            "Cell Therapeutics, Inc., Seattle, USA.",
            "Department of Internal Medicine 1, Klinikum der Universität zu Köln, Köln, Germany.",
            "Hematology Service, Hôtel Dieu 1, Nantes, France.",
            "Division of Hematology, Queen Elizabeth II Health Sciences Centre, Halifax, Canada.",
            "Cell Therapeutics, Inc., Seattle, USA.",
            "Cell Therapeutics, Inc., Seattle, USA.",
            "Department of Oncology/Hematology, Sharp HealthCare, San Diego, USA."
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "08",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.",
        "AuthorList": [
            "Jing Zhang",
            "Bobin Chen",
            "Xiaoping Xu"
        ],
        "AffiliationList": [
            "Department of Hematology, Huashan Hospital, Shanghai Medical School, Fudan University , Shanghai , China.",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "07",
                "Day": "29"
            }
        ]
    },
    {
        "ArticleTitle": "Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients: a prospective randomized trial in Algeria.",
        "AuthorList": [
            "Mourad Aribi",
            "Naima Mesli",
            "Nesrine Remla",
            "Badr-Eddine Sari",
            "Abdesselam Taleb",
            "Hadj Touhami",
            "Mohamed-Amine Bekadja",
            "Zahia Zouaoui-Benhadji"
        ],
        "AffiliationList": [
            "Division of Molecular Biology, Immunology and Pathology, Toxicomed Laboratory, Faculty of Medical Sciences, Abou-Bekr Belkaïd University, Algeria.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.",
        "AuthorList": [
            "John D Hainsworth",
            "Ian W Flinn",
            "David R Spigel",
            "Bobby L Clark",
            "Paula L Griner",
            "Elizabeth R Vazquez",
            "Habib H Doss",
            "Dianna Shipley"
        ],
        "AffiliationList": [
            "Sarah Cannon Research Institute, Nashville, TN 37203, USA. jhainsworth@tnonc.com",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Michael Dickinson",
            "Javier Briones",
            "Alex F Herrera",
            "Eva González-Barca",
            "Nilanjan Ghosh",
            "Raul Cordoba",
            "Sarah C Rutherford",
            "Eirini Bournazou"
        ],
        "AffiliationList": [
            "Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.",
            "Hematology Department, Hospital de la Santa Creu i Sant Pau, Sant Pau, Spain.",
            "Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.",
            "Department of Hematology, Institut Català d'Oncologia, Hospital duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, L'Hospitalet de LLobregat, Barcelona, Spain.",
            "Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC.",
            "Department of Hematology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain.",
            "Meyer Cancer Center, Division of Hematology and Medical Oncology, Weill Department of Medicine, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, NY.",
            "Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis.",
        "AuthorList": [
            "Liping Qiu",
            "Hanlu Zheng",
            "Xiaoying Zhao"
        ],
        "AffiliationList": [
            "Department of Hematology, The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China.",
            "Department of Hematology, The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China.",
            "Department of Hematology, The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China. zrxz@zju.edu.cn."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "03",
                "Day": "27"
            }
        ]
    },
    {
        "ArticleTitle": "A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Bertrand Coiffier",
            "Catherine Thieblemont",
            "Sophie de Guibert",
            "Jehan Dupuis",
            "Vincent Ribrag",
            "Réda Bouabdallah",
            "Franck Morschhauser",
            "Robert Navarro"
        ],
        "AffiliationList": [
            "Centre Hospitalier Lyon Sud, Pierre Bénite, France.",
            "Department of Hemato-oncology - Paris Diderot 7 University, APHP - Hôpital Saint-Louis, Paris, France.",
            "CHU de Rennes, Rennes, France.",
            "Hopital Henri Mondor, Créteil, France.",
            "Institut Gustave Roussy, Villejuif, France.",
            "Institut Paoli Calmettes, Marseille, France.",
            "CHRU - Hôpital Claude Huriez, Lille, France.",
            "CHU Saint Eloi, Montpellier, France."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "03",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study.",
        "AuthorList": [
            "Alex F Herrera",
            "Manish R Patel",
            "John M Burke",
            "Ranjana Advani",
            "Bruce D Cheson",
            "Jeff P Sharman",
            "Elicia Penuel",
            "Andrew G Polson"
        ],
        "AffiliationList": [
            "City of Hope Medical Center, Duarte, California.",
            "Sarah Cannon Research Institute and Florida Cancer Specialists, Sarasota, Florida.",
            "US Oncology and Rocky Mountain Cancer Centers, Aurora, Colorado.",
            "Stanford Cancer Center, Stanford, California.",
            "Georgetown University Hospital, Washington, DC.",
            "US Oncology and Willamette Valley Cancer Institute, Springfield, Oregon.",
            "Genentech, Inc., South San Francisco, California.",
            "Genentech, Inc., South San Francisco, California."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma.",
        "AuthorList": [
            "Auro Viswabandya",
            "Sandip Shah",
            "Asis Mukhopadhyay",
            "Rajnish Vasant Nagarkar",
            "Sonica Sachdeva Batra",
            "Luis Lopez-Lazaro",
            "Suresh Kankanwadi",
            "Alok Srivastava"
        ],
        "AffiliationList": [
            "Christian Medical College, Vellore, India.",
            "Vedanta Institute of Medical Sciences, Ahmedabad, India.",
            "Netaji Subhash Chandra Bose Cancer Research Institute, Kolkata, India.",
            "Curie Manavata Cancer Centre, Nashik, India.",
            "Dr Reddy's Laboratories, Hyderabad, India.",
            "Dr Reddy's Laboratories, Basel, Switzerland.",
            "Dr Reddy's Laboratories, Basel, Switzerland.",
            "Christian Medical College, Vellore, India."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.",
        "AuthorList": [
            "Richard R Furman",
            "Peter Martin",
            "Jia Ruan",
            "Ying-Kuen K Cheung",
            "Julie M Vose",
            "Ann S LaCasce",
            "Rebecca Elstrom",
            "Morton Coleman"
        ],
        "AffiliationList": [
            "Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York 10021, USA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2010",
                "Month": "07",
                "Day": "27"
            }
        ]
    },
    {
        "ArticleTitle": "Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.",
        "AuthorList": [
            "Umberto Vitolo",
            "Annalisa Chiappella",
            "Silvia Franceschetti",
            "Angelo Michele Carella",
            "Ileana Baldi",
            "Giorgio Inghirami",
            "Michele Spina",
            "Vincenzo Pavone"
        ],
        "AffiliationList": [
            "Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Turin, Italy. Electronic address: uvitolo@cittadellasalute.to.it.",
            "Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.",
            "Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy.",
            "Unit of Hematology 1, Istituto di Ricovero e Cura a Carattere Scientifico Hospital and University, Istituto dei Tumori San Martino, Genoa, Italy.",
            "Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.",
            "Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies, University of Turin, Turin, Italy; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.",
            "Division of Medical Oncology A, Centro di Riferimento Oncologico Aviano National Cancer Institute, Aviano, Italy.",
            "Unit of Hematology and Hemopoietic Stem Cell Transplantation, Ospedale Cardinale G Panico, Tricase, Italy."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "05",
                "Day": "13"
            }
        ]
    },
    {
        "ArticleTitle": "The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity.",
        "AuthorList": [
            "Fabienne Desmots",
            "Delphine Rossille",
            "Mikael Roussel",
            "Céline Pangault",
            "Laetitia Louarn",
            "Mylène De Saint Jore",
            "Steven Le Gouill",
            "Krimo Bouabdallah"
        ],
        "AffiliationList": [
            "Université de Rennes 1, INSERM, Établissement Français du Sang de Bretagne, UMR_S1236, Rennes, France.",
            "Université de Rennes 1, INSERM, Établissement Français du Sang de Bretagne, UMR_S1236, Rennes, France.",
            "Université de Rennes 1, INSERM, Établissement Français du Sang de Bretagne, UMR_S1236, Rennes, France.",
            "Université de Rennes 1, INSERM, Établissement Français du Sang de Bretagne, UMR_S1236, Rennes, France.",
            "Université de Rennes 1, INSERM, Établissement Français du Sang de Bretagne, UMR_S1236, Rennes, France.",
            "Laboratoire d'Hématologie, Pôle de Biologie, Centre Hospitalier Universitaire, Rennes, France.",
            "Service d'hématologie, Centre Hospitalier Universitaire, Inserm, CIRCINA, Nantes, France.",
            "Service d'hématologie et de thérapie cellulaire, Centre Hospitalier Universitaire, Bordeaux, France."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).",
        "AuthorList": [
            "Pieternella Johanna Lugtenburg",
            "Peter de Nully Brown",
            "Bronno van der Holt",
            "Francesco A D'Amore",
            "Harry R Koene",
            "Eva de Jongh",
            "Rob Fijnheer",
            "Joost W van Esser"
        ],
        "AffiliationList": [
            "Erasmus MC Cancer Institute, Rotterdam, the Netherlands.",
            "Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.",
            "Haemato Oncology Foundation for Adults in the Netherlands (HOVON) Data Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.",
            "Aarhus University Hospital, Aarhus, Denmark.",
            "St Antonius Hospital, Nieuwegein, the Netherlands.",
            "Albert Schweitzer Hospital, Dordrecht, the Netherlands.",
            "Meander MC, Amersfoort, the Netherlands.",
            "Amphia Hospital, Breda, the Netherlands."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "07",
                "Day": "30"
            }
        ]
    },
    {
        "ArticleTitle": "Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up.",
        "AuthorList": [
            "Andrew J Davies",
            "Sharon Barrans",
            "Louise Stanton",
            "Josh Caddy",
            "Sam Wilding",
            "Geoff Saunders",
            "Christoph Mamot",
            "Urban Novak"
        ],
        "AffiliationList": [
            "School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.",
            "Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals, Leeds, United Kingdom.",
            "Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.",
            "Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.",
            "Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.",
            "Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.",
            "Cantonal Hospital Aarau, Aarau, Switzerland.",
            "Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "03",
                "Day": "27"
            }
        ]
    },
    {
        "ArticleTitle": "Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.",
        "AuthorList": [
            "Daniel O Persky",
            "Hongli Li",
            "Deborah M Stephens",
            "Steven I Park",
            "Nancy L Bartlett",
            "Lode J Swinnen",
            "Paul M Barr",
            "Jerome D Winegarden"
        ],
        "AffiliationList": [
            "Division of Hematology/Oncology, University of Arizona, Tucson, AZ.",
            "SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA.",
            "Division of Hematology, University of Utah, Salt Lake City, UT.",
            "Department of Medicine, Levine Cancer Institute/Atrium Health, Charlotte, NC.",
            "Department of Medicine, Washington University School of Medicine, St. Louis, MO.",
            "Division of Medical Oncology, Johns Hopkins Cancer Center, Baltimore, MD.",
            "Division of Hematology/Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, NY.",
            "IHA Hematology Oncology Consultants/Michigan CRC NCORP, Ann Arbor, MI."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "07",
                "Day": "13"
            }
        ]
    },
    {
        "ArticleTitle": "Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial.",
        "AuthorList": [
            "Yan Qin",
            "Yuqin Song",
            "Zhixiang Shen",
            "Xin Du",
            "Wei Ji",
            "Wanling Hsu",
            "Jun Zhu",
            "Yuankai Shi"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P. R. China.",
            "Department of Lymphoma, Beijing Cancer Hospital, Peking University, Beijing, 100142, P. R. China.",
            "Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University, Shanghai, 200025, P. R. China.",
            "Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou, 510030, Guangdong, P. R. China.",
            "Clinical Science, Shanghai Roche Pharmaceuticals Ltd, Shanghai, 201203, P. R. China.",
            "Statistics, Roche (China) Holding Ltd, Shanghai, 201203, P. R. China.",
            "Department of Lymphoma, Beijing Cancer Hospital, Peking University, Beijing, 100142, P. R. China.",
            "Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P. R. China. syuankai@cicams.ac.cn."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "05",
                "Day": "30"
            }
        ]
    },
    {
        "ArticleTitle": "End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA.",
        "AuthorList": [
            "Lale Kostakoglu",
            "Maurizio Martelli",
            "Laurie H Sehn",
            "David Belada",
            "Angelo-Michele Carella",
            "Neil Chua",
            "Eva Gonzalez-Barca",
            "Xiaonan Hong"
        ],
        "AffiliationList": [
            "Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA.",
            "Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.",
            "BC Cancer Center for Lymphoid Cancer and the University of British Columbia, Vancouver, BC, Canada.",
            "4th Department of Internal Medicine-Hematology, Faculty of Medicine, Charles University, Hradec Králové, Czech Republic.",
            "Hematology and Bone Marrow Transplantation Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Martino, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy.",
            "Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.",
            "Institut Català d'Oncologia, Institut d'Investigació Biomédica de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.",
            "Fudan University Shanghai Cancer Center, Shanghai, China."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.",
        "AuthorList": [
            "Anas Younes",
            "Laurie H Sehn",
            "Peter Johnson",
            "Pier Luigi Zinzani",
            "Xiaonan Hong",
            "Jun Zhu",
            "Caterina Patti",
            "David Belada"
        ],
        "AffiliationList": [
            "1 Memorial Sloan Kettering Cancer Center, New York, NY.",
            "2 BC Cancer Agency, Vancouver, British Columbia, Canada.",
            "3 University of Southampton, Southampton, United Kingdom.",
            "4 \"Seràgnoli\" University of Bologna, Bologna, Italy.",
            "5 Fudan University, Shanghai, People's Republic of China.",
            "6 Peking University Cancer Hospital, Beijing, People's Republic of China.",
            "7 Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.",
            "8 Charles University, Hradec Králové, Czech Republic."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "03",
                "Day": "22"
            }
        ]
    },
    {
        "ArticleTitle": "Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.",
        "AuthorList": [
            "Thierry Jo Molina",
            "Danielle Canioni",
            "Christiane Copie-Bergman",
            "Christian Recher",
            "Josette Brière",
            "Corinne Haioun",
            "Françoise Berger",
            "Christophe Fermé"
        ],
        "AffiliationList": [
            "Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; Catherine Thieblemont, L'Institut National de la Santé et de la Recherche Médicale (INSERM) U728; Bettina Fabiani, AP-HP, Saint-Antoine, Paris; Christiane Copie-Bergman, Corinne Haioun, Karen Leroy, and Philippe Gaulard, AP-HP, Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Université Paris-Est Créteil; Christiane Copie-Bergman, Karen Leroy, and Philippe Gaulard, INSERM Unité U955 Équipe 9, Créteil; Christian Recher, Centre Hospitalier Universitaire (CHU) Purpan, Université Toulouse III Paul Sabatier, Toulouse; Françoise Berger, Gilles Salles, and Bertrand Coiffier, Hospices Civils de Lyon, Université Claude Bernard, Pierre-Bénite; Christophe Fermé, Institut Gustave Roussy, Villejuif; Marie-Christine Copin and Franck Morschauser, CHU Lille, Lille; Olivier Casasnovas and Tony Petrella, CHU Dijon, Dijon; Nicolas Mounier, CHU Nice, Nice; and Fabrice Jardin and Hervé Tilly, Centre Henri Becquerel, Université de Rouen, Rouen, France. thierry.molina@nck.aphp.fr.",
            "Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; Catherine Thieblemont, L'Institut National de la Santé et de la Recherche Médicale (INSERM) U728; Bettina Fabiani, AP-HP, Saint-Antoine, Paris; Christiane Copie-Bergman, Corinne Haioun, Karen Leroy, and Philippe Gaulard, AP-HP, Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Université Paris-Est Créteil; Christiane Copie-Bergman, Karen Leroy, and Philippe Gaulard, INSERM Unité U955 Équipe 9, Créteil; Christian Recher, Centre Hospitalier Universitaire (CHU) Purpan, Université Toulouse III Paul Sabatier, Toulouse; Françoise Berger, Gilles Salles, and Bertrand Coiffier, Hospices Civils de Lyon, Université Claude Bernard, Pierre-Bénite; Christophe Fermé, Institut Gustave Roussy, Villejuif; Marie-Christine Copin and Franck Morschauser, CHU Lille, Lille; Olivier Casasnovas and Tony Petrella, CHU Dijon, Dijon; Nicolas Mounier, CHU Nice, Nice; and Fabrice Jardin and Hervé Tilly, Centre Henri Becquerel, Université de Rouen, Rouen, France.",
            "Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; Catherine Thieblemont, L'Institut National de la Santé et de la Recherche Médicale (INSERM) U728; Bettina Fabiani, AP-HP, Saint-Antoine, Paris; Christiane Copie-Bergman, Corinne Haioun, Karen Leroy, and Philippe Gaulard, AP-HP, Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Université Paris-Est Créteil; Christiane Copie-Bergman, Karen Leroy, and Philippe Gaulard, INSERM Unité U955 Équipe 9, Créteil; Christian Recher, Centre Hospitalier Universitaire (CHU) Purpan, Université Toulouse III Paul Sabatier, Toulouse; Françoise Berger, Gilles Salles, and Bertrand Coiffier, Hospices Civils de Lyon, Université Claude Bernard, Pierre-Bénite; Christophe Fermé, Institut Gustave Roussy, Villejuif; Marie-Christine Copin and Franck Morschauser, CHU Lille, Lille; Olivier Casasnovas and Tony Petrella, CHU Dijon, Dijon; Nicolas Mounier, CHU Nice, Nice; and Fabrice Jardin and Hervé Tilly, Centre Henri Becquerel, Université de Rouen, Rouen, France.",
            "Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; Catherine Thieblemont, L'Institut National de la Santé et de la Recherche Médicale (INSERM) U728; Bettina Fabiani, AP-HP, Saint-Antoine, Paris; Christiane Copie-Bergman, Corinne Haioun, Karen Leroy, and Philippe Gaulard, AP-HP, Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Université Paris-Est Créteil; Christiane Copie-Bergman, Karen Leroy, and Philippe Gaulard, INSERM Unité U955 Équipe 9, Créteil; Christian Recher, Centre Hospitalier Universitaire (CHU) Purpan, Université Toulouse III Paul Sabatier, Toulouse; Françoise Berger, Gilles Salles, and Bertrand Coiffier, Hospices Civils de Lyon, Université Claude Bernard, Pierre-Bénite; Christophe Fermé, Institut Gustave Roussy, Villejuif; Marie-Christine Copin and Franck Morschauser, CHU Lille, Lille; Olivier Casasnovas and Tony Petrella, CHU Dijon, Dijon; Nicolas Mounier, CHU Nice, Nice; and Fabrice Jardin and Hervé Tilly, Centre Henri Becquerel, Université de Rouen, Rouen, France.",
            "Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; Catherine Thieblemont, L'Institut National de la Santé et de la Recherche Médicale (INSERM) U728; Bettina Fabiani, AP-HP, Saint-Antoine, Paris; Christiane Copie-Bergman, Corinne Haioun, Karen Leroy, and Philippe Gaulard, AP-HP, Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Université Paris-Est Créteil; Christiane Copie-Bergman, Karen Leroy, and Philippe Gaulard, INSERM Unité U955 Équipe 9, Créteil; Christian Recher, Centre Hospitalier Universitaire (CHU) Purpan, Université Toulouse III Paul Sabatier, Toulouse; Françoise Berger, Gilles Salles, and Bertrand Coiffier, Hospices Civils de Lyon, Université Claude Bernard, Pierre-Bénite; Christophe Fermé, Institut Gustave Roussy, Villejuif; Marie-Christine Copin and Franck Morschauser, CHU Lille, Lille; Olivier Casasnovas and Tony Petrella, CHU Dijon, Dijon; Nicolas Mounier, CHU Nice, Nice; and Fabrice Jardin and Hervé Tilly, Centre Henri Becquerel, Université de Rouen, Rouen, France.",
            "Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; Catherine Thieblemont, L'Institut National de la Santé et de la Recherche Médicale (INSERM) U728; Bettina Fabiani, AP-HP, Saint-Antoine, Paris; Christiane Copie-Bergman, Corinne Haioun, Karen Leroy, and Philippe Gaulard, AP-HP, Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Université Paris-Est Créteil; Christiane Copie-Bergman, Karen Leroy, and Philippe Gaulard, INSERM Unité U955 Équipe 9, Créteil; Christian Recher, Centre Hospitalier Universitaire (CHU) Purpan, Université Toulouse III Paul Sabatier, Toulouse; Françoise Berger, Gilles Salles, and Bertrand Coiffier, Hospices Civils de Lyon, Université Claude Bernard, Pierre-Bénite; Christophe Fermé, Institut Gustave Roussy, Villejuif; Marie-Christine Copin and Franck Morschauser, CHU Lille, Lille; Olivier Casasnovas and Tony Petrella, CHU Dijon, Dijon; Nicolas Mounier, CHU Nice, Nice; and Fabrice Jardin and Hervé Tilly, Centre Henri Becquerel, Université de Rouen, Rouen, France.",
            "Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; Catherine Thieblemont, L'Institut National de la Santé et de la Recherche Médicale (INSERM) U728; Bettina Fabiani, AP-HP, Saint-Antoine, Paris; Christiane Copie-Bergman, Corinne Haioun, Karen Leroy, and Philippe Gaulard, AP-HP, Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Université Paris-Est Créteil; Christiane Copie-Bergman, Karen Leroy, and Philippe Gaulard, INSERM Unité U955 Équipe 9, Créteil; Christian Recher, Centre Hospitalier Universitaire (CHU) Purpan, Université Toulouse III Paul Sabatier, Toulouse; Françoise Berger, Gilles Salles, and Bertrand Coiffier, Hospices Civils de Lyon, Université Claude Bernard, Pierre-Bénite; Christophe Fermé, Institut Gustave Roussy, Villejuif; Marie-Christine Copin and Franck Morschauser, CHU Lille, Lille; Olivier Casasnovas and Tony Petrella, CHU Dijon, Dijon; Nicolas Mounier, CHU Nice, Nice; and Fabrice Jardin and Hervé Tilly, Centre Henri Becquerel, Université de Rouen, Rouen, France.",
            "Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; Catherine Thieblemont, L'Institut National de la Santé et de la Recherche Médicale (INSERM) U728; Bettina Fabiani, AP-HP, Saint-Antoine, Paris; Christiane Copie-Bergman, Corinne Haioun, Karen Leroy, and Philippe Gaulard, AP-HP, Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Université Paris-Est Créteil; Christiane Copie-Bergman, Karen Leroy, and Philippe Gaulard, INSERM Unité U955 Équipe 9, Créteil; Christian Recher, Centre Hospitalier Universitaire (CHU) Purpan, Université Toulouse III Paul Sabatier, Toulouse; Françoise Berger, Gilles Salles, and Bertrand Coiffier, Hospices Civils de Lyon, Université Claude Bernard, Pierre-Bénite; Christophe Fermé, Institut Gustave Roussy, Villejuif; Marie-Christine Copin and Franck Morschauser, CHU Lille, Lille; Olivier Casasnovas and Tony Petrella, CHU Dijon, Dijon; Nicolas Mounier, CHU Nice, Nice; and Fabrice Jardin and Hervé Tilly, Centre Henri Becquerel, Université de Rouen, Rouen, France."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "11",
                "Day": "10"
            }
        ]
    },
    {
        "ArticleTitle": "Clinical efficacy and safety of subcutaneous rituximab in non-Hodgkin lymphoma: a systematic literature review and meta-analysis.",
        "AuthorList": [
            "Tianyu Si",
            "Xiaolin Ma",
            "Wenwei Zhu",
            "Yongming Zhou"
        ],
        "AffiliationList": [
            "Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.",
            "Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.",
            "Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.",
            "Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "11",
                "Day": "27"
            }
        ]
    },
    {
        "ArticleTitle": "Autoimmune disease-related primary CNS lymphoma: systematic review and meta-analysis.",
        "AuthorList": [
            "Leon D Kaulen",
            "Philipp Karschnia",
            "Jorg Dietrich",
            "Joachim M Baehring"
        ],
        "AffiliationList": [
            "Department of Neurology, Yale School of Medicine, 15 York Street, New Haven, CT, 06510, USA.",
            "Department of Neurology, Yale School of Medicine, 15 York Street, New Haven, CT, 06510, USA.",
            "Division of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA.",
            "Department of Neurology, Yale School of Medicine, 15 York Street, New Haven, CT, 06510, USA. joachim.baehring@yale.edu."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "07",
                "Day": "18"
            }
        ]
    },
    {
        "ArticleTitle": "High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era.",
        "AuthorList": [
            "Makiko Ban-Hoefen",
            "Jennifer L Kelly",
            "Steven H Bernstein",
            "Jane Liesveld",
            "Louis Constine",
            "Michael Becker",
            "Laurie Milner",
            "Gordon Phillips"
        ],
        "AffiliationList": [
            "James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY , USA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "12",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.",
        "AuthorList": [
            "Mehdi Hamadani",
            "John Radford",
            "Carmelo Carlo-Stella",
            "Paolo F Caimi",
            "Erin Reid",
            "Owen A O'Connor",
            "Jay M Feingold",
            "Kirit M Ardeshna"
        ],
        "AffiliationList": [
            "Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI.",
            "Manchester Academic Health Science Centre, University of Manchester and Christie NHS Foundation Trust, Manchester, United Kingdom.",
            "Department of Oncology and Hematology, Humanitas Clinical and Research Center-Istituto di Ricovero e Cura a Carattere Scientifico and Humanitas University, Milan, Italy.",
            "University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH.",
            "Division of Hematology/Oncology, Moores Cancer Center, University of California San Diego, La Jolla, CA.",
            "E. Couric Cancer Center, University of Virginia Cancer Center, Charlottesville, VA.",
            "Clinical Development, ADC Therapeutics, Murray Hill, NJ.",
            "Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494).",
        "AuthorList": [
            "Vicki A Morrison",
            "Edie A Weller",
            "Thomas M Habermann",
            "Shuli Li",
            "Richard I Fisher",
            "Bruce D Cheson",
            "Bruce A Peterson"
        ],
        "AffiliationList": [
            "a Division of Hematology, Oncology, and Transplantation , University of Minnesota and Hennepin County Medical Center , Minneapolis , MN , USA.",
            "c Eastern Cooperative Oncology Group , Statistical Center , Boston , MA , USA.",
            "d Department of Medicine, Division of Hematology , Mayo Clinic , Rochester , MN , USA.",
            "c Eastern Cooperative Oncology Group , Statistical Center , Boston , MA , USA.",
            "e Wilmot Cancer Center , University of Rochester Medical Center , Rochester , NY , USA.",
            "f Division of Hematology , Lombardi Cancer Center, Georgetown University Hospital , Washington, DC , USA.",
            "g Division of Hematology, Oncology, and Transplantation , University of Minnesota , Minneapolis , MN , USA."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "12",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.",
        "AuthorList": [
            "Jeff P Sharman",
            "Andres Forero-Torres",
            "Luciano J Costa",
            "Ian W Flinn",
            "Lowell Inhorn",
            "Kevin Kelly",
            "Alberto Bessudo",
            "Luis E Fayad"
        ],
        "AffiliationList": [
            "a Willamette Valley Cancer Institute and Research Center , US Oncology Research , Eugene , OR , USA.",
            "b University of Alabama School of Medicine , Birmingham , AL , USA.",
            "c Division of Hematology/Oncology , Medical University of South Carolina , Charleston , SC , USA.",
            "d Sarah Cannon Research Institute , Nashville , TN , USA.",
            "e Blue Ridge Cancer Care , Roanoke , VA , USA.",
            "f USC Norris Comprehensive Cancer Center , Los Angeles , CA , USA.",
            "g California Cancer Associates for Research and Excellence , San Diego , CA , USA.",
            "h Department of Lymphoma and Myeloma , M.D. Anderson Cancer Center, University of Texas , Houston , TX , USA."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "10",
                "Day": "02"
            }
        ]
    },
    {
        "ArticleTitle": "A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Bertrand Coiffier",
            "John Radford",
            "André Bosly",
            "Giovanni Martinelli",
            "Gregor Verhoef",
            "Gabriela Barca",
            "Andrew Davies",
            "Didier Decaudin"
        ],
        "AffiliationList": [
            "Service d'Hematologie, Hospices Civils de Lyon, Lyon, France.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "08",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Kieron Dunleavy",
            "Richard F Little",
            "Stefania Pittaluga",
            "Nicole Grant",
            "Alan S Wayne",
            "Jorge A Carrasquillo",
            "Seth M Steinberg",
            "Robert Yarchoan"
        ],
        "AffiliationList": [
            "Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2010",
                "Month": "02",
                "Day": "03"
            }
        ]
    },
    {
        "ArticleTitle": "Estimating the global burden of Epstein-Barr virus-related cancers.",
        "AuthorList": [
            "Yide Wong",
            "Michael T Meehan",
            "Scott R Burrows",
            "Denise L Doolan",
            "John J Miles"
        ],
        "AffiliationList": [
            "Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD, 4878, Australia. yide.wong@jcu.edu.au.",
            "Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, QLD, 4811, Australia.",
            "QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia.",
            "Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD, 4878, Australia.",
            "Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD, 4878, Australia."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "10",
                "Day": "27"
            }
        ]
    },
    {
        "ArticleTitle": "Insecticide use and risk of non-Hodgkin lymphoma subtypes: A subset meta-analysis of the North American Pooled Project.",
        "AuthorList": [
            "Linda Kachuri",
            "Laura E Beane Freeman",
            "John J Spinelli",
            "Aaron Blair",
            "Manisha Pahwa",
            "Stella Koutros",
            "Shelia Hoar Zahm",
            "Kenneth P Cantor"
        ],
        "AffiliationList": [
            "Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, California, USA.",
            "Division of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Bethesda, Maryland, USA.",
            "Population Oncology, BC Cancer, Vancouver, British Columbia, Canada.",
            "Division of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Bethesda, Maryland, USA.",
            "Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Ontario, Canada.",
            "Division of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Bethesda, Maryland, USA.",
            "Division of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Bethesda, Maryland, USA.",
            "Division of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Bethesda, Maryland, USA."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "07",
                "Day": "31"
            }
        ]
    },
    {
        "ArticleTitle": "Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.",
        "AuthorList": [
            "Emilia Pardal",
            "Mónica Coronado",
            "Alejandro Martín",
            "Carlos Grande",
            "Ana Marín-Niebla",
            "Carlos Panizo",
            "José Luis Bello",
            "Eulogio Conde"
        ],
        "AffiliationList": [
            "Department of Haematology, Hospital Virgen del Puerto, Plasencia, Spain.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "07",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial).",
        "AuthorList": [
            "Juan C Ramos",
            "Joseph A Sparano",
            "Amy Chadburn",
            "Erin G Reid",
            "Richard F Ambinder",
            "Eric R Siegel",
            "Page C Moore",
            "Paul G Rubinstein"
        ],
        "AffiliationList": [
            "Department of Medicine, University of Miami School of Medicine, Miami, FL.",
            "Department of Oncology, Albert Einstein Comprehensive Cancer Center, Bronx, NY.",
            "Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY.",
            "Department of Medicine, University of California, San Diego, San Diego, CA.",
            "Department of Oncology, Johns Hopkins University, Baltimore, MD.",
            "Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR.",
            "Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR.",
            "Section of Hematology/Oncology, John H. Stroger Jr Hospital of Cook County, Chicago, IL."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Thierry Lamy",
            "Gandhi Damaj",
            "Pierre Soubeyran",
            "Emmanuel Gyan",
            "Guillaume Cartron",
            "Krimo Bouabdallah",
            "Rémy Gressin",
            "Jérôme Cornillon"
        ],
        "AffiliationList": [
            "Hematology Department, Rennes University Hospital, INSERM Research Unit 1236, Rennes, France.",
            "Hematology Department, Centre Hospitalier Universitaire (CHU) d'Amiens, INSERM U1245, Amiens, France.",
            "Bergonié Bordeaux Institute and Bordeaux University, Bordeaux, France.",
            "Hematology and Cell Therapy Department, Clinical Investigation Center (CIC) INSERM U1415, CHU de Tours, Université François Rabelais, Tours, France.",
            "Hematology Department, CHU Montpellier, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 5235, Montpellier, France.",
            "Hematology and Cell Therapy Department, University Hospital of Bordeaux, Bordeaux, France.",
            "Onco Hematology Department, Hospital University Grenoble, INSERM U1209, CNRS UMR 5309, Université Grenoble Alpes, Site Santé, La Tronche, Grenoble, France.",
            "Hematology Department, Cancer Institute Lucien Neuwirth, Saint-Priest-en-Jarez, France."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "10",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Matthew J Maurer",
            "Ivana N M Micallef",
            "James R Cerhan",
            "Jerry A Katzmann",
            "Brian K Link",
            "Joseph P Colgan",
            "Thomas M Habermann",
            "David J Inwards"
        ],
        "AffiliationList": [
            "Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "03",
                "Day": "07"
            }
        ]
    },
    {
        "ArticleTitle": "Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis.",
        "AuthorList": [
            "Narendranath Epperla",
            "Mehdi Hamadani",
            "Tea Reljic",
            "Mohamed A Kharfan-Dabaja",
            "Bipin N Savani",
            "Ambuj Kumar"
        ],
        "AffiliationList": [
            "Division of Hematology, Department of Medicine, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio.",
            "Blood and Marrow Transplant (BMT) and Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, Wisconsin.",
            "Program for Comparative Effectiveness Research, Morsani College of Medicine, University of South Florida, Tampa, Florida.",
            "Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Mayo Clinic, Jacksonville, Florida.",
            "Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.",
            "Program for Comparative Effectiveness Research, Morsani College of Medicine, University of South Florida, Tampa, Florida."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "08",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.",
        "AuthorList": [
            "M Gleeson",
            "N Counsell",
            "D Cunningham",
            "N Chadwick",
            "A Lawrie",
            "E A Hawkes",
            "A McMillan",
            "K M Ardeshna"
        ],
        "AffiliationList": [
            "Department of Medicine, The Royal Marsden Hospital, London and Surrey, UK.",
            "Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.",
            "Department of Medicine, The Royal Marsden Hospital, London and Surrey, UK;. Electronic address: david.cunningham@rmh.nhs.uk.",
            "Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.",
            "Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.",
            "Department of Oncology and Clinical Haematology, Austin Health, Heidelberg, Melbourne, Australia;; Department of Medical Oncology, Eastern Health, Melbourne, Australia.",
            "Department of Haematology, Nottingham City Hospital, Nottingham, UK.",
            "Department of Haematology, University College London, London, UK;; Department of Haematology, Mount Vernon Cancer Centre, Northwood, UK."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).",
        "AuthorList": [
            "Michael A Fridrik",
            "Ulrich Jaeger",
            "Andreas Petzer",
            "Wolfgang Willenbacher",
            "Felix Keil",
            "Alois Lang",
            "Johannes Andel",
            "Sonja Burgstaller"
        ],
        "AffiliationList": [
            "Department of Internal Medicine 3 - Hematology and Oncology, Kepler University Hospital, Johannes Kepler University, Linz, Austria. Electronic address: michael.fridrik@akh.linz.at.",
            "Medical University Vienna, Department of Medicine I, Hematology and Hemostaseology, Austria.",
            "Barmherzige Schwestern Hospital Linz, Department of Medical Oncology, Hematology and Gastroenterology, Austria.",
            "University of Innsbruck, Internal Medicine V: Hematology-Oncology, Austria.",
            "Hanusch Hospital Vienna, Department of Medicine III: Hematology Oncology, Austria.",
            "LKH Feldkirch, Department of Internal Medicine, Austria.",
            "LKH Steyr, Department of Internal Medicine II, Austria.",
            "Klinikum Wels-Grieskirchen, Department of Internal Medicine IV, Austria."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "03",
                "Day": "15"
            }
        ]
    },
    {
        "ArticleTitle": "Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.",
        "AuthorList": [
            "Michael Pfreundschuh",
            "Viola Poeschel",
            "Samira Zeynalova",
            "Mathias Hänel",
            "Gerhard Held",
            "Norbert Schmitz",
            "Andreas Viardot",
            "Martin H Dreyling"
        ],
        "AffiliationList": [
            "Michael Pfreundschuh, Viola Poeschel, Gerhard Held, Tanja Rixecker, Carsten Zwick, and Niels Murawski, Universitätsklinikum des Saarlandes, Homburg; Samira Zeynalova, Leipzig University, Leipzig; Mathias Hänel, Klinikum Chemnitz, Chemnitz; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg; Andreas Viardot, Universitätsklinikum Ulm, Ulm; Martin H. Dreyling, Klinikum Großhadern; Ulrich Keller, Klinikum Rechts der Isar, Munich; Michael Hallek, Carsten Mueller, and Martin H.J. Wiesen, Universitätsklinik Köln, Köln; Mathias Witzens-Harig, Universitätsklinik Heidelberg, Heidelberg; and Lorenz Truemper, Universitätsklinikum Göttingen, Göttingen, Germany. michael.pfreundschuh@uks.eu.",
            "Michael Pfreundschuh, Viola Poeschel, Gerhard Held, Tanja Rixecker, Carsten Zwick, and Niels Murawski, Universitätsklinikum des Saarlandes, Homburg; Samira Zeynalova, Leipzig University, Leipzig; Mathias Hänel, Klinikum Chemnitz, Chemnitz; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg; Andreas Viardot, Universitätsklinikum Ulm, Ulm; Martin H. Dreyling, Klinikum Großhadern; Ulrich Keller, Klinikum Rechts der Isar, Munich; Michael Hallek, Carsten Mueller, and Martin H.J. Wiesen, Universitätsklinik Köln, Köln; Mathias Witzens-Harig, Universitätsklinik Heidelberg, Heidelberg; and Lorenz Truemper, Universitätsklinikum Göttingen, Göttingen, Germany.",
            "Michael Pfreundschuh, Viola Poeschel, Gerhard Held, Tanja Rixecker, Carsten Zwick, and Niels Murawski, Universitätsklinikum des Saarlandes, Homburg; Samira Zeynalova, Leipzig University, Leipzig; Mathias Hänel, Klinikum Chemnitz, Chemnitz; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg; Andreas Viardot, Universitätsklinikum Ulm, Ulm; Martin H. Dreyling, Klinikum Großhadern; Ulrich Keller, Klinikum Rechts der Isar, Munich; Michael Hallek, Carsten Mueller, and Martin H.J. Wiesen, Universitätsklinik Köln, Köln; Mathias Witzens-Harig, Universitätsklinik Heidelberg, Heidelberg; and Lorenz Truemper, Universitätsklinikum Göttingen, Göttingen, Germany.",
            "Michael Pfreundschuh, Viola Poeschel, Gerhard Held, Tanja Rixecker, Carsten Zwick, and Niels Murawski, Universitätsklinikum des Saarlandes, Homburg; Samira Zeynalova, Leipzig University, Leipzig; Mathias Hänel, Klinikum Chemnitz, Chemnitz; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg; Andreas Viardot, Universitätsklinikum Ulm, Ulm; Martin H. Dreyling, Klinikum Großhadern; Ulrich Keller, Klinikum Rechts der Isar, Munich; Michael Hallek, Carsten Mueller, and Martin H.J. Wiesen, Universitätsklinik Köln, Köln; Mathias Witzens-Harig, Universitätsklinik Heidelberg, Heidelberg; and Lorenz Truemper, Universitätsklinikum Göttingen, Göttingen, Germany.",
            "Michael Pfreundschuh, Viola Poeschel, Gerhard Held, Tanja Rixecker, Carsten Zwick, and Niels Murawski, Universitätsklinikum des Saarlandes, Homburg; Samira Zeynalova, Leipzig University, Leipzig; Mathias Hänel, Klinikum Chemnitz, Chemnitz; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg; Andreas Viardot, Universitätsklinikum Ulm, Ulm; Martin H. Dreyling, Klinikum Großhadern; Ulrich Keller, Klinikum Rechts der Isar, Munich; Michael Hallek, Carsten Mueller, and Martin H.J. Wiesen, Universitätsklinik Köln, Köln; Mathias Witzens-Harig, Universitätsklinik Heidelberg, Heidelberg; and Lorenz Truemper, Universitätsklinikum Göttingen, Göttingen, Germany.",
            "Michael Pfreundschuh, Viola Poeschel, Gerhard Held, Tanja Rixecker, Carsten Zwick, and Niels Murawski, Universitätsklinikum des Saarlandes, Homburg; Samira Zeynalova, Leipzig University, Leipzig; Mathias Hänel, Klinikum Chemnitz, Chemnitz; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg; Andreas Viardot, Universitätsklinikum Ulm, Ulm; Martin H. Dreyling, Klinikum Großhadern; Ulrich Keller, Klinikum Rechts der Isar, Munich; Michael Hallek, Carsten Mueller, and Martin H.J. Wiesen, Universitätsklinik Köln, Köln; Mathias Witzens-Harig, Universitätsklinik Heidelberg, Heidelberg; and Lorenz Truemper, Universitätsklinikum Göttingen, Göttingen, Germany.",
            "Michael Pfreundschuh, Viola Poeschel, Gerhard Held, Tanja Rixecker, Carsten Zwick, and Niels Murawski, Universitätsklinikum des Saarlandes, Homburg; Samira Zeynalova, Leipzig University, Leipzig; Mathias Hänel, Klinikum Chemnitz, Chemnitz; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg; Andreas Viardot, Universitätsklinikum Ulm, Ulm; Martin H. Dreyling, Klinikum Großhadern; Ulrich Keller, Klinikum Rechts der Isar, Munich; Michael Hallek, Carsten Mueller, and Martin H.J. Wiesen, Universitätsklinik Köln, Köln; Mathias Witzens-Harig, Universitätsklinik Heidelberg, Heidelberg; and Lorenz Truemper, Universitätsklinikum Göttingen, Göttingen, Germany.",
            "Michael Pfreundschuh, Viola Poeschel, Gerhard Held, Tanja Rixecker, Carsten Zwick, and Niels Murawski, Universitätsklinikum des Saarlandes, Homburg; Samira Zeynalova, Leipzig University, Leipzig; Mathias Hänel, Klinikum Chemnitz, Chemnitz; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg; Andreas Viardot, Universitätsklinikum Ulm, Ulm; Martin H. Dreyling, Klinikum Großhadern; Ulrich Keller, Klinikum Rechts der Isar, Munich; Michael Hallek, Carsten Mueller, and Martin H.J. Wiesen, Universitätsklinik Köln, Köln; Mathias Witzens-Harig, Universitätsklinik Heidelberg, Heidelberg; and Lorenz Truemper, Universitätsklinikum Göttingen, Göttingen, Germany."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "11",
                "Day": "17"
            }
        ]
    },
    {
        "ArticleTitle": "Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.",
        "AuthorList": [
            "Christian Gisselbrecht",
            "Bertram Glass",
            "Nicolas Mounier",
            "Devinder Singh Gill",
            "David C Linch",
            "Marek Trneny",
            "Andre Bosly",
            "Nicolas Ketterer"
        ],
        "AffiliationList": [
            "Hôpital Saint Louis, 1 Avenue Claude Vellefaux, 75010 Paris, France. christian.gisselbrecht@sls.aphp.fr",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2010",
                "Month": "07",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "[Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma].",
        "AuthorList": [
            "Tamás Schneider",
            "Zsuzsanna Molnár",
            "Beáta Deák",
            "Erika Várady",
            "Erika Tóth",
            "Judit Csomor",
            "András Matolcsy",
            "József Lovey"
        ],
        "AffiliationList": [
            "Országos Onkológiai Intézet, Malignus Lymphoma Központ, Budapest. schneider@oncol.hu",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Hepatitis B virus and risk of non-Hodgkin lymphoma: An updated meta-analysis of 58 studies.",
        "AuthorList": [
            "M Li",
            "Y Gan",
            "C Fan",
            "H Yuan",
            "X Zhang",
            "Y Shen",
            "Q Wang",
            "Z Meng"
        ],
        "AffiliationList": [
            "State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.",
            "State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.",
            "Department of Etiology, Qidong People's Hospital/Qidong Liver Cancer Institute, Qidong, China.",
            "State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.",
            "Shanghai Medical Insurance Affairs Management Center, Shanghai, China.",
            "Department of Head and Neck Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.",
            "State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.",
            "State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "04",
                "Day": "02"
            }
        ]
    },
    {
        "ArticleTitle": "Oral CHOP-like chemotherapy in 60-80 years-old patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Stephanie Guidez",
            "Laurence Lacotte-Thierry",
            "Cecile Tomowiak",
            "Isabelle Princet",
            "Brigitte Dreyfus",
            "Gaelle Olivier",
            "Emmanuel Fleck",
            "Anne Corby"
        ],
        "AffiliationList": [
            "Oncology-Hematology and Cell Therapy, CHU, Poitiers, France.",
            "Oncology-Hematology and Cell Therapy, CHU, Poitiers, France.",
            "Oncology-Hematology and Cell Therapy, CHU, Poitiers, France.",
            "Central pharmacy, CHU, Poitiers, France.",
            "Oncology-Hematology and Cell Therapy, CHU, Poitiers, France.",
            "Internal Medecine, CH, Niort, France.",
            "Oncology-Hematology, CH, La Rochelle, France.",
            "Oncology-Hematology, CH, La Rochelle, France."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "07",
                "Day": "15"
            }
        ]
    },
    {
        "ArticleTitle": "Limited efficacy of high-dose methotrexate in patients with neurolymphomatosis.",
        "AuthorList": [
            "Hiroki Kobayashi",
            "Yoshiaki Abe",
            "Daisuke Miura",
            "Kentaro Narita",
            "Akihiro Kitadate",
            "Masami Takeuchi",
            "Kosei Matsue"
        ],
        "AffiliationList": [
            "Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa, Chiba, 296-8602, Japan. hiro.k2302@gmail.com.",
            "Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa, Chiba, 296-8602, Japan.",
            "Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa, Chiba, 296-8602, Japan.",
            "Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa, Chiba, 296-8602, Japan.",
            "Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa, Chiba, 296-8602, Japan.",
            "Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa, Chiba, 296-8602, Japan.",
            "Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa, Chiba, 296-8602, Japan."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "01",
                "Day": "03"
            }
        ]
    },
    {
        "ArticleTitle": "Elevated soluble CD23 level indicates increased risk of B cell non-Hodgkin's lymphomas: evidence from a meta-analysis.",
        "AuthorList": [
            "Yi-Shu Huang",
            "Xiang Zhou",
            "Zhi-Fang Yang",
            "Zheng-Tao Lv"
        ],
        "AffiliationList": [
            "Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.",
            "Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany.",
            "Department Thyroid and Breast Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. yangzhifangtj@163.com.",
            "Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. 630105736@qq.com."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "05",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "LEP and LEPR polymorphisms in non-Hodgkin lymphoma risk: a systematic review and pooled analysis.",
        "AuthorList": [
            "Hai-Yan Lin",
            "Hui Shi",
            "Chun-Yan Li",
            "Quan-Chi Chen",
            "Tian-Bao Huang",
            "Peng-Cheng Liu",
            "Lie-ming Lou"
        ],
        "AffiliationList": [
            "1Department of Orthopedics, Shanghai Tenth People's Hospital, Tongji University, School of Medicine, Shanghai, China.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly.",
        "AuthorList": [
            "Mariapaola Fina",
            "Monica Tani",
            "Vittorio Stefoni",
            "Gerardo Musuraca",
            "Enrica Marchi",
            "Cinzia Pellegrini",
            "Lapo Alinari",
            "Enrico Derenzini"
        ],
        "AffiliationList": [
            "Institute of Hematology and Medical Oncology L. & A. Seràgnoli, University of Bologna, Bologna, Italy.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.",
        "AuthorList": [
            "Xuan Zhou",
            "Sanfang Tu",
            "Chunsheng Wang",
            "Rui Huang",
            "Lan Deng",
            "Chaoyang Song",
            "Chunyan Yue",
            "Yanjie He"
        ],
        "AffiliationList": [
            "Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.",
            "Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.",
            "Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.",
            "Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.",
            "Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.",
            "Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.",
            "Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.",
            "Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "11",
                "Day": "27"
            }
        ]
    },
    {
        "ArticleTitle": "Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi.",
        "AuthorList": [
            "Francesco Zaja",
            "Flavia Salvi",
            "Maura Rossi",
            "Elena Sabattini",
            "Andrea Evangelista",
            "Giovannino Ciccone",
            "Emanuele Angelucci",
            "Gianluca Gaidano"
        ],
        "AffiliationList": [
            "a Clinica Ematologica ed Unità di Terapie Cellulari 'Carlo Melzi', DAME , University of Udine , Udine , Italy.",
            "b S.C. Ematologia , A.O. SS. Antonio e Biagio e C. Arrigo , Alessandria , Italy.",
            "c Unit of Haemolymphopathology, Department of Experimental, Diagnostic and Specialty Medicine , University Hospital of Bologna , Bologna , Italy.",
            "d Unit of Haemolymphopathology, Department of Hematology and Oncology , University Hospital of Bologna , Bologna , Italy.",
            "d Unit of Haemolymphopathology, Department of Hematology and Oncology , University Hospital of Bologna , Bologna , Italy.",
            "e Unit of Clinical Epidemiology , AOU Città della Salute e della Scienza di Torino and CPO Piemonte , Torino , Italy.",
            "f U.O.C. Ematologia , IRCCS A.O.U. San Martino-IST , Genova , Italy.",
            "g Division of Hematology, Department of Translational Medicine , Amedeo Avogadro University of Eastern Piedmont , Novara , Italy."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "04",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Tissue microarray in a subset of South African patients with DLBCL.",
        "AuthorList": [
            "Gerhard Sissolak",
            "Lucille Wood",
            "Lynette Smith",
            "John Wing C Chan",
            "James Armitage",
            "Peter Jacobs"
        ],
        "AffiliationList": [
            "Division of Clinical Haematology, Faculty of Health Sciences, Stellenbosch University, Tygerberg Academic Hospital, South Africa.",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "08",
                "Day": "12"
            }
        ]
    },
    {
        "ArticleTitle": "Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI).",
        "AuthorList": [
            "Ranjana H Advani",
            "Haiyan Chen",
            "Thomas M Habermann",
            "Vicki A Morrison",
            "Edie A Weller",
            "Richard I Fisher",
            "Bruce A Peterson",
            "Randy D Gascoyne"
        ],
        "AffiliationList": [
            "Stanford University, Stanford, CA 94305, USA. radvani@stanford.edu",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.",
        "AuthorList": [
            "Jonathan W Friedberg",
            "Jeff Sharman",
            "John Sweetenham",
            "Patrick B Johnston",
            "Julie M Vose",
            "Ann Lacasce",
            "Julia Schaefer-Cutillo",
            "Sven De Vos"
        ],
        "AffiliationList": [
            "James P. Wilmot Cancer Center, University of Rochester, NY 14642, USA. jonathan_friedberg@urmc.rochester.edu",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2009",
                "Month": "11",
                "Day": "17"
            }
        ]
    },
    {
        "ArticleTitle": "Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area.",
        "AuthorList": [
            "Caroline Gay",
            "Richard Delarue",
            "Noel Milpied",
            "Lucie Oberic",
            "Bertrand Coiffier",
            "Sami Boussetta",
            "Corinne Haioun",
            "Hervé Tilly"
        ],
        "AffiliationList": [
            "Service de Pharmacie, Centre Hospitalier Universitaire (CHU) de Rennes, Rennes, France.",
            "Service d'Hématologie Adultes, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Necker Enfants Malades, Paris, France.",
            "Service d'Hématologie et Thérapie Cellulaire, CHU Bordeaux, University of Bordeaux, Bordeaux, France.",
            "Département d'Hématologie, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France.",
            "Hospices Civils de Lyon, Université Claude Bernard, Pierre-Bénite, France.",
            "Lymphoma Academic Research Organisation, Centre Hospitalier Lyon-Sud, Lyon, France.",
            "Lymphoid Malignancies Unit, Hospital Henri Mondor, Créteil, France.",
            "Centre Henri Becquerel, UMR918, Université de Rouen, Rouen, France; and."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "03",
                "Day": "16"
            }
        ]
    },
    {
        "ArticleTitle": "Pleiotropy of cancer susceptibility variants on the risk of non-Hodgkin lymphoma: the PAGE consortium.",
        "AuthorList": [
            "Unhee Lim",
            "Jonathan M Kocarnik",
            "William S Bush",
            "Tara C Matise",
            "Christian Caberto",
            "Sungshim Lani Park",
            "Christopher S Carlson",
            "Ewa Deelman"
        ],
        "AffiliationList": [
            "Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, United States of America.",
            "Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.",
            "Center for Human Genetics Research, Vanderbilt University, Nashville, Tennessee, United States of America.",
            "Department of Genetics, Rutgers University, Piscataway, New Jersey, United States of America.",
            "Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, United States of America.",
            "Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.",
            "Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.",
            "Department of Genetics, Rutgers University, Piscataway, New Jersey, United States of America."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "03",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC).",
        "AuthorList": [
            "Pau Abrisqueta",
            "Julio Delgado",
            "Miguel Alcoceba",
            "Ana Carla Oliveira",
            "Javier Loscertales",
            "Jose A Hernández-Rivas",
            "Christelle Ferrà",
            "Raul Cordoba"
        ],
        "AffiliationList": [
            "Department of Hematology, Hospital Vall d'Hebron, Barcelona, Spain.",
            "Department of Hematology, Hospital Clínic, Barcelona, Spain.",
            "Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.",
            "Department of Hematology, Institut Català d'Oncologia, L'Hospitalet de LLobregat, Hospitalet, Spain.",
            "Department of Hematology, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain.",
            "Department of Hematology, Hospital Universitario Infanta Leonor, Madrid, Spain.",
            "Department of Hematology, University Hospital GermansTrias y Pujol, Badalona, Spain.",
            "Department of Hematology, Fundación Jiménez Díaz, Madrid, Spain."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "06",
                "Day": "09"
            }
        ]
    },
    {
        "ArticleTitle": "Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarily.",
        "AuthorList": [
            "Dorte Tholstrup",
            "Peter De Nully Brown",
            "Jesper Jurlander",
            "Palle Bekker Jeppesen",
            "Mogens Groenvold"
        ],
        "AffiliationList": [
            "Department of Hematology, Rigshospitalet, Copenhagen, Denmark. dortetholstrup@dadlnet.dk",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "01",
                "Day": "21"
            }
        ]
    },
    {
        "ArticleTitle": "Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.",
        "AuthorList": [
            "Stephen M Ansell",
            "Michael B Maris",
            "Alexander M Lesokhin",
            "Robert W Chen",
            "Ian W Flinn",
            "Ahmed Sawas",
            "Mark D Minden",
            "Diego Villa"
        ],
        "AffiliationList": [
            "Division of Hematology, Mayo Clinic, Rochester, Minnesota. ansell.stephen@mayo.edu.",
            "Colorado Blood Cancer Institute and Sarah Cannon Research Institute, Denver, Colorado.",
            "Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.",
            "Department of Hematology and Hematopoietic Transplantation, City of Hope Medical Center, Duarte, California.",
            "Sarah Cannon Research Institute, Nashville, Tennessee.",
            "Center for Lymphoid Malignancies, Columbia University Medical Center, College of Physicians and Surgeons, New York, New York.",
            "Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.",
            "Division of Medical Oncology and Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "01",
                "Day": "15"
            }
        ]
    },
    {
        "ArticleTitle": "Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.",
        "AuthorList": [
            "Ranjana H Advani",
            "Daniel Lebovic",
            "Andy Chen",
            "Mark Brunvand",
            "Andre Goy",
            "Julie E Chang",
            "Ephraim Hochberg",
            "Sreeni Yalamanchili"
        ],
        "AffiliationList": [
            "Stanford University Medical Center, Stanford, California. radvani@stanford.edu.",
            "University of Michigan Medical School, Ann Arbor, Michigan.",
            "Oregon Health and Science University, Portland, Oregon.",
            "Rocky Mountain Cancer Center, Denver, Colorado.",
            "Hackensack University Medical Center, Hackensack, New Jersey.",
            "University of Wisconsin-Madison, Madison, Wisconsin.",
            "Massachusetts General Hospital, Boston, Massachusetts.",
            "Genentech, Inc., South San Francisco, California."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "09",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Yasuhiro Oki",
            "Jason R Westin",
            "Francisco Vega",
            "Hubert Chuang",
            "Nathan Fowler",
            "Sattva Neelapu",
            "Fredrick B Hagemeister",
            "Peter McLaughlin"
        ],
        "AffiliationList": [
            "Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "10",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial.",
        "AuthorList": [
            "Paul A Fields",
            "William Townsend",
            "Andrew Webb",
            "Nicholas Counsell",
            "Christopher Pocock",
            "Paul Smith",
            "Andrew Jack",
            "Nadjet El-Mehidi"
        ],
        "AffiliationList": [
            "Paul A. Fields, Guys and St Thomas' and King's College Hospitals; William Townsend, Nicholas Counsell, Paul Smith, and Nadjet El-Mehidi, Cancer Research UK and University College London Cancer Trials Centre; David C. Linch, University College London Hospital; David Cunnningham, Royal Marsden Hospital, London; Andrew Webb, Royal Sussex Cancer Centre, Brighton; Christopher Pocock, Kent and Canterbury Hospital, Kent; Andrew Jack, St James Hospital, Leeds; Peter W. Johnson, Southampton General Hospital, Southampton; and John Radford, Christie Hospital, Manchester, United Kingdom.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "11",
                "Day": "12"
            }
        ]
    },
    {
        "ArticleTitle": "Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.",
        "AuthorList": [
            "Daniel O Persky",
            "Joseph M Unger",
            "Catherine M Spier",
            "Baldassarre Stea",
            "Michael LeBlanc",
            "Matthew J McCarty",
            "Lisa M Rimsza",
            "Richard I Fisher"
        ],
        "AffiliationList": [
            "Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2008",
                "Month": "04",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas.",
        "AuthorList": [
            "Jettie J F Muris",
            "Saskia A G M Cillessen",
            "Wim Vos",
            "Inge S van Houdt",
            "J Alain Kummer",
            "Johan H J M van Krieken",
            "N Mehdi Jiwa",
            "Patty M Jansen"
        ],
        "AffiliationList": [
            "Department of Clinical Pathology, VU Medical Center, De Boelelaan 1117, 1007 MB Amsterdam, The Netherlands.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2004",
                "Month": "12",
                "Day": "02"
            }
        ]
    },
    {
        "ArticleTitle": "Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.",
        "AuthorList": [
            "Jakub Svoboda",
            "Steven M Bair",
            "Daniel J Landsburg",
            "Sunita Dwivedy Nasta",
            "Sarah J Nagle",
            "Stefan K Barta",
            "Nadia Khan",
            "Joanne Filicko-O'Hara"
        ],
        "AffiliationList": [
            "University of Pennsylvania, Philadelphia, PA, USA.",
            "University of Pennsylvania, Philadelphia, PA, USA.",
            "University of Pennsylvania, Philadelphia, PA, USA.",
            "University of Pennsylvania, Philadelphia, PA, USA.",
            "Oregon Health and Science University, Portland, OR, USA.",
            "University of Pennsylvania, Philadelphia, PA, USA.",
            "Fox Chase Cancer Center, Philadelphia, PA, USA.",
            "Thomas Jefferson University, Philadelphia, PA, USA."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "06",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial.",
        "AuthorList": [
            "Kai Xue",
            "Juan J Gu",
            "Qunling Zhang",
            "Xiaojian Liu",
            "Jiachen Wang",
            "Xiao-Qiu Li",
            "Jianfeng Luo",
            "Francisco J Hernandez-Ilizaliturri"
        ],
        "AffiliationList": [
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.",
            "Department of Medicine & Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA.",
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.",
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.",
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.",
            "Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.",
            "Department of Biostatistics, School of Public Health, Fudan University, Shanghai, China.",
            "Department of Medicine & Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma.",
        "AuthorList": [
            "Gaetano Corazzelli",
            "Ferdinando Frigeri",
            "Filippo Russo",
            "Chiara Frairia",
            "Manuela Arcamone",
            "Gennaro Esposito",
            "Annarosaria De Chiara",
            "Emanuela Morelli"
        ],
        "AffiliationList": [
            "Haematology-Oncology and Stem Cell Transplantation Unit, Fondazione 'G. Pascale,' IRCCS, Naples, Italy. g.corazzelli@istitutotumori.na.it",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "11",
                "Day": "21"
            }
        ]
    },
    {
        "ArticleTitle": "Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Julio García-Suárez",
            "Elena Flores",
            "Marta Callejas",
            "Ignacio Arribas",
            "Juan-José Gil-Fernández",
            "Gabriel Olmedilla",
            "Natalia Curto",
            "Helga Guillén"
        ],
        "AffiliationList": [
            "Haematology Service, Department of Medicine, Príncipe de Asturias University Hospital, University of Alcalá, Alcalá de Henares, Madrid, Spain. jgarciasu.hupa@salud.madrid.org",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "12",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.",
        "AuthorList": [
            "Karin Hohloch",
            "Carsten Oliver Sahlmann",
            "Vijai J Lakhani",
            "Gerald Wulf",
            "Bertram Glass",
            "Justin Hasenkamp",
            "Johannes Meller",
            "Joachim Riggert"
        ],
        "AffiliationList": [
            "Department of Hematology and Oncology, University Medicine, Georg-August-University, Robert Koch Str. 40, 37075 Göttingen, Germany. karo.hohloch@med.uni-goettingen.de",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "03",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.",
        "AuthorList": [
            "Junji Hiraga",
            "Akihiro Tomita",
            "Takumi Sugimoto",
            "Kazuyuki Shimada",
            "Masafumi Ito",
            "Shigeo Nakamura",
            "Hitoshi Kiyoi",
            "Tomohiro Kinoshita"
        ],
        "AffiliationList": [
            "Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Japan.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2009",
                "Month": "02",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma.",
        "AuthorList": [
            "Paul L R Mitchell",
            "Paula Marlton",
            "Andrew Grigg",
            "John F Seymour",
            "Mark Hertzberg",
            "Arno Enno",
            "Richard Herrmann",
            "Rodney Bond"
        ],
        "AffiliationList": [
            "Austin Hospital, Melbourne, Australia.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study.",
        "AuthorList": [
            "John Kuruvilla",
            "Philippe Armand",
            "Mehdi Hamadani",
            "Justin Kline",
            "Craig H Moskowitz",
            "David Avigan",
            "Joshua D Brody",
            "Vincent Ribrag"
        ],
        "AffiliationList": [
            "Princess Margaret Cancer Centre, Toronto, Canada.",
            "Dana-Farber Cancer Institute, Boston, MA, USA.",
            "Medical College of Wisconsin, Milwaukee, WI, USA.",
            "Department of Medicine, University of Chicago, Chicago, IL, USA.",
            "Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.",
            "Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.",
            "Icahn School of Medicine at Mount Sinai, New York, NY, USA.",
            "Gustave Roussy, Villejuif, France."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "11",
                "Day": "18"
            }
        ]
    },
    {
        "ArticleTitle": "Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era.",
        "AuthorList": [
            "Rebecca L King",
            "Grzegorz S Nowakowski",
            "Thomas E Witzig",
            "David W Scott",
            "Richard F Little",
            "Fangxin Hong",
            "Randy D Gascoyne",
            "Brad S Kahl"
        ],
        "AffiliationList": [
            "Mayo Clinic, Rochester, MN, USA. rebecca.king98@gmail.com.",
            "Mayo Clinic, Rochester, MN, USA.",
            "Mayo Clinic, Rochester, MN, USA.",
            "British Columbia Cancer Agency, Vancouver, BC, Canada.",
            "Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA.",
            "Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, USA.",
            "British Columbia Cancer Agency, Vancouver, BC, Canada.",
            "Washington University School of Medicine, St. Louis, MO, USA."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "02",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.",
        "AuthorList": [
            "Hervé Tilly",
            "Franck Morschhauser",
            "Laurie H Sehn",
            "Jonathan W Friedberg",
            "Marek Trněný",
            "Jeff P Sharman",
            "Charles Herbaux",
            "John M Burke"
        ],
        "AffiliationList": [
            "From the Department of Hematology and INSERM Unité 1245, Centre Henri-Becquerel and University of Rouen, Rouen (H.T.), Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, ULR 7365 - GRITA - Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille (F.M.), CHU de Montpellier, Montpellier (C.H.), the Department of Hematology, Institut Universitaire du Cancer, Toulouse-Oncopole, Toulouse (L.O.), and the Department of Hematology, Centre Hospitalier Régional Universitaire - Besançon, Besançon (A.C.) - all in France; the Centre for Lymphoid Cancer at BC Cancer and the University of British Columbia, Vancouver (L.H.S.), the Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto (M.C.C.), and F. Hoffmann-La Roche, Mississauga, ON (M.Y.) - all in Canada; the Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and Memorial Sloan Kettering Cancer Center, New York (M.M., G.S.) - both in New York; the First Faculty of Medicine, Charles University and the General University Hospital, Prague, Czech Republic (M.T.); the Willamette Valley Cancer Institute and Research Center, the US Oncology Network, Eugene, OR (J.P.S.); Rocky Mountain Cancer Centers, Aurora, CO (J.M.B.); Memorial Sloan Kettering Cancer Center, Montvale, NJ (M.M.); the Department of Hematology and Rheumatology, Kindai University, Faculty of Medicine, Osaka-Sayama City (S.R.), and the National Cancer Center Hospital, Tokyo (K.I.) - both in Japan; Washington University in St. Louis, St. Louis (N.M.-S.); the Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland (W.J.); Peking University Cancer Hospital, Beijing (Y.S.); the 3rd Medical Department, Paracelsus Medical University, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, and Cancer Cluster Salzburg, Salzburg, Austria (R.G.); the Feofaniya Clinical Hospital, Kyiv, Ukraine (L.M.); Hospital San Pedro de Alcántara, Cáceres (J.M.B.-B.), and the Department of Hematology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (P.A.) - both in Spain; the Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples, Italy (A.P.); the Division of Hematology-Oncology, Department of Internal Medicine, Research Institute of Medical Science, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea (H.-J.S.); Princess Alexandra Hospital, Brisbane, QLD, Australia (G.H.); Hospital Erasto Gaertner, Curitiba, Brazil (E.M.); Taipei Veterans General Hospital, Taipei, Taiwan (J.-P.G.); Genentech, South San Francisco, CA (J.H., Y.J., C.L.); and M.D. Anderson Cancer Center, Houston (C.R.F.).",
            "From the Department of Hematology and INSERM Unité 1245, Centre Henri-Becquerel and University of Rouen, Rouen (H.T.), Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, ULR 7365 - GRITA - Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille (F.M.), CHU de Montpellier, Montpellier (C.H.), the Department of Hematology, Institut Universitaire du Cancer, Toulouse-Oncopole, Toulouse (L.O.), and the Department of Hematology, Centre Hospitalier Régional Universitaire - Besançon, Besançon (A.C.) - all in France; the Centre for Lymphoid Cancer at BC Cancer and the University of British Columbia, Vancouver (L.H.S.), the Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto (M.C.C.), and F. Hoffmann-La Roche, Mississauga, ON (M.Y.) - all in Canada; the Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and Memorial Sloan Kettering Cancer Center, New York (M.M., G.S.) - both in New York; the First Faculty of Medicine, Charles University and the General University Hospital, Prague, Czech Republic (M.T.); the Willamette Valley Cancer Institute and Research Center, the US Oncology Network, Eugene, OR (J.P.S.); Rocky Mountain Cancer Centers, Aurora, CO (J.M.B.); Memorial Sloan Kettering Cancer Center, Montvale, NJ (M.M.); the Department of Hematology and Rheumatology, Kindai University, Faculty of Medicine, Osaka-Sayama City (S.R.), and the National Cancer Center Hospital, Tokyo (K.I.) - both in Japan; Washington University in St. Louis, St. Louis (N.M.-S.); the Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland (W.J.); Peking University Cancer Hospital, Beijing (Y.S.); the 3rd Medical Department, Paracelsus Medical University, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, and Cancer Cluster Salzburg, Salzburg, Austria (R.G.); the Feofaniya Clinical Hospital, Kyiv, Ukraine (L.M.); Hospital San Pedro de Alcántara, Cáceres (J.M.B.-B.), and the Department of Hematology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (P.A.) - both in Spain; the Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples, Italy (A.P.); the Division of Hematology-Oncology, Department of Internal Medicine, Research Institute of Medical Science, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea (H.-J.S.); Princess Alexandra Hospital, Brisbane, QLD, Australia (G.H.); Hospital Erasto Gaertner, Curitiba, Brazil (E.M.); Taipei Veterans General Hospital, Taipei, Taiwan (J.-P.G.); Genentech, South San Francisco, CA (J.H., Y.J., C.L.); and M.D. Anderson Cancer Center, Houston (C.R.F.).",
            "From the Department of Hematology and INSERM Unité 1245, Centre Henri-Becquerel and University of Rouen, Rouen (H.T.), Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, ULR 7365 - GRITA - Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille (F.M.), CHU de Montpellier, Montpellier (C.H.), the Department of Hematology, Institut Universitaire du Cancer, Toulouse-Oncopole, Toulouse (L.O.), and the Department of Hematology, Centre Hospitalier Régional Universitaire - Besançon, Besançon (A.C.) - all in France; the Centre for Lymphoid Cancer at BC Cancer and the University of British Columbia, Vancouver (L.H.S.), the Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto (M.C.C.), and F. Hoffmann-La Roche, Mississauga, ON (M.Y.) - all in Canada; the Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and Memorial Sloan Kettering Cancer Center, New York (M.M., G.S.) - both in New York; the First Faculty of Medicine, Charles University and the General University Hospital, Prague, Czech Republic (M.T.); the Willamette Valley Cancer Institute and Research Center, the US Oncology Network, Eugene, OR (J.P.S.); Rocky Mountain Cancer Centers, Aurora, CO (J.M.B.); Memorial Sloan Kettering Cancer Center, Montvale, NJ (M.M.); the Department of Hematology and Rheumatology, Kindai University, Faculty of Medicine, Osaka-Sayama City (S.R.), and the National Cancer Center Hospital, Tokyo (K.I.) - both in Japan; Washington University in St. Louis, St. Louis (N.M.-S.); the Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland (W.J.); Peking University Cancer Hospital, Beijing (Y.S.); the 3rd Medical Department, Paracelsus Medical University, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, and Cancer Cluster Salzburg, Salzburg, Austria (R.G.); the Feofaniya Clinical Hospital, Kyiv, Ukraine (L.M.); Hospital San Pedro de Alcántara, Cáceres (J.M.B.-B.), and the Department of Hematology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (P.A.) - both in Spain; the Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples, Italy (A.P.); the Division of Hematology-Oncology, Department of Internal Medicine, Research Institute of Medical Science, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea (H.-J.S.); Princess Alexandra Hospital, Brisbane, QLD, Australia (G.H.); Hospital Erasto Gaertner, Curitiba, Brazil (E.M.); Taipei Veterans General Hospital, Taipei, Taiwan (J.-P.G.); Genentech, South San Francisco, CA (J.H., Y.J., C.L.); and M.D. Anderson Cancer Center, Houston (C.R.F.).",
            "From the Department of Hematology and INSERM Unité 1245, Centre Henri-Becquerel and University of Rouen, Rouen (H.T.), Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, ULR 7365 - GRITA - Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille (F.M.), CHU de Montpellier, Montpellier (C.H.), the Department of Hematology, Institut Universitaire du Cancer, Toulouse-Oncopole, Toulouse (L.O.), and the Department of Hematology, Centre Hospitalier Régional Universitaire - Besançon, Besançon (A.C.) - all in France; the Centre for Lymphoid Cancer at BC Cancer and the University of British Columbia, Vancouver (L.H.S.), the Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto (M.C.C.), and F. Hoffmann-La Roche, Mississauga, ON (M.Y.) - all in Canada; the Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and Memorial Sloan Kettering Cancer Center, New York (M.M., G.S.) - both in New York; the First Faculty of Medicine, Charles University and the General University Hospital, Prague, Czech Republic (M.T.); the Willamette Valley Cancer Institute and Research Center, the US Oncology Network, Eugene, OR (J.P.S.); Rocky Mountain Cancer Centers, Aurora, CO (J.M.B.); Memorial Sloan Kettering Cancer Center, Montvale, NJ (M.M.); the Department of Hematology and Rheumatology, Kindai University, Faculty of Medicine, Osaka-Sayama City (S.R.), and the National Cancer Center Hospital, Tokyo (K.I.) - both in Japan; Washington University in St. Louis, St. Louis (N.M.-S.); the Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland (W.J.); Peking University Cancer Hospital, Beijing (Y.S.); the 3rd Medical Department, Paracelsus Medical University, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, and Cancer Cluster Salzburg, Salzburg, Austria (R.G.); the Feofaniya Clinical Hospital, Kyiv, Ukraine (L.M.); Hospital San Pedro de Alcántara, Cáceres (J.M.B.-B.), and the Department of Hematology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (P.A.) - both in Spain; the Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples, Italy (A.P.); the Division of Hematology-Oncology, Department of Internal Medicine, Research Institute of Medical Science, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea (H.-J.S.); Princess Alexandra Hospital, Brisbane, QLD, Australia (G.H.); Hospital Erasto Gaertner, Curitiba, Brazil (E.M.); Taipei Veterans General Hospital, Taipei, Taiwan (J.-P.G.); Genentech, South San Francisco, CA (J.H., Y.J., C.L.); and M.D. Anderson Cancer Center, Houston (C.R.F.).",
            "From the Department of Hematology and INSERM Unité 1245, Centre Henri-Becquerel and University of Rouen, Rouen (H.T.), Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, ULR 7365 - GRITA - Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille (F.M.), CHU de Montpellier, Montpellier (C.H.), the Department of Hematology, Institut Universitaire du Cancer, Toulouse-Oncopole, Toulouse (L.O.), and the Department of Hematology, Centre Hospitalier Régional Universitaire - Besançon, Besançon (A.C.) - all in France; the Centre for Lymphoid Cancer at BC Cancer and the University of British Columbia, Vancouver (L.H.S.), the Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto (M.C.C.), and F. Hoffmann-La Roche, Mississauga, ON (M.Y.) - all in Canada; the Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and Memorial Sloan Kettering Cancer Center, New York (M.M., G.S.) - both in New York; the First Faculty of Medicine, Charles University and the General University Hospital, Prague, Czech Republic (M.T.); the Willamette Valley Cancer Institute and Research Center, the US Oncology Network, Eugene, OR (J.P.S.); Rocky Mountain Cancer Centers, Aurora, CO (J.M.B.); Memorial Sloan Kettering Cancer Center, Montvale, NJ (M.M.); the Department of Hematology and Rheumatology, Kindai University, Faculty of Medicine, Osaka-Sayama City (S.R.), and the National Cancer Center Hospital, Tokyo (K.I.) - both in Japan; Washington University in St. Louis, St. Louis (N.M.-S.); the Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland (W.J.); Peking University Cancer Hospital, Beijing (Y.S.); the 3rd Medical Department, Paracelsus Medical University, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, and Cancer Cluster Salzburg, Salzburg, Austria (R.G.); the Feofaniya Clinical Hospital, Kyiv, Ukraine (L.M.); Hospital San Pedro de Alcántara, Cáceres (J.M.B.-B.), and the Department of Hematology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (P.A.) - both in Spain; the Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples, Italy (A.P.); the Division of Hematology-Oncology, Department of Internal Medicine, Research Institute of Medical Science, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea (H.-J.S.); Princess Alexandra Hospital, Brisbane, QLD, Australia (G.H.); Hospital Erasto Gaertner, Curitiba, Brazil (E.M.); Taipei Veterans General Hospital, Taipei, Taiwan (J.-P.G.); Genentech, South San Francisco, CA (J.H., Y.J., C.L.); and M.D. Anderson Cancer Center, Houston (C.R.F.).",
            "From the Department of Hematology and INSERM Unité 1245, Centre Henri-Becquerel and University of Rouen, Rouen (H.T.), Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, ULR 7365 - GRITA - Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille (F.M.), CHU de Montpellier, Montpellier (C.H.), the Department of Hematology, Institut Universitaire du Cancer, Toulouse-Oncopole, Toulouse (L.O.), and the Department of Hematology, Centre Hospitalier Régional Universitaire - Besançon, Besançon (A.C.) - all in France; the Centre for Lymphoid Cancer at BC Cancer and the University of British Columbia, Vancouver (L.H.S.), the Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto (M.C.C.), and F. Hoffmann-La Roche, Mississauga, ON (M.Y.) - all in Canada; the Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and Memorial Sloan Kettering Cancer Center, New York (M.M., G.S.) - both in New York; the First Faculty of Medicine, Charles University and the General University Hospital, Prague, Czech Republic (M.T.); the Willamette Valley Cancer Institute and Research Center, the US Oncology Network, Eugene, OR (J.P.S.); Rocky Mountain Cancer Centers, Aurora, CO (J.M.B.); Memorial Sloan Kettering Cancer Center, Montvale, NJ (M.M.); the Department of Hematology and Rheumatology, Kindai University, Faculty of Medicine, Osaka-Sayama City (S.R.), and the National Cancer Center Hospital, Tokyo (K.I.) - both in Japan; Washington University in St. Louis, St. Louis (N.M.-S.); the Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland (W.J.); Peking University Cancer Hospital, Beijing (Y.S.); the 3rd Medical Department, Paracelsus Medical University, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, and Cancer Cluster Salzburg, Salzburg, Austria (R.G.); the Feofaniya Clinical Hospital, Kyiv, Ukraine (L.M.); Hospital San Pedro de Alcántara, Cáceres (J.M.B.-B.), and the Department of Hematology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (P.A.) - both in Spain; the Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples, Italy (A.P.); the Division of Hematology-Oncology, Department of Internal Medicine, Research Institute of Medical Science, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea (H.-J.S.); Princess Alexandra Hospital, Brisbane, QLD, Australia (G.H.); Hospital Erasto Gaertner, Curitiba, Brazil (E.M.); Taipei Veterans General Hospital, Taipei, Taiwan (J.-P.G.); Genentech, South San Francisco, CA (J.H., Y.J., C.L.); and M.D. Anderson Cancer Center, Houston (C.R.F.).",
            "From the Department of Hematology and INSERM Unité 1245, Centre Henri-Becquerel and University of Rouen, Rouen (H.T.), Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, ULR 7365 - GRITA - Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille (F.M.), CHU de Montpellier, Montpellier (C.H.), the Department of Hematology, Institut Universitaire du Cancer, Toulouse-Oncopole, Toulouse (L.O.), and the Department of Hematology, Centre Hospitalier Régional Universitaire - Besançon, Besançon (A.C.) - all in France; the Centre for Lymphoid Cancer at BC Cancer and the University of British Columbia, Vancouver (L.H.S.), the Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto (M.C.C.), and F. Hoffmann-La Roche, Mississauga, ON (M.Y.) - all in Canada; the Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and Memorial Sloan Kettering Cancer Center, New York (M.M., G.S.) - both in New York; the First Faculty of Medicine, Charles University and the General University Hospital, Prague, Czech Republic (M.T.); the Willamette Valley Cancer Institute and Research Center, the US Oncology Network, Eugene, OR (J.P.S.); Rocky Mountain Cancer Centers, Aurora, CO (J.M.B.); Memorial Sloan Kettering Cancer Center, Montvale, NJ (M.M.); the Department of Hematology and Rheumatology, Kindai University, Faculty of Medicine, Osaka-Sayama City (S.R.), and the National Cancer Center Hospital, Tokyo (K.I.) - both in Japan; Washington University in St. Louis, St. Louis (N.M.-S.); the Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland (W.J.); Peking University Cancer Hospital, Beijing (Y.S.); the 3rd Medical Department, Paracelsus Medical University, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, and Cancer Cluster Salzburg, Salzburg, Austria (R.G.); the Feofaniya Clinical Hospital, Kyiv, Ukraine (L.M.); Hospital San Pedro de Alcántara, Cáceres (J.M.B.-B.), and the Department of Hematology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (P.A.) - both in Spain; the Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples, Italy (A.P.); the Division of Hematology-Oncology, Department of Internal Medicine, Research Institute of Medical Science, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea (H.-J.S.); Princess Alexandra Hospital, Brisbane, QLD, Australia (G.H.); Hospital Erasto Gaertner, Curitiba, Brazil (E.M.); Taipei Veterans General Hospital, Taipei, Taiwan (J.-P.G.); Genentech, South San Francisco, CA (J.H., Y.J., C.L.); and M.D. Anderson Cancer Center, Houston (C.R.F.).",
            "From the Department of Hematology and INSERM Unité 1245, Centre Henri-Becquerel and University of Rouen, Rouen (H.T.), Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, ULR 7365 - GRITA - Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille (F.M.), CHU de Montpellier, Montpellier (C.H.), the Department of Hematology, Institut Universitaire du Cancer, Toulouse-Oncopole, Toulouse (L.O.), and the Department of Hematology, Centre Hospitalier Régional Universitaire - Besançon, Besançon (A.C.) - all in France; the Centre for Lymphoid Cancer at BC Cancer and the University of British Columbia, Vancouver (L.H.S.), the Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto (M.C.C.), and F. Hoffmann-La Roche, Mississauga, ON (M.Y.) - all in Canada; the Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and Memorial Sloan Kettering Cancer Center, New York (M.M., G.S.) - both in New York; the First Faculty of Medicine, Charles University and the General University Hospital, Prague, Czech Republic (M.T.); the Willamette Valley Cancer Institute and Research Center, the US Oncology Network, Eugene, OR (J.P.S.); Rocky Mountain Cancer Centers, Aurora, CO (J.M.B.); Memorial Sloan Kettering Cancer Center, Montvale, NJ (M.M.); the Department of Hematology and Rheumatology, Kindai University, Faculty of Medicine, Osaka-Sayama City (S.R.), and the National Cancer Center Hospital, Tokyo (K.I.) - both in Japan; Washington University in St. Louis, St. Louis (N.M.-S.); the Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland (W.J.); Peking University Cancer Hospital, Beijing (Y.S.); the 3rd Medical Department, Paracelsus Medical University, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, and Cancer Cluster Salzburg, Salzburg, Austria (R.G.); the Feofaniya Clinical Hospital, Kyiv, Ukraine (L.M.); Hospital San Pedro de Alcántara, Cáceres (J.M.B.-B.), and the Department of Hematology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (P.A.) - both in Spain; the Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples, Italy (A.P.); the Division of Hematology-Oncology, Department of Internal Medicine, Research Institute of Medical Science, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea (H.-J.S.); Princess Alexandra Hospital, Brisbane, QLD, Australia (G.H.); Hospital Erasto Gaertner, Curitiba, Brazil (E.M.); Taipei Veterans General Hospital, Taipei, Taiwan (J.-P.G.); Genentech, South San Francisco, CA (J.H., Y.J., C.L.); and M.D. Anderson Cancer Center, Houston (C.R.F.)."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "12",
                "Day": "14"
            }
        ]
    },
    {
        "ArticleTitle": "Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.",
        "AuthorList": [
            "Magdalena Klanova",
            "Laurie H Sehn",
            "Isabelle Bence-Bruckler",
            "Federica Cavallo",
            "Jie Jin",
            "Maurizio Martelli",
            "Douglas Stewart",
            "Umberto Vitolo"
        ],
        "AffiliationList": [
            "1st Department of Medicine, Charles University General Hospital, Prague, Czech Republic.",
            "Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada.",
            "The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, ON, Canada.",
            "Division of Hematology, University of Turin, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.",
            "Department of Hematology, The First Affiliated Hospital of Zheijiang University College of Medicine, Zheijiang, China.",
            "Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.",
            "Department of Oncology, Tom Baker Cancer Centre, Calgary, AB, Canada.",
            "AOU Citta' Della Salute e della Scienza, SC Ematologia, Turin, Italy."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "01",
                "Day": "07"
            }
        ]
    },
    {
        "ArticleTitle": "How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience.",
        "AuthorList": [
            "Bin-Tao Huang",
            "Qing-Chun Zeng",
            "Jessica Yu",
            "Zhen Xiao",
            "Bing-Sheng Li",
            "Chun-Lai Zhang",
            "Hong-Bo Ji"
        ],
        "AffiliationList": [
            "Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical College, 1 TongDao Avenue North, 010059, Hohhot, People's Republic of China. huangbintao1979@sina.com",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "11",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.",
        "AuthorList": [
            "Tycel Phillips",
            "Paul M Barr",
            "Steven I Park",
            "Kathryn Kolibaba",
            "Paolo F Caimi",
            "Saurabh Chhabra",
            "Edwin C Kingsley",
            "Thomas Boyd"
        ],
        "AffiliationList": [
            "University of Michigan Comprehensive Cancer Center, 1500 E. Medical Center Dr. SPC 591, Ann Arbor, MI, 48109, USA. tycelp@med.umich.edu.",
            "James P. Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY, 14642, USA.",
            "Levine Cancer Institute and Carolinas Healthcare System, 100 Medical Park Dr Ste 110, Concord, NC, 28025, USA.",
            "Northwest Cancer Specialists, P.C, 210 SE. 136th Ave, Vancouver, WA, 98684, USA.",
            "Case Western Reserve University, University Hospitals Cleveland Medical Center, 11100 Euclid Ave Ste 1, Cleveland, OH, 44106, USA.",
            "Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI, 53226, USA.",
            "Comprehensive Cancer Centers of Nevada, 3730 S. Eastern Ave, Las Vegas, NV, 89169, USA.",
            "Yakima Valley Memorial Hospital, North Star Lodge, 808 N 39 Ave, Yakima, WA, 98902, USA."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "08",
                "Day": "22"
            }
        ]
    },
    {
        "ArticleTitle": "Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the \"Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas\" (PETAL) trial.",
        "AuthorList": [
            "Andreas Hüttmann",
            "Jan Rekowski",
            "Stefan P Müller",
            "Bernd Hertenstein",
            "Christiane Franzius",
            "Rolf Mesters",
            "Matthias Weckesser",
            "Frank Kroschinsky"
        ],
        "AffiliationList": [
            "Klinik für Hämatologie, Universitätsklinikum Essen, Essen, Germany.",
            "Institut für Medizinische Informatik, Biometrie und Epidemiologie, Universität Duisburg-Essen, Essen, Germany.",
            "Klinik für Nuklearmedizin, Universitätsklinikum Essen, Essen, Germany.",
            "Medizinische Klinik I, Klinikum Bremen-Mitte, Bremen, Germany.",
            "Zentrum für moderne Diagnostik (Zemodi), Zentrum für Nuklearmedizin und PET/CT, Bremen, Germany.",
            "Medizinische Klinik A, Universitätsklinikum Münster, Münster, Germany.",
            "Klinik für Nuklearmedizin, Universitätsklinikum Münster, Münster, Germany.",
            "Medizinische Klinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Germany."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "01",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Mark Bosch",
            "Ariz Akhter",
            "Bingshu E Chen",
            "Adnan Mansoor",
            "David Lebrun",
            "David Good",
            "Michael Crump",
            "Lois Shepherd"
        ],
        "AffiliationList": [
            "University of Saskatchewan, SK, Canada.",
            "University of Calgary, AB, Canada.",
            "Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.",
            "University of Calgary, AB, Canada.",
            "Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.",
            "Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.",
            "University of Toronto, ON, Canada.",
            "Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "11",
                "Day": "02"
            }
        ]
    },
    {
        "ArticleTitle": "Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience.",
        "AuthorList": [
            "Ali Mazloom",
            "Nathan Fowler",
            "L Jeffrey Medeiros",
            "Puneeth Iyengar",
            "Patrecia Horace",
            "Bouthaina S Dabaja"
        ],
        "AffiliationList": [
            "Division of Epidemiology, The University of Texas School of Public Health, Houston, TX 77030, USA.",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "[Clinical Analysis of Autologous Cytokine-induced Killer Cells Combined with IL-2 for Treating of Elderly Patients with B-cell Malignant Lymphoma].",
        "AuthorList": [
            "Yi Wu",
            "Lin Shi",
            "Lei Feng",
            "Dian-Liang Lv"
        ],
        "AffiliationList": [
            "Department of Hematology, Traditional Chinese Medicine Hospital of Henan Province, Zhengzhou 450002, Henan Province, China.",
            "Department of Hematology, Traditional Chinese Medicine Hospital of Henan Province, Zhengzhou 450002, Henan Province, China. E-mail: slin7085@163.com.",
            "Department of Hematology, Traditional Chinese Medicine Hospital of Henan Province, Zhengzhou 450002, Henan Province, China.",
            "Department of Hematology, Traditional Chinese Medicine Hospital of Henan Province, Zhengzhou 450002, Henan Province, China."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas.",
        "AuthorList": [
            "Victor Moreno",
            "Maria Vieito",
            "Juan Manuel Sepulveda",
            "Vladimir Galvao",
            "Tatiana Hernández-Guerrero",
            "Bernard Doger",
            "Omar Saavedra",
            "Carmelo Carlo-Stella"
        ],
        "AffiliationList": [
            "START Madrid-FJD, Hospital Universitario Fundación Jimenez Diaz, Madrid, Spain. victor.moreno@startmadrid.com.",
            "Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.",
            "Hospital Universitario 12 de Octubre, Madrid, Spain.",
            "Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.",
            "START Madrid-FJD, Hospital Universitario Fundación Jimenez Diaz, Madrid, Spain.",
            "START Madrid-FJD, Hospital Universitario Fundación Jimenez Diaz, Madrid, Spain.",
            "Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.",
            "Department of Biological Sciences, Humanitas University, Rozzano, Milano, Italy."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "03",
                "Day": "13"
            }
        ]
    },
    {
        "ArticleTitle": "Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.",
        "AuthorList": [
            "T E Witzig",
            "K Tobinai",
            "L Rigacci",
            "T Ikeda",
            "A Vanazzi",
            "M Hino",
            "Y Shi",
            "J Mayer"
        ],
        "AffiliationList": [
            "MayoClinic, Rochester, USA. Electronic address: witzig.thomas@mayo.edu.",
            "Department of Hematology, National Cancer Centre Hospital, Tokyo, Japan.",
            "Hematology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.",
            "Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Centre, Shizuoka, Japan.",
            "Division of Clinical Hemato-Oncology, Istituto Europeo di Oncologia, Milan, Italy.",
            "Department of Clinical Hematology and Diagnostics, Osaka University Graduate School of Medicine, Osaka, Japan.",
            "Department of Medical Oncology, National Cancer Centre, Beijing; Cancer Hospital, Chinese Academy of Medical Sciences, Beijing; Peking Union Medical College, Beijing, China.",
            "Department of Internal Medicine, University Hospital Brno, Brno, Czech Republic."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404).",
        "AuthorList": [
            "Lode J Swinnen",
            "Hailun Li",
            "Andrew Quon",
            "Randy Gascoyne",
            "Fangxin Hong",
            "Erik A Ranheim",
            "Thomas M Habermann",
            "Brad S Kahl"
        ],
        "AffiliationList": [
            "Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.",
            "Dana Farber Cancer Institute, Boston, MA, USA.",
            "Stanford University Medical Center, Stanford, CA, USA.",
            "British Columbia Cancer Agency, Centre for Lymphoid Cancer, Vancouver, BC, Canada.",
            "Dana Farber Cancer Institute, Boston, MA, USA.",
            "University of Wisconsin, Madison, WI, USA.",
            "Mayo Clinic, Rochester, MN, USA.",
            "University of Wisconsin, Madison, WI, USA."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "03",
                "Day": "30"
            }
        ]
    },
    {
        "ArticleTitle": "Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.",
        "AuthorList": [
            "Christopher R Flowers",
            "Luciano J Costa",
            "Marcelo C Pasquini",
            "Jennifer Le-Rademacher",
            "Michael Lill",
            "Tsiporah B Shore",
            "William Vaughan",
            "Michael Craig"
        ],
        "AffiliationList": [
            "Department of Hematology and Medical Oncology, Winship Cancer Institute, Division of BMT, Emory University, Atlanta, Georgia.",
            "Medical University of South Carolina, Charleston, South Carolina.",
            "Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.",
            "Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.",
            "Cedars-Sinai Medical Center, Los Angeles, California.",
            "Weill Cornell Medical Center Hematology/Oncology, The New York Hospital, New York, New York.",
            "Bone Marrow Transplantation Program, University of Alabaman at Birmingham, Birmingham, Alabama.",
            "West Virginia University, Health Science Center, Morgantown, West Virginia."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "03",
                "Day": "31"
            }
        ]
    },
    {
        "ArticleTitle": "Efficacy of R-GCVP in patients with late relapse of diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Faouzi Djebbari",
            "Joseph A Browning",
            "Louise Stanton",
            "Stephen Booth",
            "Catherine Hildyard",
            "John Willan",
            "Jenny Bosworth",
            "Sona M Vora"
        ],
        "AffiliationList": [
            "Department of Pharmacy, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.",
            "Department of Haematology, Wycombe General Hospital, High Wycombe, UK.",
            "Southampton Clinical Trials Unit, University of Southampton, Southampton General Hospital, Southampton, UK.",
            "Department of Haematology, Royal Berkshire Hospital NHS Foundation Trust, Reading, UK.",
            "Department of Haematology, Milton Keynes Hospital, Milton Keynes, UK.",
            "Department of Haematology, Wexham Park Hospital, Slough, UK.",
            "Department of Haematology, Frimley Park Hospital, Frimleyv, UK.",
            "Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "06",
                "Day": "20"
            }
        ]
    },
    {
        "ArticleTitle": "Bearing 19q13 aberration predicts poor prognosis in non-germinal centre type of CD5<sup>+</sup> DLBCL.",
        "AuthorList": [
            "Yuko Mishima",
            "Yasuhito Terui",
            "Masahiro Yokoyama",
            "Noriko Nishimura",
            "Kyoko Ueda",
            "Yoshiharu Kusano",
            "Hirofumi Yamauchi",
            "Norihito Inoue"
        ],
        "AffiliationList": [
            "Department of Haematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.",
            "Department of Haematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.",
            "Department of Haematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.",
            "Department of Haematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.",
            "Department of Haematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.",
            "Department of Haematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.",
            "Department of Haematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.",
            "Department of Haematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "10",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.",
        "AuthorList": [
            "Luke Coyle",
            "Nicholas J Morley",
            "Alessandro Rambaldi",
            "Kylie D Mason",
            "Gregor Verhoef",
            "Caroline L Furness",
            "Alicia Zhang",
            "A Scott Jung"
        ],
        "AffiliationList": [
            "Department of Haematology, Royal North Shore Hospital, St. Leonards, Australia.",
            "Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.",
            "Department of Oncology-Hematology, University of Milan and Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.",
            "Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia.",
            "Department of Hematology, UZ Leuven, University Hospitals Leuven, Leuven, Belgium.",
            "Department of Paediatric Haemato-Oncology, Royal Marsden NHS Foundation Trust, London, UK.",
            "Global Biostatistical Science, Amgen Inc, Thousand Oaks, CA, USA.",
            "Global Development, Amgen Inc, Thousand Oaks, CA, USA."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "06",
                "Day": "16"
            }
        ]
    },
    {
        "ArticleTitle": "Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202).",
        "AuthorList": [
            "Morton Coleman",
            "David Belada",
            "René-Olivier Casasnovas",
            "Rémy Gressin",
            "Hui-Peng Lee",
            "Amitkumar Mehta",
            "Javier Munoz",
            "Gregor Verhoef"
        ],
        "AffiliationList": [
            "Clinical Research Alliance/Weill Cornell Medicine, New York, NY, USA.",
            "4th Department of Internal Medicine - Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.",
            "University Hospital F. Mitterrand and Inserm UMR 1231, Dijon, France.",
            "Department of Oncohaematology, University Hospital Grenoble-Alpes, Grenoble, France.",
            "Flinders Medical Centre, Bedford Park, SA, Australia.",
            "UAB School of Medicine, Birmingham, AL, USA.",
            "Banner MD Anderson Cancer Center, Gilbert, AZ, USA.",
            "Department of Hematology, University Hospitals Leuven, Leuven, Belgium."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "11",
                "Day": "03"
            }
        ]
    },
    {
        "ArticleTitle": "Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.",
        "AuthorList": [
            "David Belada",
            "Pencho Georgiev",
            "Shaker Dakhil",
            "Lowell F Inhorn",
            "David Andorsky",
            "J Thaddeus Beck",
            "Donald Quick",
            "Ruth Pettengell"
        ],
        "AffiliationList": [
            "4th Department of Internal Medicine - Hematology, Charles University Hospital & Faculty of Medicine, Hradec Králové, Czech Republic.",
            "UMHAT \"Sveti Georgi\", Plovdiv, Clinical Haematology Clinic, Plovdiv, Bulgaria.",
            "Cancer Center of Kansas, Wichita, KS, USA.",
            "Blue Ridge Cancer Care, Roanoke, VA, USA.",
            "Rocky Mountain Cancer Center, Boulder, CO, USA.",
            "Highlands Oncology Group, Fayetteville, AR, USA.",
            "Joe Arrington Cancer Research & Treatment Center, Lubbock, TX, USA.",
            "St George's Healthcare NHS Trust, Tooting, London, UK."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "04",
                "Day": "20"
            }
        ]
    },
    {
        "ArticleTitle": "Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era.",
        "AuthorList": [
            "Christopher D Fletcher",
            "Brad S Kahl"
        ],
        "AffiliationList": [
            "UW Carbone Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health , Madison, WI , USA.",
            "null"
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "02",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.",
        "AuthorList": [
            "Reem Karmali",
            "Melissa L Larson",
            "James E Wooldridge",
            "Stephanie A Gregory",
            "Teresa O'Brien",
            "Jamile M Shammo",
            "Katherine Bueschel",
            "Parameswaran Venugopal"
        ],
        "AffiliationList": [
            "Rush University Medical Center, Department of Hematology/Oncology, Chicago, IL 60612, USA. reem_karmali@rush.edu",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2011",
                "Month": "06",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "Both chronic HBV infection and naturally acquired HBV immunity confer increased risks of B-cell non-Hodgkin lymphoma.",
        "AuthorList": [
            "Xi Zhou",
            "Huaxiong Pan",
            "Peng Yang",
            "Pian Ye",
            "Haiyan Cao",
            "Hao Zhou"
        ],
        "AffiliationList": [
            "Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.",
            "Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.",
            "Department of General Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.",
            "Department of Hepatology and Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.",
            "Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.",
            "Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. zhouhao@hust.edu.cn."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "05",
                "Day": "22"
            }
        ]
    },
    {
        "ArticleTitle": "Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol.",
        "AuthorList": [
            "Pierre Morel",
            "Jean-Nicolas Munck",
            "Bertrand Coiffier",
            "Christian Gisselbrecht",
            "Dana Ranta",
            "Andre Bosly",
            "Hervé Tilly",
            "Bruno Quesnel"
        ],
        "AffiliationList": [
            "Service d'Hématologie Clinique, Centre Hospitalier Schaffner, Lens, France. pmorel@ch-lens.fr",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP.",
        "AuthorList": [
            "Takeshi Yoshikawa",
            "Takeshi Hara",
            "Hisashi Tsurumi",
            "Naoe Goto",
            "Masato Hoshi",
            "Junichi Kitagawa",
            "Nobuhiro Kanemura",
            "Senji Kasahara"
        ],
        "AffiliationList": [
            "First Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2009",
                "Month": "11",
                "Day": "07"
            }
        ]
    },
    {
        "ArticleTitle": "A phase two study of high dose blinatumomab in Richter's syndrome.",
        "AuthorList": [
            "Philip A Thompson",
            "Xianli Jiang",
            "Pinaki Banerjee",
            "Rafet Basar",
            "Naveen Garg",
            "Ken Chen",
            "Mecit Kaplan",
            "Vandana Nandivada"
        ],
        "AffiliationList": [
            "Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. Pathompson2@mdanderson.org.",
            "Bioinformatics and Computational Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.",
            "Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.",
            "Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.",
            "Abdominal Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.",
            "Bioinformatics and Computational Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.",
            "Stem Cell Transplantation Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.",
            "Stem Cell Transplantation Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "08",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis.",
        "AuthorList": [
            "Baoping Guo",
            "Xiaohong Tan",
            "Qing Ke",
            "Hong Cen"
        ],
        "AffiliationList": [
            "Department of Chemotherapy, Guangxi Cancer Hospital and of Guangxi Medical University Affiliated Cancer Hospital, Nanning, Guangxi, People's Republic of China.",
            "Department of Chemotherapy, Guangxi Cancer Hospital and of Guangxi Medical University Affiliated Cancer Hospital, Nanning, Guangxi, People's Republic of China.",
            "Department of Chemotherapy, Guangxi Cancer Hospital and of Guangxi Medical University Affiliated Cancer Hospital, Nanning, Guangxi, People's Republic of China.",
            "Department of Chemotherapy, Guangxi Cancer Hospital and of Guangxi Medical University Affiliated Cancer Hospital, Nanning, Guangxi, People's Republic of China."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "01",
                "Day": "09"
            }
        ]
    },
    {
        "ArticleTitle": "Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.",
        "AuthorList": [
            "Kevin R Kelly",
            "Jonathan W Friedberg",
            "Steven I Park",
            "Kevin McDonagh",
            "John Hayslip",
            "Daniel Persky",
            "Jia Ruan",
            "Soham Puvvada"
        ],
        "AffiliationList": [
            "USC Norris Comprehensive Cancer Center, Los Angeles, California (previously University of Texas Health Science Center at San Antonio, San Antonio, Texas). kevin.kelly@med.usc.edu.",
            "University of Rochester Medical Center, Rochester, New York.",
            "Levine Cancer Institute and Carolinas Healthcare System, Charlotte, North Carolina.",
            "Vanderbilt University, Nashville, Tennessee (previously University of Kentucky Markey Cancer Center, Lexington, Kentucky).",
            "University of Kentucky Markey Cancer Center, Lexington, Kentucky.",
            "University of Arizona, Tucson, Arizona.",
            "Weill Cornell Medical College, New York, New York.",
            "University of Arizona, Tucson, Arizona."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "08",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.",
        "AuthorList": [
            "Catherine Thieblemont",
            "Susannah Howlett",
            "René-Olivier Casasnovas",
            "Nicolas Mounier",
            "Aurore Perrot",
            "Franck Morschhauser",
            "Christophe Fruchart",
            "Nicolas Daguindau"
        ],
        "AffiliationList": [
            "Hemato-Oncology, APHP, Hôpital Saint-Louis, Paris, France.",
            "Celgene Corporation, Summit, NJ, USA.",
            "Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Dijon and INSERM UMR1231, Dijon, France.",
            "Hématologie, Centre Hospitalier Universitaire de Nice - Hôpital de l'Archet, Nice, France.",
            "Service d'Hématologie, Centre Hospitalier Universitaire de Nancy, Nancy, France.",
            "Institute of Hematology-Transfusion, Centre Hospitalier Universitaire Régional de Lille, Lille, France.",
            "Service d'Hématologie, Institut d'Hématologie de Basse-Normandie, Centre Hospitalier Universitaire de Caen, Caen, France.",
            "Service d'Hématologie Clinique, Centre Hospitalier Annecy Genevois, Annecy, France."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "11",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "R-CHOP-14 versus R-CHOP-14/CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908 study.",
        "AuthorList": [
            "Yoshitoyo Kagami",
            "Kazuhito Yamamoto",
            "Taro Shibata",
            "Kensei Tobinai",
            "Yoshitaka Imaizumi",
            "Toshiki Uchida",
            "Kazuyuki Shimada",
            "Koichiro Minauchi"
        ],
        "AffiliationList": [
            "Department of Hematology, Toyota Kosei Hospital, Toyota, Japan.",
            "Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.",
            "JCOG Data Center/Operations Office, National Cancer Center, Tokyo, Japan.",
            "Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.",
            "Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.",
            "Department of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan.",
            "Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.",
            "Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "09",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "TP53 mutation and survival in aggressive B cell lymphoma.",
        "AuthorList": [
            "Thorsten Zenz",
            "Markus Kreuz",
            "Maxi Fuge",
            "Wolfram Klapper",
            "Heike Horn",
            "Annette M Staiger",
            "Doris Winter",
            "Hanne Helfrich"
        ],
        "AffiliationList": [
            "Molecular Therapy in Haematology and Oncology and Department of Translational Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (dkfz), Heidelberg, Germany.",
            "Institute for Medical Informatics, Statistics and Epidemiology, Universität Leipzig, Leipzig, Germany.",
            "Dept. of Internal Medicine III, University of Ulm, Ulm, Germany.",
            "Institute of Pathology, Hematopathology Section and Lymph Node Registry, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.",
            "Department of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, and University of Tübingen, Stuttgart, Germany.",
            "Department of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, and University of Tübingen, Stuttgart, Germany.",
            "Dept. of Internal Medicine III, University of Ulm, Ulm, Germany.",
            "Dept. of Internal Medicine III, University of Ulm, Ulm, Germany."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "06",
                "Day": "26"
            }
        ]
    },
    {
        "ArticleTitle": "A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†.",
        "AuthorList": [
            "Tony Reiman",
            "Kerry J Savage",
            "Michael Crump",
            "Matthew C Cheung",
            "David MacDonald",
            "Rena Buckstein",
            "Stephen Couban",
            "Eugenia Piliotis"
        ],
        "AffiliationList": [
            "a Department of oncology, Saint John Regional Hospital , Dalhousie University, and University of New Brunswick , Saint John , Canada.",
            "b BC Cancer Agency , Vancouver , Canada.",
            "c Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre , Toronto , Canada.",
            "d Division of Hematology, Sunnybrook Health Services Centre , Toronto , Canada.",
            "e Department of Hematology, QEII Health Sciences Centre , Halifax , Canada.",
            "d Division of Hematology, Sunnybrook Health Services Centre , Toronto , Canada.",
            "e Department of Hematology, QEII Health Sciences Centre , Halifax , Canada.",
            "d Division of Hematology, Sunnybrook Health Services Centre , Toronto , Canada."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "10",
                "Day": "10"
            }
        ]
    },
    {
        "ArticleTitle": "Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.",
        "AuthorList": [
            "Natalia Palazón-Carrión",
            "Alejandro Martín García-Sancho",
            "Esteban Nogales-Fernández",
            "Carlos Jiménez-Cortegana",
            "Fernando Carnicero-González",
            "Eduardo Ríos-Herranz",
            "Fátima de la Cruz-Vicente",
            "Guillermo Rodríguez-García"
        ],
        "AffiliationList": [
            "Department of Clinical Oncology, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain.",
            "Department of Hematology, Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain.",
            "Department of Clinical Oncology, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain.",
            "Department of Medical Biochemistry and Molecular Biology and Immunology, Medical School, Hospital Universitario Virgen Macarena, Seville, Spain.",
            "Department of Hematology, Hospital San Pedro de Alcántara de Cáceres, Cáceres, Spain.",
            "Department of Hematology, Hospital Universitario de Valme, Seville, Spain.",
            "Department of Hematology, Hospital Universitario Virgen del Rocío, Seville, Spain.",
            "Department of Hematology, Hospital Universitario Virgen del Rocío, Seville, Spain."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.",
        "AuthorList": [
            "Michael Pfreundschuh",
            "Anthony D Ho",
            "Eva Cavallin-Stahl",
            "Max Wolf",
            "Ruth Pettengell",
            "Ingrid Vasova",
            "Andrew Belch",
            "Jan Walewski"
        ],
        "AffiliationList": [
            "Saarland University Medical School, Homburg, Germany.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2008",
                "Month": "04",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL.",
        "AuthorList": [
            "Nitin Jain",
            "Jayastu Senapati",
            "Beenu Thakral",
            "Alessandra Ferrajoli",
            "Philip Thompson",
            "Jan Burger",
            "Sreyashi Basu",
            "Tapan Kadia"
        ],
        "AffiliationList": [
            "Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies.",
        "AuthorList": [
            "Wael Harb",
            "Nehal J Lakhani",
            "Richard Messmann",
            "Barbara Klencke",
            "Ayad M Al-Katib"
        ],
        "AffiliationList": [
            "Horizon Oncology Center, Lafayette, IA.",
            "Mercy Health St. Mary's, Grand Rapids, MI.",
            "ProNAi Therapeutics, Inc., Vancouver, BC, Canada.",
            "Sierra Oncology, Inc. (formerly ProNAi Therapeutics, Inc.), Vancouver, BC, Canada. Electronic address: bklencke@sierraoncology.com.",
            "Wayne State University, Detroit, MI."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "07",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.",
        "AuthorList": [
            "Daniel J Landsburg",
            "Stefan K Barta",
            "Radhakrishnan Ramchandren",
            "Connie Batlevi",
            "Swaminathan Iyer",
            "Kevin Kelly",
            "Ivana N Micallef",
            "Sonali M Smith"
        ],
        "AffiliationList": [
            "University of Pennsylvania, Philadelphia, PA, USA.",
            "University of Pennsylvania, Philadelphia, PA, USA.",
            "University of Tennessee Knoxville, Knoxville, TN, USA.",
            "Memorial Sloan Kettering Cancer Center, New York, NY, USA.",
            "MD Anderson Cancer Center, Houston, TX, USA.",
            "University of Southern California, Los Angeles, CA, USA.",
            "Mayo Clinic, Rochester, MN, USA.",
            "University of Chicago, Chicago, IL, USA."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "08",
                "Day": "02"
            }
        ]
    },
    {
        "ArticleTitle": "Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.",
        "AuthorList": [
            "Kathryn M Cappell",
            "Richard M Sherry",
            "James C Yang",
            "Stephanie L Goff",
            "Danielle A Vanasse",
            "Lori McIntyre",
            "Steven A Rosenberg",
            "James N Kochenderfer"
        ],
        "AffiliationList": [
            "National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute Medical Oncology/Hematology Fellowship Program, Bethesda, MD.",
            "Surgery Branch, Center for Cancer Research, National Cancer Istitute, NIH, Bethesda, MD.",
            "Surgery Branch, Center for Cancer Research, National Cancer Istitute, NIH, Bethesda, MD.",
            "Surgery Branch, Center for Cancer Research, National Cancer Istitute, NIH, Bethesda, MD.",
            "Surgery Branch, Center for Cancer Research, National Cancer Istitute, NIH, Bethesda, MD.",
            "Surgery Branch, Center for Cancer Research, National Cancer Istitute, NIH, Bethesda, MD.",
            "Surgery Branch, Center for Cancer Research, National Cancer Istitute, NIH, Bethesda, MD.",
            "Surgery Branch, Center for Cancer Research, National Cancer Istitute, NIH, Bethesda, MD."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "10",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Franck Morschhauser",
            "Pierre Feugier",
            "Ian W Flinn",
            "Robin Gasiorowski",
            "Richard Greil",
            "Árpád Illés",
            "Nathalie A Johnson",
            "Jean-François Larouche"
        ],
        "AffiliationList": [
            "Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, Groupe de Recherche sur les Formes Injectables et les Technologies Associées (ULR 7365-GRITA), Lille, France.",
            "CHU de Nancy, Université de Lorraine, Vandoeuvre lès Nancy, France.",
            "Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN.",
            "Concord Hospital, University of Sydney, Sydney, NSW, Australia.",
            "Paracelcus Medical University Salzburg, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, Salzburg, Austria.",
            "Department of Hematology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.",
            "Jewish General Hospital, Montreal, QC, Canada.",
            "CHU de Québec, Hôpital de l'Enfant-Jésus, Quebec City, QC, Canada."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Yasuhito Terui",
            "Shinya Rai",
            "Koji Izutsu",
            "Motoko Yamaguchi",
            "Jun Takizawa",
            "Junya Kuroda",
            "Takayuki Ishikawa",
            "Koji Kato"
        ],
        "AffiliationList": [
            "Department of Hematology and Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.",
            "Department of Hematology and Rheumatology, Kindai University Hospital, Osaka, Japan.",
            "Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.",
            "Department of Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Japan.",
            "Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.",
            "Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.",
            "Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.",
            "Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "06",
                "Day": "04"
            }
        ]
    },
    {
        "ArticleTitle": "Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study.",
        "AuthorList": [
            "Amal Abu Sabaa",
            "Charlott Mörth",
            "Sverker Hasselblom",
            "Gustaf Hedström",
            "Max Flogegård",
            "Mimmi Stern",
            "Per-Ola Andersson",
            "Ingrid Glimelius"
        ],
        "AffiliationList": [
            "Centre for Research and Development, Uppsala University/Region Gavleborg, Sweden.",
            "Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology, Uppsala University, Sweden.",
            "Department of Research, Development and Education, Region Halland, Halmstad, Sweden.",
            "Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology, Uppsala University, Sweden.",
            "Department of Internal Medicine, Falun General Hospital, Falun, Sweden.",
            "Department of Hematology, South Alvsborg Hospital, Boras and Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.",
            "Department of Hematology, South Alvsborg Hospital, Boras and Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.",
            "Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology, Uppsala University, Sweden."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "05",
                "Day": "05"
            }
        ]
    },
    {
        "ArticleTitle": "Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.",
        "AuthorList": [
            "Pierre Sesques",
            "Emmanuelle Ferrant",
            "Violaine Safar",
            "Florent Wallet",
            "Jérémie Tordo",
            "Anthony Dhomps",
            "Lionel Karlin",
            "Gabriel Brisou"
        ],
        "AffiliationList": [
            "Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.",
            "Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.",
            "Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.",
            "Department of Critical Care, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.",
            "Department of Nuclear Medicine, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.",
            "Department of Nuclear Medicine, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.",
            "Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.",
            "Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "08",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.",
        "AuthorList": [
            "Julia Wendler",
            "Christopher P Fox",
            "Elke Valk",
            "Cora Steinheber",
            "Heidi Fricker",
            "Lisa K Isbell",
            "Simone Neumaier",
            "Jessica Okosun"
        ],
        "AffiliationList": [
            "Clinic of Hematology, Oncology and Palliative Care, Klinikum Stuttgart, Kriegsbergstraße 60, 70174, Stuttgart, Germany.",
            "Russell Centre for Clinical Haematology, Nottingham University Hospitals NHS Trust, City Campus, Hucknall Road, Nottingham, NG5 1PB, UK.",
            "Stuttgart Cancer Center - Tumorzentrum Eva Mayer-Stihl, Klinikum Stuttgart, Kriegsbergstraße 60, 70174, Stuttgart, Germany.",
            "Stuttgart Cancer Center - Tumorzentrum Eva Mayer-Stihl, Klinikum Stuttgart, Kriegsbergstraße 60, 70174, Stuttgart, Germany.",
            "Department Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Straße 55, 79106, Freiburg, Germany.",
            "Department Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Straße 55, 79106, Freiburg, Germany.",
            "Stuttgart Cancer Center - Tumorzentrum Eva Mayer-Stihl, Klinikum Stuttgart, Kriegsbergstraße 60, 70174, Stuttgart, Germany.",
            "Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "09",
                "Day": "10"
            }
        ]
    },
    {
        "ArticleTitle": "Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma.",
        "AuthorList": [
            "V Moreno",
            "J M Sepulveda",
            "M Vieito",
            "T Hernández-Guerrero",
            "B Doger",
            "O Saavedra",
            "O Ferrero",
            "R Sarmiento"
        ],
        "AffiliationList": [
            "START Madrid-FJD, Hospital Fundación Jimenez Diaz, Madrid, Spain. Electronic address: victor.moreno@startmadrid.com.",
            "Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.",
            "Department of Gene Expression and Cancer, Vall d'Hebron Institute of Oncology, Barcelona, Spain.",
            "START Madrid-FJD, Hospital Fundación Jimenez Diaz, Madrid, Spain.",
            "START Madrid-FJD, Hospital Fundación Jimenez Diaz, Madrid, Spain.",
            "Department of Gene Expression and Cancer, Vall d'Hebron Institute of Oncology, Barcelona, Spain.",
            "START Madrid-FJD, Hospital Fundación Jimenez Diaz, Madrid, Spain.",
            "Celgene Institute for Translational Research Europe, a Bristol Myers Squibb Company, Seville, Spain."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "03",
                "Day": "30"
            }
        ]
    },
    {
        "ArticleTitle": "Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis.",
        "AuthorList": [
            "Christina Howlett",
            "Sonya J Snedecor",
            "Daniel J Landsburg",
            "Jakub Svoboda",
            "Elise A Chong",
            "Stephen J Schuster",
            "Sunita Dwivedy Nasta",
            "Tatyana Feldman"
        ],
        "AffiliationList": [
            "Department of Pharmacy and Clinical Services, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.",
            "Pharmerit International, Bethesda, MD, USA.",
            "Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.",
            "Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.",
            "Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.",
            "Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.",
            "Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.",
            "John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA."
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "04",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter's syndrome.",
        "AuthorList": [
            "Toby A Eyre",
            "Ruth Clifford",
            "Corran Roberts",
            "Lucy Boyle",
            "Anne Francis",
            "Anna Schuh",
            "Susan J Dutton"
        ],
        "AffiliationList": [
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2015",
                "Month": "02",
                "Day": "13"
            }
        ]
    },
    {
        "ArticleTitle": "miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model.",
        "AuthorList": [
            "Sukhinder K Sandhu",
            "Stefano Volinia",
            "Stefan Costinean",
            "Marco Galasso",
            "Reid Neinast",
            "Ramasamy Santhanam",
            "Mark R Parthun",
            "Danilo Perrotti"
        ],
        "AffiliationList": [
            "Department of Molecular Virology, Ohio State University Medical Center, Columbus, OH 43210, USA.",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "11",
                "Day": "19"
            }
        ]
    },
    {
        "ArticleTitle": "A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features.",
        "AuthorList": [
            "Clémentine Sarkozy",
            "Franck Morschhauser",
            "Sydney Dubois",
            "Thierry Molina",
            "Jean Marie Michot",
            "Peggy Cullières-Dartigues",
            "Benjamin Suttle",
            "Lionel Karlin"
        ],
        "AffiliationList": [
            "INSERM 1052, Charles Mérieux Lyon-1 Faculty, Claude Bernard University, Lyon, France. csarkozy@bccrc.ca.",
            "Department of Hematology, U1245 Centre Hospitalier RU de Lille, Lille, France.",
            "Department of Hematology, U918 Centre Henri Becquerel, Rouen, France.",
            "Department of Pathology, Necker Enfants Malades Hospital, Université Paris, APHP, Paris, France.",
            "Department of Hematology, Gustave Roussy, Université Paris-Saclay, INSERM U1170, Villejuif, France.",
            "Department of Pathology, Gustave Roussy, Université Paris-Saclay, INSERM U1170, Villejuif, France.",
            "qPharmetra, Raleigh, Durham, North Carolina.",
            "Department of Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre Bénite cedex, France."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "03",
                "Day": "02"
            }
        ]
    },
    {
        "ArticleTitle": "Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance.",
        "AuthorList": [
            "Joel C Wight",
            "Mimi Yue",
            "Colm Keane",
            "Anna Johnston",
            "Kim Linton",
            "Collin Chin",
            "Shin Hnin Wai",
            "Dipti Talaulikar"
        ],
        "AffiliationList": [
            "Austin Health, Heidelberg, Victoria, Australia.",
            "Princess Alexandra Hospital, Brisbane, Queensland, Australia.",
            "Princess Alexandra Hospital, Brisbane, Queensland, Australia.",
            "The Christie NHS Foundation Trust, Manchester, UK.",
            "The Christie NHS Foundation Trust, Manchester, UK.",
            "Sir Charles Gardiner Hospital, Perth, Western Australia, Australia.",
            "Monash Health, Clayton, Victoria, Australia.",
            "Canberra Hospital, Canberra, Australian Capital Territory, Australia."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "06",
                "Day": "24"
            }
        ]
    },
    {
        "ArticleTitle": "Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.",
        "AuthorList": [
            "Tycel J Phillips",
            "Andres Forero-Torres",
            "Taimur Sher",
            "Catherine S Diefenbach",
            "Patrick Johnston",
            "Moshe Talpaz",
            "Jennifer Pulini",
            "Li Zhou"
        ],
        "AffiliationList": [
            "Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI.",
            "Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL.",
            "Mayo Clinic, Jacksonville, FL.",
            "Perlmutter Cancer Center, New York University School of Medicine, New York, NY.",
            "Mayo Clinic, Rochester, MN.",
            "Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI.",
            "Incyte Corporation, Wilmington, DE.",
            "Incyte Corporation, Wilmington, DE."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "04",
                "Day": "25"
            }
        ]
    },
    {
        "ArticleTitle": "Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Vikram Gota",
            "Ashwin Karanam",
            "Sanhita Rath",
            "Akanksha Yadav",
            "Prashant Tembhare",
            "P Subramanian",
            "Manju Sengar",
            "Reena Nair"
        ],
        "AffiliationList": [
            "Department of Clinical Pharmacology, ACTREC, Tata Memorial Centre, Navi Mumbai, 410210, India. vgota76@gmail.com.",
            "Department of Clinical Pharmacology, ACTREC, Tata Memorial Centre, Navi Mumbai, 410210, India.",
            "Department of Clinical Pharmacology, ACTREC, Tata Memorial Centre, Navi Mumbai, 410210, India.",
            "Department of Clinical Pharmacology, ACTREC, Tata Memorial Centre, Navi Mumbai, 410210, India.",
            "Department of Pathology, Tata Memorial Hospital, Mumbai, 400012, India.",
            "Department of Pathology, Tata Memorial Hospital, Mumbai, 400012, India.",
            "Department of Medical Oncology, Tata Memorial Hospital, Mumbai, 400012, India.",
            "Department of Medical Oncology, Tata Memorial Hospital, Mumbai, 400012, India."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "06",
                "Day": "21"
            }
        ]
    },
    {
        "ArticleTitle": "Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study.",
        "AuthorList": [
            "Yongxian Hu",
            "Yali Zhou",
            "Mingming Zhang",
            "Houli Zhao",
            "Guoqing Wei",
            "Wengang Ge",
            "Qu Cui",
            "Qitian Mu"
        ],
        "AffiliationList": [
            "Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. 1313016@zju.edu.cn.",
            "Nanjing Bioheng Biotech Co., Ltd, Nanjing, Jiangsu, China.",
            "Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.",
            "Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.",
            "Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.",
            "Nanjing Bioheng Biotech Co., Ltd, Nanjing, Jiangsu, China.",
            "Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.",
            "Laboratory of Stem Cell Transplantation, Ningbo First Hospital, Ningbo, Zhejiang, China."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "09",
                "Day": "23"
            }
        ]
    },
    {
        "ArticleTitle": "Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.",
        "AuthorList": [
            "Bonnie K Harrington",
            "Heather L Gardner",
            "Raquel Izumi",
            "Ahmed Hamdy",
            "Wayne Rothbaum",
            "Kevin R Coombes",
            "Todd Covey",
            "Allard Kaptein"
        ],
        "AffiliationList": [
            "Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, United States of America.",
            "Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, United States of America.",
            "Acerta Pharma BV, Oss, Netherlands.",
            "Acerta Pharma BV, Oss, Netherlands.",
            "Acerta Pharma BV, Oss, Netherlands.",
            "Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, United States of America.",
            "Acerta Pharma BV, Oss, Netherlands.",
            "Acerta Pharma BV, Oss, Netherlands."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "07",
                "Day": "19"
            }
        ]
    },
    {
        "ArticleTitle": "Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.",
        "AuthorList": [
            "Johannes Duell",
            "Kami J Maddocks",
            "Eva González-Barca",
            "Wojciech Jurczak",
            "Anna Marina Liberati",
            "Sven De Vos",
            "Zsolt Nagy",
            "Aleš Obr"
        ],
        "AffiliationList": [
            "Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg, Germany.",
            "Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH, USA.",
            "Department of Hematology, Institut Catalá d'Oncologia (ICO), Hospital Duran i Reynals, Universitat de Barcelona, Barcelona, Spain.",
            "Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland.",
            "Università degli Studi di Perugia, Azienda Ospedaliera Santa Maria di Terni, Terni, Italy.",
            "Department of Medicine, Ronald Reagan UCLA Medical Center, Santa Monica, CA, USA.",
            "1st Department of Internal Medicine, Semmelweis University, Budapest, Hungary.",
            "Department of Hemato-Oncology, Palacký University and University Hospital, Olomouc, Czech Republic."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "09",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.",
        "AuthorList": [
            "Wataru Munakata",
            "Yukari Shirasugi",
            "Kensei Tobinai",
            "Makoto Onizuka",
            "Shinichi Makita",
            "Rikio Suzuki",
            "Dai Maruyama",
            "Hidetsugu Kawai"
        ],
        "AffiliationList": [
            "Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.",
            "Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.",
            "Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.",
            "Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.",
            "Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.",
            "Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.",
            "Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.",
            "Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "02",
                "Day": "15"
            }
        ]
    },
    {
        "ArticleTitle": "Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.",
        "AuthorList": [
            "Greg P Coffey",
            "Jiajia Feng",
            "Andreas Betz",
            "Anjali Pandey",
            "Matt Birrell",
            "Janet M Leeds",
            "Kenneth Der",
            "Sabah Kadri"
        ],
        "AffiliationList": [
            "Biology and Pharmacology, Portola Pharmaceuticals, Inc., South San Francisco, California. gcoffey@portola.com.",
            "Research and Development, Portola Pharmaceuticals, Inc., South San Francisco, California.",
            "Research and Development, Portola Pharmaceuticals, Inc., South San Francisco, California.",
            "Medicinal Chemistry and Chemical Development, Portola Pharmaceuticals, Inc., South San Francisco, California.",
            "Corporate Development, Portola Pharmaceuticals, Inc., South San Francisco, California.",
            "Drug Metabolism and Pharmacokinetics, Portola Pharmaceuticals, Inc., South San Francisco, California.",
            "Pharmacokinetics, Portola Pharmaceuticals, Inc., South San Francisco, California.",
            "Department of Pathology, University of Chicago, Chicago, Illinois."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "10",
                "Day": "17"
            }
        ]
    },
    {
        "ArticleTitle": "<sup>18</sup>F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study.",
        "AuthorList": [
            "Coreline N Burggraaff",
            "Jakoba J Eertink",
            "Pieternella J Lugtenburg",
            "Otto S Hoekstra",
            "Anne I J Arens",
            "Bart de Keizer",
            "Martijn W Heymans",
            "Bronno van der Holt"
        ],
        "AffiliationList": [
            "Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.",
            "Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.",
            "Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.",
            "Department of Radiology and Nuclear Medicine, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.",
            "Department of Radiology, Nuclear Medicine, and Anatomy, Radboud University Medical Center, Nijmegen, The Netherlands.",
            "Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.",
            "Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; and.",
            "Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "10",
                "Day": "21"
            }
        ]
    },
    {
        "ArticleTitle": "Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma.",
        "AuthorList": [
            "Yutaka Tsutsumi",
            "Chie Nakayama",
            "Koki Kamada",
            "Ryo Kikuchi",
            "Daiki Kudo",
            "Shinichi Ito",
            "Satomi Matsuoka",
            "Souichi Shiratori"
        ],
        "AffiliationList": [
            "Department of Hematology, Hakodate Municipal Hospital 1-10-1, Minato-Cho, Hakodate, 041-8680, Japan. yutsutsu@shore.ocn.ne.jp.",
            "Department of Hematology, Hakodate Municipal Hospital 1-10-1, Minato-Cho, Hakodate, 041-8680, Japan.",
            "Department of Hematology, Hakodate Municipal Hospital 1-10-1, Minato-Cho, Hakodate, 041-8680, Japan.",
            "Department of Hematology, Hakodate Municipal Hospital 1-10-1, Minato-Cho, Hakodate, 041-8680, Japan.",
            "Department of Gastroenterology, Hakodate Municipal Hospital, Hakodate, Japan.",
            "Department of Hematology, Hakodate Municipal Hospital 1-10-1, Minato-Cho, Hakodate, 041-8680, Japan.",
            "Department of Hematology, Hakodate Municipal Hospital 1-10-1, Minato-Cho, Hakodate, 041-8680, Japan.",
            "Department of Hematology, Hokkaido Graduate School of Medicine, Sapporo, Japan."
        ],
        "Years": [
            {
                "Year": "2017",
                "Month": "09",
                "Day": "22"
            }
        ]
    },
    {
        "ArticleTitle": "Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma.",
        "AuthorList": [
            "James R Cerhan",
            "Sonja I Berndt",
            "Joseph Vijai",
            "Hervé Ghesquières",
            "James McKay",
            "Sophia S Wang",
            "Zhaoming Wang",
            "Meredith Yeager"
        ],
        "AffiliationList": [
            "Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.",
            "Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.",
            "Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.",
            "1] Department of Hematology, Centre Léon Bérard, Lyon, France. [2] Laboratoire de Biologie Moléculaire de la Cellule, UMR 5239, CNRS, Pierre-Benite, France.",
            "Genetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer, Lyon, France.",
            "Department of Cancer Etiology, City of Hope Beckman Research Institute, Duarte, California, USA.",
            "Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, Maryland, USA.",
            "Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, Maryland, USA."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "09",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma?",
        "AuthorList": [
            "C Wenger",
            "M Stern",
            "R Herrmann",
            "Ch Rochlitz",
            "M Pless"
        ],
        "AffiliationList": [
            "Medical Oncology, Univeristy Hospital Basel, Switzerland.",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).",
        "AuthorList": [
            "Michael Pfreundschuh",
            "Joerg Schubert",
            "Marita Ziepert",
            "Rudolf Schmits",
            "Martin Mohren",
            "Eva Lengfelder",
            "Marcel Reiser",
            "Christina Nickenig"
        ],
        "AffiliationList": [
            "Internal Medicine, Saarland University Medical School, Saarland University, Homburg, Germany. inmpfr@uniklinikum-saarland.de",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2008",
                "Month": "01",
                "Day": "15"
            }
        ]
    },
    {
        "ArticleTitle": "Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma.",
        "AuthorList": [
            "Yoshihiro Kameoka",
            "Naoto Takahashi",
            "Kenichi Ishizawa",
            "Yuichi Kato",
            "Jugo Ito",
            "Osamu Sasaki",
            "Kazunori Murai",
            "Hideyoshi Noji"
        ],
        "AffiliationList": [
            "Department of Hematology, Akita University Graduate School of Medicine, Akita, Japan. ykameoka@doc.med.akita-u.ac.jp",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2012",
                "Month": "10",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma.",
        "AuthorList": [
            "Nozomi Niitsu",
            "Masataka Okamoto",
            "Sadao Aoki",
            "Hirokazu Okumura",
            "Tadashi Yoshino",
            "Ikuo Miura",
            "Masami Hirano"
        ],
        "AffiliationList": [
            "Hematology Division Department of Internal Medicine, Saitama Medical School, 38 Morohongo, Moroyama, Iruma-Gun, Saitama, Japan. nniitsu@saitama-med.ac.jp",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2006",
                "Month": "02",
                "Day": "22"
            }
        ]
    },
    {
        "ArticleTitle": "Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.",
        "AuthorList": [
            "Tanya Siddiqi",
            "Paul Frankel",
            "Jan H Beumer",
            "Brian F Kiesel",
            "Susan Christner",
            "Chris Ruel",
            "Joo Y Song",
            "Robert Chen"
        ],
        "AffiliationList": [
            "Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.",
            "Department of Information Sciences, City of Hope National Medical Center, Duarte, CA, USA.",
            "Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.",
            "Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.",
            "Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.",
            "Department of Information Sciences, City of Hope National Medical Center, Duarte, CA, USA.",
            "Department of Pathology, City of Hope National Medical Center, Duarte, CA, USA.",
            "Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "10",
                "Day": "16"
            }
        ]
    },
    {
        "ArticleTitle": "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.",
        "AuthorList": [
            "Ronan T Swords",
            "Peter L Greenberg",
            "Andrew H Wei",
            "Simon Durrant",
            "Anjali S Advani",
            "Mark S Hertzberg",
            "Brian A Jonas",
            "Ian D Lewis"
        ],
        "AffiliationList": [
            "Leukemia Program, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, FL, United States. Electronic address: rswords@med.miami.edu.",
            "Stanford Cancer Institute, Stanford, CA, United States.",
            "The Alfred Hospital and Monash University, Melbourne, Australia.",
            "The Royal Brisbane and Women's Hospital, Brisbane, Australia.",
            "Cleveland Clinic, Cleveland, OH, United States.",
            "Westmead Hospital, Westmead, Australia.",
            "Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, UC Davis Comprehensive Cancer Center, United States",
            "The Royal Adelaide Hospital, Adelaide, Australia."
        ],
        "Years": [
            {
                "Year": "2016",
                "Month": "09",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis.",
        "AuthorList": [
            "Kristen N Ganjoo",
            "Caroline S An",
            "Michael J Robertson",
            "Leo I Gordon",
            "Joy A Sen",
            "Jill Weisenbach",
            "Shuli Li",
            "Edie A Weller"
        ],
        "AffiliationList": [
            "Department of Medicine (Oncology), Stanford University, CA, USA. kganjoo@stanford.edu",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL.",
        "AuthorList": [
            "Kana Miyazaki",
            "Rika Sakai",
            "Noriko Iwaki",
            "Go Yamamoto",
            "Kayoko Murayama",
            "Momoko Nishikori",
            "Kazutaka Sunami",
            "Isao Yoshida"
        ],
        "AffiliationList": [
            "Mie University, Tsu, Japan.",
            "Kanagawa Cancer Center, Yokohama, Japan.",
            "Kanazawa University, Kanazawa, Japan.",
            "Toranomon Hospital, Tokyo, Japan.",
            "Gunma Cancer Center, Ohta, Japan.",
            "Kyoto University, Kyoto, Japan.",
            "Okayama Medical Center, Okayama, Japan.",
            "Shikoku Cancer Center, Matsuyama, Japan."
        ],
        "Years": [
            {
                "Year": "2023",
                "Month": "03",
                "Day": "16"
            }
        ]
    },
    {
        "ArticleTitle": "Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies.",
        "AuthorList": [
            "Harjeet Singh",
            "Samer A Srour",
            "Denái R Milton",
            "Jessica McCarty",
            "Cuiping Dai",
            "Mahmoud R Gaballa",
            "Mariam Ammari",
            "Simon Olivares"
        ],
        "AffiliationList": [
            "Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.",
            "Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.",
            "Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.",
            "Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.",
            "Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.",
            "Cellular Therapy Program and Bone Marrow Transplant Unit, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, United States.",
            "Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.",
            "Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "11",
                "Day": "10"
            }
        ]
    },
    {
        "ArticleTitle": "PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design.",
        "AuthorList": [
            "Kristine Broglio",
            "Lale Kostakoglu",
            "Carol Ward",
            "Federico Mattiello",
            "Denis Sahin",
            "Tina Nielsen",
            "Anna McGlothlin",
            "Corrine F Elliott"
        ],
        "AffiliationList": [
            "Berry Consultants, LLC, Austin, TX, USA.",
            "Department of Nuclear Medicine, University of Virginia, Charlottesville, VA, USA.",
            "F. Hoffmann-La Roche Ltd., Basel, Switzerland.",
            "F. Hoffmann-La Roche Ltd., Basel, Switzerland.",
            "F. Hoffmann-La Roche Ltd., Basel, Switzerland.",
            "F. Hoffmann-La Roche Ltd., Basel, Switzerland.",
            "Berry Consultants, LLC, Austin, TX, USA.",
            "Berry Consultants, LLC, Austin, TX, USA."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "07",
                "Day": "11"
            }
        ]
    },
    {
        "ArticleTitle": "Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.",
        "AuthorList": [
            "Caitlin M Stewart",
            "Laure Michaud",
            "Karissa Whiting",
            "Reiko Nakajima",
            "Chelsea Nichols",
            "Stephanie De Frank",
            "Paul A Hamlin",
            "Matthew J Matasar"
        ],
        "AffiliationList": [
            "Diagnostic Molecular Pathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.",
            "Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.",
            "Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.",
            "Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.",
            "Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.",
            "Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.",
            "Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.",
            "Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "10",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.",
        "AuthorList": [
            "Rong Shi",
            "Tong Lu",
            "Grace Ku",
            "Hao Ding",
            "Tomohisa Saito",
            "Leonid Gibiansky",
            "Priya Agarwal",
            "Xiaobin Li"
        ],
        "AffiliationList": [
            "Genentech Inc., South San Francisco, CA, USA. rongshi@gmail.com.",
            "Genentech Inc., South San Francisco, CA, USA.",
            "Genentech Inc., South San Francisco, CA, USA.",
            "Genentech Inc., South San Francisco, CA, USA.",
            "Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.",
            "QuantPharm LLC, North Potomac, MD, USA.",
            "Genentech Inc., South San Francisco, CA, USA.",
            "Genentech Inc., South San Francisco, CA, USA."
        ],
        "Years": [
            {
                "Year": "2020",
                "Month": "08",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.",
        "AuthorList": [
            "Anastasios Stathis",
            "Ian W Flinn",
            "Sumit Madan",
            "Kami Maddocks",
            "Arnold Freedman",
            "Steven Weitman",
            "Emanuele Zucca",
            "Mihaela C Munteanu"
        ],
        "AffiliationList": [
            "Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland. Anastasios.Stathis@eoc.ch.",
            "Sarah Cannon Research Institute, Nashville, TN, USA.",
            "Institute for Drug Development, San Antonio, TX, USA.",
            "Ohio State University, Columbus, OH, USA.",
            "Dana Farber Cancer Institute, Boston, MA, USA.",
            "Institute for Drug Development, San Antonio, TX, USA.",
            "Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland.",
            "ImmunoGen Inc., Waltham, MA, USA."
        ],
        "Years": [
            {
                "Year": "2018",
                "Month": "02",
                "Day": "17"
            }
        ]
    },
    {
        "ArticleTitle": "Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL.",
        "AuthorList": [
            "N Murawski",
            "M Pfreundschuh",
            "S Zeynalova",
            "V Poeschel",
            "M Hänel",
            "G Held",
            "N Schmitz",
            "A Viardot"
        ],
        "AffiliationList": [
            "Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg.",
            "Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg. Electronic address: michael.pfreundschuh@uks.eu.",
            "IMISE, University Leipzig, Leipzig.",
            "Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg.",
            "Internal Medicine III, Klinikum Chemnitz, Chemnitz.",
            "Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg.",
            "Department of Haematology, Oncology and Stem Cell Transplantation, Asklepios Klinik St Georg, Hamburg.",
            "Innere Medizin, Universitätsklinikum Ulm, Ulm."
        ],
        "Years": [
            {
                "Year": "2014",
                "Month": "06",
                "Day": "13"
            }
        ]
    },
    {
        "ArticleTitle": "The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease.",
        "AuthorList": [
            "Niamh Appleby",
            "Toby A Eyre",
            "Maite Cabes",
            "Aimee Jackson",
            "Rebecca Boucher",
            "Francesca Yates",
            "Sonia Fox",
            "Andrew Rawstron"
        ],
        "AffiliationList": [
            "Molecular Diagnostic Centre, Department of Oncology, University of Oxford, Oxford, UK. niamh.appleby@oncology.ox.ac.uk.",
            "Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, UK.",
            "Molecular Diagnostic Centre, Department of Oncology, University of Oxford, Oxford, UK.",
            "Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.",
            "Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.",
            "Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.",
            "Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.",
            "St. James's Institute of Oncology, Leeds, UK."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "05",
                "Day": "20"
            }
        ]
    },
    {
        "ArticleTitle": "Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results.",
        "AuthorList": [
            "Jia Ruan",
            "Stephanie A Gregory",
            "Paul Christos",
            "Peter Martin",
            "Richard R Furman",
            "Morton Coleman",
            "John P Leonard"
        ],
        "AffiliationList": [
            "Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY.",
            "Division of Hematology and Medical Oncology, Rush University Medical Center, Chicago, IL.",
            "Division of Biostatistics and Epidemiology, Weill Cornell Medical College, New York, NY.",
            "Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY.",
            "Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY.",
            "Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY.",
            "Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY. Electronic address: jpleonar@med.cornell.edu."
        ],
        "Years": [
            {
                "Year": "2013",
                "Month": "11",
                "Day": "18"
            }
        ]
    },
    {
        "ArticleTitle": "Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.",
        "AuthorList": [
            "Wataru Munakata",
            "Kiyoshi Ando",
            "Kiyohiko Hatake",
            "Noriko Fukuhara",
            "Tomohiro Kinoshita",
            "Suguru Fukuhara",
            "Yukari Shirasugi",
            "Masahiro Yokoyama"
        ],
        "AffiliationList": [
            "Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.",
            "Department of Hematology and Oncology, Tokai University, Isehara, Japan.",
            "Department of Hematology and Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.",
            "Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.",
            "Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.",
            "Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.",
            "Department of Hematology and Oncology, Tokai University, Isehara, Japan.",
            "Department of Hematology and Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan."
        ],
        "Years": [
            {
                "Year": "2019",
                "Month": "03",
                "Day": "28"
            }
        ]
    },
    {
        "ArticleTitle": "Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial.",
        "AuthorList": [
            "Heiko Schöder",
            "Mei-Yin C Polley",
            "Michael V Knopp",
            "Nathan Hall",
            "Lale Kostakoglu",
            "Jun Zhang",
            "Howard R Higley",
            "Gary Kelloff"
        ],
        "AffiliationList": [
            "Department Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.",
            "Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN.",
            "Department Radiology, The Ohio State University, Columbus, OH.",
            "Department Radiology, Philadelphia VA Medical Center, Philadelphia, PA.",
            "Department Radiology, Mt. Sinai Medical Center, New York, NY.",
            "Department Radiology, The Ohio State University, Columbus, OH.",
            "CCS Associates, Inc., San Jose, CA.",
            "Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Rockville, MD."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494.",
        "AuthorList": [
            "Jane N Winter",
            "Shuli Li",
            "Vikas Aurora",
            "Daina Variakojis",
            "Beverly Nelson",
            "Maryla Krajewska",
            "Lijun Zhang",
            "Thomas M Habermann"
        ],
        "AffiliationList": [
            "Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. j-winter@northwestern.edu",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null",
            "null"
        ],
        "Years": [
            {
                "Year": "2010",
                "Month": "04",
                "Day": "06"
            }
        ]
    },
    {
        "ArticleTitle": "Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.",
        "AuthorList": [
            "Yuqin Song",
            "Hervé Tilly",
            "Shinya Rai",
            "Huilai Zhang",
            "Jie Jin",
            "Hideki Goto",
            "Yasuhito Terui",
            "Ho-Jin Shin"
        ],
        "AffiliationList": [
            "Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.",
            "Centre Henri Becquerel and University of Rouen, Rouen, France.",
            "Kindai University Hospital, Osaka, Japan.",
            "Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.",
            "The First Affiliated Hospital of College of Medicine, Zhejiang University, Zhejiang, China.",
            "Department of Hematology, Hokkaido University Hospital, Sapporo, Japan.",
            "The Cancer Institute Hospital of JFCR, Tokyo, Japan.",
            "Pusan National University Hospital, Busan, Republic of Korea."
        ],
        "Years": []
    },
    {
        "ArticleTitle": "Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial.",
        "AuthorList": [
            "Alice P Chen",
            "Shivaani Kummar",
            "Nancy Moore",
            "Lawrence V Rubinstein",
            "Yingdong Zhao",
            "P Mickey Williams",
            "Alida Palmisano",
            "David Sims"
        ],
        "AffiliationList": [
            "Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.",
            "Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.",
            "Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.",
            "Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.",
            "Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.",
            "Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD.",
            "Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.",
            "Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD."
        ],
        "Years": [
            {
                "Year": "2021",
                "Month": "01",
                "Day": "12"
            }
        ]
    },
    {
        "ArticleTitle": "Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.",
        "AuthorList": [
            "D Williams Parsons",
            "Katherine A Janeway",
            "David R Patton",
            "Cynthia L Winter",
            "Brent Coffey",
            "P Mickey Williams",
            "Sinchita Roy-Chowdhuri",
            "Gregory J Tsongalis"
        ],
        "AffiliationList": [
            "Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, TX.",
            "Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.",
            "Center for Biomedical Informatics and Information Technology, NCI, NIH, Bethesda, MD.",
            "Center for Biomedical Informatics and Information Technology, NCI, NIH, Bethesda, MD.",
            "Center for Biomedical Informatics and Information Technology, NCI, NIH, Bethesda, MD.",
            "Frederick National Laboratory for Cancer Research, Frederick, MD.",
            "University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Geisel School of Medicine at Dartmouth, Hanover, NH."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "03",
                "Day": "30"
            }
        ]
    },
    {
        "ArticleTitle": "Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.",
        "AuthorList": [
            "Olive S Eckstein",
            "Carl E Allen",
            "P Mickey Williams",
            "Sinchita Roy-Chowdhuri",
            "David R Patton",
            "Brent Coffey",
            "Joel M Reid",
            "Jin Piao"
        ],
        "AffiliationList": [
            "Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX.",
            "Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX.",
            "Frederick National Laboratory for Cancer Research, Frederick, MD.",
            "University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Center for Biomedical Informatics and Information Technology, NCI, NIH, Bethesda, MD.",
            "Center for Biomedical Informatics and Information Technology, NCI, NIH, Bethesda, MD.",
            "Mayo Clinic, Rochester, MN.",
            "Keck School of Medicine, University of Southern California, Los Angeles, CA."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "04",
                "Day": "01"
            }
        ]
    },
    {
        "ArticleTitle": "Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.",
        "AuthorList": [
            "Senthil Damodaran",
            "Fengmin Zhao",
            "Dustin A Deming",
            "Edith P Mitchell",
            "John J Wright",
            "Robert J Gray",
            "Victoria Wang",
            "Lisa M McShane"
        ],
        "AffiliationList": [
            "The University of Texas MD Anderson Cancer Center, Houston, TX.",
            "Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.",
            "University of Wisconsin Carbone Cancer Center, Madison, WI.",
            "Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.",
            "Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.",
            "Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.",
            "Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.",
            "Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD."
        ],
        "Years": [
            {
                "Year": "2022",
                "Month": "02",
                "Day": "08"
            }
        ]
    },
    {
        "ArticleTitle": "Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.",
        "AuthorList": [
            "Ian E Krop",
            "Opeyemi A Jegede",
            "Juneko E Grilley-Olson",
            "Josh D Lauring",
            "Edith P Mitchell",
            "James A Zwiebel",
            "Robert J Gray",
            "Victoria Wang"
        ],
        "AffiliationList": [
            "Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.",
            "Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA.",
            "University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.",
            "Johns Hopkins School of Medicine, Baltimore, MD.",
            "Thomas Jefferson University, Philadelphia, PA.",
            "National Cancer Institute, Bethesda, MD.",
            "Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA.",
            "Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA."
        ],
        "Years": []
    }
]